[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2005023806A2 - Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands - Google Patents

Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands Download PDF

Info

Publication number
WO2005023806A2
WO2005023806A2 PCT/US2004/028899 US2004028899W WO2005023806A2 WO 2005023806 A2 WO2005023806 A2 WO 2005023806A2 US 2004028899 W US2004028899 W US 2004028899W WO 2005023806 A2 WO2005023806 A2 WO 2005023806A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
pyrrolo
methoxy
ethyl
isopropyl
Prior art date
Application number
PCT/US2004/028899
Other languages
French (fr)
Other versions
WO2005023806A3 (en
Inventor
Ping Ge
Raymond F. Horvath
Lu Yan Zhang
Yasuchika Yamaguchi
Bernd Kaiser
Xuechun Zhang
Suoming Zhang
He Zhao
Stanly John
Neil Moorcroft
Greg Shutske
Original Assignee
Neurogen Corporation
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005023806(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA200600372A priority Critical patent/EA200600372A1/en
Priority to AP2006003559A priority patent/AP2006003559A0/en
Priority to CA002537829A priority patent/CA2537829A1/en
Priority to EP04788585A priority patent/EP1680424A2/en
Priority to AU2004270713A priority patent/AU2004270713A1/en
Application filed by Neurogen Corporation, Aventis Pharmaceuticals Inc. filed Critical Neurogen Corporation
Priority to BRPI0414087-7A priority patent/BRPI0414087A/en
Priority to JP2006526210A priority patent/JP2007504271A/en
Publication of WO2005023806A2 publication Critical patent/WO2005023806A2/en
Publication of WO2005023806A3 publication Critical patent/WO2005023806A3/en
Priority to IL174084A priority patent/IL174084A0/en
Priority to NO20061180A priority patent/NO20061180L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that bind with high selectivity and/ or high affinity to CRF receptors (Corticotropin Releasing Factor Receptors).
  • This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of psychiatric disorders and neurological diseases, including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. Additionally this invention relates to the use such compounds as probes for the localization of CRF receptors in cells and tissues.
  • Preferred CRF receptors are CRFl receptors.
  • Corticotropin releasing factor a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland.
  • POMC proopiomelanocortin
  • CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders.
  • a role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system.
  • CRF cerebral spinal fluid
  • CSF cerebral spinal fluid
  • CRF receptors are significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF.
  • CRF cerebral spinal fluid
  • ACTH blunted adrenocorticotropin
  • Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen jn human depression.
  • tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain. . ,
  • CRF has also been implicated in the etiology of anxiety-related disorders.
  • CRF produces anxiogenic effects in animals and interactions between benzodiazepine / non- benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models.
  • Preliminary studies using the putative CRF receptor antagonist ⁇ -helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines.
  • Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders.
  • Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test and in the acoustic startle test in rats.
  • the benzodiazepine receptor antagonist Ro 15-1788 which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner, while the benzodiazepine inverse agonist FG 7142 enhanced the actions of CRF.
  • CRF has also been implicated in the pathogeneisis of certain immunological, cardiovascular or heart-related diseases such as hypertension, tachycardia and congestive heart failure, stroke and osteoporosis, as well as in premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus and colonic hypersensitivity associated with psychopathological disturbance and stress.
  • immunological, cardiovascular or heart-related diseases such as hypertension, tachycardia and congestive heart failure, stroke and osteoporosis, as well as in premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus and colonic hypersensitivity associated with psychopathological disturbance and stress.
  • the mechanisms and sites of action through which conventional anxiolytics ' and antidepressants produce their therapeutic effects remain to be fully elucidated. It has been hypothesized however, that they are involved in the suppression of CRF hypersecretion that is observed in these disorders.
  • the invention provides novel compounds of Formula I (shown below), and pharmaceutical compositions comprising compounds of Formula I and at least one pharmaceutically acceptable carrier or excipient.
  • Such compounds bind to cell surface receptors, preferably G-coupled protein receptors, especially CRF receptors (including CRFl and CRF2 receptors) and most preferably CRF 1 receptors.
  • CRF receptors including CRFl and CRF2 receptors
  • CRF 1 receptors include CRF 1 receptors
  • Preferred compounds of the invention exhibit high affinity for CRF receptors, preferably CRF 1 receptors.
  • preferred compounds of the invention also ' exhibit high specificity for CRF receptors (i.e., they exhibit high selectivity compared to their binding to non-CRF receptors). Preferably they exhibit high specificity for CRF 1 receptors.
  • the invention provides compounds of Formula I-a
  • E is a single bond, O, S(0) m , NR i0 or CR ⁇ 0 R ⁇ i ;
  • i are independently hydrogen or -C 4 alkyl; •m is 0, 1, or 2;
  • Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R is oxygen or absent; the group:
  • Z 2 is nitrogen, oxygen, sulfur, CR 2 , CR 2 R 2 ' or NR "
  • Z 3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR 3 , or CR 3 R 3 '
  • Ri is chosen from hydrogen, halogen, hydroxy, cyano, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, optionally substituted heterocycle and optionally substituted heteroaryl, said ' optionally substituted heterocycle or heteroaryl having from 1 to 3 rings,
  • R4. and R 5 are independently chosen from hydrogen, halogen, hydroxy ' , amino, cyano, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted (cycloalkyl)alkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclie aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S.
  • the invention provides compounds of Formula I-b
  • E is a single bond, O, S(0) m , NRio or CRio i i ;
  • Rio and R ⁇ are independently hydrogen or C ⁇ -C 4 alkyl; m is 0, 1, or 2; '
  • R is oxygen or absent
  • Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; the group: .
  • Ri and Rj" are chosen from hydrogen, C]-C I0 alkyl, C 2 -C ⁇ 0 alkenyl, C 2 -C, 0 alkynyl, C 3 - C 7 cycloalkyI, (benzo)C 3 -C 7 cycloalkyl, (C 3 -C 7 cycloalkyl)C ⁇ -C alkyl, C 3- gheterocycloalkyl, (C 3-9 heterocycloalkyl)C ⁇ -C 4 alkyl, (benzo)C 3-9 heterocycloalkyl, ((benzo)C 3-9 heterocycloalkyl)C ⁇ -C alkyrand halo(Cj
  • R 2 is chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C ⁇ -C 3 alkyl, halo(C ⁇ - C 3 )alkyl, CpC 3 alkoxy, amino(C ⁇ -C 3 )alkyl, and mono and di(C ⁇ -C 6 )alkylamino;
  • R 3 is chosen from hydrogen, hydroxy, amino, halogen, cyano, nitro, C
  • C 3 )alkyl C ⁇ -C 3 alkoxy, amino(C ⁇ -C 3 )alkyI, hydroxy(C ⁇ -C 3 )alkyl, cyano(C ⁇ -C 3 )a ⁇ kyl, . and mono and di(C ⁇ -C 3 )alkylamino;
  • R 3 " is chosen from hydrogen, hydroxy, amino, C ⁇ -C 3 alkyl, halo(C ⁇ -C 3 )alkyl, C ⁇ -C 3 alkoxy, amino(C]-C 3 )alkyl, hydroxy(C ⁇ -C 3 )alkyl, cyano(C ⁇ -C 3 )alkyl, and mono and di(Cj- C 3 )alkylamino;
  • Ri', R 2 ' and R 3 ' are independently chosen from hydrogen, halogen, C ⁇ -C 6 alkyl, halo( - C 6 )alkyl, and amino(C[-C 6 )alkyl;
  • Z 5 is NR or CR 5 ; 4 and R 5 are independently chosen from hydrogen, halogen, cyano, nitro, amino, mono or di(C ! -C 6 carbhydryl)amino, CpC ⁇ Carbhydryl, (C 3 -C7cyclocarbhydryl)C 0 - C 4 carbhydryl, -0(C 3 -C 7 cyclocarbhydryl), halo ' (C ⁇ -C 6 )carbhydryl, -0(halo(C r
  • each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, C ⁇ -C 4 alkoxy, and mono- and di(C ⁇ -C 4 )alkylamino, and ' where each Cs-C ⁇ carbhydryl heterocycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, C ⁇ -C alkoxy, and mono- and di(C ⁇ -C )alkylamino; or R 5 , taken in combination with Ri or Ri", forms a 5-9 membered heterocycle; R A is independently
  • R B is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, d-Qalkyl, -0(C,-C 4 alkyl), -NH(C r C 4 alkyl), -N(C,- C 4 alkyl)( d-C 4 alkyl), -S(O)êt(alkyl), halo(C,-C 4 )alkyl, halo(C ⁇ -C 4 )alkoxy, CO(C,- C 4 alkyl), CONH(C,-C 4 alkyl), CON(C,-C 4 alkyl)( C,-C 4 alkyl), -XR C, and Y;
  • Rc and RQ are independently selected at each occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, C ⁇ -C 6 alkoxy, -NH(C ⁇ -C 6 alkyl), -N(C
  • Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, C ⁇ -C 4 alkyl, -0(C ⁇ -C 4 alkyl), -NH(C ⁇ -C 4 alkyl), - N(C]-C 4 alkyl)(C ⁇ -C 4 alkyl), -C(0)(C,-C 4 alkyl), and -S(0) n (alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2.
  • Certain preferred compounds of Formula I-a or Formula I-b include those in which at least one of Z 4 and Z 5 is not NR. Certain other preferred compounds of Formula I-a or Formula I-b include those in which Z 4 is selected from N and CR 4 and Z 5 is selected from N and CR 5 .
  • Certain preferred compounds of Formula I-b include those compounds in which Ar is chosen from phenyl which is mono-, di-, or tri-substituted with R A , and 1- naphthyl, 2- naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with R A ; and
  • Ri and Ri are chosen from C]-C 10 alkyl, C 2 -C ⁇ 0 alkenyl, C 2 -C ⁇ 0 alkynyl, C 3 - C 7 cycloalkyl, (C 3 -C 7 cycloalky ⁇ )C ⁇ -C a ⁇ kyl, (benzo)C 3 -C 7 cycloalkyl, (benzo)C 3- gheterocycloalkyl,
  • Form I is generally intended to refer to compounds of either Formula I-a or Formula I-b and subformulae thereof.
  • the invention further comprises methods of treating patients suffering from certain disorders with a therapeutically effective amount of at least one compound of the invention.
  • disorders include CNS disorders, particularly affective disorders, anxiety disorders, stress-related disorders, eating disorders and substance abuse.
  • the patient suffering from these disorders may be a human or other animal (preferably a mammal), such as a domesticated companion animal (pet) or a livestock animal.
  • Preferred compounds of the invention for such therapeutic purposes are those that antagonize the binding of CRF to CRF receptors (preferably CRF1, or less preferably CRF2 receptors).
  • the ability of compounds to act as antagonists can be measured as an IC50 value as described below.
  • the present invention provides pharmaceutical compositions comprising compounds of Formula I or the pharmaceutically acceptable salts (by which term is also encompassed pharmaceutically acceptable solvates) thereof, which compositions are useful for- the treatment of the above-recited disorders.
  • the invention further provides methods of treating patients suffering from any of the above-recited disorders with an effective amount of a compound or composition of the invention.
  • this invention relates to the use of the compounds of the invention (particularly labeled compounds of this invention) as probes for the localization of receptors in cells and tissues and as standards and reagents for use in determining the receptor-binding characteristics of test compounds.
  • Preferred heteroaryl fused pyridine, pyrazine, and pyrimidine compounds of the invention exhibit good activity, i.e., a half-maximal inhibitory concentration (IC 50 ) of less than 1 millimolar, in a standard in vitro CRF receptor binding assay such as the assay provided in Example 51, which follows.
  • Particularly preferred substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds of the invention exhibit an IC 5 oof about 1 micromolar or less, still more preferably an IC50 of about 100 nanomolar or less even more preferably an IC 50 of about 10 nanpmolar or less.
  • Certain particularly preferred compounds of the invention will exhibit an IC 5 0 of 1 nanomolar or less in such a defined standard in vitro CRF receptor binding assay.
  • R is oxygen or absent
  • Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with R A , and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with R A ; the group:
  • Z 2 is nitrogen, oxygen, sulfur, CR 2 , CR 2 R 2 ' , or NR 2 ",
  • Z is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR 3 , or CR 3 R 3 ' ;
  • Ri is chosen from i) halogen, hydroxy, cyano, amino, -Cioalkyl, -0(C ⁇ -C ⁇ alkyl), mono or di(C r C 6 alkyl)amino, (C 3 -C 7 cycloalkyl)Ci-C 4 alkyl, halo(C ⁇ -C 6 )alkyl, -0(halo(C,-C 6 )alkyl) and
  • each C 3 -C 7 cycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, C ⁇ -C 4 alkoxy, and mono- or di(C ⁇ -C 4 )alkylamino, and • ii) phenyl which is mono-, di-, or tri-substituted with R A , 1- naphthyl, 2-naphthyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridiziriyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-
  • Ri', R 2 ' and R 3 ' are independently chbsen from hydrogen, halogen, Ci-C ⁇ alkyl, halo(C ⁇ -
  • R 2 " is chosen from hydrogen, CpCealkyl, halo(C ⁇ -C 6 )alkyl, and amino(C ⁇ -C 6 )alkyl;
  • Z 4 is NR or CR 4 ;
  • Z 5 is NR or CR 5 ;
  • R4 and R5 are independently chosen from hydrogen, halogen, cyano, nitro, amino, mono or di(C ⁇ -C 6 carbhydryl)amino, Ci-C ⁇ Carbhydryl, (C 3 -C7cyclocarbhydryl)Co- C 4 carbhydryl, -0(C 3 -C 7 cyclocarbhydryl), halo(C ⁇ -Ce)carbhydryl, -0(halo(C ⁇ - C 6 )carbhydryl), -0(Ci-C 6 carbhydryl), and S(0) n (Ci-C 6 carbhydryl), where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, C ⁇ -C 4 alkoxy, and mono- and di(C ⁇ -C 4 )alkylamino, and
  • R B is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, C]-C 4 alkyl, -0(C,-C 4 alkyl), -NH(C,-C 4 alkyl), -N(d- C 4 alkyl)( d-C 4 alkyl), -S(0) n (alkyl), halo(C,-C 4 )alkyl, halo(C ⁇ -C 4 )alkoxy, CO(C
  • Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, C r C 4 alkyl, -0(C ⁇ -Qalkyl), -NH(d-C 4 alkyl), -N(C,-C 4 alkyl)(C ⁇ -C 4 alkyl),and -S(0) n (alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment • being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2.
  • Such compounds will be referred to as compounds of Formula I-c.
  • Certain preferred compounds of Formula I-c include those in which at least one of Z 4 and Z 5 is not NR. Certain other preferred compounds of Formula I-c include those in which Z 4 is selected from N and CR 4 and Z5 is selected from N and CR 5 .
  • R 2 ', R 2 ", R , R ', R " > 4 , R5 5 and Ar are as defined above for Formula I, or preferably are as defined above for Formula I-a, I-b, or I-c.
  • Ri, R,', and Ri are as defined for Formula I-a, I-b, or I-c;
  • R 2 ' and R 3 ' are hydrogen
  • R 2 (or R 2 ") is selected from hydrogen, methyl, and ethyl;
  • R 3 (or R 3 ") is selected from hydrogen, and C ⁇ -C 6 alkyl (or more preferably R 3 or R 3 " is Ci-
  • R and R 5 are independently selected from hydrogen, halogen, cyano, amino, C ⁇ -C 6 alkyl, d- C 6 alkoxy, C 3 -C 7 cycloalkyl, (C 3 -C 7 cycloalkyl)d-C 4 alkyl, (C 3 -C 7 cycloalkyl)d- C 4 alkoxy, mono and di(C ⁇ -C 6 alkyl)amino, amino(Ci-Ce)alkyl, mono and di(C ⁇ - C 6 alkyl)amino(C ⁇ -C 6 )alkyl, halo(C ⁇ -C 6 )alkyl, and halo(C ⁇ -C 6 )alkoxy; and
  • Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(d-C 6 )alkyl, halo(d-C 6 )alkoxy, hydroxy, amino, C r C 6 alkyl, C 2 - dalkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, (C3-C 7 cycloalkyl)C ⁇ -C 4 alkyl, C ⁇ -C 6 alkoxy, • mono- and di(C ⁇ -C 6 alkyl)amino, amino(C r C6)alkyl, and mono- and di(C ⁇ -C 6 alkyl)amino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula II - Formula XX, above, is substituted
  • the Rj or Ri" residue is selected, from Ci-Cioalkyl and (C 3 -C 7 cycloalkyl)Co-C 4 alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, C r - C 4 alkoxy, and mono- and di-(C ⁇ -C 4 )alkylamino.
  • the R ⁇ or Ri" residue is selected from C 3- 9heterocycloalkyl and (C3-9heterocycloalkyl)d -4 alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, Ci-C ⁇ alkyl, Ci- dalkoxy, Ci-Cehydroxyalkyl, C ⁇ -C 6 alkoxyC ⁇ -C 6 alkyl, (C,-C 6 )haloalkyl, (C ⁇ -C 6 )haloalkoxy, mono- and di-(C ⁇ -C 6 )alkylamino, -XRc- Certain preferred C 3-9 heterocycloalkyl and (C 3- 9heterocycloalkyl)C ⁇ -4 alkyl groups include those chosen from tetrahydrofur
  • Certain other preferred compounds of Formula I include those compounds in which Ri or R," is selected from 3-pentyl, 2- butyl, l-methoxy-but-2-yl, l-dimethylamino-but-2-yl, 3-(thiazol-2-yl)-lH-pyrazol-l-yl, and groups of formula:
  • X is the point of attachment to the nitrogen of the imidazo ring
  • Y is selected from C ⁇ 2 , O, S, S(O), S0 , NC ⁇ -C 8 alkyl (including linear and branched alkyl groups), NC ⁇ -C 6 haloalkyl, NC 3 -C 8 cycloalkyl, NC(0)d-C 8 alkyl (including linear and branched alkyl groups), NC(0)d-C 6 haloalkyl, NC(0)C 3 -C 8 cycloalkyl, N-benzoyl, N-benzyl, NCOOC ⁇ -C 8 alkyl (including linear and branched alkyl groups), NCOOC ⁇ -C 6 haloalkyl, NCOOC 3 -C 8 cycl ' oalkyl
  • Z is selected from hydrogen, hydroxy, amino, NC ⁇ -C 8 alkyl (including linear and branched alkyl groups), NHC ⁇ .-C 6 haloalkyl, NHC 3 -C
  • preferred compounds of Formula I include those compounds in which R] or R]" is selected from
  • X is the point of attachment to the nitrogen of the imidazo ring.
  • Ri groups are shown in the R 2 2-Matrix and particularly preferred Rj' ? groups are shown in the R ⁇ 2-Matrix, both in Example 1, which follows.
  • R ⁇ groups include groups of the formula
  • A represents up to three groups independently chosen from hydrogen, halogen, alkyl, and alkoxy.
  • Another embodiment of the invention is directed to compounds of Formula XX
  • E is a single bond, O, S(0) m , NRio or CRioRi i;
  • Rio and R ⁇ are independently hydrogen or C ⁇ -C 4 alkyl; m is 0, 1, or 2;
  • Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R is oxygen or absent; the group:
  • Z is CR 1 , CR,R, ', or NR 1 ";
  • Z 2 is nitrogen, oxygen, sulfur, CR 2 , CR 2 R 2 ' or NR ",
  • Z 3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR 3 , CR 3 R 3 ', or NR 3 " ;
  • Ri is chosen from halogen, hydroxy, cyano, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
  • Ri is chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
  • R 2 and R 3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, alkyl, haloalkyl, alkoxy, aminoalkyl, and mono and dialkylamino;
  • Ri' , R 2 ' and R 3 ' are independently chosen from hydrogen, halogen, alkyl, haloalkyl, and aminoalkyl;
  • R 2 " and R 3 " are independently chosen from hydrogen, alkyl, haloalkyl, and aminoalkyl;
  • R 4 is hydrogen, alkyl, aminoalkyl, and haloalkyl
  • Certain other preferred compounds and pharmaceutically acceptable salts of the invention include those compounds of Formula XX:
  • Formula XX or a pharmaceutically acceptable salt thereof, wherein: E is a single bond, O, S(0) m , NR10 or CR10R11; Rio and R are independently hydrogen or C ⁇ -C 4 alkyl; m is 0, 1, or 2; R is oxygen or absent;
  • Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; the group:
  • Zi is CRu CRiRi'. or NRf';
  • Z 2 is nitrogen, oxygen, sulfur, CR 2 , CR 2 R 2 ' ; orNR 2 ", Z 3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR 3 , CR3R3' or NR 3 " ;
  • Ri is chosen from i) halogen, hydroxy, cyano, amino, Ci-Ciocarbhydryl, -O(Ci-Cecarbhydryl), mono or di(C 1 - C 6 carbhydryl)amino, (C 3 -C 7 cyclocarbhydryl)C ⁇ -C carbhydryl, halo(C ⁇ - C 6 )carbhydryl, -0(halo(C,-C 6 )carbhydryl) and S(0) n (C,-C 6 carbhydryl), -0(C 3 - C 7 cyclocarbhydryl)Ci-C 4 carbhydryl, d.gheterocycloalkyl,
  • R 4 is hydrogen, Ci-C ⁇ alkyl, Ci-C ⁇ aminoalkyl, and Ci-C ⁇ haloalkyl R A is independently selected at each occurrence from halogen, cyano, nitro, halo(C C 6 )alkyl, halo(C ⁇ -C 6 )alkoxy, hydroxy, amino, d-C 6 alkyl substituted with 0-2 R B , C 2 -C 6 alkenyl substituted with 0-2 R B , C 2 -C 6 alkynyl substituted with 0-2 R B , C 3 -C 7 cycloalkyl substituted with' 0-2 R B , (C 3 -C 7 cycloalkyl) C r C 4 alkyl substituted with 0-2 R B , Ci- C 6 alkoxy substituted with 0-2 R
  • Rc and R D which may be the same or different, are independently selected at each • occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected ' from oxo, hydroxy, halogen, cyano, amino, C ⁇ -C 6 al
  • Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, d-C 4 alkyl, -0(C ⁇ -C 4 alkyl), -C(0)(C ⁇ -C4alkyl), -NH(C ⁇ -C 4 alkyl), -N(C ⁇ -C 4 alkyl)(C ⁇ -
  • Preferred compounds and pharmaceutically acceptable salts of Formula XX are those for which: Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with R A , and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with.
  • Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with R A , and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, ox
  • Zi is CRi. CRiRi'or NRi";
  • Z 2 is nitrogen, oxygen, sulfur, CR 2 , CR 2 R 2 ', orNR 2 "
  • Z 3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR 3 , CR 3 R 3 ' orNR 3 "
  • Ri is chosen from i) halogen, hydroxy, cyano, amino, C ⁇ -C 10 carbhydryl, -0(C ⁇ -C 6 carbhydryl), mono or di(d- C 6 carbhydryl)amino, (C 3 -C 7 cycloalkyl)'C ⁇ -C4carbhydryl, halo(C ⁇ C 6 )carbhydryl, - 0(halo(CiC 6 )carbhydryl) and S(0) n (C ⁇ -C 6 carbhydryl), -0(C 3 -C 7 cycloalkyi)C,- C 4 carbhydryl, and S(0) n (Ci-C 6 carbhydryi), " where each carbhydr
  • R 2 ' and R 3 ' are independently chosen from hydrogen, halogen, Ci-C ⁇ alkyl, halo(C ⁇ -C 6 )alkyl, and • amino(C i -C 6 )alky 1;
  • R 2 " and R 3 " are independently chosen from hydrogen, Ci-G ⁇ alkyl, halo(C ⁇ -C 6 )alkyl, and amino(C i -C 6 )alkyl;
  • R4 is hydrogen or Ci-C ⁇ alkyl;
  • R A is independently selected at each occurrence from halogen, cyano, nitro, halo(C ⁇ -Ce)alkyl, halo(C ⁇ -C 6 )alkoxy, hydroxy, amino, C ⁇ -C 6 alkyl substituted with 0-2 R B , -C ⁇ alkenyl substituted with 0-2 R B , C 2 -C 6 alkynyl substituted with 0-2 R B , C 3 -C 7 cycloalkyl substituted with 0-2 R B , (C 3 -C 7 cycloalkyl) C ⁇ -C 4 alkyl substituted with 0-2 R B , d- C 6 alkoxy substituted with 0-2 R B , -NH(C r C 6 alkyl) substituted with 0-2 R B , -N(C
  • R B is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, C,-C 4 alkyl, -0(C,-C 4 alkyl), -NH(C ⁇ -C 4 alkyl), -N(C GialkylX d-C 4 alkyl), -S(0) n (alkyl), halo(C,-C 4 )alkyl, halo(d-C 4 )alkoxy, CO(C C 4 alkyl), CONH(C ⁇ -C 4 alkyl), CON(C,-C 4 alkyl)( C,-C 4 alkyl), -XR C, and Y; Rc and RD, which may be the same or different, are independently selected at each occurrence from: hydrogen, and straight, branched, or cyclic
  • Ri or Ri are as defined for Formula XX, or preferably as defined for Formula XXA.
  • R 2 is selected from hydrogen, methyl, and ethyl
  • R 3 is selected from hydrogen and C ⁇ -C 6 alkyl
  • Ar is selected from the group consisting of phenyl, pyridyl which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(C ⁇ -C 6 )alkyl, halo(C ⁇ -C 6 )alkoxy, hydroxy, amino, d-C 6 alkyl, C 2 -Cealkenyl, C 2 -C 6 alkynyl,
  • Compounds of the invention are useful in treating a variety of conditions including affective disorders, anxiety disorders, stress disorders, eating disorders, and drug addiction.
  • Affective disorders include all types of depression, bipolar disorder, cyclothymia, and dysthymia.
  • Anxiety disorders include generalized anxiety disorder, panic, phobias and obsessive- compulsive disorder.
  • Stress-related disorders include post-traumatic stress disorder, hemorrhagic stress, stress-induced psychotic episodes, psychosocial dwarfism, stress headaches, stress-induced immune systems disorders such as stress-induced fever, and stress-related sleep disorders.
  • Eating disorders include anorexia nervosa, bulimia nervosa, and obesity.
  • Modulators of the CRF receptors are also useful in the treatment (e.g., symptomatic treatment)of a variety of neurological disorders including supranuclear palsy, AIDS related dementias, multiinfarct dementia, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, head trauma, spinal cord trauma, ischemic neuronal damage, amyotrophic lateral sclerosis, disorders of pain perception such as fibromyalgia and epilepsy.
  • compounds of Formula I are useful as modulators of the CRF receptor in the treatment (e.g., symptomatic treatment) of a number of gastrointestinal, cardiovascular, hormonal, autoimmune and inflammatory conditions.
  • Such conditions include irritable bowel syndrome, ulcers, Crohn's disease, spastic colon, diarrhea, post operative ilius and colonic hypersensitiviry associated with psychopathological disturbances or stress, hypertension, tachycardia, congestive heart failure, infertility, euthyroid sick syndrome, inflammatory conditions effected by rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies.
  • Compounds of Formula I are also useful as modulators of the CRFl receptor in the treatment of animal disorders associated with aberrant CRF levels. These conditions include porcine stress syndrome, bovine shipping fever, equine ' paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs, psychosocial dwarfism .and hypoglycemia.
  • Typical subjects to which compounds of the invention may be administered will be mammals, particularly primates, especially humans.
  • mammals particularly primates, especially humans.
  • livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and other domesticated animals particularly pets such as dogs and cats.
  • rodents e.g. mice, rats, hamsters
  • rabbits primates, and swine such as inbred pigs and the like.
  • body fluids e.g., blood, plasma, serum, CSF, lymph, cellular interstitial fluid, aqueous humor, saliva, synovial fluid, feces, or urine
  • cell and tissue samples of the above subjects will be suitable for use.
  • the CRF binding compounds provided by this invention and labeled derivatives thereof are also useful as standards and reagents in determining the ability of test compounds (e.g., a potential pharmaceutical) to bind to a CRF receptor.
  • Labeled derivatives the CRF antagonist compounds provided by this invention are also useful as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT).
  • PET positron emission tomography
  • SPECT single photon emission computerized tomography
  • More particularly compounds of the invention may be used for demonstrating the presence of CRF ' receptors in cell or tissue samples. This may be done by preparing a plurality of matched cell or tissue samples, at least one of which is prepared as an experiment sample and at least one of which is prepared as a control sample.
  • the experimental sample is prepared by contacting (under conditions that permit binding of CRF to CRF receptors within cell and tissue samples) at least one of the matched cell or tissue samples that has not previously been contacted with any compound or salt of the invention with an experimental solution comprising the detectably-labeled preparation of the selected compound or salt at a first measured molar concentration.
  • control sample is prepared by in the same manner as the experimental sample and is incubated in a solution that contains the same ingredients as the experimental solution but that also contains an unlabelled preparation of the same compound or salt of the invention at a molar concentration that is greater' than the first measured molar concentration.
  • the experimental and control samples are then washed to remove unbound detectably-labeled compound.
  • the amount of detectably-labeled compound remaining bound to each sample is then measured and the amount of detectably-labeled compound in the experimental and control samples is compared.
  • a comparison that indicates the detection of a greater amount of detectable label in the at least one washed experimental sample than is detected in any of the at least one washed control samples demonstrates the presence of CRF receptors in that experimental sample.
  • the detectably-labeled compound used in this procedure may be labeled with any detectable label, such as a radioactive label, a biological tag such as biotin (which can be detected by binding to detectably-labeled avidin), an enzyme (e.g., alkaline phosphatase, beta galactosidase, or a like enzyme that can be detected its activity in a colorimetric assay) or a directly or indirectly luminescent label.
  • a detectable label such as a radioactive label, a biological tag such as biotin (which can be detected by binding to detectably-labeled avidin), an enzyme (e.g., alkaline phosphatase, beta galactosidase, or a like enzyme that can be detected its activity in a colorimetric assay) or a directly or indirectly luminescent label.
  • the detectably-labeled compound is radiolabeled
  • the bound, labeled compound may be detected autoradiographically to generate an autoradiogram.
  • the amount of detectable label in an experimental or control sample may be measured by viewing the autoradiograms and comparing the exposure density of the autoradiograms.
  • the present invention also pertains to methods of inhibiting the binding of CRF to CRF receptors (preferably CFR1 receptors) which methods involve contacting a solution containing a CRF antagonist compound of the invention with cells expressing CRF receptors, wherein the compound is present in the solution at a concentration- sufficient to inhibit CRF binding to CRF receptors in vitro.
  • This method includes inhibiting the binding of CRF to CRF receptors in vivo, e.g., in a patient given an amount of a compound of Formula I that would be sufficient to inhibit the binding of CRF to CRF receptors in vitro.
  • such methods are useful in treating physiological disorders associated with excess concentrations of CRF.
  • the amount of a compound that would be sufficient to inhibit the binding of a CRF to the CRF receptor may be readily determined via a CRF receptor binding assay (see, e.g., Example 51), or from the EC 5 o of a CRF receptor functional assay, such as a standard assay of CRF receptor mediated chemotaxis.
  • the CRF receptors used to determine in vitro binding may be obtained from a variety of sources, for example from cells that naturally express CRF receptors, e.g. IMR32 cells or from cells expressing cloned human CRF receptors.
  • the present invention also pertains to methods for altering the activity of CRF receptors, said method comprising exposing cells expressing such receptors to an effective amount of a compound of the invention, wherein the compound is present in the solution at a concentration sufficient to specifically alter the signal transduction activity in response to CRF in cells expressing CRF receptors in vitro
  • preferred cells for this purpose are those that express high levels of CRF receptors (i.e., equal to or greater than the number of CRF1 receptors per cell found in differentiated IMR-32 human neuroblastoma cells), with IMR-32 cells being particularly preferred for testing the concentration of a compound required to alter the activity of CRF 1 receptors.
  • This method includes altering the signal transduction activity of CRF receptors in vivo, e.g., in a patient given an amount of a compound of Formula I that would be sufficient to alter the signal transduction activity in response to CRF in cells expressing CRF receptors in vitro.
  • the amount of a compound that would be sufficient to alter the signal transduction activity in response to CRF of CRF receptors may also be determined via an assay of CRF receptor mediated signal transduction, such as an assay wherein the binding of CRF to a cell surface CRF receptor effects a changes in reporter gene expression.
  • the present invention also pertains to packaged pharmaceutical compositions for treating disorders responsive to CRF receptor modulation, e.g., eating disorders, depression or stress.
  • the packaged pharmaceutical compositions include a container holding a therapeutically effective amount of at least one CRFl receptor modulator as described supra and instructions for using the treating disorder responsive to CRFl receptor modulation in the patient.
  • the compounds herein described may have one or more asymmetric centers or planes.
  • Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in ' the art how to prepare optically active forms, such as by resolution of racemic forms (racemates), by asymmetric synthesis, or by synthesis from optically active starting materials. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.
  • any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
  • a group is shown to be substituted with 0-2 R * , then said group may optionally be substituted with up to two R groups and R * at each occurrence is selected independently from the definition of R .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Formula I includes, but is not limited to, compounds of Formula I, IA, and II-XXII.
  • various substituents of the various formulae are "optionally substituted", including Ar 1 , Ar 2 , R l , R 2 , and R 3 of Formula I and subformulae thereof, and such substituents as recited in the sub-formulae such as Formula I and subformulae.
  • substituted means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogens on an atom are replaced.
  • the present invention is intended to include all isotopes (including radioisotopes) of atoms occurring in the present compounds.
  • substituents such as Ar, Ri, R , R 3 , R 4 , and R5 When substituents such as Ar, Ri, R , R 3 , R 4 , and R5 are further substituted, they may be so substituted at one or more available positions, typically 1 to 3 or 4 positions, by one or more suitable groups such as those disclosed herein.
  • suitable groups that may be present on a "substituted" Ar, R la R 2 , R 3 , R4, and R 5 or other group include e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C ⁇ -C 6 alkarioyl group such as acyl or the like); carboxamido; alkyl groups (including cycloalkyl groups, having 1 to about 8 carbon atoms, preferably 1, 2, 3, 4, 5, or 6 carbon atoms); alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8,
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, /-propyl, n-butyl, s- butyl, t-butyl, n-pentyl, and j-pentyl.
  • Preferred alkyl groups are C 1 -C 10 alkyl groups.
  • Especially preferred alkyl groups are methyl, ethyl, propyl, butyl, and 3-pentyl.
  • d- 4 alkyl as used herein includes alkyl groups consisting of 1 to 4 carbon atoms, which may contain a cyclopropyl moiety. Suitable examples are methyl, ethyl, and cyclopropylmethyl.
  • carbhydryl refers to both branched and straight-chain hydrocarbon groups, which are saturated or unsaturated. In other words, a carbhydryl group may be alkyl, alkenyl or alkynyl. The number of carbon atoms may be specified as indicated above.
  • Cycloalkyl is intended to include saturated ring groups, having the specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Cycloalkyl groups typically will have 3 to about 8 ring members.
  • alkyl In the term "(C 3 -C 7 cycloalky ⁇ )C ⁇ -C 4 alkyl", cycloalkyl, and alkyl are as defined above, and the point of attachment is on the alkyl group. This term encompasses, but is not limited to, cyclopropylmethyl, cyclohexylmethyl, and cyclohexylmethyl.
  • Alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more unsaturated carbon-carbon bonds, which may occur. in any stable point along the chain, such as ethenyl and propenyl. Alkenyl groups typically will have 2 to about 8 carbon atoms, more typically 2 to about 6 carbon atoms.
  • Alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more carbon-carbon triple bonds, which may occur in any stable point along the chain, such as ethynyl and propynyl. Alkynyl groups typically will have 2 to about 8 carbon atoms, more typically 2 to about 6 carbon atoms. carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds. "Haloalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms.
  • haloalkyl examples include, but are not limited to, mono-, di-, or trifluoromethyl, mono-, di-, or tri-chloromethyl, mono-, di-, tri-, terra-, or penta-fluoroethyl, and mono-, di-, tri-, tetra-, or penta-chloroethyl.
  • Typical .haloalkyl groups will have 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
  • Alkoxy represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, /-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, 77-hexoxy, 2-hexoxy, 3-hexoxy, and 3- methylpentoxy.
  • Alkoxy groups typically have 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
  • Halolkoxy represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • alkylthio includes those groups having one or more thioether linkages and preferably from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
  • alkylsulfinyl includes those groups having one or more sulfoxide (SO) linkage groups and typically from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
  • SO sulfoxide
  • alkylsulfonyl includes those groups having one or more sulfonyl (S0 2 ) linkage groups and typically from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
  • alkylamino includes those groups having one or more primary, secondary and/or tertiary amine groups and typically from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
  • Halo or "halogen” as ' used herein refers to fluoro, chloro, bromo, or iodo; and "counter-ion” is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
  • carrier group is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13-membered bicyclic or tricyclic group, any of which may be saturated, partially unsaturated, or aromatic.
  • examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctanyl, [4.3.0]bicyclononanyl, [4.4.0]bicyclodecanyl, [2.2.2]bicyclooctanyl, fluorenyl, phenyl, naphthyl, indanyl, and tetrahydronaphthyl.
  • heterocyclic group is intended to include saturated, partially unsaturated, or unsaturated (aromatic) groups having 1 to 3 (preferably fused) rings with 3 to about 8 members per ring at least one ring containing an atom selected from N, O or S.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized
  • heterocycloalkyl is used to refer to saturated heterocyclic groups having one or more non- carbon ring atoms (e.g., N, O, S, P, Si, or the like) and a specified number of carbon atoms.
  • a C 3-9 heterocycloalkyl is a cyclic group having between 3 and 9 ring carbon atoms and at least one ring heteroatom.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized.
  • aromatic heterocyclic system is intended to include any stable 5 -to 7-membered monocyclic or 10- to 14-membered bicyclic heterocyclic aromatic ring system which comprises carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 2, more preferably not more than 1.
  • heterocycles include, but are not limited to, those exemplified elsewhere herein and further include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, NH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3-Z>]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, l ⁇ -indazolyl,
  • Preferred heterocyclic groups include, but are not limited to, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, and imidazolyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. '
  • carbocyclic aryl includes groups that contain 1 to 3 separate or fused rings and from 6 to about 18 ring atoms, without hetero atoms as ring members.
  • Specifically preferred carbocyclic aryl groups include phenyl, and naphthyl including 1-napthyl and 2-naphthyl.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof, and further refers to pharmaceutically acceptable prevail solvates of such compounds and such salts.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, malefic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, pxalic, isethionic, HOOC-(CH 2 )n-COOH where n is 0-4, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, p. 1418 (1985).
  • Prodrugs are intended to include any compounds that become compounds of Formula I when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Formula I.
  • terapéuticaally effective amount of a compound of this invention means an amount effective, when administered to a human or non-human patient, to provide a therapeutic benefit such as an amelioration of symptoms, e.g., an amount effective to antagonize the effects of pathogenic levels of CRF or to treat the symptoms of stress disorders, affective disorder, anxiety or depression.
  • the compounds of general Formula I may be administered orally, topically, transdermally, parenterally, by inhalation or spray or rectally or vaginally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrathecal and like types of injection or infusion techniques.
  • a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier.
  • One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.
  • compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or yrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and abso ⁇ tion in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long- chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monoole
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p- hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl p- hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl p- hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl p- hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for " example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally- occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
  • the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable dilutent or solvent, for example as a solution in 1,3-butanediol.
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of general Formula I may also be administered in the form of suppositories, e.g., for rectal administration of the drug.
  • suppositories e.g., for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at body temperature and will therefore melt in the body to release the drug.
  • suitable non-irritating excipient include cocoa butter and polyethylene glycols.
  • Compounds of general Formula I may be administered parenterally in a sterile medium.
  • the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
  • one or more adjuvants such as preservatives, buffering agents, or local anesthetics can also be present in the vehicle.
  • Dosage levels of the order of from about 0.05 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions, preferred dosages range from about 0.1 to about 30 mg per kg and more preferably from about 0.5 to about 5 mg per kg per subject per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 0.1 mg to about 750 mg of an active ingredient. Frequency of dosage may also vary depending on the compound used and the particular disease treated.
  • a dosage regimen of four times daily, preferably three times daily, more preferably two times daily and most preferably once daily is contemplated.
  • a dosage regimen of 1 or 2 times daily is particularly preferred.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination (i.e. other drugs being used to treat the patient) and the severity of the particular disease undergoing therapy.
  • Preferred compounds of the invention will have certain pharmacological properties.
  • Such properties include, but are not limited to oral bioavailability, such that the preferred oral dosage forms discussed above can provide therapeutically effective levels of the compound in vivo. Penetration of the blood brain barrier is necessary for most compounds used to treat CNS disorders, while low brain levels of compounds used to treat periphereal disorders are generally preferred.
  • Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes may be used to predict compound toxicity, with non-toxic compounds being preferred. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of the compound in laboratory animals given the compound, e.g., intravenously.
  • Percentage of serum protein binding may be predicted from albumin binding assays. Examples of such assays are described in a review by Oravcova, et al. (Journal of Chromatography B (1996) volume 677, pages 1-27). Preferred compounds exhibit reversible serum protein binding. Preferably this binding is less than 99%, more preferably less than 95%, even more preferably less than 90%, and most preferably less than 80%.
  • Frequency of administration is generally inversely proportional to the in vivo half-life of a compound.
  • In vivo half-lives of compounds may be predicted from in vitro assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and
  • preferred compounds of the invention exhibit good activity in standard in vitro CRF receptor binding assays, preferably the assay as specified in Example 51, which follows.
  • References herein to "standard in vitro receptor binding assay” are intended to refer to standard assay protocols such as that protocol defined in Example 51, which follows.
  • Generally preferred compounds of the invention have an IC 50 (half-maximal inhibitory concentration) of about 1 micromolar or less, still more preferably and IC 50 of about 100 nanomolar or less even more preferably an IC5 0 of about 10 nanomolar or less or even 1 nanomolar or less in such a defined standard in vitro CRF receptor binding assay as exemplified by Example 51 which follows.
  • the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.
  • Preferred methods include but are not limited to those methods described below.
  • Each of the references cited below are hereby incorporated herein by reference.
  • Preferred methods for the preparation of compounds of the present invention include, but are not limited to, those described in Scheme I. Those who are skilled in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention.
  • R 2 1 -Matrix, R 2 2 -Matrix, Het-Matrix, and Ar-Matrix tables below set forth a number of compounds of the invention which are prepared by the methods illustrated in Reaction Schemes I- VII shown above.
  • Compounds are formed by combining any element from the R 2 1 Matrix or R 2-Matrix with any element from the Het-matrix to form an R 2 l-Het or R 2 2 moiety, and then combining this moiety with any element of the Ar-Matrix to form a compound of the invention.
  • the combination of element 101 from the R 2 1- Matrix, with element 408 from the Het-matrix gives the moiety 101408.
  • Mobile phase A 95% Water, 5% Methanol with 0.05% Formic acid
  • Mobile phase B 95% methanol, 5% Water with 0.025% Formic acid
  • MS conditions Electrospray positive ionization; capillary voltage 3.5kV; cone voltage 30V; desolvation and source temperature 250 °C and 100 °C respectively; mass range 120-800 with a scan time of 0.5 seconds and an inter scan delay of 0.1 min.
  • a Perkin Elmer HPLC system (tow Series 200 micro LC pumps, pump A and pump B, with a Series 200 autosampler) is used to perform flow injection.
  • Mobile phase is a combination of 85% methanol (pump B) with 15% of water (pump A).
  • the flow rate is 1.0 mL/min; and the injection volume is 3 ⁇ L.
  • MS instrumentation LC-MS experiments are. performed using a Sciex 150MA Mass Spectrometer.
  • the Nebulizer gas is 10, and ' the Curtain gas is 12.
  • the declustering potential is 30 V.
  • the Focusing potential is 200 V, and the entrance potential is -10 V.
  • Nebulizer current is -2.0 mA, and the temperature is 350 °C.
  • the Nebulizer gas is 10, and the Curtain gas is 12.
  • the declustering potential is -30 V.
  • the Focusing potential is -200 V, and the entrance potential is 10 V.
  • HPLC conditions Synergi 2U HYDRO-RP 20 x 4.0mm column, flow rate 1.0 mL/min, injection volume 5 ⁇ L.
  • Trifluoro-methanesulfonic acid 4-methoxy-pyridin-2-yl ester (0.5g) and dimethylamine (2.4 mL of 2M in THF) are dissolved in DMSO (7mL) and warmed overnight at 40°C.
  • EtOAc is added to the reaction mixture and it is washed with brine solution.
  • the organic phase is separated, dried, and evaporated under vacuum.
  • Silica gel purification gives (4- methoxypyridin-2-yl)dimethylamine. It is used in the next step without further purification.
  • Step C N-Bromosuccinimide (1.75g) is added portionwise to a solution of (4-methoxy-pyridin-2- yl)dimethylamine (1.5g) at 0°C in chloroform (30 mL). After 30 min water (4 mL) is added to the reaction mixture and it is extracted three times with methylene chloride. The combined organic phase is separated, dried and evaporated under vacuum. Silica gel purification gives (5-bromo-4-methoxy-pyridin-2-yl)dimethylamine. LCMS: Rt 1.20 min m/z 231.03(M+H) + .
  • step A The crude mixture from step A is dissolved in chloroform (150mL) and cooled to 0 °C. Addition of NBS (6.50g, in three portions) is followed by stirring for 15min. The light yellow solution is then put into a mixture of water (500mL) and sat. sodium bicarbonate (lOOmL). Extraction with DCM (3xl50mL) and drying over magnesium sulfate yields a crude mixture that is purified on silica gel. LCMS: m/z 257.10 (M+H) +
  • Step C t-BuLi (50.1mL, 1.7N in pentanes) is added to THF (200mL) at -78 °C. Slow addition of the purified material from step B (7.3 lg, in 30mL of THF) is followed by stirring for 15 min at - 78 °C. Upon LCMS check for unreacted bromide, triisopropyl borate (26.2mL) is added and the reaction mixture is warmed to room temperature over night. The yellowish solution is then put into a mixture of water (1 OOOmL) and sat. sodium bicarbonate (lOOmL). Extraction with DCM (3x300mL) and drying over magnesium sulfate yields a crude material of good purity that can be used directly in palladium mediated couplings. LCMS: m/z 223.19 (M+H) +
  • 2-Isopropyl-6-methoxypyridine (191.4g) and TMEDA (146.3g) are dissolved in diethyl ether (1565 mL) and cooled to -60°C.
  • n-BuLi 760 mL of 2M
  • the reaction mixture is allowed to warm to room temperature over 3.5 hours.
  • the reaction mixture is chilled again to -60°C, triisopropylborate (476.2g) is added and stirring is continued for 24 hours.
  • 3M HCI is then added (510 mL), followed by water (2500 mL).
  • the aqueous phase is separated and the organic layer is washed three times with 5% aqueous NaCI (1500 mL).
  • 3-Trifluoromethoxyphenol (256.42g) is dissolved in dichloromethane (2000 mL) and cooled to 5-10°C under nitrogen. Bromine (241.6g) is added dropwise over 2 hours, maintaining the temperature between 5-10°C and then the cooling bath is removed. Water (1000 mL) is added and the mixtue is stirred for 10 minutes and separated. More water is added to the organic phase (500 mL) followed by powdered sodium carbonate (10-12g) until the pH is 10-
  • Step C n-Butyllithium (156 mL of 2.5 M solution in hexanes) is added under nitrogen to THF (800 mL) over a period of 5 min while maintaining the temperature between -77 and -67 °C.
  • 2- Methoxy-4-trifluoromethoxy bromobenzene (lOOg) is added over a 10-min period while maintaining the temperature between -76.0 and-62°C.
  • Trimethylborate (53.8 g) is added over 10 min at a temperature of -76.3 to -63.2°C. After 1 hour, 200 ml of 2 N hydrochloric acid (200 mL) is added to pH 1.
  • Step A Commercially available 2-chloro-6-methoxypyridine is transformed into the ethyl compound as described for the corresponding 2-isopropyl-6-methoxypyridine.
  • step B The crude mixture (30. lg) of step B is dissolved in THF (300mL) and treated with 1,3- dibromo-5,5-dimethylhydantoine (1.0-1.2eq, in portions). Once TLC control shows completed conversion of the starting material the addition of the hydantoine is stopped and the mixture is put into water (IL). Extraction with DCM (3x300mL), drying over magnesium sulfate, and purification on silica gel affords the bromide. LCMS: m/z 215.97 (M+H) +
  • step A The ether of step A (960mg), tributyltin hydride (1.28g), and ABFN (218mg) are dissolved in toluene (20mL) and heated to 95 °C for 26h. The resulting mixture is put into water (300mL) and sat. sodium bicarbonate (30mL). Extraction with DCM (3xl00mL), drying over magnesium sulfate, and purification on silica gel yields the bicyclus. LCMS: m/z 164.13 (M+H) +
  • LCMS m/z 209.14 (M+H) +
  • step C The nitro compound (622mg) of step C is dissolved in methanol (20mL). Reduction is achieved by adding a catalytic amount of Pd/C (10%) and maintaining a hydrogen atmosphere (normal pressure) for 90min. Filtration through celite (lOg) and concentration affords a crude mixture that is directly used in step E.
  • LCMS m/z 179.1 1 (M+H) + ..
  • step D The crude mixture of step D (459mg) is dissolved in acetic acid (lOmL) and then cooled to 0 °C to yield a semi frozen mixture. Bromine (0.139mL) is slowly added and the reaction is stirred for another 5 min before being put into sat. sodium bicarbonate (100ml) and IN sodium sulfite solution (20mL). Extraction with DCM (3xl00mL), drying over magnesium sulfate, and purification on silica gel affords the bromide. LCMS: m/z 256.98 (M+H) +
  • step E The amino bromide (500mg) of step E is dissolved in a solution of sulfuric acid in methanol (lOmL, 15% sulfuric acid) and then cooled to 0 °C. After addition of sodium nitrite (268mg), the solution is allowed to warm to rt over a period of 16h. After being put into sat. sodium bicarbonate (lOOmL), the aqueous layer is extracted with DCM (3xl00mL) and dried over magnesium sulfate. Purification on silica gel affords the methoxy bromide. LCMS: m/z 272.00 (M+H) +
  • 3-Bromo-6-ethyl-5-methanesulfonyl-pyridin-2-ylamine (7.88g) ' is dissolved in H 2 S0 -H 0 (ratio 1:6) (175ml) and the mixture is cooled to 0 °C. After adding the solution of NaN0 2 (4.1g) in 15 ml H 2 0 dropwise (keep inner temperature below 5 °C), the mixture is stirred at 0 °C to room temperature for overnight. The desired product 3-bromo-6-ethyl-5- methanesulfonyl-pyridin-2-ol is collected by filtration following by washing with water (50 ml). This crude product is used for next step without further purification, m/z 280.0 (M+H) + .
  • Step D A mixture of 3-bromo-6-ethyl-5-methanesulfonyl-pyridin-2-ol (15.84g) and DMF (200ml) is cooled to 0 °C, and K 2 C0 3 (11.71g) is added, followed by ethyl iodide (11.3ml). The resulting mixture is stirred at 0 °C to room temperature for overnight. After the reaction is complete, water is added and the resulting mixture is extracted with EtOAc (3x200ml). The combined organic layers are washed with brine, dried over Na 2 S0 4 and evaporated. The pure product 3-bromo-2-ethoxy-6-ethyl-5-methanesulfonyl-pyridine is obtained after column chromatography. m/z 282.1 (M+H-Et) + .
  • 5-Bromo-6-ethyl-pyridin-2-ylamine (34g) is added to cH 2 S0 4 (110 mL) below 10 °C.
  • HN0 3 (8.2 mL) below 15 °C over 40 min.
  • the mixture is stirred at 0 °C for 1 h, at RT for 1 h and finally at 50 °C for 1 h.
  • the mixture is poured into ice-water and is basified by 50 % NaOH. Yellow crystals are collected by filtration, washed with water and dried under reduced pressure to give 5-bromo-6-ethyl-3-nitro-pyridin-2-ylamine.
  • Step C To a stirred suspension of 5-bromo-6-ethyl-3-nitro-pyridin-2-ylamine (5 g) in AcOH (20 mL) is added 48 % HBr (20 mL) below 10 °C. Bromine (2.92 mL) is added to the mixture below 10 °C over 15 min. At 0°C, a solution of NaN0 2 in water (3.65 g, 15 mL) is added over 20 min below 15 °C. The mixture is stirred at 0 °C for 30 min and at RT for lh. The mixture is cooled to 0 °C, neutralized by 50 % of NaOH, and extracted with DCM.
  • Step E To a solution of (5-bromo-6-ethyl-3-nitro-pyridin-2-yl)-isopropyl-amine (1 g) in EtOH (4 mL) is added cone. HCI (0.05 mL), water (1 mL) and reduced iron (3 g) at RT. The mixture is refluxed for 90 min. The iron residue is removed by filtration and is washed with EtOH. The combined filtrates are concentrated under reduced pressure. To the residue is added water and the mixture is extracted with EtOAc. The combined extracts are washed with brine and dried over MgS0 .
  • Step F 5-Bromo-6-ethyl-N*2*-isopropyl-pyridine-2,3-diamine (1 g) is dissolved in diethoxymethylacetate (4 mL) and is heated at 120 °C for 90 min. After cooling to RT the mixture is directly purified by flash column chromatography on silica gel to give 6-bromo-5- ethyl-3-isopropyl-3H-imidazo[4,5-b]pyridine as colorless oil.
  • Step B To a solution of 7-bromo-6-ethyl-4-isopropyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (0.2 g) in DMSO (4 mL) is added bis(pinacolate)diborane (0.2 g), KOAc (0.19 g) and PdCl 2 (dppf)-DCM complex (29 mg) at RT.
  • step A The product (205mg) of step A is dissolved in chloroform (lOmL) and NBS (99mg) is added. After being stirred for 10 min, the yellowish mixture is put into water (lOOmL), extracted- with DCM (3xlO0mL), and dried over magnesium sulfate. Purification on silica gel affords the bromide.
  • Step C The bromide (173mg) of step B and allyl bromide (0.33mL) are dissolved in DMF (5mL). Sodium hydride (lOOmg) is added and the reaction is stirred for lOmin at rt. The mixture is then put into water (lOOmL) and extracted with ethyl ether (2xl00mL). The combined organic layers are washed with water (50mL), dried over magnesium sulfate, and purified on silica gel to afford the allylated amino-compound.
  • LCMS m/z 488.11 (M+H) +
  • allyl compound (138mg) of step C tetrabutylammonium bromide (91mg), palladium acetate (6.4mg), and potassium carbonate (117mg) are dissolved in DMF (5mL). After heating to 80 °C for 90 min, the mixture is worked-up according to step C. Final purification on silica gel affords the title compound.
  • allyl compound (23.36g) of step B tetrabutylammonium bromide (19.00g), palladium acetate (1.32g), and potassium carbonate (24.8g) are dissolved in DMF (200mL). After heating to 80 °C for 20 min, the mixture is put into water (500mL) and extracted with ethyl acetate/hexane (1/4, 3x300mL). The combined organic layers are washed with water (lOOmL), dried over magnesium sulfate, and purified on silica gel to afford the Heck-product.
  • LCMS m/z 316.01 (M+H) +
  • step C (1.5g) and the previously described 2-dimethylamino-4-ethyl-5- pyridine boronic acid (1.38g) are dissolved in DME (30mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (550mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (9.5mL) whereupon the reaction is heated to 80 °C for 16h. The yellowish mixture is then put into water (200mL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 386.20 (M+H) +
  • Step C The above methanesulfonate (120mg) from step A, Lil (150mg) and methylamine (7M in NMP, 2mL) are heated at 90 °C for 4h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc (2x15mL), and dried over sodium sulfate. Purification on silica gel affords ⁇ 2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2, 3-b]pyrazin-5-yl]-butyl ⁇ -methyl-amine. LCMS: m/z 383.3 (M+H) +
  • Step B The above methanesulfonate (95mg), Lil (50mg) and morpholine (0.35mL) are heated at 90 °C for 4h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc (2x15mL), and dried over sodium sulfate. Purification on silica gel affords (R)-2-(6- isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-(l-morpholin-4-ylmethyl-propyl)-5H- pyrrolo[2,3-b]pyrazine. LCMS: m/z 438.5 (M+H) +
  • Step D The above triflate (270mg) is dissolved in toluene (5mL). After lOmin of degassing, tetrakis(triphenylphosphine)palladium(0) (35mg) is added, followed by 1 min of degassing. Upon addition of triethylborane (IN in hexane, 1.8 mL), aqueous IN sodium carbonate solution (1.2mL) andLiCl (125mg), the reaction mixture is heated at 110 °C for 6h. Subsequently, the crude mixture is put into water (lOOmL), extracted with EtOAc/hexane (1:4, 3x20mL), and dried over sodium sulfate.
  • Step A To a solution of the above nitro compound (2.63g) in ether (30mL) is added SnCl x2H 2 0 (6.54g) in cone. HCI (20mL)) dropwise at room temperature. After the addition is completed, the reaction mixture is stirred at room temperature for lh. The reaction mixture is basified with ION NaOH (cooled with ice-bath) to pH 9-10. After extracting with ether (200mLx3), the combined ether-layers are dried over Na 2 S0 to give a crude mixture that is used in step B without any further purification.
  • Step B To a solution of the crude product (166mg) from step A in DMSO (2ml) is added NaH (60%, 60mg). The reaction mixture is stirred at rt for 2h, followed by addition of 3-bromopentane (226mg). After being stirred at rt for 30min, the yellowish mixture is quenched with water and extracted with EtOAc. The organic layer is washed with water twice, then brine to be finally dried over Na 2 S0 . The crude product is purified on silica gel.
  • Step C To a solution of the alkylation product of step B (403mg) in NMP (2mL) and tetrabutylammonium bromide (cat.) is added NaH (60%, 120mg). The reaction mixture is stirred at rt for 2h followed by addition of allyl bromide (2 eq.). After being stirred at 60 °C for 3h, the mixture is quenched with water, extracted with EtOAc, and dried over Na 2 S0 . The crude product is purified on silica gel.
  • Step D A mixture of the allylamine of step C (lOOmg), Pd(OAc) 2 (5.1mg), tetrabutylammonium bromide (72.9mg), and K 2 C0 3 (93mg) in DMF (3mL) is degassed and then heated to 80 °C overnight. The mixture is subsequently quenched with water, extracted with EtOAc, and dried over Na 2 S0 . Purification on silica gel yields the title compound.
  • step A To a solution of the chloro compound froni step A (20g) in ethanol (300mL) is added SnCl 2 x2H 2 0 (132g) portionwise. After the addition is completed, the mixture is stirred for an additional 2h at 50 °C before the solvent is removed under reduced pressure. DCM (400mL) is added and the suspension is neutralized with ION NaOH and then filtered through celite. The filtrate is washed with water, brine, and finally dried over MgS0 to yield the amine. The crude mixture is used in step C without any further purification.
  • Step C To a solution of the amine (13.5g) from step B in NMP (80mL) is added tetrabutylammonium bromide (0.3g) and NaH (60%, 7.6g) at 0 °C. After being stirred at rt for 3h, 3-bromopentane (1.5 eq.) is added. The reaction mixture is then stirred for an additional 2h before being quenched with water and extracted with EtOAc. The organic layer is washed with water, brine, and dried over MgS0 . Evaporation under reduced pressure yields a crude product which is used in step D without any further purification.
  • Step D The crude material of step C (3.0g) is dissolved in CHC1 3 (20mL) and NBS (2.63g) is added at room temperature. After being stirred at rt for 30 min, the reaction mixture is washed with water, brine, and dried over Na 2 S0 4 before it is purified on silica gel to yield the bromide.
  • step D To a solution of the bromide from step D (3.66g) in NMP is added tetrabutylammonium bromide (O.lg) and NaH (60%, 1.0g) at rt. After being stirred at rt for 3h, allyl bromide (3.0g) is added and the reaction mixture is stirred for an additional 4h. The reaction mixture is then quenched with water and extracted with EtOAc. The organic layer is washed with water, brine, and dried over MgS0 to yield a crude product, which is used in step F without any further purification.
  • tetrabutylammonium bromide O.lg
  • NaH 50%, 1.0g
  • step E The crude material of step E (4.1g), Pd(OAc) 2 (275mg), tetrabutylammonium bromide (4.5g), and K 2 G0 3 (5.1g) are dissolved in DMF (20mL). After degassing, the mixture is heated to 80 °C overnight. The black solution is then diluted with EtOAc before being washed with H 2 0, brine, and dried over MgS0 . Purification on silica gel yields the bicyclic compound.
  • step F The bicyclic material of step F (118mg), Pd(PPh 3 ) 4 (70mg) and the previously described 4- ethyl-2-ethylmethylamino-3-pyridine boronic acid (104mg) are dissolved in toluene (lOmL). Upon addition of 2N Na 2 C0 3 (4mL), the mixture is degassed and then heated overnight to 80 °C. Subsequently, the mixture is diluted with EtOAc and washed with H 2 0, brine, and finally dried over MgS0 4 . Purification on silica gel yields the title compound.
  • step A The Suzuki-product of step A (718mg) is dissolved in 3N HCI (50mL) and heated to 70 °C overnight. The reaction mixture is cooled to ambient temperature, neutralized with 2N NaOH, and extracted with CHC1 3 (100mLx2). Drying over MgS0 4 yields the pyridone, which is used in step C without any further purification.
  • step B The pyridone (700nig) of step B is dissolved in CH 2 C1 2 . Triethylamine (3 eq.) is added, followed by dropwise addition of Tf 2 0 (1.5 equivalents) at 0 °C. After being stirred at rt for 2h, the reaction mixture is washed with H 2 0, brine, and dried over MgS0 4 . The triflate is used in step D without any further purification.
  • Step D The crude material of step C (48mg), Pd(PPh 3 ) 4 (11.5mg), and triethylborane (0.5mL, IN in hexane) are dissolved in toluene (2mL). After addition of 2N Na 2 C0 3 (0.5mL), the mixture is degassed and then heated at 85 °C overnight. The solution is diluted with EtOAc and washed with 2N NaOH, H 2 0, brine, and finally dried over MgS0 4 . Purification on silica gel yields the title compound.
  • Step B A mixture of bromide (9.63g, 0.03mol), allylamine(6.75ml), BINAP(1.5g), Pd 2 (dba) 3 (1.0g), Na0-t-Bu(5.77g) in toluene (150ml) is heated at 100 °C under N 2 atmosphere overnight. The reaction mixture is cooled to room temperature and quenched with water. The resulting mixture is separated and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 298.3 (M+H) +
  • Step D A mixture of bromide (6.6g), tetrabutylammonium bromide(7.07g), K 2 C0 3 (7.28g),
  • a mixture of triflate(180mg), LiCl(84mg), Pd(PPh 3 ) 4 (23mg), Na 2 CO 3 (1.0M in water, 1ml), B(C 2 H 5 ) 3 (1.0M in hexane, 1.5ml) in toluene(2ml) is heated at 100 °C in sealed tube for 2 hours.
  • the resulting mixture is cooled to room temperature and extracted with ethyl acetate.
  • the combine organic layers are washed with brine and dried with Na 2 S0 .
  • Triflate (230mg) is taken in anhydrous N-methylpyrrolidinone (2ml), CH 3 ⁇ H 2 is added as a solution of NMP (-5.5M, 2ml). The resulting mixture is heated at 85°C in a sealed tube overnight. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na 2 S0 4 .
  • Step J Triflate (420mg) is taken in anhydrous N-methylpyrrolidinone (3ml), C 2 H 5 ⁇ H 2 is added as a solution of THF (2.0M, 2ml). The resulting mixture is heated at 85 °C in a sealed tube overnight. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na S0 4 .
  • Step G Starting material (1.15g, 3mmol) is taken in anhydrous methylene chloride (50ml) followed by the addition of [Bis(2-methoxyethyl)amino]sulfur trifluoride (2 equiv.) at room temperature. The reaction is stirred at room temperature overnight. The reaction mixture is carefully quenched with ice-water. The resulting mixture is separated and extracted with methylene chloride and dried with Na 2 S0 .
  • Step A 2-Amino-5-bromo-3,4-dimethylpyridine (201 mg) in H 2 S0 4 (2.5N, 2.4mL) is cooled to 0 °C and subsequently treated dropwise with sodium nitrite (104mg) in H 2 0 (1 mL). The solid is collected and washed with H 2 0 and dried to afford 2-hydroxy-5-bromo-3,4-dimethylpyridine.
  • LCMS m/z 202.2 and 204.2 (M+H) + Step B
  • Step F 3- ⁇ 6-bromo-5-[(S)-2-methoxy-l-methyl-ethylamino]-3,4-dimethyl-pyridin-2-yl ⁇ -2-methoxy- 6-isopropylpyridine (2.0 g) is dissolved in NMP (15 ml). Upon addition of NaH (60%, 380mg), the reaction mixture is stirred at 25 °C for 30 min before allyl bromide (0.82 mL) is added. The reaction mixture is then heated to 50 °C overnight. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc/hexane (1:4, 2x50mL), and dried over sodium sulfate.
  • Step G 3- ⁇ 6-bromo-5-[(S)-N-allyl-2-methoxy-l-methyl-ethylamino]-3,4-dimethyl-pyridin-2-yl ⁇ -2- methoxy-6-isopropylpyridine (0.75g) is dissolved in DMF (6mL). After lOmin of degassing, Pd(OAc) 2 (36mg) is added, followed by 1 min of degassing. Upon addition of potassium carbonate (670 mg) and Bn NBr (650mg), the reaction mixture is heated to 90 °C for 2h. Subsequently, the crude mixture is put into water (lOOmL), extracted with EtOAc/hexane (1 :2, 3x50mL), and dried over sodium sulfate. Purification on silica gel affords 5-(6-
  • step B The amino compound of step B is dissolved in chloroform (200mL) and NBS (0.9-1.0 eq) is added in portions until TCL control verifies full conversion of the starting material. Subsequently, the yellowish mixture is put into water (200mL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the bromide.
  • Step E 5 The allyl compound (7.89g) of step D, tetrabutylammonium bromide (5.85g), palladium — - acetate f (0.41g), and potassium carbonate (7.53g) are dissolved in DMF (150mL). After heating to 80 °C for 30 min, the mixture is worked-up according to step D. Final purification on silica gel affords the title compound. . LCMS: m/z 354.39.(M+H) + 0 EXAMPLE 16
  • Step B The triflate (50mg) of step A and cyclopropyl boronic acid (91mg) are dissolved in toluene (5mL). After being degassed for 5 min, tetrakis(triphenylphosphine)palladium (0) (12mg) is added and the mixture is degassed again. Adding a potassium carbonate solution (0.50mL, 2N) is followed by heating to 110 °CTor 16h. Subsequently, the mixture is put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over -magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 364.45-(M+H) +
  • step A The triflate (lOOmg) of step A is dissolved in a 5N NMP-solution of dimethylamine (1.50mL) and subsequently heated to 80 °C for 8h. The reaction mixture is then put into water (1 OOmL); extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the title compound.
  • Step G To a solution of (3S,4R)-3-hydroxy-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester (1.88 g) in DMF (15 mL) is added sodium hydride (0.44 g) and bromofluoroethane (0.82 mL) at RT. After stirring at RT for 2.5 h, the mixture is poured into ice-water and is extracted with EtOAc. The combined extracts are washed with brine and are dried over MgS0 .
  • Step C To a solution of ((S)-2 -m ethoxy- 1 -methyl-ethyl)-[6-(2-methoxy-4-trifluoromethoxy-phenyl)- 5-methyl-pyridin-3-yl]-amine (1 g) in chloroform (5 mL) is added NBS (0.48 g) at RT. After stirring at RT for 5 min, the mixture is directly purified by flash column chromatography on silica gel to give [2-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]- ((S)-2-methoxy-l-methyl-ethyl)-amine as white solid.
  • Step F To a solution of give [2-ethynyl-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin- 3-yl]-((S)-2-methoxy-l-methyl-ethyl)-amine (0.1 g) in NMP (3 mL) is added tBuOK (28 mg) at RT. The mixture is stirred at 80 °C for lh. The mixture is diluted with EtOAc and is washed with water and brine. After drying over MgS0 4 , the solvent is evaporated.
  • Step G To a solution of l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy- phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine (65 mg) in chloroform (2 mL) is added NBS (32 mg). The mixture is stirred at RT for 30 min and is diluted with EtOAc. The mixture is washed with water and brine and dried over MgS0 .
  • Step C To a stirred solution of 5-(6-isopropyl-2 -methoxy -pyridin-3-yl)-l-((S)-2 -methoxy- 1-methyl- ethyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine-3-carbaldehyde (0.13 g) in DCM (3 mL) is added hydroxylamine hydrochloride (36 mg) and Et N (0.07 mL) at RT. The mixture is stirred at RT for 2 h and is diluted with EtOAc. The mixture is washed with water and dried over MgS0 .
  • Step A A mixture of 2,5-dibromo-3-methyl pyridine (40g), 2-methoxy-4-trifluoromethoxy-l- phenylboronic acid (39.5g) and 2M K 2 C0 3 (159ml) in toluene (300ml) is degassed with N 2 for 2 min, followed by addition of Pd(PPh 3 ) 4 (5.5g). The resulting mixture is stirred at 85 °C under N for overnight. After reaction is complete, the mixture is poured into water (300ml) and extracted with ethyl acetate (3x150ml). The combined organic layers are washed with brine, dried over Na S0 and evaporated.
  • Step C 257mg of [(S)-l-(terr-Butyl-dimethyl-silanyloxymethyl)-propyl]-[6-(2-methoxy-4- trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]-amine is dissolved in CHC1 3 (6ml) and NBS (95mg) is added at room temperature. After stirring at room temperature for 10 min, the mixture is diluted with CHC1 3 and washed with H 2 0, brine and dried over Na 2 S0 .
  • Step B A mixture of l-((S)-l-chloromethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine (55mg), KI (15mg) and 0.8 ml pyrrolidine in DMSO (4ml) is heated to 120 °C for 19 h. After starting.material disappears, the mixture is poured into water and extracted with CH 2 C1 2 (3x20ml). The combined organic layers are washed . with brine, dried over Na 2 S0 4 and evaporated.
  • Step E A mixture of allyl-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-(2,6-dibromo-5- ethyl-pyridin-3-yl)-amine (8.3g), tetrabutylammonium bromide (6.0g), K 2 C0 3 (6.99g) in DMF (100ml) is degassed for 3 min, followed by addition of Pd(OAc) 2 . The resulting mixture is stirred at 80 °C for 18 h. After the mixture is complete, the mixture is poured into H 2 0 (200ml), extracted with EtOAc(3xl00 ml).
  • Step F A mixture of 5-bromo-l-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-6-ethyl-3- methyl-lH-pyrrolo[3,2-b]pyridine (2.21g), 2M K 2 C0 3 (5.4ml), and 2-methoxy-6-isopropyl-3- pyridylboronic acid (1.20g) in DME (25 ml) is degassed with N 2 for 2 min, followed by addition of Pd(PPh 3 ) . The resulting mixture is stirred at 85 °C for 16 h before it is poured into water (80ml),- and extracted with EtOAc (3x30ml).
  • Step E A mixture of 5,6-dibromo-l-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-3-methyl- lH-pyrrolo[3,2-b]pyridine (3.66g), 2M K 2 C0 3 (22ml), 2-methoxy-6-isopropyl-3- pyridylboronic acid (1.64g) in DME is degassed with N 2 for 5 min, followed by addition of Pd(PPh 3 ) (444mg). The resulting mixture is allowed to stir at 85 °C for 3.5 h before it is poured into H 2 0 (50ml), extracted with EtOAc (3x40ml).
  • Step G A mixture of (S)-2-[6-bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2- b]pyridin-l-yl]-butan-l-ol (2.0g) in THF (40ml) is added 60% NaH (463mg) and the mixture is stirred at 0 °C for 10 min before Mel (578 ⁇ l) is added. After stirring at room temperature for 3.5 h, the mixture is poured into water (50ml) and extracted with EtOAc(3x30ml). The combined organic layers are washed with brine, dried over Na 2 S0 4 and evaporated.
  • Step H 6-Bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-l-methoxymethyl- propyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine (450mg) in EtOH (30ml) is added 10% Pd/C (200mg) under N 2 and the mixture is shaken under 40 psi H 2 pressure for 48 h. the catalyst is removed by filtering through celite.
  • Step B Crude product from previous step is dissolved in CH 2 C1 (30 ml) and the mixture is cooled to 0 °C, followed by addition of triethylamine (1.11ml) and trifluoromethanesulfonic anhydride (898 ⁇ l). After stirring at room temperature for 3 h, the mixture is poured into H 0 (30 ml) and extracted with EtOAc (3x30ml). The combined organic layers are washed with brine, dried over Na 2 S0 4 and evaporated.
  • Step E A mixture of ⁇ 3-[6-Ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ⁇ -methyl-amine (130mg) in CH 3 CN (5ml) is cooled to 0 °C followed by addition of NBS (61mg). The resulting mixture is stirred at 0 °C for 30 min and then it is diluted with H 2 0 (20ml), extracted with EtOAc(3x25 ml). The combined organic layers are washed with brine, dried over Na 2 S0 4 and evaporated.
  • Step F A mixture of ⁇ 5-bromo-3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ⁇ -methyl-amine (60mg), 2M K 2 C0 3 (lml), cyclopropyl boronic acid (56mg) in toluene (5ml) is degassed with N for 2 min, followed by addition of Pd(PPh 3 ) 4 (15mg).
  • Step G Analogous to the synthesis of trifluoro-methanesulfonic acid 3-(3,6-dimethyl-l-propyl-lH- pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl ester the reaction of 6-isopropyl-3-[6- methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- pyridin-2-ol (200mg) with triflic anhydride (0.1 ImL) in the presence oftriethyl amine (0.136mL) gives, after purification on silica gel trifluoro-methanesulfonic acid 6-isopropyl-3- [6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]
  • Step B Similar to a procedure by Bargar et al. (J. Het Chem 22, 1583, 1985) a stirred suspension of 3-chloro-2-methoxy-pyridine (9.3g) and sodium acetate (5.4g) in glacial acetic acid (30mL) is treated with bromine (6.7mL) dropwise over 15 mins. After the exotherm has subsided, the mixture is heated at 80°C for one hour. The reaction mixture is cooled to room temperature and diluted with ether (200mL) and washed with sodium hydroxide solution (IM) and sodium thiosulphate solution (lOOmL, 2M). The ether layer is dried over magnesium sulfate and evaporated to give 5-bromo-3-chloro-2-methoxy-pyridine. This compound is used without further purification in the next reaction.
  • IM sodium hydroxide solution
  • thiosulphate solution lOOmL, 2M
  • Step C Analogous to the preparation of ((S)-2-methoxy-l-methyl-ethyl)-(5-methoxy-pyridin-3-yI)- amine, the palladium mediated amination of 5-bromo-3-chloro-2-methoxy-pyridine (4.0g) with (S)-l-methoxy-2-propylamine (2.1 mL) affords, after purification on silica gel (5- chloro-6-methoxy-pyridin-3-yl)-((S)-2-methoxy-l -methyl-ethyl)-amine. LCMS: m/z 231.1/233.1 (M+H) + , Rt 2.19 mins.
  • Step M Analogous to the preparation of ethyl- ⁇ 6-isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l- methyl-ethyl)-3-methyl-lH-py ⁇ Olo[3,2-b]pyridin-5-yl]-pyridin-2-yl ⁇ -amine, the reaction of trifluoro-methanesulfonic acid 3-[6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester (85mg) with methyl amine solution in THF (0.9mL, 2M) gives, after purification on silica gel ⁇ 3-[6-chloro-l-((S)-2-methoxy-l- methyl-ethyl)-3-methyl-lH-pyrrolo[
  • N-Chlorosuccinimide 33mg is added to a solution of ⁇ 3-[l-(l-fluoromethyl-2-methoxy- ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ⁇ -methyl-amine (94mg) in chloroform (3mL). After 18 hr additional N-chlorosuccinimide (lOmg) is added and then after a further 5 min water (lOmL) and dichloromethane (lOmL) are added to the reaction mixture.
  • Step F A mixture of 2-bromo-7-(l-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5- methyl-5H-pyrrolo[2,3-b]pyrazine (47 mg, 0.1 mmol), Et 3 B (IM solution in hexane, 0.2 mL, 0.2 mmol) in 2M Na 2 C0 3 (0.5 mL, 1 mmol) and toluene (1 mL) is treated with Pd(PPh 3 ) 4 (10 mg) under nitrogen at 90 °C for 16 h.
  • Step C [3-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-methyl-amine is prepared by the same procedure as described in step A.
  • [3-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-(3-ethyl-pent-2- enyl)-methyl-amine is prepared by the same procedure for [3,5-dibromo-6-(2-methoxy-4- trifluoromethoxy-phenyl)-pyrazin-2-yl]-(3-ethyl-pent-2-enyl)-methyl-amine.
  • Step C The crude allyl compound (116.0g) of step B, tetrabutylammonium bromide (75.3g), palladium acetate (5.2g), and potassium carbonate (97.0g) are dissolved in DMF (1200mL). After being heated to 80 °C for 6h, the mixture is worked-up according to step B. Final purification on silica gel affords the bicyclic compound.
  • step C The bicyclic compound (1.83g) of step C is dissolved in toluene (50mL). . After degassing, tetrakis(triphenylphosphine)palladium (0) (0.67g) is added. A second degassing is followed by addition of triethylborane (28.9mL, IN in hexane) and of a 2N potassium carbonate solution (6.0mL) whereupon the reaction is heated to 80 °C for 36h. The yellowish mixture is then put into water (200mL), extracted with DCM (3xl50mL), and dried over magnesium sulfate. Purification on silica gel affords the ethyl derivative. LCMS: m/z 266.14 (M+H) +
  • step D The ethyl derivative (500mg) of step D and the previously described 2-diethylamino-4-ethyl- 5-pyridine boronic acid (526mg) are dissolved in DME (15mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (183mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (3.2mL) whereupon the reaction is heated to 80 °C for 40h. The yellowish mixture is then put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 408.37 (M+H) +
  • step F The crude mixture (82. Og) of step F is dissolved in cone. HBr (250mL). After 20 min or once NMR control shows completed conversion, the dark mixture is put into water (500mL), extracted with DCM (3x250mL), and dried over magnesium sulfate. The crude mixture is used without any further purification in step B.
  • allylic compound (892mg) of step A tetrabutylammonium bromide (575mg), palladium acetate (40mg), and potassium carbonate (737mg) are dissolved in DMF (lOmL). After heating to 80 °C for 30 min, the mixture is worked-up according to step A. Purification on silica gel affords the Heck-product.
  • Step C The Heck product (356mg) of step B is dissolved in THF (2.5mL) and added to a solution of t-BuLi (1.05mL, 1.7N in pentane) in THF (8.5mL) at -78 °C. After being stirred for 10 min, methyl iodide (0.21mL) is added and the reaction mixture is stirred for another lh at -78 °C. Subsequently, the mixture is put into water (lOOmL) and sat. sodium bicarbonate (50ml), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the methyl derivative.
  • step C The methyl product of step C (238mg) and the previously described 2- jopropyl-6-methoxy- 5-pyridine boronic acid (158mg) are dissolved in DME (5.0mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (77mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (1.35mL) whereupon the reaction is heated to 80 °C for 3h. The yellowish mixture is then put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the coupled product. LCMS: m/z 469.15 (M+H) +
  • step D The Suzuki product of step D is dissolved in THF (5.0mL). After addition of TBAF monohydrate (650mg), the reaction mixture is stirred for 30 min. Subsequently, the yellow solution is put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound.
  • Step B The mesylate (54mg) of step A is dissolved in acetonitrile (LOmL). After addition of morpholine (200mg), the reaction is heated to 80 °C for 3h. Subsequently, the clear solution is put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound.
  • allyl compound of step C (330mg), Pd(OAc) 2 (40mg), tetrabutylammonium bromide (219mg), and K 2 C0 3 (250mg) are dissolved in DMF (3mL), degassed, and heated to 80 °C overnight. The mixture is then diluted with EtOAc and washed with H 2 0, brine, and dried over MgS0 4 . Purification on silica gel yields the Heck product.
  • Step E The Heck product of step D (80mg), methylboronic acid (60mg), and Pd(PPh 3 ) 4 (lOmg) are dissolved in toluene (5mL). After addition of 2N Na 2 C0 3 (3mL), the reaction mixture is degassed and then heated to 85 °C overnight. Subsequently, the solution is diluted with EtOAc and washed with 2N NaOH, H 2 0, and brine before being dried over MgS0 4 . Purification on silica gel yields the title compound.
  • step A To a solution of the trichloride from step A (1.03g) in NMP (20mL) is added tetrabutylammonium bromide (0.2g) and NaH (60%, 0.38g). After being stirred at rt for 3h, 3,3-diethylallyl chloride (0.97g, prepared analogously to the previously described 3,3- diethylallyl bromide) is added and the reaction mixture is stirred for an additional 36h. The yellow solution is then quenched with water and extracted with EtOAc. The organic layer is washed with water, brine, and dried over MgS0 to yield the crude allylamine which was used in step C without any further purification.
  • Step C The allyl compound of step B (lOOmg), Pd(OAc) 2 (lOmg), TBAB (116mg), and K 2 C0 3
  • step C the previously described 2-methoxy-4-trifluoromethoxyphenyl boronic acid, and Pd(PPh3) are dissolved in toluene. After addition of a 2N Na 2 C0 3 , the reaction mixture is degassed and then heated to 85 °C overnight. Subsequently, the solution is diluted with EtOAc and washed with 2N NaOH, H 2 0, and brine before being dried over MgS0 4 . Purification on silica gel yields the title compound.
  • TBDMSC1 (20g) is added to a cold (0°C) solution of 4-hydroxy-2-butanone (17.6g), DMAP (200mg), imidazole (10.8g) in DMF (160ml). The reaction mixture is warmaed naturally to room temperature and stirred for 24 hours. The reaction mixture is added with water and extracted with ethyl acetate and dried with Na 2 S0 4 . Purification by column with hexane/ethyl acetate gives product. Rf: 0.4(hexane/ethyl acetate: 8:1)
  • Triethyl phosphonoacetate (17.3ml) is added as a solution of THF (30ml) to a cold (0°C) suspension of NaH (0.131mol) in anhydrous THF (80ml). The resulting mixture is stirred at 0°C for 1 hour before ketone (17.67g) is added as a solution of THF (10ml). The reaction is continued at room temperature for another 2 hours. Saturated aqueous NH C1 is carefully added and separated. Aqueous layer is extracted with ether. The combined organic layers are washed with water, brine. Purification by column with hexane/ethyl acetate gives product. Rf: 0.4(hexane/ethyl acetate: 15:1)
  • Step C Starting material (21.3g) is treated with DIB AL-H( l.OM in toluene, 196ml) at 0°C for 6 hours. Water is carefully added to quench the excess DIBAL. The reaction mixture is filtered and washed with ethyl acetate. The filtrate is concentrated to afford the crude product. Rf: 0.4(hexane/ethyl acetate: 3:1).
  • Step G The crude starting material is taken in anhydrous CHC1 3 (100ml). 4.0 equivalent of NBS is added in one portion at 0°C. The reaction is complete in 0.5 hour. The reaction mixture is washed with water and dried with Na 2 S0 4 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 496.1 (M+H) +
  • Step I A mixture of bromide (9.26g), tetrabutylammonium bromide (5.95g), K 2 C0 3 (6.12g),
  • Step J To a solution of t-BuLi(l .7M/pentane, 7ml)in THF (30ml) at -78°C is added a solution of bromide (3.07g) in THF (5ml). The resulting mixture is stirred at -78°C for 10 minutes before iodomethane (1.4ml) is added. The reaction is continued for 30minutes. The reaction is carefully quenched with EtOH. The resulting mixture is washed with water and brine, dried with Na 2 S0 4 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.4(hexane/ethyl acetate: 10:1).
  • Step L Starting material (lOOmg) is taken in anhydrous DMF (4ml), NaH (52mg, 60%) is added followed by the addition of CH 3 I (5 equiv.). The reaction is continued overnight. The reaction is quenched with water and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 382.3 (M+H) +
  • Step J To a solution of t-BuLi(l .7M/pentane, 7ml)in THF (30ml) at -78°C is added a solution of bromide (3.07g) in THF (5ml). The resulting mixture is stirred at -78°C for 10 minutes before iodomethane (1.4ml) is added. The reaction is continued for 30minutes. The reaction is carefully quenched with EtOH. The resulting mixture is washed with water and brine, dried with Na 2 S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.4(hexane/ethyl acetate: 10:1).
  • Step L Starting material (lOOmg) is taken in anhydrous DMF (4ml), NaH (52mg, 60%) is added followed by the addition of CH 3 I (5 equiv.). The reaction is continued overnight. The reaction is quenched with water and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na 2 S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 382.3 (M+H) +
  • the following assay is defined herein as a standard in vitro CRF receptor binding assay.
  • the pharmaceutical utility of compounds of this invention is indicated by the following assay for CRFl receptor activity.
  • the CRF receptor binding is performed using a modified version of the assay described by Grigoriadis and De Souza (Methods in Neurosciences, Vol. 5, 1991).
  • IMR-32 human neuroblastoma cells a cell-line that naturally expresses the CRFl receptor, are grown in IMR-32 Medium, which consists of EMEM w/Earle's BSS (JRH Biosciences, Cat# 51411) plus, as supplements, 2mM L-Glutamine, 10% Fetal Bovine Serum, 25mM HEPES (pH 7.2), ImM Sodium Pyruvate and Non-Essential Amino Acids
  • the cells are grown to confluence and split three times (all splits and harvest are carried out using NO-ZYME - JRH Biosciences, Cat# 59226).
  • the cells are first split 1:2, incubated for 3 days and split 1:3, and finally incubated for 4 days and split 1:5.
  • the cells are then incubated for an additional 4 days before being differentiated by treatment with 5-bromo-2'deoxyuridine (BrdU, Sigma, Cat# B9285).
  • the medium is replaced every 3-4 days with IMR-32 medium w/2.5uM BrdU and the cells are harvested after 10 days of BrdU treatment and washed with calcium and magnesium-free PBS.
  • receptor containing membranes cells are homogenized in wash buffer (50 mM Tris HCI, 10 mM MgCl 2 , 2 mM EGTA, pH 7.4) and centrifuged at 48,000 x g for 10 minutes at 4°C. The pellet is re-suspended in wash buffer and the homogenization and centrifugation steps are performed two additional times.
  • wash buffer 50 mM Tris HCI, 10 mM MgCl 2 , 2 mM EGTA, pH 7.4
  • Membrane pellets (containing CRF receptors) are re-suspended in 50 mM Tris buffer pH 7.7 containing 10 mM MgCl 2 and 2 mM EDTA and centrifuged for 10 minutes at 48,000g. Membranes are washed again and brought to a final concentration of 1500 ug/ml in binding buffer (Tris buffer above with 0.1 % BSA, 15 mM bacitracin and 0.01 mg/ml aprotinin.). For the binding assay, 100 ul of the membrane preparation are added to 96 well microtube plates containing 100 ul of 125 I-CRF (SA 2200 Ci/mmol, final concentration of 100 pM) and 50 ul of test compound.
  • binding buffer Tris buffer above with 0.1 % BSA, 15 mM bacitracin and 0.01 mg/ml aprotinin.
  • Binding is carried out at room temperature for 2 hours. Plates are then harvested on a BRANDEL 96 well cell harvester and filters are counted for gamma emissions on a Wallac 1205 BETAPLATE liquid scintillation counter. Non-specific binding is defined by 1 mM cold CRF. IC50 values are calculated with the non-linear curve fitting program RS/1 (BBN Software Products Corp., Cambridge, MA). The binding affinity for the compounds of Formula I expressed as IC 50 value, generally ranges from about 0.5 nanomolar to about 10 micromolar.
  • Preferred compounds of Formula I exhibit IC 50 values of less than or equal to 1.5 micromolar, more preferred compounds of Formula I exhibit IC50 values of less than 500 nanomolar, still more preferred compounds of Formula I exhibit IC50 values of less than 100 nanomolar, and most preferred compound of Formula I exhibit IC50 values of less than 10 nanomolar.
  • the compounds shown in Examples 1-33 have been tested in this assay and found to exhibit IC 50 values of less than or equal to 4 micromolar.
  • the compounds of the invention are prepared as radiolabeled probes by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope.
  • the radioisotope is preferably selected from of at least one of carbon (preferably 1 C), hydrogen (preferably 3 H), sulfur (preferably j5 S), or iodine (preferably 125 I).
  • Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds. Such suppliers include Amersham Corporation, Arlington Heights, IL; Cambridge Isotope Laboratories, Inc.
  • Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas. Such preparations are also conveniently carried out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. In addition, certain precursors may be subjected to tritium-halogen exchange with tritium gas, tritium gas reduction of unsaturated bonds, or reduction using sodium borotritide, as appropriate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Description

HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS
This application claims priority from U.S. Provisional Application serial number 60/500,414 filed on September 5, 2003.
FIELD OF THE INVENTION The present invention relates to novel substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that bind with high selectivity and/ or high affinity to CRF receptors (Corticotropin Releasing Factor Receptors). This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of psychiatric disorders and neurological diseases, including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. Additionally this invention relates to the use such compounds as probes for the localization of CRF receptors in cells and tissues. Preferred CRF receptors are CRFl receptors.
BACKGROUND OF THE INVENTION Corticotropin releasing factor (CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors.
Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system.
In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen jn human depression. There is also preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain. . ,
CRF has also been implicated in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine / non- benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models. Preliminary studies using the putative CRF receptor antagonist α-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test and in the acoustic startle test in rats. The benzodiazepine receptor antagonist Ro 15-1788, which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner, while the benzodiazepine inverse agonist FG 7142 enhanced the actions of CRF. CRF has also been implicated in the pathogeneisis of certain immunological, cardiovascular or heart-related diseases such as hypertension, tachycardia and congestive heart failure, stroke and osteoporosis, as well as in premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus and colonic hypersensitivity associated with psychopathological disturbance and stress. The mechanisms and sites of action through which conventional anxiolytics ' and antidepressants produce their therapeutic effects remain to be fully elucidated. It has been hypothesized however, that they are involved in the suppression of CRF hypersecretion that is observed in these disorders. Of particular interest are that preliminary studies examining the effects of a CRF receptor antagonist peptide (α-helical CRF9- ]) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines.
SUMMARY OF THE INVENTION
The invention provides novel compounds of Formula I (shown below), and pharmaceutical compositions comprising compounds of Formula I and at least one pharmaceutically acceptable carrier or excipient. Such compounds bind to cell surface receptors, preferably G-coupled protein receptors, especially CRF receptors (including CRFl and CRF2 receptors) and most preferably CRF 1 receptors. Preferred compounds of the invention exhibit high affinity for CRF receptors, preferably CRF 1 receptors. Additionally, preferred compounds of the invention also' exhibit high specificity for CRF receptors (i.e., they exhibit high selectivity compared to their binding to non-CRF receptors). Preferably they exhibit high specificity for CRF 1 receptors.
Thus, in certain aspects, the invention provides compounds of Formula I-a
Figure imgf000004_0001
and the pharmaceutically acceptable salts thereof, wherein: E is a single bond, O, S(0)m, NRi0 or CRι0Rι i ;
' Rio and R| i are independently hydrogen or -C4 alkyl; •m is 0, 1, or 2; Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R is oxygen or absent; the group:
Figure imgf000005_0001
represents a saturated, unsaturated or aromatic 5-membered ring system containing 0 or 1 heteroatoms, wherein:
Figure imgf000005_0002
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2' or NR ", Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, or CR3R3'; Ri is chosen from hydrogen, halogen, hydroxy, cyano, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, optionally substituted heterocycle and optionally substituted heteroaryl, said ' optionally substituted heterocycle or heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, alkyl, haloalkyl, alkoxy, aminoalkyl, hydroxyalkyl and mono and dialkylamino, wherein when R or Ri" is optionally substituted alkyl, then R3 is optionally substituted C[-3alkyl; R\ R2' and R3' are independently chosen from hydrogen, halogen, alkyl, haloalkyl, and aminoalkyl; R2" is chosen from hydrogen, optionally substituted alkyl, optionally substituted haloalkyl, and optionally substituted aminoalkyl;
Figure imgf000005_0003
Z5 is NR or CR5;
R4. and R5 are independently chosen from hydrogen, halogen, hydroxy', amino, cyano, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted (cycloalkyl)alkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclie aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S.
In certain other aspects, the invention provides compounds of Formula I-b
Figure imgf000006_0001
Formula I-b or a pharmaceutically acceptable salt thereof, wherein:
E is a single bond, O, S(0)m, NRio or CRio i i ;
Rio and Rπ are independently hydrogen or Cι-C4 alkyl; m is 0, 1, or 2;'
R is oxygen or absent;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; the group: .
Figure imgf000006_0002
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein: Zi is CRi, CR|R,' or Rι"; Z2 is CR2 or CR2R2'; Z3 is CR3, CR3R3', or R3"; Ri and Rj"are chosen from hydrogen, C]-CI0alkyl, C2-Cι0alkenyl, C2-C,0alkynyl, C3- C7cycloalkyI, (benzo)C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C alkyl, C3- gheterocycloalkyl, (C3-9heterocycloalkyl)Cι-C4alkyl, (benzo)C3-9heterocycloalkyl, ((benzo)C3-9heterocycloalkyl)Cι-C alkyrand halo(Cj-C6)alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Ci-Cβalkyl, Cι-C6alkoxy, haloC)-C6alkoxy,Cι-C6aιkanoyl, Q- C6alkanoyloxy, Cι-C6alkoxycarbpnyl„ N-(Cι-C6aIkanoyI)-N-(C0-C6alkyl)amino, N- (C]-C6alkanoyloxy)-N-(Co-C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(C0- C6alkyl)amino, Ci-Cόalkylsulfonamide, Ci-Cδalkylsulfonyl, Ci-Cβalkylsulfonyloxy, CrCβhydroxyalkyl, Ci-CόalkoxyCi-Cealkyl, Cι-C6haloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di-(Cι-C6)alkylamino, N- (CrC6alkanoyl)-N-(Co-C6alkyl)amino, N-(Cι-C6alkanoyloxy)-N-(C0-C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(C0-C6alkyl)amino, mono- and di-(C C6)alkylcarbamoyl, -XRc and X-Z, with the proviso that Ri and Ri" is not aryl or heteroaryl substituted alkyl;
R2 is chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, Cι-C3alkyl, halo(Cι- C3)alkyl, CpC3alkoxy, amino(Cι-C3)alkyl, and mono and di(Cι-C6)alkylamino;
R3 is chosen from hydrogen, hydroxy, amino, halogen, cyano, nitro, C|-C3alkyl, halo(C
C3)alkyl, Cι-C3alkoxy, amino(Cι-C3)alkyI, hydroxy(Cι-C3)alkyl, cyano(Cι-C3)aιkyl, . and mono and di(Cι-C3)alkylamino;
R3" is chosen from hydrogen, hydroxy, amino, Cι-C3alkyl, halo(Cι-C3)alkyl, Cι-C3alkoxy, amino(C]-C3)alkyl, hydroxy(Cι-C3)alkyl, cyano(Cι-C3)alkyl, and mono and di(Cj- C3)alkylamino;
Ri', R2' and R3' are independently chosen from hydrogen, halogen, Cι-C6alkyl, halo( - C6)alkyl, and amino(C[-C6)alkyl;
Figure imgf000007_0001
Z5 is NR or CR5; 4 and R5 are independently chosen from hydrogen, halogen, cyano, nitro, amino, mono or di(C!-C6carbhydryl)amino, CpCόCarbhydryl, (C3-C7cyclocarbhydryl)C0- C4carbhydryl, -0(C3-C7cyclocarbhydryl), halo'(Cι-C6)carbhydryl, -0(halo(Cr
C6)carbhydryl), -0(CrC6carbhydryl), S(0)n(Ct-C6carbhγdryI), and 4 to 7 membered heterocycloalkyl, where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cι-C4alkoxy, and mono- and di(Cι-C4)alkylamino, and ' where each Cs-Cγcarbhydryl heterocycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, Cι-C alkoxy, and mono- and di(Cι-C )alkylamino; or R5, taken in combination with Ri or Ri", forms a 5-9 membered heterocycle; RA is independently selected at each occurrence from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, Cι-C6alkyl substituted with 0-2 RB, C2-C6alkenyl substituted with 0-2 RB, C2-C6alkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with 0-2 RB, (C3-C7cycloalkyl)Ci-C4alkyl substituted with 0-2 RB, Cι-C6alkoxy substituted with 0-2 RB, -NH(C|-C6alkyl) substituted with 0-2 RB, -N(Cι-C6alkyl)( CrC6alkyl) each Cι-C6alkyl independently substituted with 0-2 RB, -
XRc, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, d-Qalkyl, -0(C,-C4alkyl), -NH(CrC4alkyl), -N(C,- C4alkyl)( d-C4alkyl), -S(O)„(alkyl), halo(C,-C4)alkyl, halo(Cι-C4)alkoxy, CO(C,- C4alkyl), CONH(C,-C4alkyl), CON(C,-C4alkyl)( C,-C4alkyl), -XRC, and Y;
Rc and RQ, which may be the same or different, are independently selected at each occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, Cι-C6alkoxy, -NH(Cι-C6alkyl), -N(C|- C6alkyl)(C1-C6alkyl), -NHC(=0)(C,-C6alkyl), -N(C1-C6alkyl)C(=0)(C1-C6alkyl), - - NHS(0)n(CrC6alkyl), -S(0)n(C,-C6alkyl), -S(0)πNH(C,-C6alkyl), -S(O)„N(Cr
C6alkyl)(C,-C6alkyl), and Z; X is independently selected at each occurrence from the group consisting of -0-, -C(=0)0-, - S(O)„-, -NH-, -NRD-, -C(=0)NH-, -C(=0)NRD-, -S(0)πNH-, -S(0)nNRD-,.-OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(0)n-, -OSiH2-, -OSiH(C,-C4alkyl)-, -OSi(C,- C4alkyl)(C,-C4alkyl)-, and -NRDS(0)n-;
Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, Cι-C4alkyl, -0(Cι-C4alkyl), -NH(Cι-C4alkyl), - N(C]-C4alkyl)(Cι-C4alkyl), -C(0)(C,-C4alkyl), and -S(0)n(alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2.
Certain preferred compounds of Formula I-a or Formula I-b include those in which at least one of Z4 and Z5 is not NR. Certain other preferred compounds of Formula I-a or Formula I-b include those in which Z4 is selected from N and CR4 and Z5 is selected from N and CR5.
Certain preferred compounds of Formula I-b include those compounds in which Ar is chosen from phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2- naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; and
Ri and Ri" are chosen from C]-C10alkyl, C2-Cι0alkenyl, C2-Cι0alkynyl, C3- C7cycloalkyl, (C3-C7cycloalkyι)Cι-C aιkyl, (benzo)C3-C7cycloalkyl, (benzo)C3- gheterocycloalkyl,
((benzo)C3-9heterocycloalkyl)Cι-C4alkyl, and halo(Cι-Ce)alkyl, each of which is substituted with 0, 1, 2, or 3 substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Ci-Cβalkyl, Cr alkoxy, halόCι-C6alkoxy,C]-C6alkanoyl, C]-C6alkanoyloxy, C]- Cδalkoxycarbonyl,, N-(Cι-C6alkanoyl)-N-(Co-C6alkyl)amino, N-(Cι-C6alkanoyloxy)-N-(Co- C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(Co-C6alkyl)amino, Ci-Cealkylsulfonamide, C\- Cόalkylsulfonyl, Ci-Cealkylsulfonyloxy, Cι-C6hydroxyalkyl, Cι-C6alkoxyCι-C6alkyl, Cj- Cghaloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di- (CrC6)alkylamino, N-(Cι-C6alkanoyl)-N~(C0-C6alkyl)amino, N-(Cι-C6alkanoyloxy)-N-(C0- C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(C0-C6alkyl)amino, mono- and di-(Cp C6)alkylcarbamoyl, -XRC and X-Z.
As used herein the term "Formula I" is generally intended to refer to compounds of either Formula I-a or Formula I-b and subformulae thereof.
The invention further comprises methods of treating patients suffering from certain disorders with a therapeutically effective amount of at least one compound of the invention. These disorders include CNS disorders, particularly affective disorders, anxiety disorders, stress-related disorders, eating disorders and substance abuse. The patient suffering from these disorders may be a human or other animal (preferably a mammal), such as a domesticated companion animal (pet) or a livestock animal. Preferred compounds of the invention for such therapeutic purposes are those that antagonize the binding of CRF to CRF receptors (preferably CRF1, or less preferably CRF2 receptors). The ability of compounds to act as antagonists can be measured as an IC50 value as described below. According to yet another aspect, the present invention provides pharmaceutical compositions comprising compounds of Formula I or the pharmaceutically acceptable salts (by which term is also encompassed pharmaceutically acceptable solvates) thereof, which compositions are useful for- the treatment of the above-recited disorders. The invention further provides methods of treating patients suffering from any of the above-recited disorders with an effective amount of a compound or composition of the invention.
Additionally this invention relates to the use of the compounds of the invention (particularly labeled compounds of this invention) as probes for the localization of receptors in cells and tissues and as standards and reagents for use in determining the receptor-binding characteristics of test compounds.
Preferred heteroaryl fused pyridine, pyrazine, and pyrimidine compounds of the invention exhibit good activity, i.e., a half-maximal inhibitory concentration (IC50) of less than 1 millimolar, in a standard in vitro CRF receptor binding assay such as the assay provided in Example 51, which follows. Particularly preferred substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds of the invention exhibit an IC5oof about 1 micromolar or less, still more preferably an IC50 of about 100 nanomolar or less even more preferably an IC50 of about 10 nanpmolar or less. Certain particularly preferred compounds of the invention will exhibit an IC50 of 1 nanomolar or less in such a defined standard in vitro CRF receptor binding assay.
DETAILED DESCRIPTION OF THE INVENTION
In addition to compounds of Formula I-a, described above, the invention is further directed to compounds and pharmaceutically acceptable salts of Formula I wherein: R is oxygen or absent; Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; the group:
Figure imgf000011_0001
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein:
Figure imgf000011_0002
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2', or NR2",
Z is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, or CR3R3';
Ri is chosen from i) halogen, hydroxy, cyano, amino, -Cioalkyl, -0(Cι-Cδ alkyl), mono or di(Cr C6alkyl)amino, (C3-C7cycloalkyl)Ci-C4alkyl, halo(Cι-C6)alkyl, -0(halo(C,-C6)alkyl) and
S(O)„(Cι-C6aιkyl), -C d^cycloalky C^alkyl, and S(0)n(Ci-C6alkyl), where each alkyl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Q. C\- C4alkoxy, and mono- or di(Cι-C4)alkylamino, and where each C3-C7cycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, Cι-C4alkoxy, and mono- or di(Cι-C4)alkylamino, and • ii) phenyl which is mono-, di-, or tri-substituted with RA, 1- naphthyl, 2-naphthyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridiziriyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, CrC3alkyl, halo(Cι-C3)alkyl, Cι-C3alkoxy, amino(Cι-C3)aikyl, and mono and di(C C6)alkylamino;
Ri', R2' and R3' are independently chbsen from hydrogen, halogen, Ci-Cδalkyl, halo(Cι-
C6)alkyl, and amino(Cι-C6)alkyl; R2" is chosen from hydrogen, CpCealkyl, halo(Cι-C6)alkyl, and amino(Cι-C6)alkyl; Z4 is NR or CR4; Z5 is NR or CR5;
R4 and R5 are independently chosen from hydrogen, halogen, cyano, nitro, amino, mono or di(Cι-C6carbhydryl)amino, Ci-CδCarbhydryl, (C3-C7cyclocarbhydryl)Co- C4carbhydryl, -0(C3-C7cyclocarbhydryl), halo(Cι-Ce)carbhydryl, -0(halo(Cι- C6)carbhydryl), -0(Ci-C6carbhydryl), and S(0)n(Ci-C6carbhydryl), where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cι-C4alkoxy, and mono- and di(Cι-C4)alkylamino, and where each C3-C7carbhydryl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, - alkoxy, and mono- and di(C C )alkylamino; RA is independently selected at each occurrence from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, Ci-Cόalkyl substituted with 0-2 RB, C2-C6alkenyl substituted with 0-2 RB, C2-C6alkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with 0-2 RB, (C3-C7cycloalkyl) Cι-C4alkyl substituted with 0-2 RB, Cι-C6aIkoxy substituted with 0-2 RB, -NH(Cι-C6alkyl) substituted with 0-2 RB,
-N(C1-C6aikyl)( Cι-C6alkyl) each Cι-C6alkyl independently substituted with 0-2 RB, - XRc, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, C]-C4alkyl, -0(C,-C4alkyl), -NH(C,-C4alkyl), -N(d- C4alkyl)( d-C4alkyl), -S(0)n(alkyl), halo(C,-C4)alkyl, halo(Cι-C4)alkoxy, CO(C
C4alkyl), CONH(d-C4alkyl), CON(CrC4alkyl)( CrC4alkyl), -XRc, and Y; Rc and RD, which may be the same or different, are independently selected at each, occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, d-Qalkoxy, - NH(CrC6alkyl), -N(Cι-C6alkyl)(C,-C6alkyl), -NHC(=0)(C1-C6alkyl), -N(Cr C6alkyl)C(=0)(C,-C6alkyl), -NHS(O)„(Cι-C6alkyl), -S(O)„(C C6aιkyl), -
S(0)nNH(d-C6alkyl), -S(0)nN(C,-C6alkyl)(d-C6alkyl), and Z; X is independently selected at each occurrence from the group consisting of -CH?-, -CHRD-, - 0-, -C(=0)-, -C(=0)0-, -S(0)n-, -NH-, -NRD-, -C(=0)NH-, -C(=0)NRD-, -S(0)πNH-, -S(0)πNRD-, -OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(0)n-, -OSiH2-, -OSiH(Cι- Qalkyl)-, -OSi(C1-C4alkyl)(C1-C4alkyl)-, and -NRDS(0)n-;
Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, CrC4alkyl, -0(Cι -Qalkyl), -NH(d-C4alkyl), -N(C,-C4alkyl)(Cι-C4alkyl),and -S(0)n(alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment • being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2. Such compounds will be referred to as compounds of Formula I-c.
Certain preferred compounds of Formula I-c include those in which at least one of Z4 and Z5 is not NR. Certain other preferred compounds of Formula I-c include those in which Z4 is selected from N and CR4 and Z5 is selected from N and CR5.
Particular embodiments of the invention include compounds having the following Formula:
Figure imgf000014_0001
Formula II Formula III
Figure imgf000014_0002
Formula IV Formula V
Figure imgf000014_0003
Formula VI Formula VTI
Figure imgf000015_0001
Figure imgf000016_0001
For each of the compounds and salts of Formula II- Formula XIX, R , R\', R ", R2,
R2', R2", R , R ', R "> 4, R55 and Ar are as defined above for Formula I, or preferably are as defined above for Formula I-a, I-b, or I-c.
More prefereably
Ri, R,', and Ri" are as defined for Formula I-a, I-b, or I-c;
R2' and R3' are hydrogen;
R2 (or R2") is selected from hydrogen, methyl, and ethyl; R3 (or R3") is selected from hydrogen, and Cι-C6alkyl (or more preferably R3 or R3" is Ci-
C3alkyl when Zi is NR," or when Z3 is NR3";
R and R5 are independently selected from hydrogen, halogen, cyano, amino, Cι-C6alkyl, d- C6alkoxy, C3-C7cycloalkyl, (C3-C7cycloalkyl)d-C4alkyl, (C3-C7cycloalkyl)d- C4alkoxy, mono and di(Cι-C6alkyl)amino, amino(Ci-Ce)alkyl, mono and di(Cι- C6alkyl)amino(Cι-C6)alkyl, halo(Cι-C6)alkyl, and halo(Cι-C6)alkoxy; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(d-C6)alkyl, halo(d-C6)alkoxy, hydroxy, amino, CrC6alkyl, C2- dalkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C4alkyl, Cι-C6alkoxy, • mono- and di(Cι-C6alkyl)amino, amino(CrC6)alkyl, and mono- and di(Cι-C6alkyl)amino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula II - Formula XX, above, is substituted.
In certain preferred compounds of Formula I (e.g., I-a and I-b) and various subformulae thereof which comprise a or Ri" group, the Rj or Ri" residue is selected, from Ci-Cioalkyl and (C3-C7cycloalkyl)Co-C4alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cr- C4alkoxy, and mono- and di-(Cι-C4)alkylamino.
In certain other preferred compounds of Formula I (e.g., I-a and I-b) and various subformulae thereof which comprise a R| or Ri" group, the R\ or Ri" residue is selected from C3-9heterocycloalkyl and (C3-9heterocycloalkyl)d-4alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, Ci-Cβalkyl, Ci- dalkoxy, Ci-Cehydroxyalkyl, Cι-C6alkoxyCι-C6alkyl, (C,-C6)haloalkyl, (Cι-C6)haloalkoxy, mono- and di-(Cι-C6)alkylamino, -XRc- Certain preferred C3-9heterocycloalkyl and (C3- 9heterocycloalkyl)Cι-4alkyl groups include those chosen from tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2]-azabicyclic rings, [3.3.1]-azabicyclic rings, quinuclidinyl, azetidinyl, azetidinon-yl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl, each of which is substituted with from 0 to 2 substituents independently chosen from: (i) halogen, hydroxy, amino, cyano, or (ii) Cι-C4alkyl, d-C4a!koxy, and mono- and di-(Cι-C4)alkylamino, each of which is substituted with 0 or 1 substituents selected from halogen, hydroxy, amino, C]-2alkoxy, or C3- gheterocycloalkyl.
Certain other preferred compounds of Formula I (e.g., I-a or I-b) and compounds of Formulae II-XIX include those compounds in which Ri or R," is selected from 3-pentyl, 2- butyl, l-methoxy-but-2-yl, l-dimethylamino-but-2-yl, 3-(thiazol-2-yl)-lH-pyrazol-l-yl, and groups of formula:
Figure imgf000017_0001
wherein X is the point of attachment to the nitrogen of the imidazo ring, Y is selected from CΗ2, O, S, S(O), S0 , NCι-C8alkyl (including linear and branched alkyl groups), NCι-C6haloalkyl, NC3-C8cycloalkyl, NC(0)d-C8alkyl (including linear and branched alkyl groups), NC(0)d-C6haloalkyl, NC(0)C3-C8cycloalkyl, N-benzoyl, N-benzyl, NCOOCι-C8alkyl (including linear and branched alkyl groups), NCOOCι-C6haloalkyl, NCOOC3-C8cycl'oalkyl, and Z is selected from hydrogen, hydroxy, amino, NCι-C8alkyl (including linear and branched alkyl groups), NHCι.-C6haloalkyl, NHC3-C3cycloalkyl, NHC(0)C,-C3alkyl (including linear and branched alkyl groups), NHC(0)d-C6haloalkyl, NHC(0)C3- Cscycloalkyl, NH-benzoyl, NH-benzyl, NHCOOC C8alkyl (including linear and branched alkyl groups), NHCOOC,-C6haloalkyl, NHCOOC3-C8cycloalkyl, C,-C8alkoxy (including linear and branched alkoxy groups), d-dhaloalkoxy, C3-C8cycloalkoxy, OC(0)C|-C8alkyl (including linear and branched alkyl groups), OC(0)Cι-C6haloalkyl, OC(0)C3-C8cycloalkyl, benzoyloxy, benzyloxy, OCONHC]-C8alkyl (including linear and branched alkyl groups), OCONHCi-Qhaloalkyl, OCONHC3-C8cycloalkyl, C,-C8alkylthio (including linear and branched alkyl groups), CpCehaloalkylthio, C3-C8cycloalkylthio, S(0)d-C8alkyl(including linear and branched alkyl groups), S(0)Ci-C6haloalkyl, S(0)C3-C8cycloalkyl, S02Ci-C8alkyl (including linear, and branched alkyl groups), S02Cι-Cehaloalkyl, S02C3-C8cycloalkyl.
In yet other aspects, preferred compounds of Formula I (e.g., I-a or I-b) and compounds of Formulae II-XIX include those compounds in which R] or R]" is selected from
Figure imgf000018_0001
wherein X is the point of attachment to the nitrogen of the imidazo ring.
Particularly preferred Ri groups are shown in the R22-Matrix and particularly preferred Rj'? groups are shown in the Rι2-Matrix, both in Example 1, which follows.
Other preferred R\ groups include groups of the formula
Figure imgf000018_0002
and groups of the formula
Figure imgf000018_0003
where A represents up to three groups independently chosen from hydrogen, halogen, alkyl, and alkoxy. Another embodiment of the invention is directed to compounds of Formula XX
Figure imgf000019_0001
Formula XX or a pharmaceutically acceptable salt thereof, wherein:
E is a single bond, O, S(0)m, NRio or CRioRi i;
Rio and Rπ are independently hydrogen or Cι-C4 alkyl; m is 0, 1, or 2;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R is oxygen or absent; the group:
Figure imgf000019_0002
represents a saturated, unsaturated or aromatic 5-membered ring system containing 0 or 1 heteroatoms, wherein:
Z, is CR1, CR,R, ', or NR1";
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2' or NR ",
Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, CR3R3', or NR3";
Ri is chosen from halogen, hydroxy, cyano, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
Ri" is chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, alkyl, haloalkyl, alkoxy, aminoalkyl, and mono and dialkylamino;
Ri', R2' and R3' are independently chosen from hydrogen, halogen, alkyl, haloalkyl, and aminoalkyl;
R2" and R3" are independently chosen from hydrogen, alkyl, haloalkyl, and aminoalkyl; and
R4 is hydrogen, alkyl, aminoalkyl, and haloalkyl
Certain other preferred compounds and pharmaceutically acceptable salts of the invention include those compounds of Formula XX:
Figure imgf000020_0001
Formula XX or a pharmaceutically acceptable salt thereof, wherein: E is a single bond, O, S(0)m, NR10 or CR10R11; Rio and R are independently hydrogen or Cι-C4 alkyl; m is 0, 1, or 2; R is oxygen or absent;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; the group:
Figure imgf000021_0001
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein: Zi is CRu CRiRi'. or NRf';
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2'; orNR2", Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, CR3R3' or NR3"; Ri is chosen from i) halogen, hydroxy, cyano, amino, Ci-Ciocarbhydryl, -O(Ci-Cecarbhydryl), mono or di(C 1 - C6carbhydryl)amino, (C3-C7cyclocarbhydryl)Cι-C carbhydryl, halo(Cι- C6)carbhydryl, -0(halo(C,-C6)carbhydryl) and S(0)n(C,-C6carbhydryl), -0(C3- C7cyclocarbhydryl)Ci-C4carbhydryl, d.gheterocycloalkyl, (C3-9heterocycloalkyl)Cι- C4alkyl, and S(0)n(d-C6carbhydryl), where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, where each heterocycloalkyl has 1 or 2 ring heteroatoms selected from N, O, or S and the point of attachment is carbon or nitrogen; and where each carbhydryl, heterocycloalkyl, or cyclocarbhydryl is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Ci-Cδalkyl, d-C6alkoxy, haloCι-C6alkoxy,Cι-C6alkanoyl, d-
C6alkanoyloxy, Ci-Cδalkoxycarbonyl,, N-(Cι-C6alkanoyl)-N-(Co-C6alkyl)amino, N-
(Cι-C6alkanoyloxy)-N-(Co-C6alkyl)amino, N-(d-C6alkoxycarbonyl)-N-(C0- C6alkyl)amino, Cι-C6alkylsulfonamide, Cι-C6alkylsulfonyl, Ci-Cόalkylsulfonyloxy,
C]-C6hydroxyalkyl, d-CδalkoxyCi-Cόalkyl, Ci-Cδhaloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di-(Cι-C6)alkylamino, N- (Cι-C6alkanoyl)-N-(C0-C6alkyl)amino, N-(Cι-C6alkanoyloxy)-N-(Co-C6alkyl)amino, N-(Ci-C6alkoxycarbonyl)-N-(C0-C6alkyl)amino, mono- and di-(C
C6)alkylcarbamoyl, -XRc and X-Z, and ii) phenyl which is mono-, di-, or tri-substituted with RA, i- naphthyl, 2-naphthyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; Ri" is chosen from Cι-Cιoalkyl, C2-Cιoalkenyl, C2-Cιoalkynyl, C3-C7cycloalkyl, (C3- C7cycloalkyl)Cι-C4alkyl, C3-9heterocycloalkyl, (C3-9heterocycloalkyl)Cι-C alkyl and halo(Cι-C6)alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cι-C6alkyl, d- Cβalkoxy, haloCι-C6alkoxy,Cι-Cόalkanoyl, Cι-C6alkanoyloxy, Cι-C6alkoxycarbonyl„ N-(C, -C5alkanoyl)-N-(Co-C6alkyl)amino, N-(C , -C6alkanoy loxy)-N-(C0- C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(Co-C6alkyl)amino, Ci-
C6alkylsulfonamide, d-Cόalkylsulfonyl, Ci-Qialkylsulfonyloxy, Ci-Cόhydroxyalkyl, Cι-C6alkoxyCι-C6alkyl, d-dhaloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di-(C|-C6)alkylamino, N-(Cι-C6alkanoyl)-N- (Co-Cealky amino, N-(Ci-C6alkanoyloxy)-N-(C0-C6alkyl)amino, N-(Cι- C6alkoxycarbonyl)-N-(Co-C6alkyl)amino, mono- and di-(d-C6)alkylcarbamoyl, -XRC and X-Z; R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, Ci-Cβalkyl, halo(Cι-C6)alkyl, Cι-C6alkoxy, amino(Cι-C6)alkyl, and mono and di(Cι-C6)alkylamino; R2' and R ' are independently chosen from hydrogen, halogen, Ci-Cβalkyl, halo(Cι-Ce)alkyl, and amino(Cι-Cό)alkyl; R2" and R3" are independently chosen from hydrogen,. d-Cδalkyl, halo(Cι-C6)alkyl, and amino(Cι-C6)alkyl; R4 is hydrogen, Ci-Cβalkyl, Ci-Cβaminoalkyl, and Ci-Cδhaloalkyl RA is independently selected at each occurrence from halogen, cyano, nitro, halo(C C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, d-C6alkyl substituted with 0-2 RB, C2-C6alkenyl substituted with 0-2 RB, C2-C6alkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with' 0-2 RB, (C3-C7cycloalkyl) CrC4alkyl substituted with 0-2 RB, Ci- C6alkoxy substituted with 0-2 RB, -NH(CrC5alkyl) substituted with 0-2 RB, -N(C,- C6alkyl)( Ci-Qalkyi) each Cι-C6alkyl independently substituted with 0-2 RB, -XRC, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, d-C4alkyl, -0(C,-C4alkyl), -NH(d-C4alkyl), -N(Cr
C4alkyl)( C,-C4alkyl), -S(0)n(alkyl), halo(Cι-C4)alkyl, halo(Cι-C4)alkoxy, CO(C C4alkyl), CONH(C,-C4alkyI), CON(Cι-C4alkyl)( C,-C4alkyl), -XRc, and Y; Rc and RD, which may be the same or different, are independently selected at each • occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected ' from oxo, hydroxy, halogen, cyano, amino, Cι-C6alkoxy, -NH(Cι-C6alkyl), -N(Cι-
C6alkyl)(Cι-C6alkyl), -NHC(=0)(C,-C6alkyl), -N(Ci-C6alkyl)C(=0)(d-C6alkyl), - NHS(0)n(C,-C6alkyl), -S(0)n(Cι-C6alkyl), -S(0)nNH(C,-C6alkyl), -S(O)„N(C,- C6alky 1)(C , -C6alkyl), and Z; X is independently selected at each occurrence from the group consisting of -CH2-, -CHRD-, - 0-, -C(=0)-, -C(=0)0-, -S(0)n-, -NH-, -NRD-, -C(=0)NH-, -C(=0)NRD-, -S(0)nNH-,
-S(0)nNRD-, -OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(0)n-, -OSiH2-, -OSiH(d- C4alkyl)-, -OSi(CrC4alkyl)(Cι-C4alkyl)-, and -NRDS(O)„-; Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, d-C4alkyl, -0(Cι-C4alkyl), -C(0)(Cι-C4alkyl), -NH(Cι-C4alkyl), -N(Cι-C4alkyl)(Cι-C4alkyl),and -S(0)n(alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from-N, O, and S, with the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2. Preferred compounds and pharmaceutically acceptable salts of Formula XX are those for which: Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with.
the gro
Figure imgf000024_0001
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein: Zi is CRi. CRiRi'or NRi";
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2', orNR2", Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, CR3R3' orNR3"; Ri is chosen from i) halogen, hydroxy, cyano, amino, Cι-C10carbhydryl, -0(Cι-C6 carbhydryl), mono or di(d- C6carbhydryl)amino, (C3-C7cycloalkyl)'Cι-C4carbhydryl, halo(CιC6)carbhydryl, - 0(halo(CiC6)carbhydryl) and S(0)n(Cι-C6carbhydryl), -0(C3-C7cycloalkyi)C,- C4carbhydryl, and S(0)n(Ci-C6carbhydryi), " where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cj. Cι-C4alkoxy, and mono- or di(Cι-C )alkylamino, and where each C3-C7cycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, d-Qalkoxy, and mono- or di(Cι-C4)alkylamino, and ii) phenyl which is mono-, di-, or tri-substituted with RA, 1- naphthyl, 2-naphthyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; Ri" is chosen from
C i -C i ocarbhy dry 1, (C3-C7cycloalkyl)C ι -C4carbhydryl, halo(C i C6)carbhydryl, where each carbhydryl is independently straight, branched, or cyclic, contains zero or
1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, ariiino, oxo, cyano, C|- C alkoxy, and mono- or di(Cι-C4)alkylamino, and where each d-dcycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, d-Qalkoxy, and mono- or di(Cι-C4)alkylamino, and ii) phenyl which is mono-, di-, or tri-substituted with RA, 1- naphthyl, 2-naphthyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, Cι-C6alkyl, halo(Cι-Ce)alkyl, Ci-dalkoxy, amino(Cι-C6)alkyl, and mono and di(Cι- C6)alkylamino;
R2' and R3' are independently chosen from hydrogen, halogen, Ci-Cβalkyl, halo(Cι-C6)alkyl, and • amino(C i -C6)alky 1; R2" and R3" are independently chosen from hydrogen, Ci-Gδalkyl, halo(Cι-C6)alkyl, and amino(C i -C6)alkyl; R4 is hydrogen or Ci-Cβalkyl;
RA is independently selected at each occurrence from halogen, cyano, nitro, halo(Cι-Ce)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, Cι-C6alkyl substituted with 0-2 RB, -Cόalkenyl substituted with 0-2 RB, C2-C6alkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with 0-2 RB, (C3-C7cycloalkyl) Cι-C4alkyl substituted with 0-2 RB, d- C6alkoxy substituted with 0-2 RB, -NH(CrC6alkyl) substituted with 0-2 RB, -N(C
C6alkyl)( CrC6alkyl) each C C6alkyl independently substituted with 0-2 RB, -XRC, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, C,-C4alkyl, -0(C,-C4alkyl), -NH(Cι-C4alkyl), -N(C GialkylX d-C4alkyl), -S(0)n(alkyl), halo(C,-C4)alkyl, halo(d-C4)alkoxy, CO(C C4alkyl), CONH(Cι-C4alkyl), CON(C,-C4alkyl)( C,-C4alkyl), -XRC, and Y; Rc and RD, which may be the same or different, are independently selected at each occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, C C6alkoxy, -NH(Cι-C6alkyl), -N(Cj- C6alkyl)(Cι-C6alkyl), -NHC(=0)(d-C6alkyl), -N(C,-C6alkyl)C(=0)(d-C6alkyl), - NHS(0)n(C,-C6alkyl), -S(0)n(C,-C6alkyl), -S(0)nNH(C,-C6alkyl), -S(0)nN(C,- C6alkyl)(Cι-C6alkyl), and Z;
X is independently selected at each occurrence from the group consisting of -CH2-, -CHRD-, - 0-, -C(=0)-, -C(=0)0-, -S(0)n-, -NH-, -NRD-, -C(=0)NH-, -C(=0)NRD-, -S(0)„NH-, -S(0)nNRD-, -OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(0)n-, -OSiH2-, -OSiH(d- C4alkyl)-,
Figure imgf000026_0001
and -NRDS(0)n-; Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, d-C4alkyl, -0(CrC4alkyl), -NH(Cι-C4alkyl), -N(d-C4alkyl)(d-C4alkyl),and -S(0)n(aιkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2. Such compounds will be referred to as compounds of Formula XXA. The invention is particularly directed to compounds and salts of the following
Formula:
Figure imgf000027_0001
Preferred compounds and salts of Formula XXI and Formula XXII
Ri or Ri" are as defined for Formula XX, or preferably as defined for Formula XXA.
R2 is selected from hydrogen, methyl, and ethyl;
R3 is selected from hydrogen and Cι-C6alkyl; and
Ar is selected from the group consisting of phenyl, pyridyl which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, d-C6alkyl, C2-Cealkenyl, C2-C6alkynyl,
C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C alkyl, d-C6alkoxy, mono- and di(Cι-
C6alkyl)amino, amino(Cι-C6)alkyl, and mono- and di(Cι-C6alkyl)amino, wherein, in
Ar, at least one of the positions ortho to the point of attachment of Ar shown in
Formula XXI or XXII is substituted.
Compounds of the invention are useful in treating a variety of conditions including affective disorders, anxiety disorders, stress disorders, eating disorders, and drug addiction.
Affective disorders include all types of depression, bipolar disorder, cyclothymia, and dysthymia.
Anxiety disorders include generalized anxiety disorder, panic, phobias and obsessive- compulsive disorder.
Stress-related disorders include post-traumatic stress disorder, hemorrhagic stress, stress-induced psychotic episodes, psychosocial dwarfism, stress headaches, stress-induced immune systems disorders such as stress-induced fever, and stress-related sleep disorders.
Eating disorders include anorexia nervosa, bulimia nervosa, and obesity. Modulators of the CRF receptors are also useful in the treatment (e.g., symptomatic treatment)of a variety of neurological disorders including supranuclear palsy, AIDS related dementias, multiinfarct dementia, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, head trauma, spinal cord trauma, ischemic neuronal damage, amyotrophic lateral sclerosis, disorders of pain perception such as fibromyalgia and epilepsy. Additionally compounds of Formula I are useful as modulators of the CRF receptor in the treatment (e.g., symptomatic treatment) of a number of gastrointestinal, cardiovascular, hormonal, autoimmune and inflammatory conditions. Such conditions include irritable bowel syndrome, ulcers, Crohn's disease, spastic colon, diarrhea, post operative ilius and colonic hypersensitiviry associated with psychopathological disturbances or stress, hypertension, tachycardia, congestive heart failure, infertility, euthyroid sick syndrome, inflammatory conditions effected by rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies.
Compounds of Formula I are also useful as modulators of the CRFl receptor in the treatment of animal disorders associated with aberrant CRF levels. These conditions include porcine stress syndrome, bovine shipping fever, equine ' paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs, psychosocial dwarfism .and hypoglycemia.
Typical subjects to which compounds of the invention may be administered will be mammals, particularly primates, especially humans. For veterinary applications, a wide variety of subjects will be suitable, e.g. livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and other domesticated animals particularly pets such as dogs and cats. For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents (e.g. mice, rats, hamsters), rabbits, primates, and swine such as inbred pigs and the like. Additionally, for in vitro applications, such as in vitro diagnostic and research applications, body fluids (e.g., blood, plasma, serum, CSF, lymph, cellular interstitial fluid, aqueous humor, saliva, synovial fluid, feces, or urine) and cell and tissue samples of the above subjects will be suitable for use..
The CRF binding compounds provided by this invention and labeled derivatives thereof are also useful as standards and reagents in determining the ability of test compounds (e.g., a potential pharmaceutical) to bind to a CRF receptor. Labeled derivatives the CRF antagonist compounds provided by this invention are also useful as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT).
More particularly compounds of the invention may be used for demonstrating the presence of CRF ' receptors in cell or tissue samples. This may be done by preparing a plurality of matched cell or tissue samples, at least one of which is prepared as an experiment sample and at least one of which is prepared as a control sample. The experimental sample is prepared by contacting (under conditions that permit binding of CRF to CRF receptors within cell and tissue samples) at least one of the matched cell or tissue samples that has not previously been contacted with any compound or salt of the invention with an experimental solution comprising the detectably-labeled preparation of the selected compound or salt at a first measured molar concentration. The control sample is prepared by in the same manner as the experimental sample and is incubated in a solution that contains the same ingredients as the experimental solution but that also contains an unlabelled preparation of the same compound or salt of the invention at a molar concentration that is greater' than the first measured molar concentration.
The experimental and control samples are then washed to remove unbound detectably-labeled compound. The amount of detectably-labeled compound remaining bound to each sample is then measured and the amount of detectably-labeled compound in the experimental and control samples is compared. A comparison that indicates the detection of a greater amount of detectable label in the at least one washed experimental sample than is detected in any of the at least one washed control samples demonstrates the presence of CRF receptors in that experimental sample.
The detectably-labeled compound used in this procedure may be labeled with any detectable label, such as a radioactive label, a biological tag such as biotin (which can be detected by binding to detectably-labeled avidin), an enzyme (e.g., alkaline phosphatase, beta galactosidase, or a like enzyme that can be detected its activity in a colorimetric assay) or a directly or indirectly luminescent label. When tissue sections are used in this procedure and
"the detectably-labeled compound is radiolabeled, the bound, labeled compound may be detected autoradiographically to generate an autoradiogram. When autoradiography is used, the amount of detectable label in an experimental or control sample may be measured by viewing the autoradiograms and comparing the exposure density of the autoradiograms. The present invention also pertains to methods of inhibiting the binding of CRF to CRF receptors (preferably CFR1 receptors) which methods involve contacting a solution containing a CRF antagonist compound of the invention with cells expressing CRF receptors, wherein the compound is present in the solution at a concentration- sufficient to inhibit CRF binding to CRF receptors in vitro. This method includes inhibiting the binding of CRF to CRF receptors in vivo, e.g., in a patient given an amount of a compound of Formula I that would be sufficient to inhibit the binding of CRF to CRF receptors in vitro. In one embodiment, such methods are useful in treating physiological disorders associated with excess concentrations of CRF. The amount of a compound that would be sufficient to inhibit the binding of a CRF to the CRF receptor may be readily determined via a CRF receptor binding assay (see, e.g., Example 51), or from the EC5o of a CRF receptor functional assay, such as a standard assay of CRF receptor mediated chemotaxis. The CRF receptors used to determine in vitro binding may be obtained from a variety of sources, for example from cells that naturally express CRF receptors, e.g. IMR32 cells or from cells expressing cloned human CRF receptors.
The present invention also pertains to methods for altering the activity of CRF receptors, said method comprising exposing cells expressing such receptors to an effective amount of a compound of the invention, wherein the compound is present in the solution at a concentration sufficient to specifically alter the signal transduction activity in response to CRF in cells expressing CRF receptors in vitro, preferred cells for this purpose are those that express high levels of CRF receptors (i.e., equal to or greater than the number of CRF1 receptors per cell found in differentiated IMR-32 human neuroblastoma cells), with IMR-32 cells being particularly preferred for testing the concentration of a compound required to alter the activity of CRF 1 receptors. This method includes altering the signal transduction activity of CRF receptors in vivo, e.g., in a patient given an amount of a compound of Formula I that would be sufficient to alter the signal transduction activity in response to CRF in cells expressing CRF receptors in vitro. The amount of a compound that would be sufficient to alter the signal transduction activity in response to CRF of CRF receptors may also be determined via an assay of CRF receptor mediated signal transduction, such as an assay wherein the binding of CRF to a cell surface CRF receptor effects a changes in reporter gene expression.
The present invention also pertains to packaged pharmaceutical compositions for treating disorders responsive to CRF receptor modulation, e.g., eating disorders, depression or stress. The packaged pharmaceutical compositions include a container holding a therapeutically effective amount of at least one CRFl receptor modulator as described supra and instructions for using the treating disorder responsive to CRFl receptor modulation in the patient.
Chemical description and terminology
The compounds herein described may have one or more asymmetric centers or planes. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in' the art how to prepare optically active forms, such as by resolution of racemic forms (racemates), by asymmetric synthesis, or by synthesis from optically active starting materials. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral (enantiomeric and diastereomeric), and racemic forms, as well as all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R*, then said group may optionally be substituted with up to two R groups and R* at each occurrence is selected independently from the definition of R . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
Formula I includes, but is not limited to, compounds of Formula I, IA, and II-XXII. As indicated above, various substituents of the various formulae (compounds of Formula I, I, IA, and II-XXII) are "optionally substituted", including Ar1, Ar2, Rl, R2, and R3 of Formula I and subformulae thereof, and such substituents as recited in the sub-formulae such as Formula I and subformulae. The term "substituted," as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound. When a substituent is oxo (keto, i.e., =0), then 2 hydrogens on an atom are replaced. The present invention is intended to include all isotopes (including radioisotopes) of atoms occurring in the present compounds. When substituents such as Ar, Ri, R , R3, R4, and R5 are further substituted, they may be so substituted at one or more available positions, typically 1 to 3 or 4 positions, by one or more suitable groups such as those disclosed herein. Suitable groups that may be present on a "substituted" Ar, Rla R2, R3, R4, and R5 or other group include e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a Cι-C6 alkarioyl group such as acyl or the like); carboxamido; alkyl groups (including cycloalkyl groups, having 1 to about 8 carbon atoms, preferably 1, 2, 3, 4, 5, or 6 carbon atoms); alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, preferably 2, 3, 4, 5 or 6, carbon atoms); alkoxy groups having one or more oxygen linkages and from 1 to about 8, preferably 1, 2, 3, 4, 5 or 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to' about 8 carbon atoms, preferably 1, 2, 3, 4, 5 or 6 carbon atoms; alkylsulfinyl groups including those having one or more sulfinyl linkages and from 1 to about 8 carbon atoms, preferably 1, 2, 3, 4, 5, or 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, preferably 1, 2, 3, 4, 5, or 6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, preferably 1, 2, 3, 4, 5 or 6, carbon atoms; carbocyclic aryl having 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyl being a preferred arylalkyl group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with O-benzyl being a preferred arylalkoxy group; or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydrapyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino.
As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, /-propyl, n-butyl, s- butyl, t-butyl, n-pentyl, and j-pentyl. Preferred alkyl groups are C1-C10 alkyl groups. Especially preferred alkyl groups are methyl, ethyl, propyl, butyl, and 3-pentyl. The term d- 4 alkyl as used herein includes alkyl groups consisting of 1 to 4 carbon atoms, which may contain a cyclopropyl moiety. Suitable examples are methyl, ethyl, and cyclopropylmethyl. The term "carbhydryl" refers to both branched and straight-chain hydrocarbon groups, which are saturated or unsaturated. In other words, a carbhydryl group may be alkyl, alkenyl or alkynyl. The number of carbon atoms may be specified as indicated above.
"Cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Cycloalkyl groups typically will have 3 to about 8 ring members.
In the term "(C3-C7cycloalkyι)Cι-C4alkyl", cycloalkyl, and alkyl are as defined above, and the point of attachment is on the alkyl group. This term encompasses, but is not limited to, cyclopropylmethyl, cyclohexylmethyl, and cyclohexylmethyl. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more unsaturated carbon-carbon bonds, which may occur. in any stable point along the chain, such as ethenyl and propenyl. Alkenyl groups typically will have 2 to about 8 carbon atoms, more typically 2 to about 6 carbon atoms.
"Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more carbon-carbon triple bonds, which may occur in any stable point along the chain, such as ethynyl and propynyl. Alkynyl groups typically will have 2 to about 8 carbon atoms, more typically 2 to about 6 carbon atoms. carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms. Examples of haloalkyl include, but are not limited to, mono-, di-, or trifluoromethyl, mono-, di-, or tri-chloromethyl, mono-, di-, tri-, terra-, or penta-fluoroethyl, and mono-, di-, tri-, tetra-, or penta-chloroethyl. Typical .haloalkyl groups will have 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
"Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, /-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, 77-hexoxy, 2-hexoxy, 3-hexoxy, and 3- methylpentoxy. Alkoxy groups typically have 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
"Halolkoxy" represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
As used herein, the term "alkylthio" includes those groups having one or more thioether linkages and preferably from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
As used herein, the term "alkylsulfinyl" includes those groups having one or more sulfoxide (SO) linkage groups and typically from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
As used herein, the term "alkylsulfonyl" includes those groups having one or more sulfonyl (S02) linkage groups and typically from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms. As used herein, the term "alkylamino" includes those groups having one or more primary, secondary and/or tertiary amine groups and typically from 1 to about 8 carbon atoms, more typically 1 to about 6 carbon atoms.
"Halo" or "halogen" as' used herein refers to fluoro, chloro, bromo, or iodo; and "counter-ion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
As used herein, "carbocyclic group" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13-membered bicyclic or tricyclic group, any of which may be saturated, partially unsaturated, or aromatic. In addition to those exemplified elsewhere , herein, examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctanyl, [4.3.0]bicyclononanyl, [4.4.0]bicyclodecanyl, [2.2.2]bicyclooctanyl, fluorenyl, phenyl, naphthyl, indanyl, and tetrahydronaphthyl.
As ■ used herein, the term "heterocyclic group" is intended to include saturated, partially unsaturated, or unsaturated (aromatic) groups having 1 to 3 (preferably fused) rings with 3 to about 8 members per ring at least one ring containing an atom selected from N, O or S. The nitrogen and sulfur heteroatoms may optionally be oxidized The term , or "heterocycloalkyl" is used to refer to saturated heterocyclic groups having one or more non- carbon ring atoms (e.g., N, O, S, P, Si, or the like) and a specified number of carbon atoms. Thus, a C3-9heterocycloalkyl is a cyclic group having between 3 and 9 ring carbon atoms and at least one ring heteroatom.
The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. As used herein, the term "aromatic heterocyclic system" is intended to include any stable 5 -to 7-membered monocyclic or 10- to 14-membered bicyclic heterocyclic aromatic ring system which comprises carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 2, more preferably not more than 1.
Examples of heterocycles include, but are not limited to, those exemplified elsewhere herein and further include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, NH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3-Z>]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lΗ-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl;- l,2,5oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazoie, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4Η-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-l,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4- thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.
Preferred heterocyclic groups include, but are not limited to, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, and imidazolyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. '
As used herein, the term "carbocyclic aryl" includes groups that contain 1 to 3 separate or fused rings and from 6 to about 18 ring atoms, without hetero atoms as ring members. Specifically preferred carbocyclic aryl groups include phenyl, and naphthyl including 1-napthyl and 2-naphthyl.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof, and further refers to pharmaceutically acceptable „ solvates of such compounds and such salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, malefic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, pxalic, isethionic, HOOC-(CH2)n-COOH where n is 0-4, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, p. 1418 (1985).
"Prodrugs" are intended to include any compounds that become compounds of Formula I when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Formula I.
Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent. The term "therapeutically effective amount" of a compound of this invention means an amount effective, when administered to a human or non-human patient, to provide a therapeutic benefit such as an amelioration of symptoms, e.g., an amount effective to antagonize the effects of pathogenic levels of CRF or to treat the symptoms of stress disorders, affective disorder, anxiety or depression.
Pharmaceutical Preparations
The compounds of general Formula I may be administered orally, topically, transdermally, parenterally, by inhalation or spray or rectally or vaginally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrathecal and like types of injection or infusion techniques. In addition, there is provided a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier. One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients. The pharmaceutical compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or yrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absoφtion in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long- chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p- hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for" example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally- occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable dilutent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of general Formula I may also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at body temperature and will therefore melt in the body to release the drug. Such materials include cocoa butter and polyethylene glycols.
Compounds of general Formula I may be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, one or more adjuvants such as preservatives, buffering agents, or local anesthetics can also be present in the vehicle.
Dosage levels of the order of from about 0.05 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions, preferred dosages range from about 0.1 to about 30 mg per kg and more preferably from about 0.5 to about 5 mg per kg per subject per day. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 0.1 mg to about 750 mg of an active ingredient. Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most CNS and gastrointestinal disorders, a dosage regimen of four times daily, preferably three times daily, more preferably two times daily and most preferably once daily is contemplated. For the treatment of stress and depression a dosage regimen of 1 or 2 times daily is particularly preferred. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination (i.e. other drugs being used to treat the patient) and the severity of the particular disease undergoing therapy. Preferred compounds of the invention will have certain pharmacological properties.
Such properties include, but are not limited to oral bioavailability, such that the preferred oral dosage forms discussed above can provide therapeutically effective levels of the compound in vivo. Penetration of the blood brain barrier is necessary for most compounds used to treat CNS disorders, while low brain levels of compounds used to treat periphereal disorders are generally preferred.
Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes may be used to predict compound toxicity, with non-toxic compounds being preferred. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of the compound in laboratory animals given the compound, e.g., intravenously.
Percentage of serum protein binding may be predicted from albumin binding assays. Examples of such assays are described in a review by Oravcova, et al. (Journal of Chromatography B (1996) volume 677, pages 1-27). Preferred compounds exhibit reversible serum protein binding. Preferably this binding is less than 99%, more preferably less than 95%, even more preferably less than 90%, and most preferably less than 80%.
Frequency of administration is generally inversely proportional to the in vivo half-life of a compound. In vivo half-lives of compounds may be predicted from in vitro assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and
Disposition, (1998) volume 26, pages 1120-1127). Preferred half lives are those allowing for a preferred frequency of administration.
As discussed above, preferred compounds of the invention exhibit good activity in standard in vitro CRF receptor binding assays, preferably the assay as specified in Example 51, which follows. References herein to "standard in vitro receptor binding assay" are intended to refer to standard assay protocols such as that protocol defined in Example 51, which follows. Generally preferred compounds of the invention have an IC50 (half-maximal inhibitory concentration) of about 1 micromolar or less, still more preferably and IC50 of about 100 nanomolar or less even more preferably an IC50 of about 10 nanomolar or less or even 1 nanomolar or less in such a defined standard in vitro CRF receptor binding assay as exemplified by Example 51 which follows.
EXAMPLES Preparation of Compounds
The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Each of the references cited below are hereby incorporated herein by reference. Preferred methods for the preparation of compounds of the present invention include, but are not limited to, those described in Scheme I. Those who are skilled in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention. Scheme I
Synthesis of Pyrrolo[2,3-b]pyrazines and Furo[2,3-b]pyrazines
- R< ArB(0H)2(2) f^ RQOH. ^ OCI3 v^ ^ 4
3 4 5 6
5 ROOH C'
Figure imgf000042_0001
Figure imgf000042_0002
11 . 12 13
Figure imgf000042_0003
14 16 17
Scheme II
Figure imgf000042_0004
18 " 19 20 21
Figure imgf000042_0005
22 23 25 26
Scheme III
Figure imgf000043_0001
27 28 29 30
Figure imgf000043_0002
Scheme IV
N
Figure imgf000043_0003
34 35 37 38 39
Figure imgf000043_0004
41 42 43 44
Scheme V
Figure imgf000043_0005
51 52 53 54 Scheme VI
Figure imgf000044_0001
55 56 57 58
Figure imgf000044_0002
59 60 61
Scheme VII
"A H2NNHC(SCH3)=NH2 + I" (63) , »- 0r" 21-' mcpba
Figure imgf000044_0003
62 64 66
Figure imgf000044_0004
67 68
Exemplified compounds of the Invention
The R21 -Matrix, R22 -Matrix, Het-Matrix, and Ar-Matrix tables below set forth a number of compounds of the invention which are prepared by the methods illustrated in Reaction Schemes I- VII shown above. Compounds are formed by combining any element from the R21 Matrix or R 2-Matrix with any element from the Het-matrix to form an R2l-Het or R22 moiety, and then combining this moiety with any element of the Ar-Matrix to form a compound of the invention. For example, the combination of element 101 from the R21- Matrix, with element 408 from the Het-matrix, gives the moiety 101408. This moiety is then combined with element 504 from the Ar-matrix, to form a compound of the invention, compound 101408504, which is 3-(2,4-Dimethoxy-phenyl)-2-ethyl-7-(l-ethyl-propyl)- furo[2,3-b]pyrazine.
(R21
Figure imgf000044_0005
R,l-Matrix
Figure imgf000045_0001
R22-Matrix
Figure imgf000045_0002
Figure imgf000046_0001
Hetl-Matrix
Figure imgf000046_0002
Figure imgf000047_0001
Het2-Matrix
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Ar-Matrix
Figure imgf000050_0002
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
All compounds listed below are characterized at least by H-NMR and LCMS. One of the following LCMS methods is used for the compounds shown below.
Method 1.
HPLC instrumentation: Analyses are performed using a Waters 600 series pump (Waters
Corp.), a Waters 996 Diode Array detector and a Gilson 215 auto-sampler (Gilson Inc.). Data are acquired using MassLynx 4.0 software, with OpenLynx processing.
HPLC conditions: 4.6x50mm, XTerra MS C 18, 5 mm column (Waters Corp.); UV 10 spectra sec, 220, 254nm; flow rate 4.0 mL/min; injection volume 1-10 μl; Gradient conditions
- Mobile phase A 95% Water, 5% Methanol with 0.05% Formic acid; Mobile phase B 95% methanol, 5% Water with 0.025% Formic acid;
Gradient: Time (min) %B
0 5
0.01 5
1.0 100
2.0 100
2.1 5 MS instrumentation: LC-MS experiments are performed using a Waters ZMD II Mass Spectrometer.
MS conditions: Electrospray positive ionization; capillary voltage 3.5kV; cone voltage 30V; desolvation and source temperature 250 °C and 100 °C respectively; mass range 120-800 with a scan time of 0.5 seconds and an inter scan delay of 0.1 min.
Method 2.
Flow Injection Condition:
A Perkin Elmer HPLC system (tow Series 200 micro LC pumps, pump A and pump B, with a Series 200 autosampler) is used to perform flow injection. Mobile phase is a combination of 85% methanol (pump B) with 15% of water (pump A). The flow rate is 1.0 mL/min; and the injection volume is 3 μL. MS instrumentation: LC-MS experiments are. performed using a Sciex 150MA Mass Spectrometer. MS conditions: Ion source is Heated Nebulizer (atmosphere pressure chemical ionization). The mass range is 100-1000 amu. Both positive and negative modes are in place. For positive ion mode, Nebulizer current is 2.0 mA, and the temperature is 350 °C. The Nebulizer gas is 10, and' the Curtain gas is 12. The declustering potential is 30 V. The Focusing potential is 200 V, and the entrance potential is -10 V. For negative ion mode, Nebulizer current is -2.0 mA, and the temperature is 350 °C. The Nebulizer gas is 10, and the Curtain gas is 12. The declustering potential is -30 V. The Focusing potential is -200 V, and the entrance potential is 10 V.
Method 3. HPLC Instrumentation: HP1100 PUMP, HP1100 UV detector with 220 nm, HTS/PAL autosampler from Leap Technology, data acquired by Micromass Ma
HPLC conditions: Synergi 2U HYDRO-RP 20 x 4.0mm column, flow rate 1.0 mL/min, injection volume 5 μL.
Gradient conditions: 0.1% formic acid in aqueous acetonitrile,! 0-90% acetonitrile over 3 min, then 100% acetonitrile, end at 5 min.
MS instrumentation: Micromass LCT-TOF MS
MS conditions: Scan m/z 100-1200, capillary voltage 3000V, cone voltage 25V, desolvation
200 °C and source temperature 100 °C. EXAMPLE 1. Preparation of boronic acid intermediates: a. Synthesis of2-(Dimethylamino)-4~methoxypyridin-5-boronic acid
Figure imgf000055_0001
Step A
To a stirred solution of 4-methoxy-lH-pyridin-2-one (Walters and Shay, Tetrahedron Letters 36 (1995), 7575) in methylene chloride (30 mL) at 0°C is added triflic anhydride (12.9g) followed by triethylamine (8.4g). The reaction mixture is stirred for 20 rain and then allowed to warm to room temperature. The volatile components are evaporated under vacuum and then the residue is dissolved in EtOAc and washed consecutively with aqueous sodium bicarbonate, water and brine solution. The organic phase is separated, dried and evaporated under vacuum to give trifluoro-methanesulfonic acid 4-methoxy-pyridin-2-yl ester. It is used in the next step without further purification.
Step B
Trifluoro-methanesulfonic acid 4-methoxy-pyridin-2-yl ester (0.5g) and dimethylamine (2.4 mL of 2M in THF) are dissolved in DMSO (7mL) and warmed overnight at 40°C. EtOAc is added to the reaction mixture and it is washed with brine solution. The organic phase is separated, dried, and evaporated under vacuum. Silica gel purification gives (4- methoxypyridin-2-yl)dimethylamine. It is used in the next step without further purification.
Step C N-Bromosuccinimide (1.75g) is added portionwise to a solution of (4-methoxy-pyridin-2- yl)dimethylamine (1.5g) at 0°C in chloroform (30 mL). After 30 min water (4 mL) is added to the reaction mixture and it is extracted three times with methylene chloride. The combined organic phase is separated, dried and evaporated under vacuum. Silica gel purification gives (5-bromo-4-methoxy-pyridin-2-yl)dimethylamine. LCMS: Rt 1.20 min m/z 231.03(M+H)+.
Step D
To a mixture of n-butyllithium (2.68 mL of 1.6M in hexanes) and toluene (7.4 mL) at -65°C is added dropwise (5-bromo-4-methoxy-pyridin-2-yl)dimethylamine (0.9g) in toluene (4 mL). The reaction mixture is stirred in the cold for 30 min and the THF (1.6 mL) is added and stirring is continued for a further 15 min. Triisopropylborate (1.5g) is then added slowly and stirring is continued for 45 min. The reaction mixture is then allowed to warm to room temperature overnight and IN HCI (10 mL) is added. The aqueous layer is separated and the organic phase is washed consecutively with IN HCI and water. The combined aqueous phase was adjusted to pH7 with solid sodium bicarbonate and extracted with 1 : 1 EtOAc/THF. The organic phase is separated, dried and evaporated under vacuum to give 2-(dimethylamino)-4- methoxypyridin-5-boronic acid. LCMS: Rt 2.56 min m/z 197.12(M+H)+
b. Synthesis of2-(diethylamino)-4-ethylpyridin-5-boronic acid
Figure imgf000056_0001
Step A
2-Amino-4-ethylpyridine (4.70g) is dissolved in dichloromethane (80mL). Addition of acetaldehyde (8.60mL) and stirring for 10 min is followed by addition of sodium triacetoxyborohydride (24.6g). After lh, the reaction is put into a mixture of water (300mL) and sat. sodiunTbicarbonate (50mL). Extraction with DCM (3x200mL) and drying over magnesium sulfate yields a crude mixture that is used in step B without any further purification. LCMS: m/z 179.17 (M+H)+
Step B
The crude mixture from step A is dissolved in chloroform (150mL) and cooled to 0 °C. Addition of NBS (6.50g, in three portions) is followed by stirring for 15min. The light yellow solution is then put into a mixture of water (500mL) and sat. sodium bicarbonate (lOOmL). Extraction with DCM (3xl50mL) and drying over magnesium sulfate yields a crude mixture that is purified on silica gel. LCMS: m/z 257.10 (M+H)+
Step C t-BuLi (50.1mL, 1.7N in pentanes) is added to THF (200mL) at -78 °C. Slow addition of the purified material from step B (7.3 lg, in 30mL of THF) is followed by stirring for 15 min at - 78 °C. Upon LCMS check for unreacted bromide, triisopropyl borate (26.2mL) is added and the reaction mixture is warmed to room temperature over night. The yellowish solution is then put into a mixture of water (1 OOOmL) and sat. sodium bicarbonate (lOOmL). Extraction with DCM (3x300mL) and drying over magnesium sulfate yields a crude material of good purity that can be used directly in palladium mediated couplings. LCMS: m/z 223.19 (M+H)+
2-(Dimethylamino)-4-ethylpyridin-5-boronic acid (MS m/z 195.09 (M+H)+) and 2-(ethyl- methyl-amino)-4-ethylpyridin-5-boronic acid (MS m/z 209.16 (M+H)+) are analogously prepared.
c. Synthesis of2-isopropyl-6-methoxypyridine-3-boronic acid
Figure imgf000057_0001
Step A
Following the procedure of Furstner et al. (JACS 124 (2002) 13856), 2-chloro-6- methoxypyridine (lOOg) is stirred at -30°Cϊn a mixture of THF (2300 mL) and NMP (335 mL). Fe(acac)3 (14.8g) is added, followed by isopropyl magnesium chloride (490 mL of 2M in THF). The reaction mixture is allowed to warm to 0°C over 1 hour and then saturated aqueous ammonium chloride (1000 L) is added. The aqueous phase is separated and the organic layer is washed two times with water (1000 mL). The organic layer is distilled under reduced pressure to give 2-isopropyl-6-methoxypyridine. LCMS: Rt 1.95 min m/z 152.12(M+H)+ Step B
2-Isopropyl-6-methoxypyridine (191.4g) and TMEDA (146.3g) are dissolved in diethyl ether (1565 mL) and cooled to -60°C. n-BuLi (760 mL of 2M) is added over 10 min. and the reaction mixture is allowed to warm to room temperature over 3.5 hours. The reaction mixture is chilled again to -60°C, triisopropylborate (476.2g) is added and stirring is continued for 24 hours. 3M HCI is then added (510 mL), followed by water (2500 mL). The aqueous phase is separated and the organic layer is washed three times with 5% aqueous NaCI (1500 mL). The four aqueous phases are sequentially extracted with diethyl ether (2000 mL) and the combined ether extracts are concentrated under vacuum to give 2- isopropyl-6-methoxypyridine-3-boronic acid. LCMS: Rt 2.80 min m/z 196.11(M+H)+
d. Synthesis of2-methoxy-4-triflιιoromethoxyphenylboronic acid
Figure imgf000058_0001
Step A
3-Trifluoromethoxyphenol (256.42g) is dissolved in dichloromethane (2000 mL) and cooled to 5-10°C under nitrogen. Bromine (241.6g) is added dropwise over 2 hours, maintaining the temperature between 5-10°C and then the cooling bath is removed. Water (1000 mL) is added and the mixtue is stirred for 10 minutes and separated. More water is added to the
Figure imgf000058_0002
organic phase (500 mL) followed by powdered sodium carbonate (10-12g) until the pH is 10-
11. The organic layer is separated again, dried and concentrated under vacuum. Distillation affords 2-bromo-5-trifluoromethoxyphenol, which is used in the next step without further purification.
Step B
To 2-bromo-5-trifluoromethoxyphenol (479g) dissolved in toluene (2600 mL) at 1-10°C is added a solution of sodium hydroxide (80g) in water (400 mL). The reaction mixture is stirred for 20 min and then tetra-n-butylammonium bromide (24g) is added. Dimethyl sulfate (239.3g) is divided into four portions and one portion is added to the mixture every 30 min, maintaining the internal temperature around 12-15°C. The reaction mixture is stirred overnight at this temperature and then water (1000 mL) is added and the organic layer is separated. It is washed consecutively with water (600 mL) and brine (600 mL) and then dried and evaporated to give 3-trifluoromethoxyanisole, which is used in the next step without further purification.
Step C n-Butyllithium (156 mL of 2.5 M solution in hexanes) is added under nitrogen to THF (800 mL) over a period of 5 min while maintaining the temperature between -77 and -67 °C. 2- Methoxy-4-trifluoromethoxy bromobenzene (lOOg) is added over a 10-min period while maintaining the temperature between -76.0 and-62°C. Trimethylborate (53.8 g) is added over 10 min at a temperature of -76.3 to -63.2°C. After 1 hour, 200 ml of 2 N hydrochloric acid (200 mL) is added to pH 1. The mixture is allowed to warm to room temperature and the organic phase is separated and concentrated under vacuum to give crude 2-methoxy-4- trifluorornethoxyphenylboronic acid. The solid is treated with boiling ^-heptane to give 2- methoxy-4-trifluoromethoxyphenylboronic acid. Η-NMR (CDC13, 400 MHz) δ 7.89 (d, J = 8.5 Hz, IH), 6.90 (d, J = 8.5 Hz, IH), 6.75 (s, IH), 6.13 (bs, 2H), 3.94 (s, 3H), Rt 2.87min m/z 281.02(M+HCOO)".
e. Synthesis of 2-ethyl-6-methoxy-3-pyridine boronic acid
Figure imgf000059_0001
Step A Commercially available 2-chloro-6-methoxypyridine is transformed into the ethyl compound as described for the corresponding 2-isopropyl-6-methoxypyridine. Step B
The crude mixture (30. lg) of step B is dissolved in THF (300mL) and treated with 1,3- dibromo-5,5-dimethylhydantoine (1.0-1.2eq, in portions). Once TLC control shows completed conversion of the starting material the addition of the hydantoine is stopped and the mixture is put into water (IL). Extraction with DCM (3x300mL), drying over magnesium sulfate, and purification on silica gel affords the bromide. LCMS: m/z 215.97 (M+H)+
Step C
Conversion of the bromide into the corresponding boronic acid follows the last step of the previously described synthesis of 2-diethylamino-4-ethyl-5-pyridine boronic acid with methyl borate. being used as electrophile. The resulting crude material is of good purity and can be used directly in palladium mediated couplings. LCMS: m/z 182.05 (M+H)+
/ Synthesis of 3-isopropyl-5-methoxy-2,3-dihydro-furo[3,2-b]pyridine 6-boronic acid
Figure imgf000060_0001
Step A
Commercially available 2-bromo-3-hydroxypyridine (9.41 g) and 3,3-dimethylallyl bromide (9.67g) are dissolved in acetone (150mL). After addition of potassium carbonate (17.9g), the mixture is refluxed for 90min before being put into water (300rnL). Extraction with DCM (4x200mL), drying over magnesium sulfate and purification on silica gel affords the allyl ether. LCMS: m/z 241.98 (M+H)+ Step B
The ether of step A (960mg), tributyltin hydride (1.28g), and ABFN (218mg) are dissolved in toluene (20mL) and heated to 95 °C for 26h. The resulting mixture is put into water (300mL) and sat. sodium bicarbonate (30mL). Extraction with DCM (3xl00mL), drying over magnesium sulfate, and purification on silica gel yields the bicyclus. LCMS: m/z 164.13 (M+H)+
Step C
The cyclic ether (524mg) of step B is dissolved in cone, sulfuric acid (5mL) and then cooled to 0 °C. After slow addition of fuming nitric acid (1.25mL), the reaction mixture is stirred for 2h before being put onto 30 ml of ice. The resulting suspension is basified (ph=10) with ION NaOH and subsequently extracted with DCM (3xl00mL). Drying over magnesium sulfate and purification on silica gel affords the desired nitro compound. LCMS: m/z 209.14 (M+H)+
Step D
, The nitro compound (622mg) of step C is dissolved in methanol (20mL). Reduction is achieved by adding a catalytic amount of Pd/C (10%) and maintaining a hydrogen atmosphere (normal pressure) for 90min. Filtration through celite (lOg) and concentration affords a crude mixture that is directly used in step E. LCMS: m/z 179.1 1 (M+H)+ ..
Step E
The crude mixture of step D (459mg) is dissolved in acetic acid (lOmL) and then cooled to 0 °C to yield a semi frozen mixture. Bromine (0.139mL) is slowly added and the reaction is stirred for another 5 min before being put into sat. sodium bicarbonate (100ml) and IN sodium sulfite solution (20mL). Extraction with DCM (3xl00mL), drying over magnesium sulfate, and purification on silica gel affords the bromide. LCMS: m/z 256.98 (M+H)+
Step F
The amino bromide (500mg) of step E is dissolved in a solution of sulfuric acid in methanol (lOmL, 15% sulfuric acid) and then cooled to 0 °C. After addition of sodium nitrite (268mg), the solution is allowed to warm to rt over a period of 16h. After being put into sat. sodium bicarbonate (lOOmL), the aqueous layer is extracted with DCM (3xl00mL) and dried over magnesium sulfate. Purification on silica gel affords the methoxy bromide. LCMS: m/z 272.00 (M+H)+
Ste G Conversion of the bromide into the corresponding boronic acid follows the last step of the previously described synthesis of 2-diethylamino-4-ethy 1-5 -pyridine boronic acid with methyl borate being used as electrophile. The resulting crude material is of good purity and can be used directly in palladium mediated couplings. LCMS: m/z 238.04 (M+H)+
g. Synthesis of2-ethoxy-6-ethyl-5-methanesιdfonyl-3-(4,4,5,5-tetramethyl- [1,3, 2] dioxaborolan-2-yl) -pyridine
Figure imgf000062_0001
Step A
A mixture of 18.8g of 6-ethyl-pyridin-2-ylamine in 400 ml CH2C12 is added NBS (55.32g) portionwise at room temperature. After addition, the resulting mixture is stirred at room temperature for 10 min before it is washed with water and brine. The resulting organic phase is dried, evaporated and purified by column chromatography (Hexane/EtOAc=7/l) to give desired product 3, 5-dibromo-6-ethyl-pyridin-2-ylamine. m/z 281.0 (M+H)+.
Step B
3, 5-Dibromo-6-ethyl-pyridin-2-ylamine (37.5g) is dissolved in anhydrous DMSO (300ml) and the mixture is degassed with N2 for 2 min followed by addition of sodium methylsulfonate (19.5g), (CuOTf)2.Ph.H (3.9g) and trans- 1,2-cyclohexane-diamine (3.06g). After stirring at 110 °C for 20 hours, the resulting mixture is diluted with water, extracted with EtOAc- (4x100ml), washed with brine and dried over Na2S0 . After evaporation of solvent, the residue is purified by column chromatography (Hexane/EtOAc=l/l) to give desired product 3-bromo-6-ethyl-5-methanesulfonyl-pyridin-2-ylamine. m/z 281.2 (M+H)+.
Step C
3-Bromo-6-ethyl-5-methanesulfonyl-pyridin-2-ylamine (7.88g) 'is dissolved in H2S0 -H 0 (ratio 1:6) (175ml) and the mixture is cooled to 0 °C. After adding the solution of NaN02 (4.1g) in 15 ml H20 dropwise (keep inner temperature below 5 °C), the mixture is stirred at 0 °C to room temperature for overnight. The desired product 3-bromo-6-ethyl-5- methanesulfonyl-pyridin-2-ol is collected by filtration following by washing with water (50 ml). This crude product is used for next step without further purification, m/z 280.0 (M+H)+.
Step D A mixture of 3-bromo-6-ethyl-5-methanesulfonyl-pyridin-2-ol (15.84g) and DMF (200ml) is cooled to 0 °C, and K2C03 (11.71g) is added, followed by ethyl iodide (11.3ml). The resulting mixture is stirred at 0 °C to room temperature for overnight. After the reaction is complete, water is added and the resulting mixture is extracted with EtOAc (3x200ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. The pure product 3-bromo-2-ethoxy-6-ethyl-5-methanesulfonyl-pyridine is obtained after column chromatography. m/z 282.1 (M+H-Et)+.
Step E
A mixture of 3-bromo-2-ethoxy-6-ethyl-5-methanesulfonyl-pyridine (400mg) in DMSO , (20ml) is added bis(pinacolato) diboron (396mg), KOAc (382mg) and PdCl2(dppf) (49mg) and the resulting mixture is stirred at 90 °C for overnight. After the reaction is complete, the mixture is poured into water and extracted with ethyl acetate (3x40ml). The combined organic layers are washed with brine, dried over Na2S0 . Flash column chromatography purification (Hexane/EtOAc=8/l) gives the pure product 2-ethoxy-6-ethyl-5- methanesulfonyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridine. m/z 356.3 (M+H)+. h. Synthesis of 5-ethyl-3-isopropyl-6-(4, 4,5, 5-teh-amethyl-[l ,3,2] dioxaborolan-2-yl)-3H- imidazo[4, 5-b] pyridine
Figure imgf000064_0001
B
Figure imgf000064_0002
Step A
To a solution of 2-amino-6-ethyl-pyridine (50 g) in chloroform (250 mL) is added NBS (73 g) at 0 °C over 30 min. The mixture is stirred for additional 30 min and is directly purified by flash column chromatography on silica gel to give 5-bromo-6-ethyl-pyridin-2-ylamine as white solid. Rf (hexane : EtOAc = 4: 1) = 0.34.
Step B
5-Bromo-6-ethyl-pyridin-2-ylamine (34g) is added to cH2S04 (110 mL) below 10 °C. To the stirred mixture is added HN03 (8.2 mL) below 15 °C over 40 min. The mixture is stirred at 0 °C for 1 h, at RT for 1 h and finally at 50 °C for 1 h. The mixture is poured into ice-water and is basified by 50 % NaOH. Yellow crystals are collected by filtration, washed with water and dried under reduced pressure to give 5-bromo-6-ethyl-3-nitro-pyridin-2-ylamine. Rf (hexane : EtOAc = 4:1) = 0.5.
Step C To a stirred suspension of 5-bromo-6-ethyl-3-nitro-pyridin-2-ylamine (5 g) in AcOH (20 mL) is added 48 % HBr (20 mL) below 10 °C. Bromine (2.92 mL) is added to the mixture below 10 °C over 15 min. At 0°C, a solution of NaN02 in water (3.65 g, 15 mL) is added over 20 min below 15 °C. The mixture is stirred at 0 °C for 30 min and at RT for lh. The mixture is cooled to 0 °C, neutralized by 50 % of NaOH, and extracted with DCM. The extract is dried over MgS04 and is concentrated under reduced pressure to give 2^5-dibromo-6-ethyl-3-nitro- pyridine as yellow oil. Rf (hexane : EtOAc = 9:1) = 0.7 Step D
To a stirred suspension of 2,5-dibromo-6-ethyl-3-nitro-pyridine (20 g) in EtOH (20 mL) is added a solution of isopropylamine (25 mL) in water (60 mL) at 0 °C. The mixture is stirred at 0 °C for 10 min and at RT for 2 h. Red-yellow crystals formed are collected by filtration and are washed with water. The wet crystals are dissolved in DCM (250 mL). After drying over MgS0 , the solvent is removed under reduced pressure to give (5-bromo-6-ethyl-3- nitro-pyridin-2-yl)-isopropyl-amine as red-yellow solid. Rf (hexane : EtOAc = 9:1) = 0.77
Step E To a solution of (5-bromo-6-ethyl-3-nitro-pyridin-2-yl)-isopropyl-amine (1 g) in EtOH (4 mL) is added cone. HCI (0.05 mL), water (1 mL) and reduced iron (3 g) at RT. The mixture is refluxed for 90 min. The iron residue is removed by filtration and is washed with EtOH. The combined filtrates are concentrated under reduced pressure. To the residue is added water and the mixture is extracted with EtOAc. The combined extracts are washed with brine and dried over MgS0 . The solvent is removed under reduced pressure to give 5-bromo-6- ethyl-N*2*-isopropyl-pyridine-2,3-diamine as gum. LCMS Rt 1.20 min, m/z 258.05 / 260.04 (M+H)+
Step F 5-Bromo-6-ethyl-N*2*-isopropyl-pyridine-2,3-diamine (1 g) is dissolved in diethoxymethylacetate (4 mL) and is heated at 120 °C for 90 min. After cooling to RT the mixture is directly purified by flash column chromatography on silica gel to give 6-bromo-5- ethyl-3-isopropyl-3H-imidazo[4,5-b]pyridine as colorless oil. Rf (hexane : EtOAc = 2:1) = 0.32
Step G
To a solution of 6-bromo-5-ethyl-3-isopropyl-3H-imidazo[4,5-b]pyridine (59 mg) in DMSO (2 mL) is added bis(pinacolate)diborane (69 mg), KOAc (65 mg) and PdCl2(dppf)-DCM complex (9 mg) at RT. The mixture is stirred at 90 °C for 20 h to give 5-ethyl-3-isopropyl-6- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-3H-imidazo[4,5-b]pyridine, which is able to be used for the coupling. LCMS Rt 1.66 min, m/z 316.22 (M+H)+ Synthesis of 6-Ethyl-4-isopropyl-2-methyl-7-(4,4,5,5-tetramethyl-[l, 3,2] dioxaborolan-2- yl)-4H-pyrido[2,3-b]pyra∑in-3-orιe
Figure imgf000066_0001
Step A
To a solution of 5-bromo-6-ethyl-N*2*-isopropyl-pyridιne-2,3-diamine (2.38 g) in toluene (10 mL) is added ethyl pyruvate (2.05 mL) at RT. The mixture is refluxed for 18 h and is poured into water and is extracted with EtOAc. The extract is washed with brine and is dried over MgS04. After removal of the solvent under reduced pressure the residue is purified by flash column chromatography on silica gel to give 7-bromo-6-ethyl-4-isopropyl-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one as white crystal. LCMS Rt 1.74 min, m/z 310.02 / 312.02 (M+H)+
Step B To a solution of 7-bromo-6-ethyl-4-isopropyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (0.2 g) in DMSO (4 mL) is added bis(pinacolate)diborane (0.2 g), KOAc (0.19 g) and PdCl2(dppf)-DCM complex (29 mg) at RT. The mixture is stirred at 90 °C for 20 h to give 6- ethyl-4-isopropyl-2-methyl-7-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-4H-pyrido[2,3- b]pyrazin-3-one, which is able to be used for the coupling. LCMS Rt 1.80 min, m/z 358.22 (M+H)+
EXAMPLE 2
Synthesis of 5-(l-ethyl-propyl)-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-
5H-py r rolo [2,3-b] p razine
Figure imgf000067_0001
Step A
The previously described 2-bromo-3-methyl-5-wopentylaminopyrazine (870mg) and the literature known 2-methoxy-4-trifluoromethoxyphenyl boronic acid (796mg) are dissolved in DME (15mL). After degassing, tetrakis(triphenylphosphine)palladium'(0) (390mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (6.74mL) whereupon the reaction is heated to 80 °C for 6h. The yellowish mixture is then put into water (200mL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica- gel affords the coupled product. LCMS: m/z 370.17 (M+H)+
Step B
The product (205mg) of step A is dissolved in chloroform (lOmL) and NBS (99mg) is added. After being stirred for 10 min, the yellowish mixture is put into water (lOOmL), extracted- with DCM (3xlO0mL), and dried over magnesium sulfate. Purification on silica gel affords the bromide. LCMS: m/z 448.11 (M+H)+
Step C The bromide (173mg) of step B and allyl bromide (0.33mL) are dissolved in DMF (5mL). Sodium hydride (lOOmg) is added and the reaction is stirred for lOmin at rt. The mixture is then put into water (lOOmL) and extracted with ethyl ether (2xl00mL). The combined organic layers are washed with water (50mL), dried over magnesium sulfate, and purified on silica gel to afford the allylated amino-compound. LCMS: m/z 488.11 (M+H)+
Step D
The allyl compound (138mg) of step C, tetrabutylammonium bromide (91mg), palladium acetate (6.4mg), and potassium carbonate (117mg) are dissolved in DMF (5mL). After heating to 80 °C for 90 min, the mixture is worked-up according to step C. Final purification on silica gel affords the title compound. LCMS: m/z 408.21 (M+H)+
EXAMPLE 3 Synthesis of {5-[3-chloro-5-(l-ethyI-propyI)-7-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl]-4- ethyl-pyridin-2-yl}-dimethyl-amine
Figure imgf000068_0001
Step A
The previously described 2-chloro-6-«øpentylaminopyrazine (25. lg) is dissolved in chloroform (450mL) and NBS (47. lg) is added in portions. After being stirred for 30 min, the yellowish mixture is put into water (400mL) and sat. sodium bicarbonate (lOOmL), extracted with DCM (3x200mL), and dried over magnesium sulfate. The crude material is carried on to step B without any further purification. Rf = 0.57 in hex/ethyl acetate (10/1)
Ste B The crude material (28.37g) of step A and allyl bromide (20.6mL) are dissolved in DMF (200mL). Sodium hydride (4.76g) is added in portions and the reaction is stirred for 5h at rt. The mixture is then put into water (500mL) and extracted with ethyl acetate/hexane (1/20, 3x300mL). The combined organic layers are dried over magnesium sulfate and purified on silica gel to afford the allylated product. LCMS: m/z 395.85 (M+H)+
Step C
The allyl compound (23.36g) of step B, tetrabutylammonium bromide (19.00g), palladium acetate (1.32g), and potassium carbonate (24.8g) are dissolved in DMF (200mL). After heating to 80 °C for 20 min, the mixture is put into water (500mL) and extracted with ethyl acetate/hexane (1/4, 3x300mL). The combined organic layers are washed with water (lOOmL), dried over magnesium sulfate, and purified on silica gel to afford the Heck-product. LCMS: m/z 316.01 (M+H)+
Step D
The Heck-product of step C (1.5g) and the previously described 2-dimethylamino-4-ethyl-5- pyridine boronic acid (1.38g) are dissolved in DME (30mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (550mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (9.5mL) whereupon the reaction is heated to 80 °C for 16h. The yellowish mixture is then put into water (200mL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 386.20 (M+H)+
EXAMPLE 4
Synthesis of 3-chloro-5-(l-ethyl-propyl)-2-(3-isopropyl-5-methoxy-furo [3,2-b]pyridin-6-yI)-7-methyl-5H-pyrrolo[2,3-b]pyrazine
Figure imgf000070_0001
Step A
The previously described bromide (85mg) and the also previously described pyridine boronic acid (64mg) are dissolved in DME (3mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (31mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (0.54mL) whereupon the reaction is heated to 80 °C for 16h. The yellowish mixture is then put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the coupled product. LCMS: m/z 429.08 (M+H)+
Step B
The Suzuki product (52mg) of step A and DDQ (41mg) are dissolved in benzene (5mL) and heated to 80 °C for 3h. The reaction mixture is then put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 427.12 (M+H)+
EXAMPLE 5 Synthesis of (S)-3-chloro-2-(6-isopropyI-2-methoxy-pyridin-3-yI)-5-(2-methoxy-l- methyl-ethyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazine and (S)-3-ethyl-2-(6-isopropyI-2- methoxy-pyridin-3-yl)-5-(2-methoxy-l-methyl-ethyl)-7-methyl-5H-pyrrolo[2,3- b] pyrazine
Figure imgf000071_0001
Pd(OAc)2 Step F
Figure imgf000071_0002
Step A
2,6-Dichloropyrazine (11.7g), (S)-(+)-l-methoxy-2-propylamine (7g) and Et N (15 mL) in EtOH (100 mL) are heated at 105 °C for 2 days. The mixture is evaporated and dissolved in EtOAc and washed with sat. NaHC03, H20 and dried. Evaporation affords 2-chloro-6-[(S)-l- methoxy-2-propyl]aminopyrazine. LCMS: m/z 202.3 and 204.3 (M+H)+
Step B
2-Chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazine (8.3g) is dissolved in CHC13 (250mL). Upon addition of NBS (7.33g), the reaction mixture is stirred at 25 °C for 30 min. Subsequently, the crude mixture is evaporated, dissolved in EtOAc/hexane (1:4, 500mL), washed with water and dried over sodium sulfate. Purification on silica gel affords 3-bromo- 2-chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazine. LCMS: m/z 280.2, 282.2 and 284.2 (M+H)+
Step C
3-Bromo-2-chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazine (10.7g) and 2-methoxy-6- isopropyl-3-pyridineboronic acid (9.7g) are dissolved in DME (250mL). After lOmin of degassing, tetrakis(triphenylphosphine)palladium(0) (2.2g) is added, followed by 1 min of degassing. Upon addition of an aqueous IN sodium carbonate solution (76mL), the reaction mixture is heated at 90 °C for 12h. Subsequently, the crude mixture is put into water (800mL), extracted with EtOAc/hexane (1:1, 3x250mL), and dried over sodium sulfate. Purification on silica gel affords 3-{2-chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazin-3-yI}- 2-methoxy-6-isopropylpyridine. LCMS: m/z 351.3 and 353.3 (M+H)+
Step D
3-{2-Chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazin-3-yl}-2-methoxy-6-isopropylpyridine (4.85g) is dissolved in CHC13 (60mL). Upon addition of NBS (2.46g), the reaction mixture is stirred at 25 °C for 30 min. Subsequently, the crude mixture is evaporated, dissolved in
EtOAc/hexane (1:4, 250mL), washed with water and dried over sodium sulfate. Purification on silica gel affords 3-{5-bromo-2-chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazin-3-yl}-2- methoxy-6-isopropylpyridine. LCMS: m/z 429.2, 431.2 and 433.2 (M+H)+
Step E
3-{5-Bromo-2-chloro-6-[(S)-l-methoxy-2-propyl]aminopyrazin-3-yl}-2-methoxy-6- isopropylpyridine (4.3 g) is dissolved in DMSO (50 ml). Upon addition of NaH (60%, 0.8g), the reaction mixture is stirred at 25 °C for 30 min before allyl bromide (1.7 mL) is added. The reaction mixture is stirred at 25 °C for 2h. Subsequently, the crude mixture is put into water (250mL), extracted with EtOAc/hexane (1 :4, 2x250mL), and dried over sodium sulfate. Purification on silica gel affords 3-{5-bromo-2-chloro-6-[(S)-N-allyl-l-methoxy-2- propyl]aminopyrazin-3-yl}-2-methoxy-6-isopropylpyridine . LCMS: m/z 469.3, 471.3 and 473.3 (M+H)+
Step F
3-{5-Bromo-2-chloro-6-[(S)-N-allyl-l-methoxy-2-propyl]aminopyrazin-3-yl}-2-methoxy-6- isopropylpyridine (4.6g) is dissolved in DMF (80mL). After lOmin of degassing, Pd(OAc)2 (225mg) is added, followed by 1 min of degassing. Upon addition of potassium carbonate (4.1 g) and Bn4NBr (4.0g), the reaction mixture is heated at 90 °C for lh. Subsequently, the crude mixture is put into water (500mL), extracted with EtOAc/hexane (1:2, 3xl50mL), and dried over sodium sulfate. Purification on silica gel affords (S)-3-chloro-2-(6-isopropyl-2- methoxy-pyridin-3-yl)-5-(2-methoxy-l-methyl-ethyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazine. LCMS: m/z 389.4 and 391.4 (M+H)+ Step G
(S)-3-Chloro-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-5-(2-methoxy-l-methyl-ethyl)-7- methyl-5H-pyrrolo[2,3-b]pyrazine (400mg) is dissolved in toluene (5mL). After lOmin of degassing, tetrakis(triphenylphosphine)palladium(0) (35mg) is added, followed by 1 min of degassing. Upon addition of triethylborane (IN in hexane, 3 mL) and aqueous IN sodium carbonate solution (2mL), the reaction mixture is heated at 110 °C for 36h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc/hexane (1:3, 3x25mL), and dried over sodium sulfate. Purification on silica gel affords (S)-3-ethyl-2-(6-isopropyl-2- methoxy-pyridin-3-yl)-5-(2-methoxy-l-methyl-ethyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazine. LCMS: m/z 383.4 (M+H)+
EXAMPLE 6 Synthesis of methanesulfonic acid 2-[(S)-2-(6-isopropyI-2-methoxy-pyridin-3-yl)-3,7- dimethyI-pyrrolo[2,3-b]pyrazin-5-yl]-butyl ester, 3-{2-[(S)-2-(6-isopropyl-2-methoxy- pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yI]-butyl}-oxazolidin-2-one, {2-[(S)~ 2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyI}- methyl-amine, N-{2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyI- pyrrolo[2,3-b]pyrazin-5-yl]-butyI}-N-methy.I-acetamide, N-{2-[(S)-2-(6-isopropyl-2- methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyI}-N-methyl- methanesulfonamide, {2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl- pyrrolo[2,3-b]pyrazin-5-yl]-butyl}-methyl-carbamic acid methyl ester and (S)-2-(6- isopropyI-2-methoxy-pyridin-3-yl)-5-(l-methoxymethyl-ropyI)-3,7-dimethyl-5H- pyrrolo[2,3-b] pyrazine
Figure imgf000074_0001
Step A
2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butan-1-ol (275 mg) is dissolved in CH2C12 (6mL). MsCl (0.07 mL) and Et3N (0.16mL) are added at r.t. and the mixture is stirred for lh. The mixture is evaporated and dissolved in EtOAc/hexane (1:1) and washed with sat. NaHC03, H20 and dried. Evaporation affords the methanesulfonate. LCMS: m/z 447.1 (M+Hf
Step B
2-Oxazolidone (26 mg) is dissolved in DMF (3mL). NaH (12 mg, 60%) is added at r.t. and the mixture is stirred for 10 min at 85 °C. Upon addition of the methanesulfonate from step A (35mg), the reaction mixture is heated at 85 °C for 3h. Subsequently, the mixture is poured into H20 and extracted with EtOAc. Evaporation and purification on silica gel affords 3-{2-. [(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butyl}-oxazolidin-2-one. LCMS: m/z 438.4(M+H)+
Step C The above methanesulfonate (120mg) from step A, Lil (150mg) and methylamine (7M in NMP, 2mL) are heated at 90 °C for 4h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc (2x15mL), and dried over sodium sulfate. Purification on silica gel affords {2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2, 3-b]pyrazin-5-yl]-butyl}-methyl-amine. LCMS: m/z 383.3 (M+H)+
Step D
{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2, 3-b]pyrazin-5-yl]-butyl}-methyl-amine (30mg) is dissolved in CH2C12 (1 mL). Acetyl chloride (0.017 mL) and Et3N (0.033 mL) are added. The resulting reaction mixture is stirred at r.t. for 30 min. Subsequently, the crude mixture is put into water (2mL), extracted with EtOAc (2x5mL), washed with sat. NaHC03 (2 mL) and dried over sodium sulfate. Purification on silica gel affords N-{2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yι)-3,7- dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyl}-N-methyl-acetamide. LCMS: m/z 424.5 (M+H)+
Step E
{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2, 3-b]pyrazin-5-yl]-butyl}-methyl-amine (20mg) is dissolved in CH C12 (1 mL). Methanesulfonyl chloride (0.008 mL) and Et3N (0.021 mL) are added. The resulting reaction mixture is stirred at r.t. for 30 min. Subsequently, the crude mixture is put into water (2mL), extracted with EtOAc (2x5mL), washed with sat. NaHC03 (2 mL) and dried over sodium sulfate. Purification on silica gel affords N-{2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)- 3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyl}-N-methyl-methanesulfonamide. LCMS: m/z 460.3 (M+H)+
Step F
{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2, 3-b]pyrazin-5-yl]-butyl}-methylamine (20mg) is dissolved in CH2C12 (1 mL). Methyl chloroformate (0.012 mL) and Et3N (0.013 mL) are added. The resulting reaction mixture is stirred at r.t. for 30 min. Subsequently, the crude mixture is put into water (2mL), extracted with EtOAc (2x5mL), washed with sat. NaHC03 (2 mL) and dried over sodium sulfate. Purification on silica gel affords {2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7- dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyl}-methyl-carbamic acid methyl ester. LCMS: m/z 440.4 (M+H)+
Step G
2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butan-1-ol (40 mg) is dissolved in DMF (JmL). NaH (60%, 7 mg) is added, followed by CH3I (0.02mL) at r.t. and the mixture is stirred for lh. The mixture is evaporated and dissolved in EtOAc/hexane (1 :1) and washed with sat. NaHC03, H20 and dried. Evaporation affords (S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-5-(l-methoxymethyl-ropyl)-3,7- dimethyl-5H-pyrrolo[2,3-b]pyrazine. LCMS: m/z 383.2 (M+H)+
EXAMPLE 7
Synthesis of (R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-(l-morpholin-4- ylmethyl-propyI)-5H-pyrrolo[2,3-b]pyrazine, diethyl-{2-[(R)-2-(6-isopropyl-2-methoxy- pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyl}-amine, (R)-2-(6-isopropyl- 2-methoxy-pyridin-3-yl)-5-(l-methoxymethyl-propyl)-3,7-dimethyI-5H-pyrrolo[2,3- bjpyrazine, acetic acid 2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl- pyrroIo[2,3-b]pyrazin-5-yl]-butyl ester, and dimethylcarbamic acid 2-[(R)-2-(6- isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yI]-butyl ester
Figure imgf000076_0001
sCI Step A
Figure imgf000076_0002
Step A
2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butan-1-ol (275 mg) is dissolved in CH2C12 (6mL). MsCl (0.07 mL) and Et3N (0.16mL) are added at r.t. and the mixture is stirred for lh. The mixture is evaporated and dissolved in EtOAc/hexane (1:1) and washed with sat. NaHC03, H20 and dried. Evaporation affords the methanesulfonate. LCMS: m/z 447.1 (M+H)+
Step B The above methanesulfonate (95mg), Lil (50mg) and morpholine (0.35mL) are heated at 90 °C for 4h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc (2x15mL), and dried over sodium sulfate. Purification on silica gel affords (R)-2-(6- isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-(l-morpholin-4-ylmethyl-propyl)-5H- pyrrolo[2,3-b]pyrazine. LCMS: m/z 438.5 (M+H)+
Step C
The above methanesulfonate (115mg), Lil (50mg) and diethylamine (0.5mL) in CH3CN (3mL) are heated at 90 °C for 4h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc (2x15mL), and dried over sodium sulfate. Purification on silica gel affords diethyl-{2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- b]pyrazin-5-yl]-butyl}-amine. LCMS: m/z 424.14 (M+H)+
Step D
2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butan-1-ol (185mg) is dissolved in DMF (2mL). NaH (60%, 40 mg) is added, followed by CH3I (O.lmL) at r.t. and the resulting mixture is stirred for lh. The mixture is evaporated and dissolved in EtOAc/hexane (1:1) and washed with sat. NaHC03, H20 and dried. Evaporation affords (R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-5-(l-methoxymethyl-propyl)-3, 7- dimethyl-5H-pyrrolo[2,3-b]pyrazine. LCMS: m/z 383.2 (M+H)+
Step E
2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butan-1-ol (37mg) is dissolved in CH2C12 (1 mL). Acetyl chloride (0.015 mL) and Et3N (0.028 mL) are added. The resulting reaction mixture is stirred at r.t. for 30 min. Subsequently, the crude mixture is put into water (2mL), extracted with EtOAc (2x5mL), washed with sat. NaHC03 (2 mL) and dried over sodium sulfate. Purification on silica gel affords acetic acid 2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- b]pyrazin-5-yl]-butyl ester. LCMS : m/z 411.4 (M+H)+
Step F
2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]- butan-1-ol (70mg) is dissolved in CH2C12 (2 mL). Dimethylcarbamyl chloride (0.08 mL) and pyridine (0.2 mL) are added. The resulting reaction mixture is stirred at 75 °C overnight. Subsequently, the crude mixture is put into water (2mL), extracted with EtOAc (2x1 OmL), washed with sat. NaHC03 (4 mL) and dried over sodium sulfate. Purification on silica gel affords dimethylcarbamic acid 2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl- pyrrolo[2,3-b]pyrazin-5-yl]-butyl ester. LCMS: m/z 440.4 (M+H)+
EXAMPLE 8
Synthesis of [6-isopropyl-3-(5-isopropyl-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)- pyridin-2-yl]-methyl-amine and 2-(2-ethyI-6-isopropyl-pyridin-3-yl)-5-isopropyl-3,7- dimethyl-5H-pyrrolo [2,3-b] pyrazine
Figure imgf000079_0001
eNH2 Step C
Figure imgf000079_0002
Et3B / Pd(PP 3)4 Step D
Figure imgf000079_0003
Step A.
5-Isopropyl-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine (900 mg) is heated in HCI (4N, 6mL) at 75 °C for 8h. The mixture is then neutralized and extracted with CHC13 (2x25mL). Evaporation affords 5-isopropyl-2-(6-isopropyl-2-hydroxy- pyridin-3-yl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine LCMS: m/z 325.4 (M+H)+
Step B
5-Isopropyl-2-(6-isopropyl-2-hydroxy-pyridin-3-yl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine (400mg) is dissolved in CH C12 (8mL). Tf20 (0.26 mL) and Et3N (0.26mL) are added at r.t. and the mixture is stirred for 30 min. The mixture is evaporated and dissolved in EtOAc/hexane (1:1) and washed with sat. NaHC03, H20 and dried. Evaporation affords the triflate. LCMS: m/z 457.4 (M+H)+ Step C
The above triflate (215mg) and methylamine (5M in NMP, 2mL) are heated at 90 °C for 4h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc/hexane (1 : 1, 2x15mL), and dried over sodium sulfate. Purification on silica gel affords [6-isopropyl-3-(5- isopropyl-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-pyridin-2-yl]-methyl-amine. LCMS: m/z 338.3 (M+H)+
Step D The above triflate (270mg) is dissolved in toluene (5mL). After lOmin of degassing, tetrakis(triphenylphosphine)palladium(0) (35mg) is added, followed by 1 min of degassing. Upon addition of triethylborane (IN in hexane, 1.8 mL), aqueous IN sodium carbonate solution (1.2mL) andLiCl (125mg), the reaction mixture is heated at 110 °C for 6h. Subsequently, the crude mixture is put into water (lOOmL), extracted with EtOAc/hexane (1:4, 3x20mL), and dried over sodium sulfate. Purification on silica gel affords 2-(2-ethyl-6- isopropyl-pyridin-3-yl)-5-isopropyl-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine. LCMS: m/z 337.2 (M+H)+
EXAMPLE 9
Synthesis of l-(l-ethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl- lH-pyrrolo[3,2-b]pyridine
Figure imgf000080_0001
Figure imgf000080_0002
Step A To a solution of the above nitro compound (2.63g) in ether (30mL) is added SnCl x2H20 (6.54g) in cone. HCI (20mL)) dropwise at room temperature. After the addition is completed, the reaction mixture is stirred at room temperature for lh. The reaction mixture is basified with ION NaOH (cooled with ice-bath) to pH 9-10. After extracting with ether (200mLx3), the combined ether-layers are dried over Na2S0 to give a crude mixture that is used in step B without any further purification. Η NMR (CDC13, δppm): 7.26 (IH, d, J= 8.3 Hz), 6.93 (IH, s), 6.89 (IH, d, J= 8.3 Hz ), 6.79 (IH, s), 4.03(2H, brs), 3.78 (3H, s), 2.05 (3H, s).
Step B To a solution of the crude product (166mg) from step A in DMSO (2ml) is added NaH (60%, 60mg). The reaction mixture is stirred at rt for 2h, followed by addition of 3-bromopentane (226mg). After being stirred at rt for 30min, the yellowish mixture is quenched with water and extracted with EtOAc. The organic layer is washed with water twice, then brine to be finally dried over Na2S0 . The crude product is purified on silica gel. Η NMR (CDC13, δppm): 7.26 (IH, d, J= 8.3 Hz), 6.87 (IH, d, J= 8.3 Hz ), 6.77 (IH, s), 6.76 (IH, s), 4.13 (IH, d, J= 8.6 Hz), 3.74 (3H, s), 3.24-3.29 (IH, m), 2.07 (3H, s), 1.59-1.69 (2H, m), 1.49-1.59 (2H, m), 0.97 (6H, t, J= 7.3 Hz ).
Step C To a solution of the alkylation product of step B (403mg) in NMP (2mL) and tetrabutylammonium bromide (cat.) is added NaH (60%, 120mg). The reaction mixture is stirred at rt for 2h followed by addition of allyl bromide (2 eq.). After being stirred at 60 °C for 3h, the mixture is quenched with water, extracted with EtOAc, and dried over Na2S0 . The crude product is purified on silica gel. Η NMR (CDC13, δppm): 7.29 (IH, d, J= 8.2 Hz), 7.17 (IH, s), 6.86 (IH, d, J= 8.2 Hz ), 6.76 (IH, brs), 5.66-5.75 (IH, m), 5.18 (IH, d, J = 18Hz), 5.05 (IH, d, J= l.OHz), 3.77-3.81 (5H, CH2, CH3), 3.32 (IH, m), 2.07 (3H, s), 1.54- 1.63 (4H, m), 0.95 (6H, t, j= 7.5 Hz ).
Step D A mixture of the allylamine of step C (lOOmg), Pd(OAc)2 (5.1mg), tetrabutylammonium bromide (72.9mg), and K2C03 (93mg) in DMF (3mL) is degassed and then heated to 80 °C overnight. The mixture is subsequently quenched with water, extracted with EtOAc, and dried over Na2S0 . Purification on silica gel yields the title compound. 'H NMR (CDC13, δppm): 7.43 (IH, s), 7.35 (IH, d, J= 8.3 Hz ), 7.08 (IH, d, J= 1.0 Hz), 6.91-6.94 (IH, dm), 6.80 (IH, brs), 3.99 (IH, m), 3.77 (3H, s), 2.40( 3H, s), 2.21 (3H, s), 1.85-1.91 (4H, m), 0.80 (6H, brs).
EXAMPLE 10
Synthesis of ethyl-{4-ethyl-5-[l-(l-ethyI-propyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-
5-yl]-pyridin-2-yl}-methyl-amine
Figure imgf000082_0001
Step A
The shown nitropyridine (25g) in POCl3 (lOOmL) is refluxed for 8h. After completed reaction, the reaction mixture is concentrated at reduced pressure to dryness. Ice (lOOg ) is added to the residue, which is then neutralized with 2N NaOH. Extraction with EtOAc (200mLx2) and drying over MgS04 yields a crude product which is used in step B without any further purification.
Step B
To a solution of the chloro compound froni step A (20g) in ethanol (300mL) is added SnCl2x2H20 (132g) portionwise. After the addition is completed, the mixture is stirred for an additional 2h at 50 °C before the solvent is removed under reduced pressure. DCM (400mL) is added and the suspension is neutralized with ION NaOH and then filtered through celite. The filtrate is washed with water, brine, and finally dried over MgS0 to yield the amine. The crude mixture is used in step C without any further purification.
Step C To a solution of the amine (13.5g) from step B in NMP (80mL) is added tetrabutylammonium bromide (0.3g) and NaH (60%, 7.6g) at 0 °C. After being stirred at rt for 3h, 3-bromopentane (1.5 eq.) is added. The reaction mixture is then stirred for an additional 2h before being quenched with water and extracted with EtOAc. The organic layer is washed with water, brine, and dried over MgS0 . Evaporation under reduced pressure yields a crude product which is used in step D without any further purification. Η NMR (CDC13, δppm): 7.48 (IH, s), 6.67 (IH, s ), 4.07 (IH, d, J= 8.2Hz), 3.2-3.24 (IH, m), 2.23 (3H, s), 1.48-1.68 (4H, m), 0.93 (6H, t, J= 7.3 Hz).
Step D The crude material of step C (3.0g) is dissolved in CHC13 (20mL) and NBS (2.63g) is added at room temperature. After being stirred at rt for 30 min, the reaction mixture is washed with water, brine, and dried over Na2S04 before it is purified on silica gel to yield the bromide. Η NMR (CDC.l3, δppm): 6.74 (IH, s), 4.04 (IH, d, J= 7.8Hz), 3.17-3.22 (IH, m), 2.29 (3H, s), 1.47-1.56 (2H, m), 1.56-1.66 (2H, m), 0.93 (6H, t, J= 7.4 Hz).
Step E
To a solution of the bromide from step D (3.66g) in NMP is added tetrabutylammonium bromide (O.lg) and NaH (60%, 1.0g) at rt. After being stirred at rt for 3h, allyl bromide (3.0g) is added and the reaction mixture is stirred for an additional 4h. The reaction mixture is then quenched with water and extracted with EtOAc. The organic layer is washed with water, brine, and dried over MgS0 to yield a crude product, which is used in step F without any further purification. Η NMR (CDC13, δppm): 7.11 (IH, s), 5.56-5.66 (IH, m), 5.13 (IH, d, J = 17.4Hz), 5.13 (IH, d, J= 10Hz), 3.70-3.72 (2H, m), 3.22-3.26 (IH, m), 2.29 (3H, s), 1.52-1.60 (4H, m), 0.91 (6H, t, J= 7.4Hz).
Step F
The crude material of step E (4.1g), Pd(OAc)2 (275mg), tetrabutylammonium bromide (4.5g), and K2G03 (5.1g) are dissolved in DMF (20mL). After degassing, the mixture is heated to 80 °C overnight. The black solution is then diluted with EtOAc before being washed with H20, brine, and dried over MgS0 . Purification on silica gel yields the bicyclic compound. Η NMR (CDCls, δ ppm): 7.43 (IH, s), 7.05 (IH, s ), 3.89-3.92 (IH, m), 2.48 (3H, s), 2.36 ( 3H, s), 1.76-1.88 (4H, m), 0.72 (6H, t, J= 7.3 Hz).
Step G
The bicyclic material of step F (118mg), Pd(PPh3)4 (70mg) and the previously described 4- ethyl-2-ethylmethylamino-3-pyridine boronic acid (104mg) are dissolved in toluene (lOmL). Upon addition of 2N Na2C03 (4mL), the mixture is degassed and then heated overnight to 80 °C. Subsequently, the mixture is diluted with EtOAc and washed with H20, brine, and finally dried over MgS04. Purification on silica gel yields the title compound. 1H NMR (CDC13, δ ppm): 8.00 (IH, s), 7.43 (IH, s ), 7.07 (IH, brs), 6.45 (IH, s), 3.96-4.01 (IH, m), 3.62 (2H, q, J=.7.0 Hz), 2.48 (3H, s), 3.06 (3H, s), 2.42 (2H, q, J= 7.5 Hz), 2.39 ( 3H, s), 2.23 (3H, s), 1.81-1.90 (4H, m), 1.18 (3H, t, J= 7.2 Hz), 1.03 (3H, t, J= 7.5 Hz), 0.81 (6H, t, J= 7.3 Hz).
EXAMPLE 11
Synthesis of 5-(2-ethyI-6-isopropyl-pyridin-3-yl)-l-(l-ethyl-propyl)-3,6-dimethyl-lH- py rrolo [3,2-b] pyridine
Figure imgf000084_0001
Figure imgf000084_0002
Step A
The previously described bicyclic bromide (590mg), the also previously described 6- isόpropyι-2-methoxy-3-pyridine boronic acid (507mg), and Pd(PPh3)4 (115mg) are dissolved in toluene (30mL). Upon addition of 2N Na2C03 (6mL), the mixture is degassed and then ' heated overnight to 85 °C. Subsequently, the mixture is diluted with EtOAc and washed with 2N NaOH, H20, brine, and finally dried over MgS0 . Purification on silica gel yields the coupled product. 1H NMR (CDC13, δ ppm): 7.55 (IH, d, J= 7.3 Hz), 7.42 (IH, s ), 7.06 (IH, d, J= 1.1 Hz), 6.84 (IH, d, J= 7.5 Hz), 3.96-4.00 (IH, ), 3.91 (3H, s), 2.98-3.01 (IH, m), 2.39 (3H, d, J= 1.1 Hz), 2.25 (3H, s), 1.82-1.90 (4H, m), 1.31 (6H, d; J= 7.0Hz), 0.80 (6H, t, J= 7.5 Hz).
Step B
The Suzuki-product of step A (718mg) is dissolved in 3N HCI (50mL) and heated to 70 °C overnight. The reaction mixture is cooled to ambient temperature, neutralized with 2N NaOH, and extracted with CHC13 (100mLx2). Drying over MgS04 yields the pyridone, which is used in step C without any further purification.
Step C
The pyridone (700nig) of step B is dissolved in CH2C12. Triethylamine (3 eq.) is added, followed by dropwise addition of Tf20 (1.5 equivalents) at 0 °C. After being stirred at rt for 2h, the reaction mixture is washed with H20, brine, and dried over MgS04. The triflate is used in step D without any further purification.
Step D The crude material of step C (48mg), Pd(PPh3)4 (11.5mg), and triethylborane (0.5mL, IN in hexane) are dissolved in toluene (2mL). After addition of 2N Na2C03 (0.5mL), the mixture is degassed and then heated at 85 °C overnight. The solution is diluted with EtOAc and washed with 2N NaOH, H20, brine, and finally dried over MgS04. Purification on silica gel yields the title compound. Η NMR (CDC13, δ ppm): 7.46 (IH, d, J= 7.9 Hz), 7.44 (IH, s ), 7.09 (IH, d, J= 0.8 Hz), 7.06 (IH, d, J= 7.7 Hz), 3.97-4.01 (IH, m), 3.10-3.13 (IH, m), 2.60 (2H, q, J= 7.3Hz), 2.39 (3H, d, J= 0.8 Hz), 2.16 (3H, s), 1.81-1.90 (4H, m), 1.32 (6H, d, J= ■ 7.0Hz), 1.15 (3H, t, J= 7.3Hz), 0.80 (6H, t, J= 7.6 Hz). EXAMPLE 12
Synthesis of 5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-l-propyl-lH-pyrrolo [3,2- bjpyridine, [3-(3,6-dimethyl-l-propyl-lH-pyrroIo[3,2-b]pyridin-5-yl)-6-isopropyl- pyridin-2-yl]-methyI-amine and [3-(3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5- yl)-6-isopropyl-pyridin-2-yl]-ethyl-amine
Figure imgf000086_0001
Step A
A mixture of 2,5-dibromo-3-methylpyridine (5.02g, 0.02mol)), 2-methoxy-6-isopropyl-3- pyridylboronic acid (4.10g, 0.021mol), Pd(PPh3)4 (924mg), aqueous Na2C03 solution (l.OM, 40ml), and toluene (50ml) is heated at 100 °C under the N2 atmosphere overnight. The reaction mixture is cooled to room temperature and separated. The aqueous layer is extracted with ethyl acetate. The combined organic layers are washed with brine and dried with Na2S04. Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 323.3 (M+H)+
Step B A mixture of bromide (9.63g, 0.03mol), allylamine(6.75ml), BINAP(1.5g), Pd2(dba)3(1.0g), Na0-t-Bu(5.77g) in toluene (150ml) is heated at 100 °C under N2 atmosphere overnight. The reaction mixture is cooled to room temperature and quenched with water. The resulting mixture is separated and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 298.3 (M+H)+
Step C
The starting material (6.67g) is taken in anhydrous CHCl3(100ml). 1.0 equivalent of NBS is added in one portion at 0 °C. The reaction is complete in 0.5 hour. The reaction mixture is washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 376.4 (M+H)+
Step D A mixture of bromide (6.6g), tetrabutylammonium bromide(7.07g), K2C03(7.28g),
Pd(OAc)2(150mg) in DMF(70ml) is heated at 80 °C under N2 atmosphere for 0.5 hour. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as off- white solid. LCMS: m/z 296.4 (M+H)+
Step E
NaH (lOOmg, 60% in mineral oil) is added to a solution of starting material (58mg) in anhydrous DMF (5ml) and stirred for lOminutes. 1-iodopropane (0.5ml) is added and stirred for 05 hour. The reaction mixture is carefully quenched with 1ml of methanol and diluted ith water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 338.4 (M+H)+
Step F
Starting material (360mg) is taken into 4N HCI (20ml) and heated at 75 °C overnight. Reaction mixture is cooled to 0 °C and the pH value is adjusted to -12 by adding ION aqueous NaOH solution. The resulting mixture is extracted with chloroform. The combine organic layers are washed with brine and dried with Na2S04. Concentration gives crude product as an off-white solid. It is used for the next step reaction without further purification. LCMS: m/z 324.4 (M+H)+
Step G
Pyridone (330mg) is taken in anhydrous methylene chloride (20ml) and cooled to 0 °C, Triflic anhydride (1.5equiv.) is added followed by the addition of triethylamine(2 equiv.). The reaction is complete in 0.5 hour. The reaction mixture is washed with saturated NaHC03 and dried with Na2S04. The crude product is used for the next step reaction without further purification. LCMS: m/z 456.4 (M+H)+
Step H
A mixture of triflate(180mg), LiCl(84mg), Pd(PPh3)4(23mg), Na2CO3(1.0M in water, 1ml), B(C2H5)3(1.0M in hexane, 1.5ml) in toluene(2ml) is heated at 100 °C in sealed tube for 2 hours. The resulting mixture is cooled to room temperature and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives 5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6- • dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridine as clear oil. LCMS: m/z 336.4 (M+H)+
Step I
Triflate (230mg) is taken in anhydrous N-methylpyrrolidinone (2ml), CH3ΝH2 is added as a solution of NMP (-5.5M, 2ml). The resulting mixture is heated at 85°C in a sealed tube overnight. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S04. Purification by flash column with hexane/ethyl acetate gives [3- (3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]-methyl- amine as clear oil. LCMS: m/z 337.4 (M+H)+
Step J Triflate (420mg) is taken in anhydrous N-methylpyrrolidinone (3ml), C2H5ΝH2 is added as a solution of THF (2.0M, 2ml). The resulting mixture is heated at 85 °C in a sealed tube overnight. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na S04. Purification by flash column with hexane/ethyl acetate gives [3- (3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yi)-6-isopropyl-pyridin-2-yl]-ethyl-amine as clear oil. LCMS: m/z 351.5 (M+H)+
EXAMPLE13
Synthesis of (R)-2-[5-(6-isόpropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2- b]pyridin-l-yl]-3-methoxy-propan-l-ol and l-((S)-2-fluoro-l-methoxymethyl-ethyl)-5- (6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine
Figure imgf000089_0001
Step A
(i?)-2-Amino-3-methoxy-propan-l-ol hydrochloride. (CAS#: 148278-96-0) (6.74g) and imidazole(13.2g) are taken in anhydrous methylene chloride (300ml). TBDMSC1 (21.9g) is added in one portion. The reaction is carried on overnight. The reaction mixture is washed with water (200mlX3) and dried with Na2S0 . Concentration removes all volatiles. The crude product is used for next step reaction without further purification.
Step B
A mixture of bromide (6.42g, 0.02mol), amine (1.5equiv.), BINAP (l.Og), Pd2(dba)3(0.6g), NaO-t-Bu(4.0g) in toluene(80ml) is heated at 85 °C under N2 atmosphere overnight. The reaction mixture is cooled to room temperature and quenched with water. The resulting mixture is separated and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S04. Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.3 (Hexane/ethyl acetate: 3/1) Step C
The starting material (7.33g) is taken in anhydrous CHC13 (100ml). 1.0 equivalent of NBS is added in one portion at 0 °C. The reaction is complete in 0.5 hour. The reaction mixture is washed with brine and dried with Na2S04. Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.3(Hexane/ethyl acetate: 15/1)
Ste D
Starting material (5.94g) is taken in anhydrous THF (100ml). Allyl iodide (3.6ml) is added followed by the addition of KO-t-Bu/THF solution (1.0M, 44ml) at room temperature. The reaction is stirred at room temperature for 3 hours. The reaction mixture is quenched with water. The resulting mixture is separated and extracted- with ethyl acetate. The combine organic layers are washed with brine and dried with Na?S0 . The crude product is used for the next step reaction without further purification. Rf: 0.3 (Hexane/ethyl acetate: 19/1)
Step E
The crude product (6.4g) of previous reaction is taken in DMF (60ml) followed by the addition of tetrabutylammonium bromide (4.45g), K2C03 (4.58g), Pd(OAc)2 (125mg). The resulting mixture is heated at 85 °C under N2 atmosphere for one hour. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. 0.3(Hexane/ethyl acetate: 5/1)
Step F
Starting material (5.43g) is taken in THF (60ml) followed by the addition of tetrabutylammonium fluoride (2 equiv.) at room temperature. The reaction is complete after 2 hours. The reaction mixture is washed with water, brine and dried with Na2S04. Concentration gives (R)-2-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- ' pyrrolo[3,2-b]pyridin-l-yl]-3-methoxy-propan-l-ol as an off-white solid. LCMS: m/z 384.4 (M+H)+
Step G Starting material (1.15g, 3mmol) is taken in anhydrous methylene chloride (50ml) followed by the addition of [Bis(2-methoxyethyl)amino]sulfur trifluoride (2 equiv.) at room temperature. The reaction is stirred at room temperature overnight. The reaction mixture is carefully quenched with ice-water. The resulting mixture is separated and extracted with methylene chloride and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives l-((S)-2-fluoro-l-methoxymethyl-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3- yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine as clear oil. 0.3 (Hexane/ethyl acetate: 5/1)
EXAMPLE 14 Synthesis of 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)- 3,6,7-trimethyl-lH-pyrrolo[3,2-b]pyridine
Figure imgf000091_0001
ArB(OH)2
Pd(PPh3)4
Step C
Figure imgf000091_0002
Step F
Figure imgf000091_0003
Step A 2-Amino-5-bromo-3,4-dimethylpyridine (201 mg) in H2S04 (2.5N, 2.4mL) is cooled to 0 °C and subsequently treated dropwise with sodium nitrite (104mg) in H20 (1 mL). The solid is collected and washed with H20 and dried to afford 2-hydroxy-5-bromo-3,4-dimethylpyridine. LCMS: m/z 202.2 and 204.2 (M+H)+ Step B
2-Hydroxy-5-bromo-3,4-dimethylpyridine (165 mg) is dissolved in CHC13 (3mL). Triflic anhydride (0.17 mL) and Et3N (0.17mL) are added at r.t. and the mixture is stirred for 30 min. The mixture is evaporated and dissolved in EtOAc/hexane (2:8) and washed with sat. NaHC03, H20 and dried. Evaporation affords the triflate. LCMS: m/z 334.0 and 336.0 (M+H)+
Step C
The above triflate (272mg) and 2-methoxy-6-isopropyl-3-pyridineboronic acid are dissolved in DME (3.5mL). After lOmin of degassing, tetrakis(triphenylphosphine)palladium(0)
(12mg) is added, followed by 1 min of degassing. Upon addition of an aqueous IN sodium carbonate solution (1.63mL) and LiCl (140mg), the reaction mixture is heated to 90 °C for 16h. Subsequently, the crude mixture is put into water (lOOmL), extracted with EtOAc/hexane (20:80, 3x20mL), and dried over sodium sulfate. Purification on silica gel affords 3-(5-bromo-3,4-dimethyl-pyridin-2-yl)-2-methoxy-6-isopropylpyridine. LCMS: m/z 335.1 and 337.1 (M+H)+
Step D
3-(5-bromo-3,4-dimethyl-pyridin-2-yl)-2-methoxy-6-isopropylpyridine (85mg), (S)-2- methoxy- 1-methyl-ethylamine (34mg), Pd2dba3 (12mg), BINAP (16mg) and t-BuONa (37mg) are dissolved in toluene (3.5mL). The reaction mixture is heated to 90 °C for 6h. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc/hexane (1 :1, 2xlOmL), and dried over sodium sulfate. Purification on silica gel affords 3-{5-[(S)-2- methoxy-l-methyl-ethylamino]X3,4-dimethyl-pyridin-2-yl}-2-methoxy-6-isopropylpyridine. LCMS: m/z 344.4 (M+H)+
Step E
3-{5-[(S)-2-methoxy-l-methyl-ethylamino]-3,4-dimethyl-pyridin-2-yl}-2-methoxy-6- isopropylpyridine (42 mg) is dissolved in CHC13 (ImL) Upon addition of NBS (24mg), the reaction mixture is stirred at 25 °C for 30 min. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc/hexane (1:4, 2x5mL), and dried over sodium sulfate. Purification on silica gel affords 3-{6-bromo-5-[(S)-2-methoxy-l-methyI-ethylamino]-3,4- dimethyl-pyridin-2-yl}-2-methoxy-6-isopropylpyridine. LCMS: m/z 422.3 and 424.3
(M+H) +
Step F 3-{6-bromo-5-[(S)-2-methoxy-l-methyl-ethylamino]-3,4-dimethyl-pyridin-2-yl}-2-methoxy- 6-isopropylpyridine (2.0 g) is dissolved in NMP (15 ml). Upon addition of NaH (60%, 380mg), the reaction mixture is stirred at 25 °C for 30 min before allyl bromide (0.82 mL) is added. The reaction mixture is then heated to 50 °C overnight. Subsequently, the crude mixture is put into water (lOmL), extracted with EtOAc/hexane (1:4, 2x50mL), and dried over sodium sulfate. Purification on silica gel affords 3-{6-bromo-5-[(8)-N-allyl-2-methoxy- l-methyl-ethylamino]-3,4-dimethyl-pyridin-2-yl}-2-methoxy-6-isopropylpyridine. LCMS: m/z 462.4 and 464.4 (M+H)+
Step G 3-{6-bromo-5-[(S)-N-allyl-2-methoxy-l-methyl-ethylamino]-3,4-dimethyl-pyridin-2-yl}-2- methoxy-6-isopropylpyridine (0.75g) is dissolved in DMF (6mL). After lOmin of degassing, Pd(OAc)2 (36mg) is added, followed by 1 min of degassing. Upon addition of potassium carbonate (670 mg) and Bn NBr (650mg), the reaction mixture is heated to 90 °C for 2h. Subsequently, the crude mixture is put into water (lOOmL), extracted with EtOAc/hexane (1 :2, 3x50mL), and dried over sodium sulfate. Purification on silica gel affords 5-(6-
Isopropy l-2-methoxy-pyridin-3 -yl)- 1 -((S)-2-methoxy- 1 -methyl-ethy l)-3 ,6,7-trimethyl- 1 H- pyrrolo[3,2-b]pyridine. LCMS: m/z 382.3 (M+H)+
EXAMPLE 15
Synthesis of 5-(2-ethyl-6-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3, 6-dimethyl-lH-pyrrolo[3,2-b]pyridine
Figure imgf000094_0001
Step A
2,5-dibromo-3-methylpyridine (18.90g) and the previously described 2-ethyl-6-methoxy-3- pyridine boronic acid (13.70g) are dissolved in DME (200mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (3.60g) is added. A second degassing is followed by addition of a 5N sodium carbonate solution (30mL) whereupon the reaction is heated to 80 °C for 16h. The yellowish mixture is then put into water (500mL), extracted with DCM (2x300mL), and dried over sodium sulfate. Purification on silica gel affords the coupled product. LCMS: m/z 306.94 (M+H)+ ,
Step B "
The purified compound (6.40g) of step A and (S)-l-methoxy-2-aminopropane (2.04g) are dissolved in toluene (80mL) and briefly degassed. Subsequently, Pd2(dba)3 (1.03g), rac-2,2'- bis(diphenylphosphino)-l,l'-binaphthyl (0.76g), and sodium tert-butoxide (2.81g) are added before the mixture is heated to 70 °C for 16h. The black solution is then put into water (400mL) and sat. sodium bicarbonate (lOOmL), extracted with DCM (3x300mL), and dried over magnesium sulfate. Flushing the crude material through a plug of silica gel affords the 5-aminopyridine as a semi-crude that is used in step C. LCMS: m/z 316.35 (M+H)+
Step C
The amino compound of step B is dissolved in chloroform (200mL) and NBS (0.9-1.0 eq) is added in portions until TCL control verifies full conversion of the starting material. Subsequently, the yellowish mixture is put into water (200mL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the bromide. LCMS: m/z 394.21 (M+H)+
Step D
The purified bromide (7.59g) of step C and allyl bromide (2.04mL) are dissolved in DMF (lOOmL). Sodium hydride (1.16g) is added in 3 portions and the reaction is stirred for 90 min at rt. After TLC control confirms some starting material is still remaining, 0.25 equivalents of both reagents are added to drive the reaction to completion. The mixture is then put into0 water (500mL) and extracted with ethyl ether (2x300mL). The combined organic layers are washed with water (lOOmL), dried over magnesium sulfate, and purified on silica gel to afford the allylated amine. LCMS: m/z 434.23 (M+H)+
Step E 5 The allyl compound (7.89g) of step D, tetrabutylammonium bromide (5.85g), palladium — - acetatef(0.41g), and potassium carbonate (7.53g) are dissolved in DMF (150mL). After heating to 80 °C for 30 min, the mixture is worked-up according to step D. Final purification on silica gel affords the title compound. . LCMS: m/z 354.39.(M+H)+ 0 EXAMPLE 16
Synthesis of 6-ethyI-2-methoxy-5-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-N-methyl-nicotinamide
5 Step A
5-(2-Ethyl-6-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine (135mg) is dissolved in THF (lOmL) and then cooled to -40 °C. Upon addition of t-BuLi (0.45mL, 1.7N in pentane) the temperature is elevated to 0 °C and kept there for 30 min. Prior to injecting gaseous carbon dioxide, the temperature is brought to -780 °C. After injection, the solution is kept at this temperature for another 10 min and is then put into IN NaOH (lOOmL). After washing the solution with ethyl ether (2xl00mL), the aqueous layer is neutralized and extracted with DCM (3xl00mL). The combined DCM-phases are dried over magnesium sulfate. The crude has sufficient purity and is used in step B without any further purification. LCMS: m/z 398.41 (M+H)+
Step B
The crude mixture (50mg) of step A, BOP (84mg), and Huenig base (67μL) are dissolved in THF (5mL). The mixture is stirred for 5 min before methylamine (250μL, 2N in THF) is added. After stirring for 16h, the yellowish solution is put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium' sulfate. Final purification on silica gel affords the title compound. LCMS: m/z 411.41 (M+H)+
EXAMPLE 17
Synthesis of 5-(6-cycIopropylmethoxy-2-ethyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl- ethyl)-3,6-dimethyl-lH-pyrroIo[3,2-b]pyridine
Figure imgf000096_0001
Step A
5-(2-Ethyl-6-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine (5.00g) is dissolved in 4N HCI (150mL) and heated to 75 °C for 7 days. Once TLC control verifies mostly hydrolyzed material, ION NaOH (60.0mL) and sat. sodium bicarbonate (200mL) are added. Extraction with DCM (3x200mL), drying over magnesium sulfate, and purification on silica gel affords the pyridone. LCMS: m/z 340.06 (M+H)+
Step B
The pyridone (50mg) of step C, bromomethylcyclopropane (500mg), and potassium carbonate (500mg) are dissolved in DMF (3.0mL). After being stirred over night at rt, the mixture is put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 394.16 (M+H)+ EXAMPLE 18
Synthesis of 5-(6-cyclopropyl-2-ethyI-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-
3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine and {6-ethyl-5-[l-((S)-2-methoxy-l-methyl- ethyI)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-dimethyl-amine
Figure imgf000097_0001
Step A
6-Ethyl-5-[r-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- lH-pyridin-2-one (2.00g) and triethylamine, (2.05mL) are dissolved in DCM (lOOmL). After being cooled to 0 °C, trifluoromethanesulfonic anhydride is added and the reaction is stirred for 30 min at that temperature. Subsequently, the yellowish mixture is put into water (200mL), extracted with DCM (3x200mL), and dried over magnesium sulfate. Purification on silica gel affords the triflate. LCMS: m/z 472.26 (M+H)+
Step B The triflate (50mg) of step A and cyclopropyl boronic acid (91mg) are dissolved in toluene (5mL). After being degassed for 5 min, tetrakis(triphenylphosphine)palladium (0) (12mg) is added and the mixture is degassed again. Adding a potassium carbonate solution (0.50mL, 2N) is followed by heating to 110 °CTor 16h. Subsequently, the mixture is put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over -magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 364.45-(M+H)+
Step C
The triflate (lOOmg) of step A is dissolved in a 5N NMP-solution of dimethylamine (1.50mL) and subsequently heated to 80 °C for 8h. The reaction mixture is then put into water (1 OOmL); extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 367.43 (M+H)+ EXAMPLE 19
Synthesis of (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyI-2-methoxy-pyridin-3-yl)-3,6- dimethyI-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester
Figure imgf000098_0001
Step A
To a solution of (3R,4S)-3-amino-4-hydroxy-pyrrolidine-l -carboxylic acid benzyl ester (3 g) in DCM (15 mL) is added imidazole (1.3 g) at 0 °C. tert-Butyldimethylsilyl chloride (1.9 g) is added to the above solution at 0°C. After stirring at 0 °C for 30 min, the ice-bath is removed. The mixture is stirred at RT for 2h and is poured into EtOAc (200 mL). The mixture is washed with water and brine, and is dried over MgS0 . After removal of the solvent, the residue is purified by flash column chromatography to give (3R,4S)-3-amino-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l -carboxylic acid benzyl ester as colorless oil. LCMS: Rt 1.40 min, m/z 351.07 (M+H)+
Step B
To a solution of (3R,4S)-3-amino-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid benzyl ester (3 g) and 5-bromo-6'-isopropyl-2'-methoxy-3-methyl-[2,3']bipyridinyl (3.02 g) in toluene (20 mL) is added Pd2(dba)3 (0.313 g) BINAP (0.43 g) and NaOtBu (1.15 g) at RT. The mixture is stirred at 80 °C for 22 h and is poured into water (150 mL). The mixture is extracted with EtOAc and the combined extracts are washed with brine. After dring over MgS0 , the solvent is removed under reduced pressure. The residue is purified by flash column chromatography on silica gel to afford (3S,4R)-3-(tert-butyl-dimethyl-silanyloxy)-4- (6'-isopropyl-2'-methoxy-3-methyl-[2,3']bipyridinyl-5-ylamino)-pyrrolidine-l-carboxylic acid benzyl ester as amorphous. LCMS Rt 1.62 min, m/z 591.15 (M+H)+
Step C
To a stirred solution of (3S,4R)-3-(tert-butyl-dimethyl-sιlanyloxy)-4-(6'-isopropyl-2'- methoxy-3-methyl-[2,3']bipyridinyl-5-ylamino)-pyrrolidine-l-carboxylic acid benzyl ester (4.07 g) in chloroform (25 mL) is added NBS (1.23 g) at RT. After stirring at RT for 15 min, the solvent is evaporated under reduced pressure and the residue is purified by flash column chromatography on silica gel to give (3R,4S)-3-(6-bromo-6'-isopropyl-2'- methoxy-3-methyl-[2,3']bipyridinyl-5-ylamino)-4-(tert-butyl-dimethyl-silanyloxy)- pyrrolidine-1 -carboxylic acid benzyl ester as colorless amorphous. Rf (hexane : EtOAc = 2:1) = 0.55.
Step D
To a stirred solution of (3R,4S)-3-(6-bromo-6'-isopropyl-2'-methoxy-3-methyl- [2,3']bipyridinyl-5-ylamino)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid benzyl ester (4.03 g) in THF (25 mL) is added a solution of KOtBu in THF (2.41 mL, 1 M) at RT. Allyl bromide (2.04 mL) is added to the above solution over 10 min at RT. The mixture is stirred at RT for 16 h and is poured in to water. The mixture is extracted with EtOAc. The combined extracts are washed with brine and are dried over MgS04. After removal of the solvent under reduced pressure, the residue is purified by column chromatography on silica gel to give (3R,4S)-3-[allyl-(6-bromo-6'-isopropyl-2'-methoxy-3- methyl-[2,3']bipyridinyl-5-yl)-amino]-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l- carboxylic acid benzyl ester as amorphous. LCMS Rt 1.93 min, m/z 709 / 711 (M+H)+
Step E
To a solution of (3R,4S)-3-[allyl-(6-bromo-6'-isopropyl-2'-methoxy-3-methyl- [2,3']bipyridinyl-5-yl)-amino]-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid benzyl ester (3.2 g) in DMF (20 mL) is added Pd(OAc)2 (81 mg), K2C03 (1.87 g) and tetrabutylammonium bromide (1.6 g) at RT. The mixture'is stirred at 80 °C for 2 h and is poured into water. The mixture is extracted with EtOAc. The combined extracts are washed with brine and are dried over MgS0 . After evaporation of the solvent under reduced pressure, the residue is purified by flash column chromatography on silica gel to give (3S,4R)-3-(tert-butyl-dimethyl-silanyloxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6- dimethyl-pyrrolo[3 ,2-b]pyr idin- 1 -y 1] -pyrrolidine- 1 - carboxylic acid benzyl ester as amorphous. LCMS Rt 1.62 min, m/z 629.18 (M+H)+
\, Step F
To a stirred solution of (3S,4R)-3-(tert-butyl-dimethyl-silanyloxy)-4-[5-(6-isopropyl-2- methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l- carboxylic acid benzyl ester (2.3 g) in THF (14 mL) is added a solution of tetrabutylammonium fluoride in THF (4.8 mL, IM) at RT. The mixture is stirred at RT for 10 min- and is poured into ice-water (80 mL). The mixture is extracted with EtOAc. The combined extracts are washed with brine and are dried over Mg S0 . After removal of the solvent under reduced pressure, the residue is purified by flash column chromatography on silica gel to give (3S,4R)-3-hydroxy-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester as colorless amorphous. LCMS Rt 1.45 min, m/z 515.10 (M+H)+
Step G To a solution of (3S,4R)-3-hydroxy-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester (1.88 g) in DMF (15 mL) is added sodium hydride (0.44 g) and bromofluoroethane (0.82 mL) at RT. After stirring at RT for 2.5 h, the mixture is poured into ice-water and is extracted with EtOAc. The combined extracts are washed with brine and are dried over MgS0 . After evaporation of the solvent under the reduced pressure, the residue is purified by flash column chromatography on silica gel to afford (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3- yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester as colorless amorphous. LCMS Rt 1.49 min, m/z 561.11(M+H)+ EXAMPLE 20
Synthesis of (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyI-2-methoxy-pyridin-3-yl)-
3,6-dimethyl-pyrroIo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxyIic acid methyl ester
Figure imgf000101_0001
Step A
To a solution of (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester (1.9 g) in EtOH (10 mL) is added 10 % Pd/C (0.3 g) at RT. The suspension is stirred at RT under hydrogen for 14 h. The catalyst is removed by filtration and the filtrate is concentrated under reduced pressure. The residue is purified by flash column chromatography on silica gel to give l-[(3R,4S)-4-(2-fluoro-ethoxy)-pyrrolidin-3-yl]-5-(6-isopropyl-2-methoxy-pyridin-3- yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine as colorless amorphous. LCMS Rt 1.29 min, m/z 427.11 (M+H)+
Step B
To a stirred solution of l-[(3R,4S)-4-(2-fluoro-ethoxy)-pyrrolidin-3-yl]-5-(6-isopropyl-2- methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine (0.1 g) in DCM (1 mL) is added methyl chloroformate (0.03 mL) at RT. After stirring at RT for 15 min, the reaction is quenched with aqueous saturated Na2C03 (3 mL). The mixture is extracted with EtOAc. The combined extracts are dried over MgS04 and are concentrated under reduced pressure. The residue is purified by preparative TLC to give (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyl- 2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin- l-yl]-pyrrolidine-l-carboxylic acid methyl ester as colorless amorphous. LCMS Rt 1.39 min, m/z 485.13 (M+H)+ EXAMPLE 21
Synthesis of l-[(3R,4S)-4-(2-fluoro-ethoxy)-l-methanesuIfonyl-pyrrolidin-3-yl]-5-(6- isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyI-lH-pyrroIo[3,2-b]pyridine
Figure imgf000102_0001
To a stirred solution of l-[(3R,4S)-4-(2-fluoro-ethoxy)-pyrrolidin-3-yl]-5-(6-isopropyl-2- methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine (0.1 g) in DCM (1 mL) is added methanesulfonyl chloride (0.03 mL) at RT. After stirring at RT for 15 min, the reaction is quenched with aqueous saturated Na2C03 (3 mL). The mixture is extracted with EtOAc. The combined extracts are dried over MgS0 and are concentrated under reduced pressure. The residue is purified by preparative TLC to give l-[(3R,4S)-4-(2-fluoro-ethoxy)-l- methanesulfonyl-pyrrolidin-3-yl]-5-(6-isopropyl-2-meth'oxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine as colorless amorphous. LCMS Rt 1.35 min, m/z 505.10 (M+H)+
EXAMPLE 22 Synthesis of l-[(3R,4S)-4-(2-fluoro-ethoxy)-l-methyl-pyrrolidin-3-yl]-5-(6-isopropyl-2- methoxy-pyridin-3-yl)-3,6-dimethyI-lH-pyrrolo[3,2-b]pyridine
Figure imgf000102_0002
To a solution of (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)~3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid methyl ester (77 mg) in THF (1 mL) is added a solution of LiAlH4 in THF (1.5 mL, 1 M) at RT. After stirring at RT for 2 h, the reaction is quenched with water. The inorganic salts are removed by Celite filtration. The filtrates are concentrated under reduced pressure and the residue is purified by flash. chromatography on silica gel to afford l-[(3R,4S)-4-(2-fluoro-ethoxy)-l-methyl- pyrrolidin-3-yl]-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridine as colorless amorphous. LCMS Rt 1.24 min, m/z 441.14 (M+H)+
EXAMPLE 23
Synthesis of (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)- 3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid 2-morpholin-4- yl-ethyl ester
Figure imgf000103_0001
To a stirred solution of 4-(2-hyroxyethyl)morpholine (0.063 mL) in DCM (1 mL) is 1,1'- . carbonyldiimidazole (84 mg) at RT. After stirring at RT for 30 min, l-[(3R,4S)-4-(2-fluoro- ethoxy)-pyrrolidin-3-yl]-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine (0.2 g) is added to the mixture. After stirring at RT for 1 day, the mixture is purified by preparative HPLC to give. (3S,4R)-3-(2-fluoro-ethoxy)-4-[5-(6- isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l- carboxylic acid 2-morpholin-4-yl-ethyl ester as amorphous. LCMS Rt 1.38 min, m/z 584 (M+H)+
EXAMPLE 24
Synthesis of l-((S)-2-methoxy-l-methyI-ethyI)-5-(2-methoxy-4-trifluoromethoxy- phenyI)-6-methyl-lH-pyrroIo[3,2-b]pyridine and 3-bromo-l-((S)-2-methoxy-l-methyl- ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine
Figure imgf000104_0001
Step A
To a solution of 2,5-dibromo-3-methyl-pyridine (40 g) and 2-methoxy-4-trifluoromethoxy- phenyl boronic acid (39.5 g) in toluene (200 mL) is added Pd(Ph3P)4 (5.5 g) and 2M aqueous K2C03 solution (160 mL) at RT. The mixture is stirred at 85 °C for 16 h. The mixture is poured -into water and is extracted with EtOAc. The combined extracts are washed with brine and are dried over Mg S0 . After evaporation of the solvent the residue is purified by flash column chromatography on silica gel to give 5-bromo-2-(2-methoxy-4-trifluoromethoxy- phenyl)-3-methyl-pyridine as white solid. MS 362 / 364 (M+H)+
Step B
To a solution of give 5-bromo-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3-methyl-pyridine (1.04 g) in toluene (20 mL) is added (S)-2-methoxy-l-methyl-ethylamine (0.28 g), Pd2(dba)3 (0.11 g), BINAP (0.14 g) and NaOtBu (0.39 g). The mixture is stirred at 80 °C for 15h. The mixture is poured into water and is extracted with EtOAc. The combined extracts are washed with brine and dried over MgS0 . After removal of the solvent under reduced pressure the residue is purified by flash column chromatography on silica gel to give ((S)-2 -methoxy- 1- methyl-ethyl)-[6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]-amine as amorphous. Rf (hexane : EtOAc = 2:1) = 0.3
Step C To a solution of ((S)-2 -m ethoxy- 1 -methyl-ethyl)-[6-(2-methoxy-4-trifluoromethoxy-phenyl)- 5-methyl-pyridin-3-yl]-amine (1 g) in chloroform (5 mL) is added NBS (0.48 g) at RT. After stirring at RT for 5 min, the mixture is directly purified by flash column chromatography on silica gel to give [2-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]- ((S)-2-methoxy-l-methyl-ethyl)-amine as white solid. Rf (hexane : EtOAc = 4:1) = 0.3
Step D
To a solution of [2-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin- 3-yl]-((S)-2-methoxy-l-methyl-ethyl)-amine (0.2 g) in DMF (1 mL) is added ethynyl- trimethyl-silane (0.08 mL), Et3N (0.09 mL), PdCl2(Ph3P)2 (6 mg) and Cul (1 mg) at RT. The mixture is stirred at RT for 14 h. The mixture is poured into water and is extracted with EtOAc. The combined extracts are washed with brine and are dried over MgS04. After evaporation of the solvent, the residue is purified by flash column chromatography on silica gel to give ((S)-2-bethoxy-l -methyl-ethyl)- [6-(2-methoxy-4-trifluoromethoxy- phenyl)-5-methyl-2-trimethylsilanylethynyl-pyridin-3-yl]-amine as colorless oil. LCMS Rt 1.74 min, m/z 467.15 (M+H)+
Step E
To a solution of ((S)-2-bethoxy-l -methyl-ethyl)- [6-(2-methoxy-4-trifluoromethoxy-phenyl)- 5-methyl-2-trimethylsilanylethynyl-pyridin-3-yl]-amine (0.18 g) in THF (2 mL) is added a solution of nBu4NF in THF (0.48 mL, 1 M) at RT. After stirring at RT for 15 min, EtOAc is. added to the mixture. The solution is washed with water and brine, and is dried over MgS04.
After removal of the solvent under reduced pressure, the residue is purified by flash column chromatography on silica gel to give [2-ethynyl-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5- methyl-pyridin-3-yl]-((S)-2-methoxy-l-methyl-ethyl)-amine as colorless oil. LCMS Rt 1.58 min, m/z 395.09 (M+H)+
Step F To a solution of give [2-ethynyl-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin- 3-yl]-((S)-2-methoxy-l-methyl-ethyl)-amine (0.1 g) in NMP (3 mL) is added tBuOK (28 mg) at RT. The mixture is stirred at 80 °C for lh. The mixture is diluted with EtOAc and is washed with water and brine. After drying over MgS04, the solvent is evaporated. The residue is purified by flash column chromatography on silica gel to give l-((S)-2-methoxy-l- methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine as amorphous. LCMS 1.30 min, m/z 395.05 (M+H)+
Step G To a solution of l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy- phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine (65 mg) in chloroform (2 mL) is added NBS (32 mg). The mixture is stirred at RT for 30 min and is diluted with EtOAc. The mixture is washed with water and brine and dried over MgS0 . After removal of the solvent under reduced pressure, the residue is purified by preparative TLC to give 3-bromo-l-((S)-2- methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-lH- pyrrolo[3,2-b]pyridine as white solid. LCMS Rt 1.54 min, m/z 472.96 / 474.96 (M+H)+
By using steps A-F of Example 24 the following compounds are prepared analogously:
• 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6- methyl-lH-pyrrolo[3,2-b]pyridine (LCMS Rt 1.40 min, m/z 354.15 (M+H)X
• (R)-2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-pyrrolo[3,2-b]pyridin-l- yl]-butan-l-ol (LCMS Rt 1.39 min, m/z 354.12 (M+H)+)
EXAMPLE 25 Synthesis of 3-chIoro-l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4- trifluoromethoxy-phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine and l-[l-((S)-2-methoxy- l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-lH-pyrrolo[3,2- b]pyridin-7-yl]-pyrrolidine-2,5-dione
Figure imgf000106_0001
To a solution of l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy- phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine (40 mg) in chloroform (1 mL) is added NCS (15 mg) at RT. After stirring at RT for 15 h, the mixture is directly purified by preparative TLC to give 3-chloro-l-((S)-2 -methoxy- .1 -methyl-ethyl)-5-(2 -methoxy-4-trifluoromethoxy- phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine (white solid, LCMS 1.53 min, m/z 429.02 / 431.02 (M+H)+) and l-[l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy- phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridin-7-yl]-pyrrolidine-2,5-dione (amorphous, LCMS Rt 1.38 min,' m/z 492.09 (M+H)+).
EXAMPLE 26
Synthesis of 3-fluoro-l-((S)-2-methoxy-l-methyl-ethyI)-5-(2-methoxy-4- trifluoromethoxy-phenyl)-6-methyl-lH-pyrroIo[3,2-b]pyridine
Figure imgf000107_0001
To a stirred solution of 3 -bromo- l-((S)-2 -methoxy- 1-methyl-ethy l)-5-(2-methoxy-4- trifluoromethoxy-phenyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine (17 mg) in THF (1 mL) is added a solution of t-BuLi in pentane (0.09 mL, 1.7 M) at -78 °C. After stirring at the same temperature for 1 h, a solution of N-fluorobenzene-sulfonimide (46 mg) in THF (1 mL) is added. The mixture is stirred at -78 °C for 30 min and at 0 °C for 30mim. The mixture is poured into water and is extracted with EtOAc. The combined extracts are dried over MgS04 and are concentrated under reduced pressure. The residue is purified by preparative TLC to give 3-fluoro-l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)- 6-methyl-lH-pyrrolo[3,2-b]pyridine as amorphous. LCMS Rt 1.49 min, m/z 413.02 (M+H)+ EXAMPLE 27
Synthesis of 3-bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l- methyl-ethyl)-6-methyl-lH-pyrrolo[3,2-b] pyridine and 5-(6-isopropyl-2-methoxy- pyridin-3-yl)-l-((S)-2-methoxy-l-methyI-ethyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine-3- carbonitrile
Figure imgf000108_0001
Step A
To a solution of 5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l -methyl-ethyl)- 6 methyl-lH-pyrrolo[3,2-b]pyridine (1.25 g) in chloroform (10 mL) is added NBS (0.66 g) at 0 °C. The mixture is stirred at RT for 2 h and is diluted with DCM. The mixture is washed with water and brine. After drying over MgS04, the solvent is removed under reduced pressure. The residue is purified by flash column chromatography on silica gel to give 3- bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6rmethyl- lH-pyrrolo[3,2-b]pyridine as white crystal. LCMS Rt 1.59 min, m/z 432 / 434 (M+H)+
Step B "
To a solution of 3-bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l- methyl-ethyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine (-.4 g) in THF (4 mL) is treated with n- BuLi in hexane (0.44 mL, 1.6 M) at -70 °C. After stirring at -70 °C for 40 min, DMF (0.11 mL) is added to the mixture. The mixture is stirred at -70 °C for 90 min. The reaction is quenched with water and the mixture is extracted with EtOAc. The extract is dried over MgS0 and is concentrated under reduced pressure. The residue is purified by preparative TLC to give 5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6- methyl- IH-pyrrolo [3 ,2-b]pyridine-3-carbaldehyde as colorless amorphous. LCMS Rt 1.50 min, m/z 382.20 (M+H)+
Step C To a stirred solution of 5-(6-isopropyl-2 -methoxy -pyridin-3-yl)-l-((S)-2 -methoxy- 1-methyl- ethyl)-6-methyl-lH-pyrrolo[3,2-b]pyridine-3-carbaldehyde (0.13 g) in DCM (3 mL) is added hydroxylamine hydrochloride (36 mg) and Et N (0.07 mL) at RT. The mixture is stirred at RT for 2 h and is diluted with EtOAc. The mixture is washed with water and dried over MgS0 . The solvent is removed under reduced pressure to give 5-(6-isopropyl-2-methoxy- pyridin-3 -y 1)- 1 -((S)-2-methoxy- 1 -methy l-ethyl)-6-methyl- 1 H-pyrrolo[3 ,2-b]pyridine-3 - carbaldehyde oxime as a mixture of syn-and anti- isomers. LCMS Rt 1.38 min, m/z 397.21 (M+H)+and Rt 1.44 min, m/z 397.21 (M+H)+
Step D
To a solution of 5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)- 6-methyl-lH-pyrrolo[3,2-b]pyridine-3-carbaldehyde oxime (0.136 g) in DCM (3 mL) is added Et3N (0.47 mL) and methanesulfonyl chloride (0.13 mL) at RT. After stirring at RT for 15 h, the mixture is poured into water (30 mL) and is extracted with EtOAc. The extract is washed with water and brine and is dried over MgS04. After evaporation of the solvent, the residue is purified by flash column chromatography on silica gel to give 5-(6-isopropyl-2- methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6-methyl-lH-pyrrolo[3,2- , b]pyridine-3-carbonitrile as amorphous. LCMS Rt 1.59 min, m/z 379.19 (M+H)+
EXAMPLE 28
Synthesis of (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyI-pyrroIo[3,2- b]pyridin-l-yl]-butan-l-ol and l-((S)-l-methoxymethyI-propyl)-5-(2-rnethoxy-4- trifluoromethoxy-phenyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine
Figure imgf000109_0001
Step D
Figure imgf000109_0002
Step A A mixture of 2,5-dibromo-3-methyl pyridine (40g), 2-methoxy-4-trifluoromethoxy-l- phenylboronic acid (39.5g) and 2M K2C03 (159ml) in toluene (300ml) is degassed with N2 for 2 min, followed by addition of Pd(PPh3)4 (5.5g). The resulting mixture is stirred at 85 °C under N for overnight. After reaction is complete, the mixture is poured into water (300ml) and extracted with ethyl acetate (3x150ml). The combined organic layers are washed with brine, dried over Na S0 and evaporated. The product 5-bromo-2-(2-methoxy-4- trifluoromethoxy-phenyl)-3-methyl-pyridine is obtained after flash chromatography (Hexane/EtOAc=20/l). TLC Rf 0.35 (Hexane/EtOAc=4/l). '
Step B
A mixture of 5-bromo-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3-methyl-pyridine (1.3 lg), (S)-l-(tert-Butyl-dimethyl-silanyloxymethyl)-propylamine (885mg), (+/-)BINAP (181mg) and NaOBu1 (488mg) in toLuene (10ml) is degassed with N2 for 2 min, followed by addition of Pd2(dba)3 (133mg). The resulting mixture is stirred at 70 °C under N2 for 20 h. The mixture is poured into water and extracted with EtOAc (3x30ml).,The combined organic layers is washed with brine, dried over Na2S0 and evaporated. The crude product is purified by flash chromatography (Hexane/EtOAc=3/l). m/z 485.5.(M+H)+.
Step C . 257mg of [(S)-l-(terr-Butyl-dimethyl-silanyloxymethyl)-propyl]-[6-(2-methoxy-4- trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]-amine is dissolved in CHC13 (6ml) and NBS (95mg) is added at room temperature. After stirring at room temperature for 10 min, the mixture is diluted with CHC13 and washed with H20, brine and dried over Na2S0 . The pure product 2-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]-[(S)-l- (tert-butyl-dimethyl-silanyloxymethyl)-propyl]-amine is obtained after column chromatography (Hexane/EtOAc=8/l). MS m/z 563.3/565.3 (M+H)+.
Step D
2-Bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin-3-yl]-[(S)-l-(tert- butyl-dimethyl-silanyloxymethyl)-propyl]-amine (230mg) in anhydrous THF (6ml) is added IM KOBu' (1.03ml) followed by allyl bromide (71 μl) at room temperature and the resulting mixture is allowed to stir at ambient temperature for 20 h. The reaction is quenched by adding 10 ml H20 and the mixture is extracted with EtOAc (3 15ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. Flash column chromatography (Hexane/EtOAc=15/l) gives desired product. TLC Rf 0.55 (Hexane EtOAc=10/l).
Step E
A mixture of allyl-[2-bromo'-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyridin-3- yl]-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-amine (1.0g), tetrabutylammoniumbromide (589mg), K2C03 (687mg) in DMF (40ml) is degassed with N2 for 3 min, followed by addition of Pd(OAc)2 (37mg). The resulting mixture is stirred at 80 °C for 18 h. The reaction mixture is poured into water and extracted with EtOAc (3x25ml). The combined organic layers are washed with brine, dried overNa2S0 and evaporated. The crude product is purified by flash chromatography (Hexane/EtOAc=10/l). MS m/z 523.5 (M+H)+.
Step F l-[(S)-l-(tert-Butyl-dimethyl-silanyloxymethyl)-propyl]-5-(2-methoxy-4-trifluoromethoxy- phenyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine (1.19g) in THF (30ml) is added tetrabutylammonium fluoride (715mg) and the mixture is allowed to stir at room temperature for 30 min. After the reaction is complete, the solvent is removed and the crude mixture is purified by flash chromatography (CH2Cl2/MeOH=5/l) to give desired product. LC MS m/z 409.01 (M+H)+.
Step G
(S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- butan-1-ol (60mg) in anhydrous THF (5ml) is added 60% NaH (29mg) and the mixture. is allowed to stir at room temperature for 10 min before Mel (46μl) is added. After stirring at room temperature for 1 h, the reaction is quenched by adding water (15ml). The mixture is extracted with EtOAc (3x25ml), dried over Na2S04 and evaporated. The pure product 1-((S)- l-methoxymethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,^6-dimethyl-lH- pyrrolo[3,2-b]pyridine is obtained by flash column chromatography (Hexane/EtOAc=3/l). LC MS m/z 423.03 (M+H)+. EXAMPLE 29
Synthesis of l-((S)-l-chloromethyI-propyI)-5-(2-methoxy-4-triflnoromethoxy-phenyl)-
3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine and 5-(2-methoxy-4-trifluoromethoxy-phenyl)-
3,6-dimethyl-l-((S)-l-pyrrolidin-l-ylmethyl-propyl)-lH-pyrrolo[3,2-b]pyridine
Figure imgf000112_0001
Step A
(S)-2-[5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- butan-1-ol (330mg) in C1CH2CH2C1 (20ml) is cooled to 0 °C and SOCl2 (1.77ml) is added . dropwise. The reaction is allowed to stir at room temperature for 12 h. After removal of the solvent, the crude product is purified by flash column (Hexane/EtOAc=3/l). MS m/z 427.4 (M+H)+.
Step B A mixture of l-((S)-l-chloromethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine (55mg), KI (15mg) and 0.8 ml pyrrolidine in DMSO (4ml) is heated to 120 °C for 19 h. After starting.material disappears, the mixture is poured into water and extracted with CH2C12 (3x20ml). The combined organic layers are washed . with brine, dried over Na2S04 and evaporated. The pure product 5-(2-methox,y-4- trifluoremethoxy-pheny l)-3 ,6-dimethy 1- 1 -((S)- 1 -pyrrolidin- 1 -y lmethyl-propy 1)- 1 H- pyrrolo[3,2-b]pyridineis obtained by preparative TLC purification (CH2Cl2/MeOH=15/l). LC MS m/z 462.10-(M+H)+. '
Ill EXAMPLE 30
Synthesis of methanesulfonic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyI)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester, l-((S)-l-methanesulfonyImethyl- propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridine, piperidine-1-carboxylic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy- phenyI)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester and cyclopentyl-carbamic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2- b]pyridin-l-yl]-butyl ester
Figure imgf000113_0001
Step A
(S)-2-[5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- butan-1-ol (120mg) in CH2C1 (6ml) is cooled to 0 °C and the mixture is added triethylamine (82μl) followed by methanesulfonyl chloride (45μl). The mixture is allowed to stir at 0 °C to room" temperature for 16 h. After removal of the solvent, the crude mixture is purified by ■ column chromatography (CH2Cl2/MeOH=12/l). LC MS m/z 486.99 (M+H)+.
Step B
A mixture of methanesulfonic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester (39mg), KI (5mg) and CH3S02Na (lOOmg) in DMSO (2ml) were heated to 80 °C for 17 h. The mixture is poured into water and extracted with EtOAc (3x15ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The pure product l-((S)-l-methanesulfonylmethyl-propyl)-5- (2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine is obtained by preparative TLC purification (Hexane/EtOAc=l/l). LC MS m/z 471.03 (M+H)+. Step C
2 ml of methanesulfonic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3, 6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester (0.02 M in DMSO) is added 0.2 ml of . piperidine (0.2 M in toluene), followed by NaHC03 (50mg) and KI (lOmg). The resulting mixture is shaken at 80 °C for 18 h. The mixture is diluted with water, extracted with EtOAc (2x10ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The pure product piperidine-1 -carboxylic acid (S)-2-[5-(2-methoxy-4- trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester is obtained by preparative TLC purification (Hexane/EtOAc=l/l). LC MS m/z 520.11 (M+H)+.
Step D
2 ml of methanesulfonic acid (S)-2-[5-(2 -methoxy -4-trifluoromethoxy-phenyl)-3, 6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester (0.02 M in DMSO) is added 0.2 ml of cyclopentylamine (0.2 M in toluene), followed by NaHC03 (50mg) and KI (lOmg). The resulting mixture is shaken at 80 °C for 18 h. The mixture is diluted with water, extracted with EtOAc (2x10ml). The combined organic layers are washed with brine, dried over - Na2S0 and evaporated. The pure product cyclopentyl-carbamic acid (S)-2-[5- (2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester is obtained by preparative TLC purification (Hexane/EtOAc=l/l). LC MS m/z 520.12 (M+H)+.
EXAMPLE 31
Synthesis of (R)-2-[6-ethyI-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl- - pyrrolo[3,2-b]pyridin-l-yI]-propan-l-ol and 6-ethyl-5-(6-isopropyI-2-methoxy-pyridin- 3-yl)-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b] pyridine
Figure imgf000114_0001
Slep E
Figure imgf000114_0002
Step A
A mixture of 3,5-dibromopyridine (30.3 g), (R)-2-(/έτt-butyl-dimethyl-silanylo xy)-l-methyl-ethylamine (25.4g), (+/-)BINAP (6.37g) and NaOBu'fπ.lδg) in toluene (300ml) is degassed for 5 min, followed by addition of Pd2(dba)3 (4.68g). The resulting 5 mixture is stirred at 70 °C for 4 h. The reaction mixture is poured into water (200ml), extracted with EtO Ac(3xl 50ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The desired product is obtained after flash column chromatography (Hexane/EtOAc=3/l). LC MS m/z 347.24 (M+H)+.
\
10 Step B
A mixture of (5-bromo-pyridin-3-yl)-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl- ethyl]-amine (22.74g), 2M K2C03 (99ml) and 165 ml Et3B (IM in hexane) in toluene (200ml) is degassed with N2 for 5 min, followed by addition of Pd(PPh3)4 (3.8g). The resulting, mixture is allowed to stir at 110 °C for 16 h. The mixture is poured into water 15 (200ml), extracted with EtOAc (3x200ml), dried over Na2S0 and evaporated. The crude product [(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-(5-ethyl-pyridin-3-yl)-amine is used for next step without further purification. LC MS m/z 295.14 (M+H)+.
Step C
20 Crude product from last step is dissolved in CHC13 (250ml) and NBS (2 eq.) is added in one portion at room temperature. After stirring at room temperature for 15 min, the solution is washed with water (2x100ml). The organic phase is dried over Na2S04 and evaporated. The crude product is purified by flash chromatography (Hexane/EtOAc=8/l). LC MS m/z 451.12/453.11 (M+H)+.
25
Step D
(R)-2-(tert-Butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-(2,6-dibromo-5-ethyl-pyridin-3-yl)- amine (11.5g) in anhydrous THF(180ml) is added IM KOBu' (50.9ml), followed by allyl iodide (3.48ml). The resulting mixture is allowed to stir at room temperature for 22 h before - 30 it is quenched with water (100ml). The mixture is extracted with EtOAc (3x150ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. The pure product allyl-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-(2,6-dibromo-5-ethyl- pyridin-3-yl)-amine is obtained after column chromatography (Hexane/EtOAc=10/l). TLC Rf 0.6 (Hexane/EtOAc=10/l).
Step E A mixture of allyl-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-(2,6-dibromo-5- ethyl-pyridin-3-yl)-amine (8.3g), tetrabutylammonium bromide (6.0g), K2C03 (6.99g) in DMF (100ml) is degassed for 3 min, followed by addition of Pd(OAc)2. The resulting mixture is stirred at 80 °C for 18 h. After the mixture is complete, the mixture is poured into H20 (200ml), extracted with EtOAc(3xl00 ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The crude product is purified by flash column chromatography (Hexane/EtOAc=10/l). TLC Rf 0.5 (Hexane/EtOAc=4/l).
Step F A mixture of 5-bromo-l-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-6-ethyl-3- methyl-lH-pyrrolo[3,2-b]pyridine (2.21g), 2M K2C03 (5.4ml), and 2-methoxy-6-isopropyl-3- pyridylboronic acid (1.20g) in DME (25 ml) is degassed with N2 for 2 min, followed by addition of Pd(PPh3) . The resulting mixture is stirred at 85 °C for 16 h before it is poured into water (80ml),- and extracted with EtOAc (3x30ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. Flash column chromatography (Hexane EtOAc=6/l ) gives the pure product 1 -[(R)-2-(te/-t-butyl-dimethyl-silanyloxy)- 1 - methyl-ethyl]-6-ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-lH-pyrrolo[3,2- bjpyridine. LC MS m/z 482.18 (M+H)+.
Step G l-[(R)-2-(/grt-Butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-6-ethyl-5-(6-isopropyl-2-methoxy- pyridin-3-yl)-3 -methyl- IH-pyrrolo [3, 2-b]pyridine (1.87g) in THF (60ml) is added tetrabutylammonium fluoride (1.53g) and the mixture is allowed to stir at room temperature- for 15 min before the solvent is evaporated. The crude product is purified by flash chromatography (Hexane/EtOAc=l/l). MS m/z 368.4 (M+H)+. .
Step H
(R)-2-[6-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2-b]pyridin-l-yl]- propan-1-ol (1.15g) in anhydrous THF (40ml) is added NaH (627mg) and the mixture is stirred at room temperature for 5 min before Mel (978μl) is added. The reaction mixture is stirred at room temperature for 3 h and then quenched with H20 (50ml) and extracted with EtOAc (3x40ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The pure product 6-ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine is obtained by flash chromatography (Hexane/EtOAc=4/l). LC MS m/z 382.44 (M+H)+,
EXAMPLE 32
Synthesis of (S)-2-[6-bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yI)-3-methyl- pyrrolo[3,2-b]pyridin-l-yl]-butan-l-oI , 6-bromo-5-(6-isopropyl-2-methoxy-pyridin-3- yl)-l-((S)-l-methoxymethyl-propyl)-3-methyl-lH-pyrroIo[3,2-b]pyridine and 5-(6- isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyI-propyl)-3-methyl-lH- pyrrolo[3,2-b]pyridine
Figure imgf000117_0001
Step A .
A mixture of 3,5-dibromopyridine (50g), (S)-l-(tert-butyl-dimethyl-silanylo xymethy -propylamine (43.68g), (+/-)BINAP (10.51g) and NaOBu' (28.35g) in toluene (400ml) is degassed with N2 for 5 min, followed by addition of Pd2(dba)3 (7.73g). The resulting mixture is stirred at 70 °C for 23 h. The reaction mixture is poured into water (200ml), extracted with EtOAc(3x200 ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The desired product is obtained after flash column chromatography (Hexane/EtOAc=5/l). TLC Rf 0.4' (Hexane/EtOAc=4/l).
Step B
(5-Bromo-pyridin-3-yl)-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-amine (7.58g) in CHC13 (150ml) is added NBS (7.51g) and the mixture is stirred at room temperature for 15 min before it is washed with H 0 (2x50 ml). The organic layer is dried over Na2S04 and evaporated. The crude product is purified by column chromatography (Hexane/EtOAc=10/l). TLC Rf 0.7 (Hexane/EtOAc=4/l).
Step C
(S)-l-(tert-Butyl-dimethyl-silanyloxymethyl)-propyl]-(2,5,6-tribromo-pyridin-3-yl)-amine (6.33g) in THF (60ml) is added 24.5 ml KOBu' (1 M in THF) followed by allyl iodide (1.68ml). The resulting mixture is stirred at room temperature for 24 h before it is quenched with water (60ml). The mixture is extracted with EtOAc (3x30ml) and the combined organic layers are washed with brine, dried over Na2S04 and evaporated. The pure product allyl-[(S)- l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-(2,5,6-tribromo-pyridin-3-yl)-amine is obtained by flash column chromatography (Hexane/EtOAc=15/l). TLC Rf 0.6 (Heχane/EtOAc=10/l).
Step D
A mixture of allyl-[(S)-l -(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-(2,5,6-tribromo- pyridin-3-yl)-amine (5.81g), tetrabutylammonium bromide (3.7g), K2C03 (4.32g) in DMF (25ml) is degassed with N2 for 2 min, followed by addition of Pd(OAc)2 (214mg). The resulting mixture is stirred at 80 °C for 1.5 h before it is poured into water (50ml), and extracted with EtOAc (3x30ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. The crude product is purified by flash column chromatography (Hexane/EtOAc=10/l). TLC Rf 0.3 (Hexane/EtOAc=10/l).
Step E A mixture of 5,6-dibromo-l-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-3-methyl- lH-pyrrolo[3,2-b]pyridine (3.66g), 2M K2C03 (22ml), 2-methoxy-6-isopropyl-3- pyridylboronic acid (1.64g) in DME is degassed with N2 for 5 min, followed by addition of Pd(PPh3) (444mg). The resulting mixture is allowed to stir at 85 °C for 3.5 h before it is poured into H20 (50ml), extracted with EtOAc (3x40ml). The combined organic layers are washed with brine, dried over Na2S0 and evaporated. The pure product 6-bromo-l-[(S)-l- (tert-butyl-dimethyl-silanyloxymethyl)-propyl]-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3- methyl-lH-pyrrolo[3,2-b]pyridine is obtained by flash column chromatography (Hexane/EtOAc=8/l). LC MS m/z 547.3 (M+H)+. Step F
6-Bromo-l-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]-5-(6-isopropyl-2-methoxy- pyridin-3-yl)-3 -methyl- IH-pyrrolo [3, 2-b]pyridine (2.74g) in THF (50ml) is added tetrabutylammonium fluoride (1.97g) and the resulting mixture is stirred at room temperature for 2h. After removal of the solvent, the crude product is purified by column chromatography ,. (Hexane/EtOAc=l/l). LC MS m/z 433.35 (M+H)+.
Step G A mixture of (S)-2-[6-bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2- b]pyridin-l-yl]-butan-l-ol (2.0g) in THF (40ml) is added 60% NaH (463mg) and the mixture is stirred at 0 °C for 10 min before Mel (578μl) is added. After stirring at room temperature for 3.5 h, the mixture is poured into water (50ml) and extracted with EtOAc(3x30ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. Column chromatography (Hexane/EtOAc=6/l) gives the pure product 6-bromo-5-(6-isopropyl-2- methoxy-pyridin-3-yl)-l-((S)-l-methoxymethyl-propyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine. LC MS m/z .447.37 (M+H)+.
Step H 6-Bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-l-methoxymethyl- propyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine (450mg) in EtOH (30ml) is added 10% Pd/C (200mg) under N2 and the mixture is shaken under 40 psi H2 pressure for 48 h. the catalyst is removed by filtering through celite. After removal of solvent, the desired product 5-(6- isopropy l-2-methoxy-pyridin-3-yl)- 1 -((S)-2 -methoxy- 1 -methyl-propyl)-3 -methyl- 1 H- pyrrolo[3,2-b]pyridine is obtained. MS m/z 368.4 (M+H)+.
EXAMPLE 33
Synthesis of {3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-ylJ-6-isopropyI-pyridin-2-yl}-methyl-arnine, 5-chloro-3-[6-ethyl-l-((R)-2- methoxy-l-methyl-ethyI)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin- 2-yl}-methyl-amine, {5-bromo-3-[6-ethyl-l-((R)-2-methoxy-l-methyI-ethyl)-3-methyl- lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyI-amine and {5- cyclopropyl-3-[6-ethyI-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yI]-6-isopropyl-pyridin-2-yϊ}methyl-arnine
Figure imgf000120_0001
Step A
A mixture of 6-ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-2-methoxy-l-methyl- ethyl)-3-methyl-lH-pyrrofo[3,2-b]pyridine (1.02g) and 6N HCI (20ml) is heated to 75 °C for 20 h. The mixture is cooled down to 0 °C and neutralized with IO N NaOH to PH>10. The basic solution is extracted with CH C12 (3x40ml). The combined organic layers are washed with brine, dried over Na S04 and evaporated. The crude product 3-[6-ethyl-l-((R)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-ol is used for next step without further purification. TLC Rf 0.2 (CH2Cl2/MeOH=12/l).
Step B " Crude product from previous step is dissolved in CH2C1 (30 ml) and the mixture is cooled to 0 °C, followed by addition of triethylamine (1.11ml) and trifluoromethanesulfonic anhydride (898 μl). After stirring at room temperature for 3 h, the mixture is poured into H 0 (30 ml) and extracted with EtOAc (3x30ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. The pure desired product trifluoro-methanesulfonic acid 3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6- isopropyl-pyridin-2-yl ester is obtained by flash column chromatography (CH2Cl2/MeOH=6/l). TLC Rf 0.4 (CH2Cl2/MeOH=12/l).'
Step C A mixture of trifluoro-methanesulfonic acid 3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester (200mg) and NMP (6ml) is added I ml MeNH, C4M in NMP) and the mixture iς heater! tn 8D °C or 90 Thp mixture is poured into water (20ml), extracted with EtOAc (3x15ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. The pure product is obtained after preparative TLC purification (Hexane/EtOAc=2/l). LC MS m/z 381.45 (M+H)+.
Step D
{ 3 -[6-Ethy 1- 1 -((R)-2-methoxy- 1 -methy l-ethyl)-3 -methyl- 1 H-pyrrolo[3 ,2-b]pyridin-5 -yl]-6- isopropyl-pyridin-2-yl}-methyl-amine (60mg) in CHC13 (5ml) is added N-chlorosuccinimide (23mg) and the mixture is heated at 60 °C for 5 h. After the reaction is complete, the solvent is removed and the crude product is purified by preparative TLC (Hexane/EtOAc=4/l) to give 5 -chloro-3 -[6-ethyl- 1 -((R)-2 -methoxy- 1 -methyl-ethy l)-3-methyl- 1 H-pyrrolo[3 ,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}methyl-amine. MS m/z 415.4 (M+H)+.
Step E A mixture of {3-[6-Ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine (130mg) in CH3CN (5ml) is cooled to 0 °C followed by addition of NBS (61mg). The resulting mixture is stirred at 0 °C for 30 min and then it is diluted with H20 (20ml), extracted with EtOAc(3x25 ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. Flash column chromatography (Hexane/EtOAc=8/l) gives pure product {5-bromo-3-[6-ethyl-l-((R)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2- yl} -methy 1-amine. LC MS m/z 461.35 (M+H)+.
Step F A mixture of {5-bromo-3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine (60mg), 2M K2C03 (lml), cyclopropyl boronic acid (56mg) in toluene (5ml) is degassed with N for 2 min, followed by addition of Pd(PPh3)4 (15mg). The resulting mixture is stirred at 110 °C for 16 h before it is poured into water and extracted with EtOAc(3 l5ml). The combined organic layers are washed with brine, dried over Na2S04 and evaporated. The pure product {5- cyclopropyl-3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}methyl-amine is obtained after preparative TLC purification (CH2Cl2/MeOH=20/l). MS m/z 421.5 (M+H)+. EXAMPLE 34
Synthesis of ethyI-{6-isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyI-lH-pyrroIo[3,2-b]pyridin-5-yI]-pyridin-2-yl}amine and 5-(2-ethyl-6-isopropyl- pyridin-3-yl)-6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b] pyridine
Figure imgf000122_0001
Step A
Analogous to the preparation of (5-bromo-pyridin-3-yl)-[(S)-l-(tert-butyl-dimethyl- silanyloxymethyl)-prόpyl]-amine the palladium mediated amination of 3-bromo-5- methoxypyridine (4.76g) with (S)-l-methoxy-2-propylamine (4.4 mL) gives, after purification on silica gel ((S)-2-methoxy-l-methyl-ethyl)-(5-methoxy-pyridin-3-yl)-amine. LCMS: m/z 197.1 (M+H)+, Rt 2.47 mins.
Step B
The chlorination of ((S)-2-methoxy-l-methyl-ethyl)-(5-methoxy-pyridin-3-yl)-amine (5.30g) with N-chlorosuccinimide (7.21g) gives, after purification on silica gel (2,6-dichl.oro-5- methoxy-pyridin-3-yl)-((S)-2-methoxy-l -methyl-ethyl)-amine. LCMS: m/z 265.2/267.1/269.1 (M+H)+, Rt 3.03 mins.
Step C
Analogous to the synthesis of allyl-[(S)-l-(tβrt-butyl-dimethyl-silanyloxymethyl)-propyl]- (2,5,6-tribromo-pyridin-3-yl)-amine the allylation of (2,6-dichloro-5-methoxy-pyridin-3-yl)- ((S)-2-methoxy-l -methy l-ethyl)-amine (5.38g) with allyl iodide (4.0 mL) affords, after purification on silica gel allyl-(2,6-dichloro-5-methoxy-pyridin-3-yl)-((S)-2-methoxy-l- methyl-ethyl)-amine. LCMS: m/z 305.1/307.1/309.0 (M+H)+, Rt 3.49 mins.
Step D
Analogous to the synthesis of 5,6-dibromo-l-[(S)-l-(tert-butyl-dimethyl-silanyldxymethyl)- propyl]-3-methyl-lH-pyrrolo[3,2-b]pyridine the palladium mediated cyclization of allyl-(2,6- dichloro-5 -methoxy-pyridin-3-yl)-((S)-2-methoxy- 1 -methy l-ethyl)-amine (5.13 g) affords, after purification on silica gel 5-chloro-6-methoxy-l -((S)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine. LCMS: m/z 269.1/271.1 (M+H)+, Rt 2.41 mins.
Step E
Analogous to the synthesis of 6-bromo-l-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)- propyl]-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-lH-pyrrolo[3,2-b]pyridine the palladium mediated coupling of 5-chloro-6-methoxy-l-((S)-2 -methoxy- 1 -methyl-ethyl)-3 - methyl- lH-pyrrolo[3,2-b]pyridine (1.9g) with 6-isopropyl-2-methoxy-3-pyridineboronic acid (1.79g) affords, after purification on silica gel 5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6- methoxy- 1 -((S)-2-methoxy- 1 -methy l-ethyl)-3-methy 1- 1 H-pyrrolo [3 ,2-b]pyridine. LCMS: m/z 384.2 (M+H)+, Rt 2.40 mins.
Step F
A solution of 5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methoxy-l-((S)-2 methoxy-l- methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine (890mg) in concentrated hydrochloric acid (60 mL, 37%) is heated at 55 °C for 16 hours. The resulting solution is neutralized with sodium bicarbonate and diluted with a little water. The mixture is extracted with - dichloromethane (4x50mL) and dried over magnesium sulfate. Evaporation of the solvent followed by trituration with diethyl ether gives 6-isopropyl-3-[6-methoxy-l-((S)-2-methoxy- l-methyI-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-ol. LCMS: m/z 370.2 (M+H)+, Rt 2.01 mins.
Step G Analogous to the synthesis of trifluoro-methanesulfonic acid 3-(3,6-dimethyl-l-propyl-lH- pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl ester the reaction of 6-isopropyl-3-[6- methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- pyridin-2-ol (200mg) with triflic anhydride (0.1 ImL) in the presence oftriethyl amine (0.136mL) gives, after purification on silica gel trifluoro-methanesulfonic acid 6-isopropyl-3- [6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- pyridin-2-yl ester. LCMS: m/z 502.1 (M+H)+, Rt = 3.29 mins.
Step H
Analogous to the preparation of [3-(3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6- isopropyl-pyridin-2-yl]-ethyl-amine the reaction of trifluoro-methanesulfonic acid 6- isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-pyridin-2-yl ester (70mg) with ethyl amine solution in THF (0.7mL, 2M) affords, after purification on silica gel gives ethyl-{6-isopropyl-3-[6-methoxy-l-((S)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-amine. LCMS: m/z 397.3 (M+H)+, Rt = 2.14 mins.
Step I
Analogous to the preparation of 5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-l-propyl- lH-pyrrolo[3,2-b]pyridine the reaction of trifluoro-methanesulfonic acid 6-isopropyl-3-[6- methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- pyridin-2-yl ester (180mg) with triethylborane solution in hexanes (1.44mL, l.OM) affords, after purification on silica gel 5-(2-ethyl-6-isopropyl-pyridin-3-yl)-6-methoxy-l-((S)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine. LCMS: m/z 382.3 (M+H)+, Rt = 1.94 mins.
Replacing the amine used in step H of Example 34 with various other amine reagents, the following compounds are synthesized: {6-Isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-ylj -dimethyl-amine. Rt 1.97min m/z 397.2(M+H)+
{6-Isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-methyl-amine. Rt 1.93min m/z 383.3(M+H)+ -
EXAMPLE 35
Synthesis of 6-chloro-5-(2-ethyl-6-isopropyI-pyridin-3-yI)-l-((S)-2-methoxy-l-methyl- ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine, 6-ChIoro-5-(6-isopropyI-pyridin-3-yl)-l-
((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine and {3-[6-chloro-l-
((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl- pyridin-2-yl}-methyl-amine
Figure imgf000125_0001
Step A
Similar to a procedure by Testaferre it al. (Tetrahedron 41, No7, 1373-1384, 1985) a suspension of 2,3-dichloropyridine (lOg) in sodium methoxide solution in methanol (62mL, 25%) is heated to 55°C for 15 hours. The suspension is filtered and the filtrate is evaporated to low volume. The mixture is diluted with saturated brine, extracted with diethyl ether (3x50mL) and dried over magnesium sulfate. Evaporation directly gives 3-chloro-2- methoxy-pyridine. LCMS: m/z 144.0/146.0 (M+H)+, Rt 2.29 mins.
Step B Similar to a procedure by Bargar et al. (J. Het Chem 22, 1583, 1985) a stirred suspension of 3-chloro-2-methoxy-pyridine (9.3g) and sodium acetate (5.4g) in glacial acetic acid (30mL) is treated with bromine (6.7mL) dropwise over 15 mins. After the exotherm has subsided, the mixture is heated at 80°C for one hour. The reaction mixture is cooled to room temperature and diluted with ether (200mL) and washed with sodium hydroxide solution (IM) and sodium thiosulphate solution (lOOmL, 2M). The ether layer is dried over magnesium sulfate and evaporated to give 5-bromo-3-chloro-2-methoxy-pyridine. This compound is used without further purification in the next reaction.
Step C Analogous to the preparation of ((S)-2-methoxy-l-methyl-ethyl)-(5-methoxy-pyridin-3-yI)- amine, the palladium mediated amination of 5-bromo-3-chloro-2-methoxy-pyridine (4.0g) with (S)-l-methoxy-2-propylamine (2.1 mL) affords, after purification on silica gel (5- chloro-6-methoxy-pyridin-3-yl)-((S)-2-methoxy-l -methyl-ethyl)-amine. LCMS: m/z 231.1/233.1 (M+H)+, Rt 2.19 mins.
Step D
Analogous to the synthesis of (R)-2-(ter/-butyl-dimethyl-silanyloxy)-l-methyl-ethyl]-(2,6- dibromo-5-ethyl-pyridin-3-yl)-amine, the bromination of (5-chloro-6-methoxy-pyridin-3-yl)- ((S)-2-methoxy-l-methyl-ethyl)-amine (1.350g) with N-bromosuccinimide (782mg) gives, after purification on silica gel (2-bromo-5-chloro-6-methoxy-pyridin-3-yl)-((S)-2-methoxy-l- methyl-ethyl)-amine. LCMS: m/z 309.0/311.0/312.0 (M+H)+, Rt 3.00 mins. Step E
Analogous to the synthesis of allyl-[(S)-l-(tert-butyl-dimethyl-silanyloxymethyl)-propyl]- (2,5,6-tribromo-pyridin-3-yl)-amine, the allylation of (2-bromo-5-chloro-6-methoxy-pyridin- 3-yl)-((S)-2-methoxy-l-methyl-ethyl)-amine (1.05g) with allyl iodide (0.68 mL) gives, after purification on silica gel allyl-(2-bromo-5-chloro-6-methoxy-pyridin-3-yl)-((S)-2-methoxy-l- methyl-ethyl)-amine. LCMS: m/z 349.0/351.0/353.0 (M+H)+, Rt 3.32 mins.
Step F
Analogous to the synthesis of 5-chloro-6-methoxy-l-((S)-2 -methoxy- l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine, the palladium mediated cyclization of allyl-(2-bromo-5- chloro-6-methoxy-pyridin-3-yl)-((S)-2-methoxy-l -methy l-ethyl)-amine (1.12g) affords, after purification on silica gel affords 6-chloro-5-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine. LCMS: m/z 269.1/271.1 (M+H)+, Rt 2.92 mins.
Step G
6-Chloro-5-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine
(153mg) is reacted with sodium thiomethoxide (800mg). Evaporation of the solvent extracts and trituration of the crude residue with diethyl ether gives 6-chloro- l-((S)-2 -methoxy- 1 -methyl-ethyl)-3-methyl-l,4-dihydro-pyrrolo[3,2-b]pyridin-5-one. LCMS: m/z 255.1/257.1 (M+H)+, Rt 2.03 mins.
Step H
Analogous to the synthesis of trifluoro-methanesulfonic acid 6-isopropyl-3-[6-methoxy-l- ((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl ester, reaction of 6-chloro- 1 -((S)-2-methoxy- 1 -methy l-ethyl)-3 -methyl- 1 ,4-dihydro-pyrrolo[ ,2- b]pyridin-5-one (340mg) with triflic anhydride (0.27mL) in the presence of triethyl amine (0.34mL) affords, after purification on silica gel trifluoro-methanesulfonic acid 6-chloro- 1- ((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl ester. LCMS: m/z 387.0/389.0 (M+H)+, Rt = 3.22 mins.
Step I
Analogous to the synthesis of 5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methoxy-l-((S)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine, the palladium mediated coupling of trifluoro-methanesulfonic acid 6-chloro- l-((S)-2 -methoxy- 1-methyl-ethy l)-3 - methyl- IH-pyrrolo [3 ,2-b]pyridin-5-yl ester (500mg) with 6-isopropyl-2-methoxy-3- pyridineboronic acid (430mg) affords, after purification on silica gel 6-chloro-5-(6-isopropyl- 2-methoxy-pyridin-3-yl)- 1 -((S)-2-methoxy- 1 -methyl-ethy l)-3 -methyl- 1 H-pyrro lo[3 ,2- bjpyridine. LCMS: m/z 388.2/390.2 (M+H)+, Rt 3.15 mins.
Step J
Analogous to the preparation of 6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-l,4- dihydro-pyrrolo[3,2-b]pyridin-5-one, 6-chloro-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l- ((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine (300mg) is reacted with sodium thiomethoxide (500mg). Evaporation of the solvent extracts and trituration of the crude residue with diethyl ether gives 3-[6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-lH-pyridin-2 -one. LCMS: m/z 374.2/376.2 (M+H)+, Rt 2.23 mins. .
Step K
Analogous to the preparation of trifluoro-methanesulfonic acid 6-isopropyl-3-[6-methoxy-l- ((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-ylJ-pyridin-2-yl ester, reaction of 3-[6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-lH-pyridin-2-one (250mg) with triflic anhydride (0.14mL) in the presence of triethyl amine (0.17mL) gives, after purification on silica gel trifluoro- methanesulfonic acid 3-[6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester. LCMS: m/z 506.1/508.1 (M+H)+, Rt = 4.02 mins.
Step L
Analogous to the preparation of 5-(2-ethyl-6-isopropyl-pyridin-3-yl)-6-methoxy-l-((S)-2- methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine, reaction of trifluoro- methanesulfonic acid 3-[6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester (145mg) with triethylborane solution in hexanes (1.2mL, l.OM) affords, after purification on silica gel 6-chloro-5^(2- ethyl-6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- bjpyridine. LCMS: m/z 386.2/388.2 (M+H)+, Rt = 2.02 mins. Isolated as a byproduct of this reaction is 6-chloro-5-(6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine. LCMS: m/z 358.2/360.2 (M+H)+, Rt = 2.15 mins.
Step M Analogous to the preparation of ethyl-{6-isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l- methyl-ethyl)-3-methyl-lH-pyπOlo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-amine, the reaction of trifluoro-methanesulfonic acid 3-[6-chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester (85mg) with methyl amine solution in THF (0.9mL, 2M) gives, after purification on silica gel {3-[6-chloro-l-((S)-2-methoxy-l- methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl- amine. LCMS: m/z 387.2/389.2 (M+H)+, Rt = 2.09 mins.
Replacing the amine in step M of Example 35 with various other amine reagents, the following compounds are synthesized: • {3-[6-Chloro-l-(2-methoxy-l-methy]-ethyl)-3-methyl-lH-pyrro]o[3,2-b]pyridin-5- yl]-6-isopropyl-pyridin-2-yl}-dimethyl-amine Rt 2.12min m/z 401.2(M+H)+ • {3-[6-Chloro-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5- yl]-6-isopropy]-pyridin-2-yl}-ethyl-amine Rt 2.22min m/z 401.2(M+H)+
EXAMPLE 36
Synthesis of {3-[6-chloro-l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-arnine and 6-chloro-5-(2- ethyl-6-isopropyl-pyridin-3-yI)-l-((R)-l-fluoromethyl-2-methoxy-ethyI)-3-methyI-lH- pyrrolo[3,2-b]pyridine
Substituting (R)-l-(tert-Butyl-dimethyl-silanyloxymethyl)-2-methoxy-ethylamine for (S)-l- methoxy-2-propylamine in the scheme of Example 35 and introducing the fluoro group after step F as described in steps F and G of Example 13 gives {3-[6-chloro-l-((R)-l- fluoromethyl-2-methoxy-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl- pyridin-2-yl}-methyl-amine, Rt 2.09min m/z 405.2(M+H)+ and 6-chloro-5-(2-ethyl-6- isopropyl-pyridin-3-yl)-l-((R)-l-fJuoromethyl-2-methoxy-ethyl)-3-methyl-lH-pyrrolo[3,2- bjpyridine, Rt 2.34min m/z 448.12(M+H)+. EXAMPLE 37
Synthesis of {5-ChIoro-3-[l-((R)-l-fluoromethyI-2-methoxy-ethyI)-3,6-dimethyI-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine
Figure imgf000130_0001
Step A
N-Chlorosuccinimide (33mg) is added to a solution of {3-[l-(l-fluoromethyl-2-methoxy- ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine (94mg) in chloroform (3mL). After 18 hr additional N-chlorosuccinimide (lOmg) is added and then after a further 5 min water (lOmL) and dichloromethane (lOmL) are added to the reaction mixture. The organic layer is separated, dried, and evaporated to give, after chromatography over silica gel, {5-Chloro-3-[l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine. Rt 2.67min m/z 419.2(M+H)+.
EXAMPLE 38
Synthesis of l-((R)-l-fluoromethyI-2-methoxy-ethyl)-5-(6-isopropyl-2-methyI-pyridin-3- yl)-3,6-dirnethyl-lH-pyrrolo[3,2-b]pyridine
Figure imgf000130_0002
Step A
Trifluoro-methanesulfonic acid 3-[l -(l-fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester (97mg), bis(triphenylphosphine)palladium(II) chloride (4mg) and lithium chloride (25 mg) are introduced in a glass tube that was then filled with nitrogen. DMF (2mL) and tetramethyltin (30uL) are added, the tube is closed with a cap and the reaction mixture is heated at 100°C overnight. Water (2mL) and EtOAc (2mL) are added and then the organic layer is separated. The aqueous layer is extracted three more times with EtOAc and then the combined organic phase is dried and evaporated to give, after silica gel purificaticsf=l-((R)-l-Fluoromethyl-2- methoxy-ethyl)-5-(6-isopropyl-2-methyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- ojpyridine. Rt 1.83min m/z 370.2(M+H)+.
EXAMPLE 39
In a manner analogous to the synthesis of l-((R)-l-fluoromethyl-2-methoxy-ethyl)-5-(6- isopropyl-2-methyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine, trifluoro- methanesulfonic acid 3-[6-chloro- 1 -((S)-2 -methoxy- 1 -methyl-ethyl)-3 -methyl- 1 H- pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester affords 6-chloro- 1 -((R)-l -fluoro- methyl-2-methoxy-ethyl)-5-(6-isopropyl-2-methyl-pyridin-3-yl)-3-methyl-lH-pyrrolo[3,2- bjpyridine. Rt 2.17min m/z 390.11(M+H)+.
EXAMPLE 40 Synthesis of Ethyl-{3-[l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-lH- pyrroIo[3,2-b]pyridin-5-yl]-6-isopropyI-pyridin-2-yl}-arnine
In a manner analogous to the synthesis of {3-[l-((R)-l-Fluoromethyl-2-methoxy-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine, trifluoro- methanesulfonic acid 3-[l -(1 -fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-l H-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl ester and ethylamine afford ethyl-{3-[l-((R)-l- fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl- pyridin-2-yl} -amine. Rt 2.03min m/z 399.2(M+H)+.
EXAMPLE 41
Synthesis of 2-bromo-7-(l -ethyl-propyl)-3-(2-m ethoxy-4-trifluoromethoxy-phenyl)-5- methyI-5H-pyrrolo[2,3-b]pyrazine, 7-(l-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy- phenyl)-5-methyI-5H-pyrrolo[2,3-b]pyrazine and 2-ethyl-7-(l-ethyl-propyl)-3-(2- methoxy-4-trifluoromethoxy-phenyl)-5-methyl-5H-pyrrolo[2,3-b]pyrazine
Figure imgf000132_0001
Step A
A mixture of (6-chloro-pyrazin-2-yl)-methyl-amine (431 mg, 3 mmol), 2-methoxy-4- trifluoromethoxyphenyl boronic acid (780 mg, 3.3 mmol) in 2M Na2C03 (3 mL, 6 mmol) and toluene (3 mL) is treated with Pd(PPh3) (50 mg) under nitrogen at 80 °C for 16 h. After cooling to room temperature, the product is extracted with ethyl acetate (3 x 10 mL), dried, concentrated and purified by silica gel column chromatography to give[6-(2-methoxy-4- trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl-amine. LC-MS (M + 1): 300.
Step B
To a solution of [6-(2-methoxy-4-trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl-amine (1.2 g, 4 mmol) in chloroform ( 20 mL) is added NBS (1.78 g, 10 mmol) in one portion at 0 °C. The mixture is then stirred at room temperature for 15 min followed by concentration and purification by silica gel column chromatography to provide [3,5-dibromo-6-(2-methoxy-4- trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl-amine. LC-MS (M + 1): 458. Step C
To a solution of NaH (95%, 65 mg, 4.5 mmol) and Bu NBr (144 mg, 0.45 mmol) in anhydrous NMP (2 mL) is added dropwise a solution of [3,5-dibromo-6-(2-methoxy-4- trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl-amine (1.37 g, 3 mmol) in NMP (10 mL) under nitrogen at room temperature in 5 min. The mixture is continued stirring at room temperature for 1 h, followed by addition of l-chloro-3-ethyl-pent-2-ene (594 mg, 4.5 mmol). The mixture is then heated at 65 °C for 16 h. After cooling to room temperature, the product is extracted with ethyl acetate (3 x 20 mL), washed with water (2 8 mL) and brine (10 mL), dried, concentrated and purified by silica gel column chromatography to give [3,5-dibromo- 6-(2-methoxy-4-trifluoromethoxy-phenyl)-pyrazin-2-yl]-(3-ethyl-pent-2-enyl)-methyl-amine.
Step D
A mixture of [3,5-dibromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-pyrazin-2-yl]-(3-ethyl- pent-2-enyl)-methyl-amine (1.77 g, 3.2 mmol), Bu4NBr (1.02 g, 3.2 mmol), K2C03 (1.33 g, 9.6 mmol) and Pd(OAc)2 in anhydrous DMF (20 mL) under nitrogen is heated at 90 °C for 1 h. After cooling to room temperature, the reaction is quenched by addition of water (10 mL). The product is extracted with ethyl acetate (3 x 20 mL), washed with water (2 x 8 mL) and brine (10 mL), dried, concentrated and purified by silica gel column chromatography to give 2-bromo-7-(l-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-5H- pyrrolo[2,3-b]pyrazine. LC-MS (M + 1): 472
Step E
A solution of 2-bromo-7-(l -ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5- methyl-5H-pyrrolo[2,3-b]pyrazine (50 mg, 0.106 mmol) in ethyl acetate (5 mL) is hydrogenated with 5% Pd-C (10 mg) under atmosphere at room temperature overnight. After filtration and concentration, the product is purified by silica gel column chromatography to give 7-(l-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-5H-pyrrolo[2,3- bjpyrazine. 1H NMR (CDC13, δ): 0.85 (t, J= 7.2 Hz, 6H), 1.82 (m, 4H), 2.87 (m, IH), 3.87 (s, IH), 3.88 (s, 3H), 6.86 (s, IH), 6.98 (d, J= 8.4 Hz), 7.19 (s, IH), 7.87 (, d, J= 8.4 Hz, IH), 8.90 (s, IH); LC-MS (M + 1): 394.
Step F A mixture of 2-bromo-7-(l-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5- methyl-5H-pyrrolo[2,3-b]pyrazine (47 mg, 0.1 mmol), Et3B (IM solution in hexane, 0.2 mL, 0.2 mmol) in 2M Na2C03 (0.5 mL, 1 mmol) and toluene (1 mL) is treated with Pd(PPh3)4 (10 mg) under nitrogen at 90 °C for 16 h. After cooling to room temperature, the product is extracted with ethyl acetate (3 x 10 mL), dried, concentrated and purified by silica gel column chromatography to give 2-ethyl-7-(l-ethyl-propyl)-3-(2-methoxy-4- trifluoromethoxy-phenyl)-5-methyl-5H-pyrrolo[2,3-b]pyrazine. !H MR (CDC13> δ): 0.87 (t, J= 7.6 Hz, 6H), 1.17 (t, J = 7.6 Hz, 3H), 1.82 (m, 4H), 2.69 (m, 2H), 2.92 (m, IH), 3.77 (s, IH), 3.81 (s, 3H), 6.83 (s, IH), 6.94 (d, J= 8.0 Hz), 7.12 (s, IH), 7.31 (d, J= 8.0 Hz, IH); LC-MS (M + 1): 408.
EXAMPLE 42
Synthesis of 2-methyl-7-(l|-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5- methyl-5H-pyrrolo[2,3-b]pyrazine
Figure imgf000134_0001
Figure imgf000134_0002
Step A
To a solution of [6-(2-methoxy-4-trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl-amine (3 g, 10 mmol) in chloroform (25 mL) is added NBS (2.13 g, 12 mmol) in one portion at 0 °C. The mixture is then stirred at room temperature for 30 min followed by concentration and purification by silica gel column chromatography to provide [5-bromo-6-(2-methoxy-4- trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl-amine. LC-MS (M + 1): 378. Step B
A mixture of [5-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-pyrazin-2-yl]-methyl- amine (120 mg, 0.32 mmol), MeB(OH)2 (192 mm, 3.2 mmol) in 2M Na2C03 (2 mL, 4 mmol) and toluene (2 mL) is treated with Pd(PPh3)4 (20 mg) under nitrogen at 85 °C for 16 h. After cooling to room temperature, the product is extracted with ethyl acetate (3 x 10 mL), dried, concentrated and purified by silica gel column chromatography to give [6-(2-methoxy-4- trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-methyl-amine.
Step C [3-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-methyl-amine is prepared by the same procedure as described in step A. LC-MS: 392.
Step D
[3-bromo-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-(3-ethyl-pent-2- enyl)-methyl-amine is prepared by the same procedure for [3,5-dibromo-6-(2-methoxy-4- trifluoromethoxy-phenyl)-pyrazin-2-yl]-(3-ethyl-pent-2-enyl)-methyl-amine.
Step E
7-(l-Ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-2,5-dimethyl-5H-pyrrolo[2,3- bjpyrazine is prepared by the same procedure for 2-bromo-7-(l-ethyl-propyl)-3-(2-methoxy- 4-trifluoromethoxy-phenyl)-5-methyl-5H-pyrrolo[2,3-b]pyrazine. !H NMR (CDC13> δ): 0.86 (t, J= 7.6 Hz, 6H), 1.83 (m, 4H), 2.42 (s, 3H), 2.93 (m, IH), 3.78 (s, IH), 3.81 (s, 3H), 6.83 (s, IH), 6.94 (d, J= 8.0 Hz), 7.12 (s, IH), 7.31 (d, J= 8.0 Hz, IH); LC-MS (M + 1): 422.
EXAMPLE 43
Synthesis of N,N-diethyl-{4-ethyl-5-[2-ethyI-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3- b]pyrazin-3-yl]-pyridin-2-yl}-amine
Figure imgf000136_0001
Figure imgf000136_0002
Step A
The previously described 2-chloro-4-methylaminopyrazine (40. Og) is dissolved in chloroform (500mL).and NBS (104. Og) is added. After being stirred for 16h, the yellowish mixture is put into water (500mL) and sat. sodium bicarbonate (lOOmL), extracted with ethyl acetate/hexane (1/3, 2x400mL), and dried over magnesium sulfate. The crude is then flushed through a plug of silica gel (ethyl acetate/hexane = 1/3) and used without any other purification. TLC: Rf = 0.63 (ethyl acetate/hex = 1/3)
Step B The crude dibromide (73.69g) of step A and the later described 3,3-diethylallyl bromide (84.40g, step F +G) are dissolved in DMF (400mL). Sodium hydride (15.50g) is added in portions and the reaction is stirred for 30 min at rt. The mixture is then put into water (2000mL) and extracted with ethyl acetate/hexane (1/6, 4x700mL). The combined organic layers are washed with water (200mL), dried over magnesium sulfate, and filtered directly through a plug of silica gel (200g). The crude material is used directly in step C. TLC: Rf = 0.90 (EtOAc/hex= 1/6)
Step C The crude allyl compound (116.0g) of step B, tetrabutylammonium bromide (75.3g), palladium acetate (5.2g), and potassium carbonate (97.0g) are dissolved in DMF (1200mL). After being heated to 80 °C for 6h, the mixture is worked-up according to step B. Final purification on silica gel affords the bicyclic compound. TLC: Rf = 0.59 (EtOAc/hex = 1/6)
Step D
The bicyclic compound (1.83g) of step C is dissolved in toluene (50mL).. After degassing, tetrakis(triphenylphosphine)palladium (0) (0.67g) is added. A second degassing is followed by addition of triethylborane (28.9mL, IN in hexane) and of a 2N potassium carbonate solution (6.0mL) whereupon the reaction is heated to 80 °C for 36h. The yellowish mixture is then put into water (200mL), extracted with DCM (3xl50mL), and dried over magnesium sulfate. Purification on silica gel affords the ethyl derivative. LCMS: m/z 266.14 (M+H)+
Step E
The ethyl derivative (500mg) of step D and the previously described 2-diethylamino-4-ethyl- 5-pyridine boronic acid (526mg) are dissolved in DME (15mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (183mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (3.2mL) whereupon the reaction is heated to 80 °C for 40h. The yellowish mixture is then put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 408.37 (M+H)+
Step F
3-Pentanone (73.9mL) in THF (300mL) is slowly added to vinyl magnesium bromide (800mL, IN in THF) at rt. After being stirred for 24h, the mixture is put into water (2500mL) and sat. sodium bicarbonate (500mL), extracted with DCM (lxl500mL, 2x500mL), and dried over magnesium sulfate. The crude mixture is used without any further purification in step G. Step G
The crude mixture (82. Og) of step F is dissolved in cone. HBr (250mL). After 20 min or once NMR control shows completed conversion, the dark mixture is put into water (500mL), extracted with DCM (3x250mL), and dried over magnesium sulfate. The crude mixture is used without any further purification in step B.
EXAMPLE 44
Synthesis of 2-[3-(6-isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H-pyrroIo[2,3- b]pyrazin-7-yl]-propan-l-ol
Figure imgf000138_0001
Step A
The previously described 2,6-dibromo-3-chloro-5-methylaminopyrazine (550mg) and the shown allylic bromide (560mg, synthesized identically to the Me-regioisomere described by Enders βt al, Synlett 2002, 2280) are dissolved in DMF (lOmL). After addition of sodium hydride (91mg), the dark red reaction mixture is stirred for 15 min. Subsequently, the mixture is put into water (200mL) and sat. sodium bicarbonate (100ml), extracted with ethyl ether (2x1 OOmL), and dried Over magnesium sulfate. Purification on silica gel affords the allylic compound. TLC: Rf = 0.69 (EtOAc/hex = 1/6)
Step B
The allylic compound (892mg) of step A, tetrabutylammonium bromide (575mg), palladium acetate (40mg), and potassium carbonate (737mg) are dissolved in DMF (lOmL). After heating to 80 °C for 30 min, the mixture is worked-up according to step A. Purification on silica gel affords the Heck-product. LCMS: m/z 417.93 (M+H)+
Step C The Heck product (356mg) of step B is dissolved in THF (2.5mL) and added to a solution of t-BuLi (1.05mL, 1.7N in pentane) in THF (8.5mL) at -78 °C. After being stirred for 10 min, methyl iodide (0.21mL) is added and the reaction mixture is stirred for another lh at -78 °C. Subsequently, the mixture is put into water (lOOmL) and sat. sodium bicarbonate (50ml), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the methyl derivative. LCMS: m/z 354.12 (M+H)+
Step D
The methyl product of step C (238mg) and the previously described 2- jopropyl-6-methoxy- 5-pyridine boronic acid (158mg) are dissolved in DME (5.0mL). After degassing, tetrakis(triphenylphosphine)palladium (0) (77mg) is added. A second degassing is followed by addition of a IN sodium carbonate solution (1.35mL) whereupon the reaction is heated to 80 °C for 3h. The yellowish mixture is then put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the coupled product. LCMS: m/z 469.15 (M+H)+
Step E
The Suzuki product of step D is dissolved in THF (5.0mL). After addition of TBAF monohydrate (650mg), the reaction mixture is stirred for 30 min. Subsequently, the yellow solution is put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 355.16 (M+H )+
EXAMPLE 45
Synthesis of 3-(6-isopropyI-2-methoxy-pyridin-3-yl)-7-(2-methoxy-l-methyl-ethyl)-2,5- dimethyl-5H-py rrolo [2,3-b] pyrazine
Figure imgf000140_0001
2-[3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]- propan-1-ol (33mg) is dissolved in THF (5.0mL). After addition of sodium hydride (74mg), the cloudy mixture is stirred for 5min before methyl iodide (0.23mL) is added. The reaction is stirred for 16h, put into water (lOOmL) and sat. sodium bicarbonate (10ml), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 369.15 (M+H)+
EXAMPLE 46
Synthesis of 3-(6-isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-7-(l-methyl-2- morpholin-4-yl-ethyl)-5H-pyrrolo[2,3-b]pyrazine
Figure imgf000140_0002
Step A
2-[3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]- propan-1-ol (142mg) is dissolved in DCM (5.0mL) and cooled to 0 °C. Mesyl chloride (34μL) and triethylamine (78μL) are added before the reaction is stirred for 30 min at 0 °C. Subsequently, the yellow solution is put into water (lOOmL), extracted with DCM (3x1 OOmL), and dried over magnesium sulfate. The crude mixture is carried on to step B without any further purification. LCMS: m/z 433.07 (M+H )+
Step B • The mesylate (54mg) of step A is dissolved in acetonitrile (LOmL). After addition of morpholine (200mg), the reaction is heated to 80 °C for 3h. Subsequently, the clear solution is put into water (lOOmL), extracted with DCM (3xl00mL), and dried over magnesium sulfate. Purification on silica gel affords the title compound. LCMS: m/z 424.13 (M+H)+
EXAMPLE 47
Synthesis of 3-(l-ethyI-propyl)-6-(2-methoxy-4-trifluoromethoxy-phenyl)-l,5-dimethyl- lH-pyrrolo[2,3-b]pyridine
Figure imgf000141_0001
Step A
The previously described 2-chloro-6-methylaminopyridine (670mg), the also previously described 2-methoxy-4-trifluoromethoxyphenyl boronic acid (1.37g), and Pd(PPh3) (115mg) are dissolved in toluene (30mL). After addition of 2N Na2C03 (6mL), the mixture is degassed and then heated at 85 °C overnight. The solution is diluted with EtOAc and washed with 2N NaOH, H20, brine, and dried over MgS04. Purification on silica gel yields the Suzuki product. !H NMR (CDC13, δ ppm): 7.78 (IH, d, J= 8.4 Hz), 7.49 (IH, t, J= 7.6 Hz), 7.08 (IH, d, J= 1.6 Hz), 6.90 (IH, dd, J= 7.4, 2.0Hz), 6.80 (IH, d, J= 2.0Hz), 6.34 (IH, J= 8.4Hz), 4.66 (IH, brs), 3.84 (3H, s), 2.94 (3H, d, J= 5.0Hz).
Step B
To a cooled solution of the Suzuki product from Step A (l.Og) in CHC13 is added a solution nfWRS (λ 1 σ\ in CVfd at 0 °C. nver min After beinp; stirred at rt r 1 hr the rean.tinn mixture is evaporated. The residue is then purified on silica gel to yield the bromide. !H NMR (CDCI3, δ ppm): 7.80 (IH, s), 7.28 (IH, d, J= 8.4 Hz), 6.90 (IH, dd, J= 8.4, 1.1Hz), 6.79 (IH, s), 5.03 (IH, brs), 3.82 (3H, s), 2.98 (3H, d, J= 5.0Hz).
Step C
To a solution of the crude bromide (l.lg) from step B in NMP (lOmL) is added NaH (60%, 0.195g). After being stirred for 2h, freshly distilled 3,3-diethylallyl chloride (0.414g, prepared analogously to the previously described 3,3-diethylallyl bromide) is added to the reaction mixture. Stirring for an additional lh is followed by quenching with H20 and extraction with EtOAc. The organic layer is washed with H20, brine, and dried over Na2S0 . Purification on silica gel yields the allyl compound. Η NMR (CDC13, δ ppm): 7-95 (IH, s), 7.28 (IH, d, J= 8.3 Hz), 6.90 (IH, d, J= 8.3Hz), 6.79 (IH, s), 5.30 (IH, m), 3.92 (2H, d, J= 6.6Hz), 3.81 (3H, s), 2.87 (3H, s), 2.06 (4H, m), 1.01 (3H, t, J= 7.5Hz), 0.94 (3H, t, J= 7.5Hz).
Step D
The allyl compound of step C (330mg), Pd(OAc)2 (40mg), tetrabutylammonium bromide (219mg), and K2C03 (250mg) are dissolved in DMF (3mL), degassed, and heated to 80 °C overnight. The mixture is then diluted with EtOAc and washed with H20, brine, and dried over MgS04. Purification on silica gel yields the Heck product. Η NMR (CDC13, δ ppm): 8.11 (IH, s), 7.31 (IH, d, J= 8.3 Hz), 6.94 (2H, m), 6.82 (IH, d, J= 1.7 Hz), 3.81 (3H, s),3.80 (3H, s), 2.58 (IH, m), 1.62-1.79 (4H, m), 0.85 (6H, t, J= 7.3Hz).
Step E The Heck product of step D (80mg), methylboronic acid (60mg), and Pd(PPh3)4 (lOmg) are dissolved in toluene (5mL). After addition of 2N Na2C03 (3mL), the reaction mixture is degassed and then heated to 85 °C overnight. Subsequently, the solution is diluted with EtOAc and washed with 2N NaOH, H20, and brine before being dried over MgS04. Purification on silica gel yields the title compound. 'H MR (CDC13, δ ppm): 7.73 (IH, s), 7.32 (IH, d, J= 8.2 Hz), 6.93 (IH, d, J= 8.2 Hz), 6.88 (IH, s), 6.82 (IH, s), 3.81 (3H, s), 3.78 (3H, s), 2.18 (3H, s), 1.68-1.79 (4H, m), 0.86 (6H, t, J= 7.3Hz). EXAMPLE 48
Synthesis of 5-chIoro-3-(l-ethyl-propyl)-6-(2-methoxy-4-trifluoromethoxy-phenyl)-l- methyl-lH-pyrrolo[2,3-b]pyridine
Figure imgf000143_0001
Step A
NCS (2.95g)"is added to a solution of the previously described 2-chloro-6- methylaminopyridine (1.43g) in acetonitrile (40mL) whereupon the reaction mixture is heated to 70 °C for 48h. Subsequently, the yellow solution is diluted with EtOAc, washed with H20, brine, and dried over Na2S0 . Purification on silica gel yields the trichloride. Η NMR (CDC13, δ ppm): 7.50 (IH, s), 5.07 (IH, brs), 3.04 (3H, d, J= 5.0Hz).
Step B
To a solution of the trichloride from step A (1.03g) in NMP (20mL) is added tetrabutylammonium bromide (0.2g) and NaH (60%, 0.38g). After being stirred at rt for 3h, 3,3-diethylallyl chloride (0.97g, prepared analogously to the previously described 3,3- diethylallyl bromide) is added and the reaction mixture is stirred for an additional 36h. The yellow solution is then quenched with water and extracted with EtOAc. The organic layer is washed with water, brine, and dried over MgS0 to yield the crude allylamine which was used in step C without any further purification. Η NMR (CDC13, δ ppm): 7.58 (IH, s), 5.23 (IH, t, J= 6.7Hz), 3.96 (2H, d, J= 6.7Hz), 2.92 (3H, s), 2.05-2.09 (4H, m), 0.94-1.00(6H, m).
Step C The allyl compound of step B (lOOmg), Pd(OAc)2 (lOmg), TBAB (116mg), and K2C03
(132mg) are dissolved in DMF (2mL), degassed, and heated to 80 °C overnight. The mixture is then diluted with EtOAc and washed with H20, brine, and dried over MgS0 . Purification • on silica gel yields the Heck product.
Step D
The Heck product of step C, the previously described 2-methoxy-4-trifluoromethoxyphenyl boronic acid, and Pd(PPh3) are dissolved in toluene. After addition of a 2N Na2C03, the reaction mixture is degassed and then heated to 85 °C overnight. Subsequently, the solution is diluted with EtOAc and washed with 2N NaOH, H20, and brine before being dried over MgS04. Purification on silica gel yields the title compound. Η NMR (CDC13, δ ppm): 7.73 (IH, s), 7.39 (IH, d, J= 8.2 Hz), 6.95 (IH, s), 6.93 (IH, d, J= 8.2 Hz), 6.82 (IH, s), 3.81 (6H, brs), 2.59 (IH, m), 1.68-1:79 (4H, m), 0.84 (6H, t, J= 7.3Hz).
EXAMPLE 49
Synthesis of 6-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3-(l-methoxymethyl-propyl)-l,5- dimethyl-lH-pyrrolo[2,3-b]pyridine
Figure imgf000144_0001
Step A
TBDMSC1 (20g) is added to a cold (0°C) solution of 4-hydroxy-2-butanone (17.6g), DMAP (200mg), imidazole (10.8g) in DMF (160ml). The reaction mixture is warmaed naturally to room temperature and stirred for 24 hours. The reaction mixture is added with water and extracted with ethyl acetate and dried with Na2S04. Purification by column with hexane/ethyl acetate gives product. Rf: 0.4(hexane/ethyl acetate: 8:1)
Step B
Triethyl phosphonoacetate (17.3ml) is added as a solution of THF (30ml) to a cold (0°C) suspension of NaH (0.131mol) in anhydrous THF (80ml). The resulting mixture is stirred at 0°C for 1 hour before ketone (17.67g) is added as a solution of THF (10ml). The reaction is continued at room temperature for another 2 hours. Saturated aqueous NH C1 is carefully added and separated. Aqueous layer is extracted with ether. The combined organic layers are washed with water, brine. Purification by column with hexane/ethyl acetate gives product. Rf: 0.4(hexane/ethyl acetate: 15:1)
Step C Starting material (21.3g) is treated with DIB AL-H( l.OM in toluene, 196ml) at 0°C for 6 hours. Water is carefully added to quench the excess DIBAL. The reaction mixture is filtered and washed with ethyl acetate. The filtrate is concentrated to afford the crude product. Rf: 0.4(hexane/ethyl acetate: 3:1).
Step D
Starting material (8.75g) is taken in anhydrous methylene chloride (110ml), triethylamine is added. The resulting mixture is cooled to -40°C. MsCl is added dropwise and the reaction is continued for 1 hour at -40°C before LiBr (13.2g) is added as a solution of THF (120ml). The resulting reaction mixture is warmed naturally to room temperature and continued for another 1 hour. The reaction is quenched with water and separated. Aqueous layer is extracted with ether. The combined organic layers are washed with brine and dried with Na2S04. The crude product can be used for the next step reaction without further purification. Rf: 0.4(hexane/ethyl acetate: 20:1).
Step E
2,6-dichloropyridine (17g) and CH3NH2 aqueous solution (40%, 26.8g) are taken in THF (100ml) in a sealed tube and is heated at 80°C for 24 hours. The reaction is cooled to room temperature and diluted with water. The resulting mixture is separated and extracted with ethyl acetate. The combined organic layers are washed with brine and dried with Na?S04. The crude product is used for the next step reaction without further purification. LCMS: 143.3 (M+H)+
Step F
A mixture of 2-chloro-6-methylamino-pyridine (3.56, 0.025mol)), 2-methoxy-6-isopropyl-3- pyridylboronic acid (6.33g), Pd(PPh3)4 (577mg), aqueous Na2C03 solution (l.OM, 50ml), and toluene (50ml) is heated overnight at 100°C under a dinitrogen atmosphere. The reaction mixture is cooled to room temperature and separated. The aqueous layer is extracted with ethyl acetate. The combined organic layers are washed with brine and dried with Na S04. The crude product is used for the next step reaction without further purification. Rf: 0.4(hexane/ethyl acetate: 4:1).
Step G The crude starting material is taken in anhydrous CHC13 (100ml). 4.0 equivalent of NBS is added in one portion at 0°C. The reaction is complete in 0.5 hour. The reaction mixture is washed with water and dried with Na2S04. Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 496.1 (M+H)+
Step H
NaH (795mg, 60% in mineral oil) is added to a solution of starting material (6.34g) in anhydrous DMF (100ml) and stirred at room temperature for lOminutes. Bromide (4.93g) prepared in Step D is added dropwise and the resulting mixture is stirred for 3 hours. The reaction mixture is carefully quenched with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.4(hexane/ethyl acetate: 12:1).
Step I A mixture of bromide (9.26g), tetrabutylammonium bromide (5.95g), K2C03(6.12g),
Pd(OAc)2(1.0g) in DMF(80ml) is heated at 80°C under N2 atmosphere for 20 minutes. The reaction mixture is cooled to room temperature and diluted with water. The resulting mixture is extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 548.4 (M+H)+
Step J To a solution of t-BuLi(l .7M/pentane, 7ml)in THF (30ml) at -78°C is added a solution of bromide (3.07g) in THF (5ml). The resulting mixture is stirred at -78°C for 10 minutes before iodomethane (1.4ml) is added. The reaction is continued for 30minutes. The reaction is carefully quenched with EtOH. The resulting mixture is washed with water and brine, dried with Na2S04. Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.4(hexane/ethyl acetate: 10:1).
Step K
Starting material (1.26g) is taken in THF (50ml) followed by the addition of tetrabutylammonium fluoride (1.5 equiv.) at room temperature. The reaction is complete after 4 hours. The reaction mixture is washed with water, brine and dried with Na2S04.
Purification by flash column with hexane/ethyl acetate gives product. LCMS: m/z 368.3 (M+H)+
Step L Starting material (lOOmg) is taken in anhydrous DMF (4ml), NaH (52mg, 60%) is added followed by the addition of CH3I (5 equiv.). The reaction is continued overnight. The reaction is quenched with water and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 382.3 (M+H)+
EXAMPLE 50
The compounds shown in the table are analogously prepared according to the procedures given in the above schemes and further illustrated in the above examples. with Na2S04. Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 548.4 (M+H)+
Step J To a solution of t-BuLi(l .7M/pentane, 7ml)in THF (30ml) at -78°C is added a solution of bromide (3.07g) in THF (5ml). The resulting mixture is stirred at -78°C for 10 minutes before iodomethane (1.4ml) is added. The reaction is continued for 30minutes. The reaction is carefully quenched with EtOH. The resulting mixture is washed with water and brine, dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. Rf: 0.4(hexane/ethyl acetate: 10:1).
Step K
Starting material (1.26g) is taken in THF (50ml) followed by the addition of tetrabutylammonium fluoride (1.5 equiv.) at room temperature. The reaction is complete after 4 hours. The reaction mixture is washed' with water, brine and dried with Na2S0 .
Purification by flash column with hexane/ethyl acetate gives product. LCMS: m/z 368.3 (M+H)+
Step L Starting material (lOOmg) is taken in anhydrous DMF (4ml), NaH (52mg, 60%) is added followed by the addition of CH3I (5 equiv.). The reaction is continued overnight. The reaction is quenched with water and extracted with ethyl acetate. The combine organic layers are washed with brine and dried with Na2S0 . Purification by flash column with hexane/ethyl acetate gives product as clear oil. LCMS: m/z 382.3 (M+H)+
EXAMPLE 50
The compounds shown in the table are analogously prepared according to the procedures given in the above schemes and further illustrated in the above examples.
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
5-(6-Isopropyl-2- methoxy-pyr idin-3 -y 1)- l-((S)-2-methoxy-l-
408 |methyl-ethyl)-3,6- 368.2 2.28 jdimethyl-lH- lpyrrolo[3,2-b]pyridin
Figure imgf000214_0001
-
{6-Isopropyl-3-[l-((S)-
2-methoxy- 1 -methyl- ethyl)-3,6-dimethyl-
409 lH-pyrrolo[3 381.3 2.00
,2-bjpyridin-5-ylj- pyridin-2-yl} -dimethyl-
Figure imgf000214_0002
[amine
[6-Isopropyl-3-(l- |isopropyl-3,6-dimethyl-
410 1 H- pyrrolo [3,2- 351.4 2.07 bjpyridin-5-yl)-pyridin- 2-yl]-dimethyl-amine
[3-(3,6-Dimethyl-l- |propyl- 1 H-pyrrolo[3,2-
411 b]pyridin-5-yl)-6- 351.4 2.12 isopropyl-pyridin-2-ylj- |dimethyl-amine
Figure imgf000214_0003
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Example 51
Assay for CRF Receptor Binding Activity
As discussed above, the following assay is defined herein as a standard in vitro CRF receptor binding assay. The pharmaceutical utility of compounds of this invention is indicated by the following assay for CRFl receptor activity. The CRF receptor binding is performed using a modified version of the assay described by Grigoriadis and De Souza (Methods in Neurosciences, Vol. 5, 1991). IMR-32 human neuroblastoma cells, a cell-line that naturally expresses the CRFl receptor, are grown in IMR-32 Medium, which consists of EMEM w/Earle's BSS (JRH Biosciences, Cat# 51411) plus, as supplements, 2mM L-Glutamine, 10% Fetal Bovine Serum, 25mM HEPES (pH 7.2), ImM Sodium Pyruvate and Non-Essential Amino Acids
(
(JRH Biosciences, Cat# 58572). The cells are grown to confluence and split three times (all splits and harvest are carried out using NO-ZYME - JRH Biosciences, Cat# 59226). The cells are first split 1:2, incubated for 3 days and split 1:3, and finally incubated for 4 days and split 1:5. The cells are then incubated for an additional 4 days before being differentiated by treatment with 5-bromo-2'deoxyuridine (BrdU, Sigma, Cat# B9285). The medium is replaced every 3-4 days with IMR-32 medium w/2.5uM BrdU and the cells are harvested after 10 days of BrdU treatment and washed with calcium and magnesium-free PBS.
To prepare receptor containing membranes cells are homogenized in wash buffer (50 mM Tris HCI, 10 mM MgCl2, 2 mM EGTA, pH 7.4) and centrifuged at 48,000 x g for 10 minutes at 4°C. The pellet is re-suspended in wash buffer and the homogenization and centrifugation steps are performed two additional times.
Membrane pellets (containing CRF receptors) are re-suspended in 50 mM Tris buffer pH 7.7 containing 10 mM MgCl2 and 2 mM EDTA and centrifuged for 10 minutes at 48,000g. Membranes are washed again and brought to a final concentration of 1500 ug/ml in binding buffer (Tris buffer above with 0.1 % BSA, 15 mM bacitracin and 0.01 mg/ml aprotinin.). For the binding assay, 100 ul of the membrane preparation are added to 96 well microtube plates containing 100 ul of 125I-CRF (SA 2200 Ci/mmol, final concentration of 100 pM) and 50 ul of test compound. Binding is carried out at room temperature for 2 hours. Plates are then harvested on a BRANDEL 96 well cell harvester and filters are counted for gamma emissions on a Wallac 1205 BETAPLATE liquid scintillation counter. Non-specific binding is defined by 1 mM cold CRF. IC50 values are calculated with the non-linear curve fitting program RS/1 (BBN Software Products Corp., Cambridge, MA). The binding affinity for the compounds of Formula I expressed as IC50 value, generally ranges from about 0.5 nanomolar to about 10 micromolar. Preferred compounds of Formula I exhibit IC50 values of less than or equal to 1.5 micromolar, more preferred compounds of Formula I exhibit IC50 values of less than 500 nanomolar, still more preferred compounds of Formula I exhibit IC50 values of less than 100 nanomolar, and most preferred compound of Formula I exhibit IC50 values of less than 10 nanomolar. The compounds shown in Examples 1-33 have been tested in this assay and found to exhibit IC50 values of less than or equal to 4 micromolar.
Example 52
Preparation of radiolabeled probe compounds of the invention
The compounds of the invention are prepared as radiolabeled probes by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope. The radioisotope is preferably selected from of at least one of carbon (preferably 1 C), hydrogen (preferably 3H), sulfur (preferably j5S), or iodine (preferably 125I). Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds. Such suppliers include Amersham Corporation, Arlington Heights, IL; Cambridge Isotope Laboratories, Inc. Andover, MA; SRI International, Menlo Park, CA; Wizard Laboratories, West Sacramento, CA; ChemSyn Laboratories, Lexena, KS; American Radiolabeled Chemicals, Inc., St. Louis, MO; and Moravek Biochemicals Inc., Brea, CA.
Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas. Such preparations are also conveniently carried out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. In addition, certain precursors may be subjected to tritium-halogen exchange with tritium gas, tritium gas reduction of unsaturated bonds, or reduction using sodium borotritide, as appropriate.
Example 53
Receptor autoradiography Receptor autoradiography (receptor mapping) is carried out in vitro as described by Kuhar in sections 8.1.1 to 8.1.9 of Current Protocols in Pharmacology (1998) John Wiley & Sons, New York, using radiolabeled compounds of the invention prepared as described in the preceding Examples.
Example 54
Additional Aspects of Preferred Compounds of the Invention
The most preferred compounds of the invention are suitable for pharmaceutical use in treating human patients. Accordingly, such preferred compounds are non-toxic. They do not exhibit single or multiple dose acute or long-term toxicity, mutagenicity (e.g., as determined in a bacterial reverse mutation assay such as an Ames test), teratogenicity, tumorogenicity, or the like, and rarely trigger adverse effects (side effects) when administered at therapeutically effective dosages.
Preferably, administration of such preferred compounds of the invention at certain doses (i.e., doses yielding therapeutically effective in vivo concentrations or preferably doses of 10, 50, 100, 150, or 200 mg/kg administered parenterally or prefrerably orally) does not result in prolongation of heart QT intervals (i.e., as determined by electrocardiography, e.g., in guinea pigs, minipigs or dogs). When administered daily for 5 or preferably ten days, such doses of such preferred compounds also do not cause liver enlargement resulting in an increase of liver to body weight ratio of more than 100%, preferably not more than 75% and more preferably not more than 50%> over matched controls in laboratory rodents (e.g., mice or rats). In another aspect such doses of such preferred compounds also preferably do not cause liver enlargement resulting in an increase of liver to body weight ratio of more than - 50%), preferably preferably not more than 25%, and more preferably not more than 10%> over matched untreated controls in dogs or other non-rodent mammals.
In yet another aspect such doses of such preferred compounds also preferably- do not promote the release of liver enzymes (e.g., ALT, LDH, or AST) from hepatocytes in vivo. Preferably such doses do not elevate serum levels of such enzymes by more than 100%), preferably not by more than 75% and more preferably not by more than 50% over matched untreated controls in laboratory rodents. Similarly, concentrations (in culture media or other such solutions that are contacted and incubated with cells in vitro) equivalent to two, fold, preferably five-fold, and most preferably ten-fold the minimum in vivo therapeutic concentration do not cause release of any of such liver enzymes from hepatocytes into culture medium in vitro above baseline levels seen in media from untreated cells.
Becatise side effects are often due to undesirable receptor activation or antagonism, preferred compounds of the invention exert their receptor-modulatory effects with high selectivity. This means that they do not bind to certain other receptors (other than CRF receptors) with high affinity, but rather only bind to, activate, or inhibit the activity of such other receptors with affinity constants of greater than 100 nanomolar, preferably greater than 1 micromolar, more preferably greater than 10 micromolar and most preferably greater than 100 micromolar. Such receptors preferably are selected from the group including ion channel receptors, including sodium ion channel receptors, neurotransmitter receptors such as alpha- and beta-adrenergic receptors, muscarinic receptors (particularly ml, m2, and m3 receptors), dopamine receptors, and metabotropic glutamate receptors; and also include histamine receptors and cytokine receptors, e.g., interleukin receptors, particularly IL-8 receptors. The group of other receptors to which preferred compounds do not bind with high affinity also includes GABAA receptors, bioactive peptide receptors (including NPY and VIP receptors), neurokinin receptors, bradykinin receptors (e.g., BK1 receptors and BK2 receptors), and hormone receptors (including thyrotropin releasing hormone receptors and melanocyte- concentrating hormone receptors).
Example 55
Absence of Sodium Ion Channel Activity
- Preferred compounds of the invention do not exhibit activity as sodium ion channel blockers. Sodium channel activity may be measured a standard in vitro sodium channel binding assays such as the assay given by Brown et al. (J: Neurosci. 1986, 265, 17995- 18004). Preferred compounds of the invention exhibit less than 15 percent inhibition,, and more preferably less than 10 percent inhibition, of sodium channel specific ligand binding when present at a concentration of-4 uM. The sodium ion channel specific ligand used may be labeled batrachotoxinin, tetrodotoxin, or saxitoxin. Such assays, including the assay of Brown referred to above, are performed as a commercial service by CEREP, Inc., Redmond, WA.
Alternatively, sodium ion channel activity may be measured in vivo in an assay of anti-epileptic activity. Anti-epileptic activity of compounds may be measured by the ability of the compounds to inhibit hind limb extension in the supra maximal electro shock model. Male Han Wistar rats (150-200mg) are dosed i.p. with a suspension of 1 to 20 mg of test compound in 0.25% methylcellulose 2 hr. prior to test. A visual observation is carried out just prior to testing for the presence of ataxia. Using auricular electrodes a current of 200 mA, duration 200 millisec, is applied and the presence or absence of hind limb extension is noted. Preferred compounds of the invention do not exhibit significant anti-epileptic activity at the p< 0.1 level of significance or more preferably at the p< 0.05 level of significance as measured using a standard parametric assay of statistical significance such as a student's T test.
Example 56
Microsomal in vitro half-life
Compound half-life values (tI 2 values) may be determined via the following standard liver microsomal half-life assay. Pooled Human liver microsomes are obtained from XenoTech LLC, 3800 Cambridge St. Kansas's City, Kansas, 66103 (catalog # H061Q). Such liver microsomes may also be obtained from In Vitro Technologies, 1450 South Rolling Road, Baltamore, MD 21227, or from Tissue Transformation Technologies, Edison Corporate Center, 175 May Street, Suite 600, Edison, NJ 08837. 'Reactions are preformed as follows:
Reagents:
Phosphate buffer: 19 mL 0.1 M NaH2P04, 81 mL 0.1 Na2HP04, adjusted to pH 7.4 with H3P04.
CoFactor Mixture: 16.2 mg NADP, 45.4 mg Glucose-6-phosphate in 4 mL 100 mM MgCl2. Glucose-6-phosphate dehydrogenase: 214.3 ul glucose-6-phosphate dehydrogenase suspension (Boehringer-Manheim catalog no. 0737224, distributed by Roche Molecular Biochemicals, 9115 Hague Road, P.O. Box 50414, Indianapolis, IN 46250) is diluted into 1285.7 ul distilled water.
Starting Reaction Mixture: 3 mL CoFactor Mixture, 1.2 mL Glucose-6-phosphate dehydrogenase.
Reaction:
6 test reactions are prepared, each containing 25 ul microsomes, 5 ul of a 100 uM solution of test compound, and 399 ul 0.1 M phosphate buffer. A seventh reaction is prepared as a positive control containing 25 ul microsomes, 399 ul 0.1 M phosphate buffer, and 5 ul of a 100 uM solution of a compound with known metabolic properties (e.g. DIAZEPAM or CLOZEPINE). Reactions are preincubated at 39°C for 10 minutes. 71 ul Starting Reaction Mixture is added to 5 of the 6 test reactions and to the positive control, 71 ul 100 mM MgCl2 is added to the sixth test reaction, which is used as a negative control. At. each time point (0, 1, 3, 5, and 10 minutes) 75 ul of each reaction mix is pipetted into a well of a 96-well deep- well plate containing 75 ul ice-cold acetonitrile. Samples are vortexed and centrifuged 10 minutes at 3500 rpm (Sorval T 6000D centrifuge, H1000B rotor). 75 ul of supernatant from each reaction is transferred to a well of a 96-well plate containing 150 ul of a 0.5 uM solution of a compound with a known LCMS profile (internal standard) per well. LCMS analysis of each sample is carried out and the amount of unmetabolized test compound is measured as AUC, compound concentration vs time is plotted, and the tι/2 value of the test compound is extrapolated.
Preferred compounds of the invention exhibit in vitro t]/2 values of greater than 10 minutes and less than 4 hours. Most preferred compounds of the invention exhibit in vitro t a values of between 30 minutes and 1 hour in human liver microsomes.
Example 57
MDCK Toxicity Assay Compounds causing acute cytotoxicity will decrease ATP production by Madin Darby canine kidney (MDCK) cells in the following assay.
MDCK cells, ATCC no. CCL-34 (American Type Culture Collection, Manassas, VA) are maintained in sterile conditions following the instructions in the ATCC production information sheet. The PACKARD, (Meriden, CT) ATP-LITE-M Luminescent ATP detection kit, product no. 6016941, allows measurement ATP production in MDCK cells.
Prior to assay 1 ul of test compound or control sample is pipetted into PACKARD (Meriden, CT) clear bottom 96-well plates. Test compounds and control samples are diluted in DMSO to give final concentration in the assay of 10 micromolar, 100 micromolar, or 200 micromolar. Control samples are drug or other compounds having known toxicity properties. Confluent MDCK cells are trypsinized, harvested, and diluted to a concentration of
0.1 x 106 cells/ ml with warm (37°C) VITACELL Minimum Essential Medium Eagle (ATCC catalog # 30-2003). lOOul of cells in medium is pipetted into each of all but five wells of each 96-well plate. Warm medium without cells (lOOul) is pipetted in the remaining five wells of each plate to provide standard curve control wells. These wells, to which no cells are added, are used to determine the standard curve. The plates are then incubated at 37°C under 95% 02, 5% C02 for 2 hours with constant shaking. After incubation, 50 ul of mammalian cell lysis solution is added per well, the wells are covered with PACKARD TOPSEAL stickers, and plates are shaken at approximately 700 rpm on a suitable shaker for 2 minutes.
During the incubation, PACKARD ATP LITE-M reagents are allowed to equilibrate to room temperature. Once equilibrated the lyophilized substrate solution is reconstituted in 5.5 mis of substrate buffer solution (from kit). Lyophilized ATP standard solution is reconstituted in deionized water to give a 10 mM stock. For the five- control wells, 10 ul of serially diluted PACKARD standard is added to each of the five standard curve control wells to yield a final concentration in each, subsequent well of 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM.
PACKARD substrate solution (50 ul) is added to all wells. Wells are covered with PACKARD TOPSEAL stickers, and plates are shaken at approximately 700 rpm on a suitable shaker for 2 minutes. A white PACKARD sticker is attached to the bottom of each plate and samples are dark adapted by wrapping plates in foil and placing in the dark for 10 minutes. Luminescence is then measured at 22°C using a luminescence counter, e.g. PACKARD TOPCOUNT Microplate Scintillation and Luminescense Counter or TECAN SPECTRAFLUOR PLUS.
Luminescence values at each drug concentration are compared to the values computed from the standard curve for that concentration. Preferred test compounds exhibit luminescence values 80 % or more of the standard, or preferably 90 % or more of the standard, when a 10 micromolar (uM) concentration of the test compound is used. When a 100 uM concentration of the test compound is used, preferred test compounds exhibit luminescence values 50% or more of the standard, or more preferably 80% or more of the standard.

Claims

WHAT IS CLAIMED IS:
1. A compound of the Formula I-a:
Figure imgf000240_0001
Formula I-a or a pharmaceutically acceptable salt thereof, wherein:
E is a single bond, O, S(0)m, NRio or CRioRπ;
Rio and Rn are independently hydrogen or Cι-C4 alkyl; m is 0, 1, or 2;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
R is oxygen or absent; the group:
Figure imgf000240_0002
represents a saturated, unsaturated or aromatic 5-membered ring system containing 0 or 1 heteroatoms, wherein:
Figure imgf000240_0003
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2' orNR2",
Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, or CR3R3';
Ri is chosen from hydrogen, halogen, hydroxy, cyano, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, optionally substituted heterocycle and optionally substituted heteroaryl, said optionally substituted heterocycle or heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, alkyl, haloalkyl, alkoxy, aminoalkyl, hydroxyalkyl and mono and dialkylamino, • wherein when Ri or Ri " is optionally substituted alkyl, then R3 is optionally substituted CI-3alkyl; R2' and R3' are independently chosen from hydrogen, halogen, alkyl, haloalkyl, and aminoalkyl; R " is chosen from hydrogen, optionally substituted alkyl, optionally substituted haloalkyl, and optionally substituted aminoalkyl; Z4 is NR or CR^ Z5 is NR or CR5; .
Rj and R5 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted (cycloalkyl)alkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3. rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S.
A compound of the Formula I-a:
Figure imgf000241_0001
Formula I-a or a pharmaceutically acceptable salt thereof, wherein: E is a single bond, O, S(0)m, NR]0 or CR10R11; Rio and Rπ are independently hydrogen or -C4 alkyl; m is 0, 1, or 2;
R is oxygen or absent;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with
the gro
Figure imgf000242_0001
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein:
Zi is CRi or CRiRi';
Z2 is nitrogen, oxygen, sulfur, CR2, CR2R2'> or NR2", Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR3, or CR3R3'; .
Ri is chosen from i) hydrogen, halogen, hydroxy, cyano, amino, Ci-Cioalkyl, -0(Cι-Ce alkyl), mono or di(Cι-
C6alkyl)amino, (C3-C7cycloalkyl)Cι-C4alkyl, halo(d-C6)alkyl, -0(halo(Ci-C6)alkyl) and
S(0)n(Ci-C6alkyl), -0(C3-C7cycloalkyl)Ci-C4alkyl, and S(0)n(CrC6alkyl), where each alkyl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Ci. - alkoxy, and mono- or di(Cι-C )alkylamino, and where each C3-C7cycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino,' hydroxy, oxo, cyano, Cι-C4alkoxy, and mono- or di(C]-C )alkylamino, and ii) phenyl which is mono-, di-, or tri-substituted with RA, 1- naphthyl,
2-naphthyl, pyridyl, dihydropyridyi, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, Cι-C3alkyl, halo(C C3)alkyl, C]-C3alkoxy, amino(Cι-C3)alkyl, and mono and di(Cr C6)alkylamino; Ri', R2' and R3' are independently chosen from hydrogen, halogen, Ci-Cβalkyl, halo(Cι- C6)alkyl, and amino(Cι-C6)alkyl;
R2" is chosen from hydrogen, Cι-C6alkyl, halo(Cι-Ce)alkyl, and amino(Cι-C6)alkyl;
Figure imgf000243_0001
Z5 is NR or CR5; wherein Z4 and Z5 are not both NR; P and R are independently chosen from hydrogen, halogen, cyano, nitro, amino, mono or di(Cj-C6carbhydryl)amino, Ci-Cόcarbhydryl, (C3-C7cyclocarbhydryl)C0- C4carbhydryl, -0(C3-C7cyclocarbhydryl), halo(Cι-C6)carbhydryl, -0(halo(Cι- C6)carbhydryl), -O -Cecarbhydryl), and S(0)n(Ci-C6carbhydryl), where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, C]-C4alkoxy, and mono- and di(Cι-C )alkylamino, and where each C3-C7carbhydryl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano,
Cι-C4alkoxy, and mono- and di(Cι-C4)alkylamino; RA is independently selected at each occurrence from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Ci-Ce)alkoxy, hydroxy, amino, Cι-C6alkyl substituted with 0-2 RB, C2-C6alkenyl substituted with 0-2 RB, C2-Cβalkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with 0-2 RB, (C3-C7cycloalkyl) C C4alkyl substituted with 0-2 RB,
Cι-C6alkoxy substituted with 0-2 RB, -NH(Cι-C6alkyl) substituted with 0-2 RB, -N(Cι-C6alkyl)( Cι-C6alkyl) each Ci-Cόalkyl independently substituted with 0-2 RB, - XRc, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, Cι-C4alkyl, -0(CrC4alkyl), -NH(Cι-C4aIkyl), -N(Cr
C4alkyl)( C,-C4alky0, -S(O)„(alkyl), halo(C,-C4)alkyl, halo(C,-C4)alkoxy, CO(C C4alkyl), CONH(C,-C4alkyl), CON(Cι-C4alkyl)( CrC4alkyl), -XRc, and Y; Rc and RD, which may be the same or different, are independently selected at each occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, Cι-C6alkoxy, - NH(C1-C6alkyl), -N(Cι-C6alkyl)(Cl-C6alkyl), -NHC(=0)(Ci-C6alkyl), -N(C C6alkyOC(=0)(Cι-C6alkyl), -NHS(0)n(Cι-C6alkyl), -S(0)n(C,-C6alkyl), - S(0)nNH(Cι-C6alkyl), -S(0)nN(Cι-C6alkyl)(C1-C6alkyl), and Z;
X is independently selected at each occurrence from the group consisting of -CH2-, -CHRD-, - 0-, -C(=0)-, -C(=0)0-, -S(O)„-, -NH-, -NRD-, -C(=0)NH-, -C(=0)NRD-, -S(0)nNH-, -S(0)nNRD-, -OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(0)n-, -OSiH2-, -OSiH(Cr alkyl)-, -OSi(CrC4alkyl)(Cι-C4alkyl)-, and -NRDS(0)n-; Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, Cι-C4alkyl, -0(C,-C4alkyl), -NH(C,-C4alkyl), -N(C,-C4alkyl)(C1-C4alkyl),and
-S(O)„(alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2.
A compound of the Formula I-b:
Figure imgf000244_0001
Formula I-b or a pharmaceutically acceptable salt thereof, wherein:
E is a single bond, O, S(0)m, NRio or CRioRi i ;
Rio and Rπ are independently hydrogen or Cι-C alkyl; m is 0, 1, or 2;
R is oxygen or absent;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; the group:
Figure imgf000245_0001
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein: Z, is CRi, CRiRi', or NRi"; Z2 is CR2 or CR2R2'; Z3 is CR3, CR3R3', or NR3";
Ri and Rι" are chosen from hydrogen, Cι-Cι0alkyl, C2-Cι0alkenyl, C2-Cι0alkynyl, C3- Cycycloalkyl, (benzo)C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C4alkyl, C3- pheterocycloalkyl, (C3-9heterocycloalkyl)Cι-C alkyl, (benzo)C3-9heterocycloalkyl, ((benzo)C3-9heterocycloalkyl)Cι-C alkyl and halo(Cι-C6)alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cι-C6alkyl, -Cόalkoxy, haloCι-C6alkoxy,Cι-C6alkanoyl, - C6alkanoyloxy, Ci-Cδalkoxycarbonyl,, N-(Cι-C6alkanoyl)-N-(Co-C6alkyl)amino, N- (Cι-C6alkanoyloxy)-N-(C0-C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(Co- C6alkyl)amino, Cι-C6alkylsulfonamide, Ci-Cδalkylsulfonyl, Ci-Cόalkylsulfonyloxy, Ci-Cβhydroxyalkyl, Cι-C6alkoxyCι-C6alkyl, Ci-Cόhaloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di-(Cι-C6)alkylamino, N- (Cι-C6alkanoyl)-N-(Co-C6alkyl)amino, N-(Cι-C6alkanoyloxy)-N-(Co-C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(Co-C6alkyl)amino, mono- and di-(Cj- C6)alkylcarbamoyl, -XRc and X-Z, with the proviso that Ri and Ri " is not aryl or heteroaryl substituted alkyl; R2 is chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C!-C3alkyl, halo(Cr
C3)alkyl, Cι-C3alkoxy, amino(Cι-C3)alkyl, and mono and di(C1-C6)alkylamino; R3 is chosen from hydrogen, hydroxy, amino, halogen, cyano, nitro, Cι-C3alkyl, halo(Cp
C3)alkyl, Cι-C3alkoxy, amino(Cι-C3)alkyl, hydroxy(Cι-C3)alkyl, cyano(Cι-C3)alkyl, and mono and di(Cι-C3)alkylamino;
R3" is chosen from hydrogen, hydroxy, amino, Cι-C3alkyl, halo(Cι-C3)alkyl, Cι-C3alkoxy, amino(Cι-C3)alkyl, hydroxy(C]-C3)alkyl, cyano(Cι-C3)alkyl, and mono and di
(Cι- C3)alkylamino; Ri ', R2' and R3' are independently chosen from hydrogen, halogen, Cι-C6alkyl, halo(Cι- Cδ)alkyl, and amino(Cι-C6)alkyl;
Figure imgf000246_0001
Z5 is NR or CR5;
R4 and R5 are independently chosen from hydrogen, halogen, cyano, nitro, amino, mono or di(C 1 -Cgcarbhydryl)amino, C 1 -C6carbhydry 1, (C3-C7cyclocarbhydry 1)C0- C4carbhydryl, -0(C3-C7cyclocarbhydry 1), halo(C 1 -C6)carbhydryl, -0(halo(C 1 -
C6)carbhydryl), -0(Ci-C6carbhydryl), S(0)n(Ci-C6carbhydryl), and 4 to 7 membered heterocycloalkyl, where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, and is optionally substituted with one or more substituents independently chosen from halogen, -hydroxy, amino, oxo, cyano, Cι-C alkoxy, and mono- and di(Cι-C4)alkylamino, and where each C3-C7carbhydryl heterocycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, amino, hydroxy, oxo, cyano, - alkoxy, and mono- and di(Cι-C )alkylamino; or
R5, taken in combination with Ri or Ri ", forms, a 5-9 membered heterocycle; RA is independently selected at each occurrence from halogen, cyano, nitro, halo(C]-C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, -Chalky 1 substituted with 0-2 RB, C2-C6alkenyl substituted with 0-2 RB, C2-C6alkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with 0-2 RB, (C3-C7cycloalkyl)Cι-C4alkyl substituted with 0-2 RB,
CrC6alkoxy substituted with 0-2 RB, -NH(Cι-C6alkyl) substituted with 0-2 RB, . -N(Cι-C6alkyl)( Cι-C6alkyl) each Cι-C6alkyl independently substituted with 0-2 RB, - XRc, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, CrC alkyl, -0(C C4alkyl), -NH(C,-C4alkyl), -N(Cr C4alkyl)( C,-C4alkyl), -S(0)n(alkyl), halo(C,-C4)aIkyl, halo(C,-C4)alkoxy, CO(C,- C4alkyl), CONH(CrC4alkyl), CON(Cι-C4alkyl)( Cι-C4alkyl), -XRc, and Y; Rc and RD, which may be the same or different, are independently selected at each occurrence from: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, C C6alkoxy, -NH(C]-C6alkyl), -N(Cι- C6alkyl)(C,-C6alkyl), -NHC(=0)(Ci-C6alkyl), -N(C,-C6alkyl)C(=0)(C1-C6alkyl), - NHS(0)n(C,-C6alkyl), -S(0)n(C,-C6alkyl), -S(0)nNH(C1-C6alkyl), -S(.0)πN(C,- CealkylXC Cealkyl), and Z;
X is independently selected at each occurrence from the group consisting of -0-, -C(=0)0-, - S(0)n-, -NH-, -NRD-, -C(=0)NH-, -C(=O)NR0-, -S(0)nNH-, -S(0)nNRD-, -OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(OV, -OSiH2-, -OSiH(C,-C4alkyl)-, -OSi(C,- C4alkyl)(Cι-C4alkyl)-, and -NRDS(0)n-; Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, Cι-C4alkyl, -0(Cι-C4alkyl), -NH(Cι-C4alkyl), - N(Cι-C4alkyl)(Cι-C4alkyl), -C(0)(Cι-C4alkyl), and -S(0)n(alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2.
4. A compound or salt according to claim 3, wherein
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; and Ri and Rι"are chosen from hydrogen, Ci-Cioalkyl, C2-Cιoalkenyl, C2-Cι0alkynyl, C3- C cycloalkyl, (C3-C7cycloalkyl)Cι-C4alkyl, C3.9heterocycloalkyl, (C3- 9heterocycloalkyl)Cι-C4alkyl and halo(Cι-C6)alkyl, each of which is substituted with 0, 1, 2, or 3 substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cι-C6alkyl, C C6alkoxy, haloCι-C6alkoxy,Cι-C6alkanoyl, Cι-C6alkanoyloxy, C i -C6alkoxy carbonyl,, N-(C ι -C6alkanoyl)-N-(Co-C6alkyl)amino, N-(d - C6alkanoy loxy)-N-(Co-C6alkyl)amino, N-(C i -C6alkoxycarbony l)-N-(Co- CealkyOamino, Ci-Cealkylsulfonamide, Q-Cόalkylsulfonyl, Qi-Cόalkylsulfonyloxy, CrCβhydroxy alkyl, d-C6alkoxyCι-C6alkyl, Ci-Cδhaloalkoxy, 5 to 7 membered heteroaryl,
5 to 7 membered heterocycloalkyl, mono- and di-(Cι-C6)alkylamino, N- (C]-C6alkanoyl)-N-(Co-C6alkyl)amino, N-(Cι-C6alkanoyloxy)-N-(Co-C6alkyl)amino, N-(Cι-C6alkoxycarbonyl)-N-(Co-C6alkyl)amino, mono- and di-(C C6)alkylcarbamoyl, -XRc and X-Z.
A compound or salt according to Claim 3 of Formula II
Figure imgf000248_0001
Formula II wherein R,", R2, R3j R4 and Ar are as defined in Claim 3.
6. A compound or salt according to Claim 5, wherein: Ri" is as defined for Claim 3; R2 is selected from hydrogen, methyl, and ethyl; R3 is hydrogen or C i -C3alkyl;
R is selected from hydrogen, halogen, cyano, amino, Cι-C6alkyl, Cι-C6alkoxy, C3-
C7cycloalkyl, (C3-C7cycloalkyl)Cι-C4alkyl, (C3-C7cycloalkyl)Cι-C alkoxy, mono and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, mono and di(Cι-C6alkyl)amino(Cι-C6)alkyl, halo(Cι-C6)alkyl, and halo(Cι-C6)alkoxy; and Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(Cι-C6)alkyI, halo(Cι-C6)alkoxy, hydroxy, amino, Cι-C6alkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cyc.oa.kyI, (C3-C7cycloalkyl)d-C4alkyl, C C6alkoxy, mono- and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, and mono- and di(Cι-
CόalkyOamino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula II is substituted.
7. A compound or salt according to Claim 5, wherein: Ri" is selected from Ci-Cioalkyl and (C3-C7cycloalkyl)Co-C alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cι-C alkoxy, and mono- and di-(Cι-C4)alkylamino.
8. A compound or salt according to Claim 5, wherein: Ri" is selected from d^heterocycloalkyl and (C3-9heterocycloalkyl)Cι- alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, d-C6alkyl, Cj-Cβalkoxy, Ci-Cβhydroxyalkyl, Ci-CealkoxyCi-Cβalkyl, (d- C6)haloalkyl, (Ci-d haloalkoxy, mono- and di-(d-C6)alkylamino, -XRc-
9. A compound or salt according to Claim 8, wherein:
Ri" is chosen from tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2j-azabicyclic rings, [3.3.1]- azabicyclic rings, quinuclidinyl, azetidinyl, azetidinonyl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl, each of which is substituted with from 0 to 2 substituents independently chosen from:
(i) halogen, hydroxy, amino, cyano, or
(ii) Cι-C alkyl, Cι-C4alkoxy, and mono- and di-(Cι-C4)alkylamino, each of which is substituted with 0 or 1 substituents selected from halogen, hydroxy, amino, Cι-2alkoxy, or C3. heterocycloalkyl.
10. A compound or salt according to Claim 3 of Formula VI
Figure imgf000250_0001
Formula VI wherein Ri, R , R3", j, and Ar are as defined in Claim 3.
11. A compound or salt according to Claim 10, wherein: Ri is as defined for Claim 3;
R2 is selected from hydrogen, methyl, and ethyl;
R3" is hydrogen or d-C3alkyl;
R4 is selected from hydrogen, halogen, cyano, amino, Cι-C6alkyl, Ci-Cgalkoxy, C3-
Cycycloalkyl, (C3-C7cycloalkyl)d-C alkyl, (C3-C7cycloalkyl)Cι-C4alkoxy, mono and di(C]-C6alkyl)amino, amino(Cι-C6)alkyl, mono and di(Cι-C6alkyl)amino(Cι-C6)alkyl, halo(C 1 -C6)alky 1, and halo(C 1 -C6)alkoxy ; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, d-Cόalkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (C3-C7cycloaIkyl)d-C4alkyl, C,-C6alkoxy, mono- and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, and mono- and di(Cι- CόalkyOamino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula VI is substituted.
12. A compound or salt according to Claim 11, wherein:
Ri" is selected from Cι-Cι0alkyl and (C3-C7cycloalkyl)Co-C alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, d-C4alkoxy, and mono- and di-(C]-C4)alkylamino.
13. A compound or salt according to Claim 11, wherein:
Ri" is selected from d.gheterocycloalkyl and (C3-9heterocycloalkyl)Ci alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, CrC6alkyl, CrC6alkoxy, Cι-C6hydroxyalkyl, Cι-C6alkoxyCι-C6alkyl, (Cj- C6)haloalkyl, (Cι-C6)haloalkoxy, mono- and di-(Cι-C6)alkylamino, -XRC.
14. A compound or salt according to Claim 13, wherein: Ri" is chosen from tetrahydrofiiranyl, tetrahydro pyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2j-azabicyclic rings, [3.3.1]- azabicyclic rings, quinuclidinyl, azetidinyl, azetidinonyl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl, each of which is substituted with from 0 to 2 substituents independently chosen from: (i) halogen, hydroxy, amino, cyano, or
(ii) Cι-C4alkyl, CpQalkoxy, and mono- and di-(d-C4)alkylamino, each of which is substituted with 0 or 1 substituents selected from halogen, 3 hydroxy, amino, Cι-2alkoxy, or d.gheterocycloalkyl.
15. A compound or salt according to Claim 3 of Formula VIII
Figure imgf000251_0001
Formula VIII wherein Ri", R2, R3, Ri, R5, and Ar are as defined in Claim 3.
16. A compound or salt according to Claim 15, wherein:
Ri" is as defined for Claim 3; R2 is selected from hydrogen, methyl, and ethyl; ~R3 is d-dalkyl;
Pv4 and R5 are independently selected from hydrogen, halogen, cyano, amino, Ci-Cβalkyl, C\- C6alkoxy, C3-C7cycloalkyl, (C3-C7cycloalkyl)d-C4alkyl, (C3-C7cycloalkyl)Cι-
C4alkoxy, mono and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, mono and di(Cι- C6alkyl)amino(Cι-C6)alkyl, halo(Ci-C6)alkyl, and halo(Cι-C6)alkoxy; and Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Cι-C6)alkoxy, hydroxy, amino, C,-C6alkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C4alkyl, C C6alkoxy, mono- and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, and mono- and di(Cι- C6alkyl)amino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula VIII is substituted.
17. A compound or salt according to Claim 15, wherein: elected from CpCioalkyl and (C3-C cycloalkyl)Co-C4alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, d-Qalkoxy, and mono- and di-(Cι-C )alkylamino.
18. A compound or salt according to Claim 15, wherein: elected from C3-9heterocycloalkyl and (d.gheterocycloalkyOCMalkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, C i -C6alky 1, C i -C6alkoxy, C i -Cβhydroxy alky 1, C i -C6alkoxyC i -dalky 1, (C , -
C6)haloalkyl, (Ci-Q haloalkoxy, mono- and di-(Cι-C6)alkylamino, -XRc-
19. A compound or salt according to Claim 18, wherein: hosen from tetrahydrofiiranyl, tetrahydropyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2]-azabicyclic rings, [3.3.1]- azabicyclic rings, quinuclidinyl, azetidinyl, azetidinonyl, oxindolyl, dihydro imidazolyl, and pyrrolidinonyl, each of which is substituted with from 0 to 2 substituents independently chosen from:
(i) halogen, hydroxy, amino, cyano, or (ii) Cι-C4alkyl, d-C alkoxy, and mono- and di-(d-C4)alkylamino, each of which is substituted with 0 Or 1 substituents selected from halogen, hydroxy, amino, Cι- alkoxy, or d.gheterocycloalkyl.
20. A compound or salt according to Claim 3 of Formula X
Figure imgf000253_0001
Formula X wherein Rj, R2, R3", R5, and Ar are as defined in Claim 3.
21. A compound or salt according to Claim 20, wherein Ri is as defined for Claim 3;
R2 is selected from hydrogen, methyl, and ethyl;
R3" is selected from hydrogen and Ci-Cβalkyl;
R5 is selected from hydrogen, halogen, cyano, amino, Cι-C6alkyl, Ci-Qalkoxy, C3- dcycloalkyl, (C3-C7cycloalkyl)Cι-C4alkyl, (C3-C7cycloalkyl)Cι-C4alkoxy, mono and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, mono and di(Cι-C6alkyl)amino(Cι-C6)alkyl, halo(Cι-C6)alkyl, and halo(Cι-C6)alkoxy; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(Cι-C6)alkyl, halo(Cι-Ce)alkoxy, hydroxy, amino, Cι-C6alkyl, C2- Qalkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C alkyl, Cι-C6alkoxy, mono- and di(Cι-C6alkyl)amino, amino(Cι-C6)alkyl, and mono- and di(C CδalkyOamino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula X is substituted.
22. A compound or salt according to Claim 20, wherein:
Riis selected from
Figure imgf000253_0002
and (C3-C7cycloalkyl)Co-C alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, Cr alkoxy, and mono- and di-(C]-C )alkylamino.
23. A compound or salt according to Claim 20, wherein:
Ri is selected from d.gheterocycloalkyl and (C3-9heterocycloalkyl)Cι-4alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, C C6alkyl, Cι-C6alkoxy, CpCδhydroxyalkyl, Cι-C6alkoxyCι-C6alkyl, (Cp C6)haloalkyl, (Cι-C6)haloalkoxy, mono- and di-(Cι-C6)alkylamino, -XRC.
24. A compound or salt according to Claim 23, wherein: Ri is chosen from tetrahydrofiiranyl, tetrahydropyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2]-azabicyclic rings, [3.3.1]- azabicyclic rings, quinuclidinyl, azetidinyl, azetidinonyl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl, each of which is substituted with from 0 to 2 substituents independently chosen from:
(i) halogen, hydroxy, amino, cyano, or
(ii) Cι-C4alkyl, d-Qalkoxy, and mono- and di-(CpC4)alkylamino, each of which is substituted with 0 or 1 substituents selected from halogen, " hydroxy, amino, Cι-2alkoxy, or C3-9heterocycloalkyl.
25. A compound or salt according to Claim 3 of Formula XII
Figure imgf000254_0001
Formula XH wherein Ri, R2, R3", R4, R5, and Ar are as defined in Claim 3.
26. A compound or salt according to Claim 25, wherein
Ri is as defined for Claim 3;
R2 is selected from hydrogen, methyl, and ethyl;
R3" is selected from hydrogen and CpCβalkyl;
R and R5 are independently selected from hydrogen, halogen, cyano, amino, CpC6alkyl, Cι-C6alkoxy, C3-C7cycloalkyl, (C3-C7cycloalkyl)CpC4alkyl, (C3-C7cycloalkyl)Cp
C alkoxy, mono and di(CpC6alkyl)amino, amino(Cι-C6)alkyl, mono and di(CpC6alkyl)amino(CpC6)alkyl, halo(CpC6)alkyl, and halo(CpC6)alkoxy; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(CpC6)alkyl, halo(CpC6)alkoxy, hydroxy, amino, CpCβalkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (C3-C7cycloalkyl)CpC4alkyl, CpC6alkoxy, mono- and di(CpC6alkyl)amino, amino(CpC6)alkyl, and mono- and di(Cp CόalkyOamino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula XII is substituted.
27. A compound or salt according to Claim 25, wherein: lected from CpCioalkyl and (C3-C7cycloalkyl)Co-C4alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, CpC alkoxy, and mono- and di-(CpC4)alkylamino.
28. A compound or salt according to Claim 25, wherein: lected from d.gheterocycloalkyl and (Cs.gheterocycloalkyOCi^alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, CpCβalkyl, CpC6alkoxy, CpCδhydroxyalkyl, CpCδalkoxyCpCδalkyl, (Cp
Cδ)haloalkyl, (CpC6)haloalkoxy, mono- and di-(CpC6)alkylamino, -XRc-
29. A compound or salt according to Claim 28, wherein: osen from tetrahydrofiiranyl, tetrahydropyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2j-azabicyclic rings, [3.3.1]- azabicyclic rings, quinuclidinyl, azetidinyl, azetidinonyl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl, each of which is substituted with from 0 to 2 substituents independently chosen from:
(i) halogen, hydroxy, amino, cyano, or (ii) CpC4alkyl, CpC4alkoxy, and mono- and di-(CpC4)alkylamino, each of which is substituted with 0 or 1 substituents selected from halogen, hydroxy, amino, Cι-2alkoxy, or C3-9heterocycloalkyl.
30. A compound or salt according to Claim 3 of Formula XIV
Figure imgf000256_0001
Formula XIV wherein Ri", R2, R3, R5, and Ar are as defined in Claim 3.
31. A compound or salt according to Claim 30, wherein Ri" is as defined for Claim 3;
R2 is selected from hydrogen, methyl, and ethyl;
R3 is d-dalkyl; -
R5 is selected from hydrogen, halogen, cyano, amino, CpC6alkyl, CpCealkoxy, C3- dcycloalkyl, (C3-C7cycloalkyl)CpC4alkyl, (C3-C7cycloalkyOCpC4alkoxy, mono and di(CpC6alkyl)amino, amino(CpC6)alkyl, mono and di(CpC6alkyl)amino(CpC6)alkyl, halo(CpC6)alkyl, and halo(CpC6)alkoxy; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(CpC6)alkyl, halo(CpC6)alkoxy, hydroxy, amino, Cpdalkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (Cs-dcycloalkyOd-Qalkyl, CpC6alkoxy, mono- and di(Cι-C6alkyl)amino, amino(CpC6)alkyl, and mono- and di(Cp C6alkyl)amino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula XIV is substituted.
32. A compound or salt according to Claim 30, wherein:
Ri" is selected from CpCioalkyl and (C3-C7cycloalkyl)Co-C4alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, CpC4alkoxy, and mono- and di-(CpC )alkylamino.
33. A compound or salt according to Claim 30, wherein:
Rι" is selected from d.gheterocycloalkyl and (C3.9heterocycloalkyl)Cι-4alkyl, each of which is substituted with 0-4 substitutents selected from halogen, amino, hydroxy, nitro, cyano, Cpdalkyl, CpQalkoxy, CpQhydroxyalkyl, CpC6alkoxyCpC6alkyl, (Cr Ce)haloalkyl, (CpC6)haloalkoxy, mono- and di-(Cι-C6)alkylamino, -XRc-
34. A compound or salt according to Claim 33, wherein: Ri" is chosen from tetrahydrofiiranyl, tetrahydropyranyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl [2.2.1]-azabicyclic rings, [2.2.2]-azabicyclic rings, [3.3.1]- azabicyclic rings, quinuclidinyl, azetidinyl, azetidinonyl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl,- each of which is substituted with from 0 to 2 substituents independently chosen from: (i) halogen, hydroxy, amino, cyano, or
(ii) CpC4alkyl, CpQalkoxy, and mono- and di-(CpC4)alkylamino, each of which is substituted with 0 or 1 substituents selected from halogen, - hydroxy, amino, Cι-2alkoxy, or d.gheterocycloalkyl.
35. A compound of the Formula XX:
Figure imgf000257_0001
Formula XX or a pharmaceutically acceptable salt thereof, wherein:
E is a single bond, O, S(0)m, NRio or CRioRπ;
Rio and Rn are independently hydrogen or CpC4 alkyl; m is 0, 1, or 2;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from- 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;
R is oxygen or absent; the group:
Figure imgf000258_0001
represents a saturated, unsaturated or aromatic 5-membered ring system containing 0 or 1 heteroatoms, wherein: Z, is CR,, CRiR , or NRi";
Z2 is nitrogen, oxygen, sulfur, CR?, CR2R2' or NR2", Z3 is nitrogen, oxygen, sulfur, sulfoxide, sulfone, CR , CR3R3', or NR3"- Ri is chosen from halogen, hydroxy, cyano, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono or dialkylamino, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted mono- or dialkylcarboxamide, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; Ri" is chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted
(heterocycloalkyl)alkyl, optionally substituted carbocyclic aryl, and optionally substituted heteroaryl, said optionally substituted heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, alkyl, haloalkyl, alkoxy, aminoalkyl, and mono and dialkylamino; Ri', RX and R3' are independently chosen from hydrogen, halogen, alkyl, haloalkyl, and aminoalkyl; R2" and R3" are independently chosen from hydrogen, alkyl, haloalkyl, and aminoalkyl; and R4 is hydrogen, alkyl, aminoalkyl, and haloalkyl
36. A compound of the formula:
Figure imgf000259_0001
or a pharmaceutically acceptable salt thereof, wherein:
E is a single bond, O, S(0)m, NRio or CRi'oRn;
Rio and Rn are independently hydrogen or CpC alkyl; m is 0, 1, or 2;
R is oxygen or absent;
Ar is chosen from: phenyl which is mono-, di-, or tri-substituted, 1- naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; the group:
Figure imgf000259_0002
represents a saturated, unsaturated or aromatic ring system comprising 0 or 1 heteroatoms, wherein:
Zi is CRι, CRιR, ', or NRι";
Z? is nitrogen, oxygen, sulfur, CR2, CR R2'> or NR2",
Z3 is nitrogen," oxygen, sulfur, sulfoxide, sulfone, CR3, CR R3' or NR3";
Ri is chosen from i) halogen, hydroxy, cyano, amino, CpCiocarbhydryl, -0(C C6carbhydryl), mono or di(d- C6carbhydryl)amino, (C3-C7cyclocarbhydryl)CpC4carbhydryl, halo(Cp C6)carbhydryl, -0(halo(CpC6)carbhydryl) and S(0)n(CpC6carbhydryl), -0(C3- C7cyclocarbhydryl)C i -C4carbhydry 1, C3-9heterocycloalkyl, (C3-9heterocycloalkyl)C i - C4alkyl, and S(0)n(C,-C6carbhydryl), where each carbhydryl is independently straight, branched, or cyclic, contains zero or 1 or more double or triple bonds, where each heterocycloalkyl has 1 or 2 ring heteroatoms selected from N, O, or S and the point of attachment is carbon or nitrogen; and where each carbhydryl, heterocycloalkyl, or cyclocarbhydryl is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, CpCδalkyl, CpC6alkoxy, haloCpC6alkoxy,CpC6alkanoyl, Cp C6alkanoyloxy, CpCδalkoxycarbonyl,, N-(Cι-C6alkanoyl)-N-(Co-C6alkyl)amino, N-
(C i -C6alkanoy loxy)-N-(C0-C6alkyl)amino, N-(C , -C6alkoxycarbonyl)-N-(C0-
C6alkyl)amino, CpCθalkylsulfonamide, CpC6alkylsulfonyl, CpCgalkylsulfonyloxy, CpCehydroxyalkyl, CpCβalkoxyCpCealkyl, CpC6haloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di-(CpC6)alkylamino, N- (C i -C6alkanoy l)-N-(Co-C6alky l)amino, N-(C , -C6alkanoyloxy)-N-(C0-C6alkyl)amino,
N-(CpC6alkoxycarbonyl)-N-(Co-C6alkyl)amino, . mono- and di-(Cp
C6)alkylcarbamoyl, -XRc and X-Z;, and ii) phenyl which is mono-, di-, or tri-substituted with RA, 1- naphthyl, 2-naphthyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-, di-, or tri-substituted with RA; i" is chosen from CpCioalkyl, C2-Cιoalkenyl, C2-Cι0alkynyl, d-dcycloalkyl, (C3-
C7cycloalkyl)CpC4alkyl, C3-9heterocycloalkyl, (d.gheterocycloalkyOCpQalkyl and halo(CpC6)alkyl, each of which is substituted with 0 or more substituents independently chosen from halogen, hydroxy, amino, oxo, cyano, CpCβalkyl, Cp
Qalkoxy, haloCpC6alkoxy,C C6alkanoyl, C pQalkanoyloxy, CpCδalkoxycarbonyl,, N-(C , -C6alkanoyl)-N-(Co-C6alkyl)aminq, N-(C pC6alkanoy loxy)-N-(C0- CealkyOamino, N-(CpC6alkoxycarbonyl)-N-(Co-C6alkyl)amino, Cp Cόalkylsulfonamide, CpCealkylsulfonyl, CpCόalkylsulfonyloxy, CpC6hydroxyalkyl, CpCealkoxyCpCδalkyl, CpCδhaloalkoxy, 5 to 7 membered heteroaryl, 5 to 7 membered heterocycloalkyl, mono- and di-(CpC6)alkylamino, N-(Cι-C6alkanoyO-N- (C0-C6alkyl)amino, N-(CpC6alkanoyloxy)-N-(Co-C6alkyl)amino, N-(Cp C6alkoxycarbonyl)-N-(Co-C6alkyl)amino, mono- and di-(CpC6)alkylcarbamoyl, -XRC and X-Z; R2 and R3 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, d-C6alkyl, halo(CpC6)alkyl, CpC6alkoxy, amino(CpC6)alkyl, and mono and di(CpC6)alkylamino;
R2' and 'Rs' are independently chosen from hydrogen, halogen, CpC6alkyl, halo(CpC6)alkyl, and amino(CpC6)alkyl; R2" and R3" are independently chosen from hydrogen, CpCealkyl, halo(CpC6)alkyl, and amino(CpC6)alkyl; R4 is hydrogen, CpCealkyl, CpCόaminoalkyl, and CpCόhaloalkyl
RA is independently selected at each occurrence from halogen, cyano, nitro, halo(CpC6)alkyl, halo(CpC6)alkoxy, hydroxy, amino,. CpCβalkyl substituted with 0-2 RB, C2-C6alkenyl substituted with 0-2 RB, C2-C6alkynyl substituted with 0-2 RB, C3-C7cycloalkyl substituted with 0-2 RB, (C3-C7cycloalkyl) CpC4alkyl substituted with 0-2 RB, C C6alkoxy substituted with 0-2 RB, -NH(C C6alkyl) substituted with 0-2 RB, -N(Cr dalkylX-CpCealkyl) each CpCgalkyl independently substituted with 0-2 RB, -XRC, and Y; RB is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, CpC alkyl, -0(CpC4alkyl), -NH(CpC4alkyl), -N(Cp C4alkyl)( CpC4alkyl), -S(0)n(alkyl), halo(d-C4)alkyl, halo(d-C4)alkoxy, ' CO(Cp
C4alkyl), CONH(C,-C4alkyl), CON(CpC4alkyl)CCι-C4alkyl), -XRc, and Y; Rc and RD, which may be the same or different, are independently selected at each occurrence from-: hydrogen, and straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, which straight, branched, or cyclic alkyl groups contain zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, CpQalkoxy, -NH(CpC6alkyl), -N(Cp C6alkyl)(CpC6alkyl), -NHC(-0)(CpC6alkyl), -N(C,-C6alkyl)C(=0)(CpC6alkyl), -
NHS(0)n(C,-C6alkyl), -S(0)n(C,-C6alkyl), -S(0)nNH(C,-C6alkyl), -S(O)„N(C,-
C6alkyl)(CpC6alkyl), and Z; X is independently selected at each occurrence from the group consisting, of -CH2-, -CHRD-, - 0-, -C(=0)-, -C(=0)0-; -S(0)„-, -NH-, -NRD-, -C(=0)NH-, -C(=0)NRD-, -S(0)nNH-, -S(O)„NRD-, -OC(=S)S-, -NHC(=0)-, -NRDC(=0)-, -NHS(O)n-, -OSiH2-, -OSiH(Cr C4alkyl)-, -OSi(CpC4alkyl)(CpC4alkyl)-, and -NRDS(0)n-; Y and Z are independently selected at each occurrence from: 3- to 7-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, CpC alkyl, -0(CpC4alkyl), -C(0)(CpC4alkyl), -NH(CpC4alkyl), -N(CpC4alkyl)(CpC4alkyl),and -S(0)n(alkyl), wherein said 3- to 7-memberered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S, w}th the point of attachment being either carbon or nitrogen; and n is independently selected at each occurrence from 0, 1, and 2.
37. A compound or salt according to Claim 36 of Formula XXI
Figure imgf000262_0001
Formula XXI wherein,
Ri, R2, R3", R4 are as defined in Claim 37; and Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2-naphthyl, pyridyl and pyrimidinyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is .optionally mono-, di-, or tri-substituted with
RA-
38. A compound or salt according to Claim 37, wherein R) is as defined in Claim 36; R2 and R4 are independently selected from hydrogen, methyl, and ethyl; R3" is selected from hydrogen and CpCealkyl; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(CpC6)alkyl, halo(GpC6)alkoxy, hydroxy, amino, CpCealkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, (C3-C7cycloalkyl)CpC alkyl, CpC6alkoxy, mono- and di(CpCealkyl)amino, amino(CpC6)alkyl, and mono- and di(C C6alkyl)amino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula XXI is substituted.
39. A compound or salt according to Claim 36 of Formula XXII
Figure imgf000263_0001
Formula XXII wherein Ri", R2, R3, R4, and R5 are as defined in Claim 36; and Ar is chosen from: phenyl which is mono-, di-, or tri-substituted with RA, and 1- naphthyl, 2-naphthyl, pyridyl and pyrimidinyl, pyrimidinyl, pyrazinyl, pyridizinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl, and triazolyl, each of which is optionally mono-^ di-, or tri-substituted with
Figure imgf000263_0002
40. A compound or salt according to Claim 39, wherein
Ri " is as defined in Claim 39;
R2 and R4 are independently selected from hydrogen, methyl, and ethyl; R3 is selected from hydrogen and CpCealkyl; and
Ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl each of which is mono- di- or trisubstituted with substituents independently chosen from halogen, cyano, nitro, halo(CpC6)alkyl, halo(CpC6)alkoxy, hydroxy, amino, CpCealkyl, C2- Qalkenyl, C -C5alkynyl, C3-C7cycloalkyl, (C3-C7cycloalkyl)Cι-C alkyl, C C6aIkoxy, mono- and di(CpCealkyl)amino, amino(CpCe)alkyl, and mono- and di(Cp C6alkyl)amino, wherein, in Ar, at least one of the positions ortho to the point of attachment of Ar shown in Formula XXII is substituted. •
41. A compound or pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
5-(l-Ethyl-propyl)-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-5H- pyrrolo[2,3-b]pyrazine;
■ {4-Ethyl-5-[5-(l-ethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3-bjpyrazin-2-ylj-pyridin-2- yl}-dimethyl-amine; {3-Bromo-4-ethyl-5-[5-(l-ethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazin-2-ylj- pyridin-2-yl}-ethyl-methyl-amine;
Ethyl-{4-ethyl-5-[5-(l-ethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3-bjpyrazin-2-ylj- pyridin-2-yl} -methyl-amine;
{5-[5-(l-Ethyl-propyl)-3,7-dimethyi-5H-pyrrolo[2,3-b]pyrazin-2-yl]-4-methoxy-pyridin- 2-yl} -dimethyl-amine;
2-[2-Ethoxy-5-methanesulfonyl-6-(l-methyl-but-3-enyl)-pyridin-3-yl]-5-(l-ethyl-propyl)- 3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine;
2-(2-Ethόxy-6-ethyl-5-methanesulfonyl-pyridin-3-yO-5-(l-ethyl-propyl)-3,7-dimethyl- 5H-pyrrolo[2,3-b]pyrazine; {5-[3-Chloro-5-(l-ethyl-propyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazin-2-ylj-4--ethyl- pyridin-2-yl}-ethyl-methyl-amine;
- {5-[3-Chloro-5-(l-ethyl-propyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl]-4-ethyl- pyridin-2-yl} -dimethyl-amine;
{5-[3-Chloro-5-(l-ethyl-propyl)-7-methyl-5H-pyrrolo[2,3-bjpyrazin-2-yl]-4-ethyl- pyridin-2-yl}-diethyl-amine;
3-Chloro-5-(l-ethyl-propyl)-2-(3-isopropyl-5-methoxy-2,3-dihydro-fιιro[3,2-b]pyridin-6- yl)-7-methyl-5H-pyrrolo[2,3-b]pyrazine;
3-Chloro-5-(l-ethyl-propyl)-2-(3-isopropyl-5-methoxy-fιιro[3,2-b]pyridin-6-yl)-7- methyl-5H-pyrrolo[2,3-b]pyrazine; (R)-2-[2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-
3-methoxy-propan-l -ol;
5-(l-Ethyl-propyl)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5H-pyrrolo[2,3- bjpyrazine; 2-(2-Ethyl-6-isopropyl-pyridin-3-yl)-5-(l-ethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3- bjpyrazine;
2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-y0-3,7-dimethyl-pyrrolo[2,3-bjpyrazin-5-ylj- butan-1-ol; Methanesulfonic acid 2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl- pyrrolo[2,3-b]pyrazin-5-yl]-butyl ester;
3-{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- yl]-butyl}-oxazolidin-2-one;
(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-5-(l-methoxymethyl-propyl)-3,7-dimethyl- 5H-pyrrolo[2,3-b]pyrazine;
Ethyl-{2-[(S)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- bjpyrazin-5-ylj-butyl} -methyl-amine;
{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- ylj-butyl} -methyl-amine; N-{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- yl]-butyl}-N-methyl-methanesulfonamide;
N-{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- yl]-butyl}-N-methyl-acetamide;
{2-[(S)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-bjpyrazin-5- ylj-butyl} -methyl-carbamic acid methyl ester;
(R)-2-(6-Isόpropyl-2-methoxy-pyridin-3-yl)-5-(l-methoxymethyl-prqpyl)-3,7-dimethyl- 5H-pyrrolo[2,3-bjpyrazine;
Acetic acid 2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2, 3- b]pyrazin-5-ylj-butyl ester; 2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-y-lj- butan-1-ol;
,(R)-2-(2-Ethyl-6-isopropyl-pyridin-3-y0-5-(l-metho.xymethyl-propyl)-3,7-dimethyl-5H- pyrrolo [2,3 -bj pyrazine;
{6-Isopropyl-3-[(R)-5-(l-methoxymethyl-propy0-3,7-dimethyl-5H-pyrrolo[2,3- b]pyrazin-2-ylj-pyridin-2-yl}-methyl-amine;
{2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-bjpyrazin-5- yl]-butyl} -dimethyl-amine; (R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-(l-pyrrolidin-l-ylmethyl- propyl)-5H-pyrrolo[2,3-b]pyrazine;
Diethyl-{2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- b]pyrazin-5-yl]-butyl} -amine; Isopropyl-{2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- b]pyrazin-5-yl]-butyl}-methyl-amine;
(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-(l-morpholin-4-ylmethyl- propyl)-5H-pyrrolo[2,3-b]pyrazine;
Cyclobutyl-{2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- b]pyrazin-5-yl]-butyl} -amine;
{2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- ylj-butyl}-(2-methoxy-ethyl)-methyl-amine;
2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-(l-methylene-propyl)-5H- pyrrolo[2,3-b]pyrazine; Butyl-ethyl-{2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- bjpyrazin- 5 -y 1] -buty 1 } -am ine ;
5-sec-Butyl-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5H-pyrrolo[2,3- bjpyrazine;
Dimethyl-carbamic acid 2-[(R)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl- pyrrolo[2,3-b]pyrazin-5-yl]-butyl ester;
{2-[(R)-2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- ylj-butyl} -dipropyl-amine;
2-(6"-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-[(R)-l-(4-methyl-piperazin-l- ylmethyl)-propyl]-5H-pyrrolo[2,3-b]pyrazine; l-(4-{(R)-2-[2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-pyrrolo[2,3- b]pyrazin-5-yl]-butyl}-piperazin-l-yl)-ethanone;
2-(2-Ethyl-6-isopropyl-pyridin-3-yl)-3,7-dimethyl-5-((R)-l-morpholin-4-ylmethyl- propyl)-5H-pyrrolo[2,3-bjpyrazine;
{3-[3,7-Dimethyl-5-((R)-l-morpholin-4-ylmethyl-propyl)-5H-pyrrolo[2,3-bjpyrazin-2- yl]-6-isopropyl-pyridin-2-yl}-methyl-amine;
{(R)-2-[2-(4-Difluoromethoxy-2-methoxy-pheny0-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5- yl]-butyl}-ethyl-methyl-amine; {(R)-2-[2-(2-Chloro-4-methoxy-phenyl)-3,7-dimethyl-pyrrolo[2,3-b]pyrazin-5-yl]-butyl}- ethyl-methyl-amine;
5-Isopropyl-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5H-pyrrolo[2,3- bjpyrazine; [6-Isopropyl-3-(5-isopropyl-3,7-dimethyl-5H-pyrrolo[2,3-bjpyrazin-2-yl)-pyridin-2-ylj- methyl-amine;
2-(2-Ethyl-6-isopropyl-pyridin-3-yl)-5-isopropyl-3,7-dimethyl-5H-pyrrolo[2,3- . bjpyrazine;
2-(4-Difluoromethoxy-2-methoxy-phenyl)-5-isopropyl-3,7-dimethyl-5H-pyrrolo[2,3- b]pyrazine;
5-Isopropyl-2-(2-methoxy-4-trifluoromethyl-phenyl)-3,7-dimethyl-5H-pyrrolo[2,3- b] pyrazine;
[3-(3,7-Dimethyl-5-propyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-6-isopropyl-pyridin-2-yIj- methyl-amine; 2-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-5-propyl-5H-pyrrolo[2,3- bjpyrazine;
5-Isopropyl-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-5H-pyrrolo[2,3- bjpyrazine;
2-(2-Ethyl-6-isopropyl-pyridin-3-yl)-3,7-dimethyl-5-propyl-5H-pyrrolo[2,3-b]pyrazine; (R)-2-(6-Isopropyl-pyridin-3-yl)-5-(l-methoxymethyl-propyl)-3,7-dimethyl-5H- pyrrolo[2,3-bjpyrazine;
(S)-2-(2-Ethyl-6-isopropyl-pyridin-3-yl)-5-(l-methoxymethyl-propyl)-3,7-dimethyl-5H- pyrrolo[2,3-b]pyrazine;
{6-Isopropyl-3-[(S)-5-(l-methoxymethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3- b]pyrazin-2-yl]-pyridin-2-yl} -methyl-amine; \
(S)-3-Chloro-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-5-(2-methoxy-l-methyl-ethyl)-7- methyl-5H-pyrrolo[2,3-b]pyrazine;
(S)-3-Ethyl-2-(6-isopropy 1-2 -methoxy-pyridin-3 -yl)-5-(2-methoxy- 1 -methy l-ethyl)-7- methyl-5H-pyrrolo[2,3-b]pyrazine; {3-[3-Ethyl-5-((S)-2-methoxy-l-methyl-ethyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl]-
6-isopropyl-pyridin-2-yl} -methyl-amine;
{3-[3-Chloro-5-((S)-2-methoxy-l-methyl-ethyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazin-2- . ylj-6-isopropyl-pyridin-2-yl}-methyl-amine; {6-Isopropyl-3-[5-((R)-l-methoxymethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3- b]pyrazin-2-yl]-pyridin-2-yl}-dimethyl-amine;
3-Chloro-2-(6-isopropyl-2-methyl-pyridin-3-yl)-5-((S)-2-methoxy-l-ιnethyl-ethyl)-7- methyl-5H-pyrrolo[2,3-b]pyrazine; 5-((R)-l-Ethoxymethyl-propyl)-2-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,7-dimethyl-
5H-pyrrolo[2,3-b]pyrazine;
2-(6-Isopropyl-2-methyl-pyridin-3-yl)-5-((R)-l-methoxymethyl-propyl)-3,7-dimethyl- 5H-pyrrolo[2,3-bjpyrazine;
{3-[5-((R)-l-Ethoxymethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazin-2-yl]-6- isopropyl-pyridin-2-yl} -methyl-amine;
Ethyl-{6-isopropyl-3-[5-((R)-l-methoxymethyl-propyl)-3,7-dimethyl-5H-pyrrolo[2,3- b]pyrazin-2-ylj-pyridin-2-yl} -amine;
1 -(l-Ethyl-propyO-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3, 6-dimethyl- IH- pyrrolo [3,2-b] pyridine; Ethyl-{4-ethyl-5-[l-(l-ethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2-bjpyridin-5-yl]- pyridin-2-yl} -methyl-amine; l-(l-Ethyl-propyl)-5-(6-isopropyl-2-methoxy-pyridin-3-y0-3,6-dimethyl-l H-pyrrolo[3,2- bjpyridine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-(l-ethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridiήe;
{4-Ethyl-5-[l-(l-ethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2- yl} -dimethyl-amine;
{3-[l-(l-Ethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl-pyridin- 2-yl} -methyl-amine; l-sec-Butyl-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine; l-sec-Butyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine; l-(2-Methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl- lH-pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-(2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo [3 ,2-b] pyridine; l-sec-Butyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethy.l-lH-pyrrolo[3,2-b]pyridine; [3-(l-sec-Butyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-ylj- methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-(2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo [3 ,2-b] pyridine; {6-Isopropyl-3-[l-(2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5- yl]-pyridin-2-yl}-methyl-amine; l-Isopropyl-5-(2-methoxy-4-triflιιoromethoxy-phenyO-3, 6-dimethyl- 1 H-pyrrolo[3,2- b] pyridine; l-Isopropyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine;
[6-Isopropyl-3 -( 1 -isopropyl-3 , 6-dimethyl- 1 H-pyrrolo[3,2-b]pyridin-5-yl)-pyridin-2-yl]- methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine; l-sec-Bιιtyl-6-ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-lH-pyrrolo[3,2- bjpyridine;
1 -(2-Fluoro-ethy l)-5 -(6-isopropy l-2-methoxy-pyridin-3-yl)-3, 6-dimethyl- 1 H-pyrrolo[3 2- bjpyridine; l-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- ethanone;
[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-acetic acid ethyl ester;
1 -Ethyl-5 -(6-isopropy 1-2 -methoxy-pyridin-3 -y l)-3 , 6-dimethy 1- 1 H-pyrrolo [3 ,2-b j pyridine;
2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-bjpyridin-l-ylj- propionic acid ethyl ester;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l,3,6-trimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-(2-methoxy-ethyl)-3,6-dimethyl-lH-' pyrrolo[3,2-b]pyridine;
2-[5-(6-Isopropyl-2-methoxy-pyridin-3.-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- propionic acid tert-butyl ester; l-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine;
[3-(l-Ethyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]- methyl-amine; 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-l-propyl-lH-pyrrolo[3,2- b]pyridine; l-(2-Ethoxy-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine; 5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-(2-flιιoro-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine;
{3-[l-(2-Fluoro-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-ylj-6-isopropyl-pyridin- 2-yl } -methyl-amine;
2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- ethanol;
2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-N- methyl-propionamide;
5-(2-Ethyl-6-isopropyl-pyridin-3-y0-3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridine; l-Isobutyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine; l-Cyclopropylmethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; '
Ethyl-[6-isopropyl-3-(l -isopropyl-3, 6-dimethyl- lH-pyrrolo[3 ,2-b]pyridin-5-yl)-pyridin- 2-yl]-amine; [3-(3,6-Dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]- methyl-amine;
[3-(3,6-Dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-ylj- ethyl-amine; l-(3-Fluoro-propyl)-5-(6-isopropyl-2-ιnethoxy-pyridin-3-y0-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; l-[2-(2-Fluoro-ethoxy)-ethyl]-5-(6-isopropyi-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3 ,2-b j pyridine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-(3-fluoro-propyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridine; • • - {3-[l-(3-Fluoro-propyl)-3i6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6-isopropyl- pyridin-2-yl}-methyl-amine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-(3-methoxy-propyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; { 6-Isopropyl-3-[ 1 -((S)-2-methoxy- 1 -methyl-ethyl)-3,6-dimethyl- lH-pyrrolo[3 ,2- b]pyridin-5-ylj-pyridin-2-yl}-methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)- 1 -((S)-2-methoxy- 1 -methyl-ethyl)-3,6-dimethyl- 1 H- pyrrolo[3,2-b]pyridine; [3-(l-Isobutyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]- methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-isobutyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine; l-Butyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-l-(2-morpholin-4-yl-ethyl)-lH- pyrrolo[3,2-b]pyridine; l-Allyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyr'rolo[3,2-b]pyridine;
[3-(l-Bιιtyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5--yl)-6-isopropyl-pyridin-2-yl]- methyl-amine; l-Butyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine; (R)-2- [5 -(6-Isopropy 1-2-methoxy-py ridin-3-yl)-3 , 6-dimethy 1-pyrrolo [3 ,2-b]pyridin- 1 -y 1] - propan-1-ol;
{6-Isopropyl-3-[l-((R)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-pyridin-2-yl} -methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-y0-l-((R)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl- lH-pyrrolo[3,2-b]pyridine;
1 -((R)-2 -Fluoro- 1 -methy l-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3-y0-3, 6-dimethy 1- lH-pyrrolo[3 ,2-bjpyridine; 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-l-(2-methyl-allyl)-lH-pyrrolo[3,2- b]pyridine;
[3-(l-Allyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]- methyl-amine; l-Allyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine; 5-(6-Isopropyl-pyridin-3-yl)-3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridine;
(S)-2-[5-(6-IsopiOpyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- 3-methoxy-propan- 1 -ol; l-((R)-l-Fluoromethyl-2-methoxy-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine;
{3-[l-((R)-l-Fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-bjpyridin-5- yl]-6-isopropyl-pyridin-2-yl}-methyl-amine; 5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine; - • l-((R)-l-Fluoromethyl-2-methoxy-ethyl)-5-(6-isopropyl-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo [3 ,2-bjpyridine;
5-(6-Isθp'ropyl-2-methoxy-pyridin-3-yl)-l-(l-methoxymethyl-butyl)-3,6-dimethyl-lH- pyrrolo[3,2-bjpyridine;
' {5-Bromo-6-isopropyl-3-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-methyl-amine;
{5-E-thyl-6-isopropyl-3-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridin-5-yl]-pyridin-2-yl}-methyl-amine; l-((S)-l-Fluoromethyl-propyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; l-((R)-l-Fluoromethyl-propyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine;
{3-[l-((S)-l-Fluoromethyl-propyl)-3,6-dimeth'yl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6- isopropyl-pyridin-2-yl} -methyl-amine;
(S)-3-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-bjpyridin-l-yl]- 4-methoxy-butyronitrile;
(R)-2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-bjpyridin-l-ylj- pentan-1-ol; 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l -((R)- 1 -methoxymethy l-butyl)-3, 6-dimethy 1- lH-pyrrolo[3,2-b]pyridine; l-((R)-l-Fluoromethyl-butyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-(l-methoxymethyl-vinyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; >
{6-Isopropyl-3-[l-((R)-l-methoxymethyl-butyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin- 5-yl]-pyridin-2-yl} -methyl-amine; 5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-((R)-l-methoxymethyl-butyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine;
(S)-2-[6-Ethyl-5-(6-isopropyi-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2-b]pyridin-l- y 1 j -3 -methoxy-prop an- 1 -o 1 ; 6-Ethyl-l-((R)-l-fluoromethyl-2-methoxy-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3- y l)-3 -methyl- 1 H-pyrrolo [3 ,2-bjpyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-(2-methoxy-l-methoxymethyl-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-bjpyridine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-((S)-l-fluoromethyl-propyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; l-((S)-l-Fluoromethyl-propyl)-5-(6-isopropyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine;
{ 6-Isopropy 1-3 - [ 1 -(2-methoxy- 1 -methoxymethy l-ethyl)-3 , 6-d imethy 1- 1 H-pyrrolo [3 ,2- b]pyridin-5-yl]-pyridin-2-yl}-methyl-amine; l-((S)-l-Ethoxymethyl-propyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-
1 H-pyrrolo [3 ,2-b] pyridine;
(R)-2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- 3-methoxy-propan- 1 -ol; l-((S)-l-Fluoromethyl-2-methoxy-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6- dimethyl- lH-pyrrolo[3,2-b]pyridine; , -
{3-[l-((S)-l-Fluoromethyl'-2-methoxy-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5- yl]-6-isopropyl-pyridin-2-yl} -methyl-amine;
6-Ethy 1- 1 -isopropy 1-5 -(6-isopropyl-2-methoxy-pyridin-3 -y l)-3 -methyl- 1 H-pyrrolo [3 ,2- bjpyridine; [3-(6-Ethyl-l-isopropyl-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2- ylj-methyl-amine;
6-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-y0-l-isopropyl-3-methyl-lH-pyrrolo[3,2- bjpyridine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-(2-methoxy-l-methoxymethyl-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine;
{3-[l-((S)-l-Ethoxymethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-6- isopropyl-pyridin-2-yl}-methyl-amine; 2,5-Diethyi-6-[l-(l-ethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl]-3- isopropyl-3H-imidazo[4,5-b]pyridine;
(S)-2-[5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l- yl]-butan-l-ol; l-((S)-l-Methoxymethyl-piOpyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dim ethyl- 1 H-pyrrolo [3 ,2-bjpyridine;
1 -((S)- 1 -Chloroιnethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3 ,6-dimethyl- lH-pyrrolo[3,2-b]pyridine; l-((S)-2-Methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-lH-pyrrolo[3,2-bjpyridine;
5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine;
5r(2-Methoxy-4-triflιιoromethoxy^phenyl)-3,6-dimethyl-l-((S)-l-morpholin-4-ylmethyl- propyl)-lH-pyrrolo[3 ,2-bjpyridine;
{(S)-2-[5-(2-Methoxy-4-triflιιoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l- yl]-butyl}-dimethyl-amine;
5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-l-((S)-l-pyrrolidin-l-ylmethyl- propyl)-lH-pyrrolo[3 ,2-bjpyridine;
(S)-2-[5-(6-Isopropyl-2-methoxy yridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- butan-1-ol; 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-l-methoxymethyl-propyl)-3,6-dimethyl-
1 H-pyrrolo [3 ,2-b] pyridine;
Methanesulfonic acid (S)-2-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-butyl ester;
{(S)-2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l- yl]-butyl}-dimethyl-amine;
(2R,6S)-2,6-Dimethyl-morpholine-4-carboxylic acid 2-[5-(2-methoxy-4- trifluoromethoxy-phenyl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butylester;
Piperidine- 1 -carboxylic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester; 4-Methyl-piperazine-l -carboxylic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-
3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester;
Azepane-1 -carboxylic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-pyrrolo[3,2-bjpyridin-l-yl]-butyl ester; 4-Acetyl-piperazine-l -carboxylic acid (S)-2-[5-(2-methoxy-4-triflιιoromethoxy-phenyl)- 3,6-dimethyl-pyrrolo[3,2-bjpyridin-l-ylj-butyl ester;
Ethyl-methyl-carbamic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester; Diethyl-carbamic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3 6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-butyl ester;
Ethyl-(2-methoxy-ethyl)-carbamic acid'(S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)- 3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester;
(2-Methoxy-ethyl)-carbamic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-pyrrolo[3,2-b]pyridin-l-yl]-butyl ester; '
Cyclopentyl-carbamic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6- dimethyl-pyrrolo[3,2rb]pyridin-l -ylj-butyl ester;
1 -[(S)- 1 -((2S,6R)-2,6-Dimethyl-morpholin-4-ylmethyl)-propyl]-5-(2-methoxy-4- trifluoromethoxy-phenyl)-3,6-dimethyl-lH-pyrrolo[3 ,2-bjpyridine; 5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-l-((S)-l-piperidin-l-ylmethyl- propyl)-lH-pyrrolo[3 ,2-bjpyridine; l-((S)-l-Methanesulfonylmethyl-propyl)-5-(2-ιnethoxy-4-triflιιoromethoxy-phenyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine; ' 5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-l-[(S)-l-(4-methyl-piperazin-l- ylmethyl)-propyl]-lH-pyrrolo[3,2-b]pyridine;
1 -((S)- 1 -Azepan- 1 -ylmethyl-propy0-5-(2-methoxy-4-trifluoromethoxy-pheny0-3,6- dimethyl-lH-pyrrolo[3,2-bjpyridine;
Methanesulfonic acid (S)-2-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-butyl ester; 5-(6-Isopro'pyl-2-methoxy-pyridin-3-yO-3,6-dimethyl-l-((S)-l-morpholin-4-ylmethyl- propyl)- 1 H-pyrrolo[3 ,2-b]pyridine;
{3-[3,6-Dimethyl-l-((S)-l-morpholin-4-ylmethyl-propyl)-lH-pyrrolo[3,2-b]pyridin-5- yl]-6-isopropyl-pyridin-2-yl} -methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-3, 6-dimethy 1-1 -((S)-l -morpholin-4-ylmethyl- propyl)-lH-pyrrolo[3,2-b]pyridine; l-[(S)-l-(3,3-Dimethyl-piperidin-l-ylmethyl)-propyl]-5-(2-methoxy-4-trifluoromethoxy- pheny l)-3 , 6-dimethy 1- 1 H-pyrrolo [3 ,2-b]pyridine; 5-(2-Methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-l-((S)-l-thiomorpholin-4- ylmethyl-propy 1)- 1 H-pyrrolo [3 ,2-b jpyridine; l-[(S)-l-(4,4-Difluoro-piperidin-l-ylmethyl)-propyl]-5-(2-methoxy-4-trifluoromethoxy- phenyl)-3,6-dimethyl-lH-pyrrolo[3,2-bjpyridine; (R)-2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-ylj- butan-1-ol;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3, 6-dimethyl- 1-((R)-1 -morpholin-4-ylmethyl- propyl)-lH-pyrrolo[3 ,2-bjpyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-l-methoxymethyl-propyl)-3,6-dimethyl- lH-pyrrolo[3,2-b]pyridine;
{3-[3,6-Dimethyl-l-((R)-l-morpholin-4-ylmethyl-propyl)-lH-pyrrolo[3,2-b]pyridin-5- yl]-6-isopropyl-pyridin-2-yl} -methyl-amine;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-l-((R)-l-morpholin-4-ylmethyl- propyl)-lH-pyrrolo[3,2-b jpyridine; 5-(2-Ethyl-6-isopropy l-pyridin-3 -yl)- 1 -((R)- 1 -methoxymethy 1-propy l)-3 , 6-dimethyl- 1 H- pyrrolo[3,2-b]pyridine;
{6-Isopropyl-3-[l-((R)-l-methoxymethyl-propyl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridin-5-yl]-pyridin-2-yl}-methyl-amine;
5-(6-Isopropyl-pyridin-3-yl)- 1 -((R)- 1 -methoxymethy l-propyl)-3, 6-dimethyl- 1 H- pyrrolo[3,2-b]pyridine;
6-Ethy 1-5 -(6-isopropy 1-2 -methoxy-pyridin-3 -yl)- 1 -((S)-2 -methoxy- 1 -methy l-ethyl)-3 - methyl-lH-pyrrolo[3,2-b]pyridine;
(S)-2-[6-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2-b]pyridin-l- yl]-propan-l-ol; 6-Ethyl-5-(6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridine;
6-Ethyl-5 -(2-ethy 1-6- isopropyl-pyridin-3 -y 1)- 1 -((S)-2-methoxy- 1 -methy 1-ethy l)-3 -methyl- lH-pyrrolo[3,2-b]pyridine;
{3-[6-Ethyl-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-ylj- 6-isopropy l-pyridin-2-y 1 } -methyl-amine;
(R)-l-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-yl]- butan-2-ol; l-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-bjpyridin-l-yl]-2- methyl-propan-2-ol;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-2-methoxy-butyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; (R)-2-[6-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2-b]pyridin-
1-ylj-propan-l-ol;
(R)-2-[5-(2-Ethoxy-6-ethyl-5-methanesulfonyl-pyridin-3-yl)-6-ethyl-3-methyl- pyrrolo[3 ,2-b] pyridin- 1 -y l]-propan- 1 -ol;
5-(2-Ethoxy-6-ethyl-5-methanesulfonyl-pyridin-3-yl)-6-ethyl-l-((R)-2-methoxy-l- methyl^ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridine;
(R)-2-[6-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2-b]pyridin- l-yl]-butan-l-ol;
(R)-2-[5-(2-Ethoxy-6-ethyl-5-methanesulfonyl-pyridin-3-yl)-6-ethyl-3-methyl- pyrrolo[3,2-b]pyridin-l-ylj-butan-l-ol; 5-(2-Ethoxy-6-ethyl-5-methanesulfonyl-pyridin-3-yl)-6-ethyl-l-((R)-l-methoxymethyl- propyl)-3-methyl-lH-pyrrolo[3,2-bjpyridine;
6-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-l-methoxymethyl-propyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine;
6-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yO-l-((R)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b']pyridine;
5 -(2-Azetidin- 1 -yl-6-isopropyl-pyridin-3 -y 1)- 1 -((R)- 1 -methoxymethy l-propyl)-3 ,6- dimethyl- 1 H-pyrrolo[3,2-bjpyridine;
•5 -(2 Azetidin-l-y l-6-isopropyl-pyridin-3-yl)-6-ethyl-l-((R)-l -methoxymethy l-propyl)-3- methy 1- 1 H-pyrrolo [3 ,2-bjpyridine ; {3-[6-Ethyl-l-((R)-l-methoxymethyl-propy0-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-ylj-6- isopropyl-pyridin-2-yl] -methyl-amine;
6-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-y0-l-((R)-l-methoxymethyl-propyl)-3-methyl- lH-pyrrolo[3,2-b]pyridine;
6-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-l-((R)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine;
{3-[6-Ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- 6-isopropyl-pyridin-2-yl] -methyl-amine; 6-Ethyl-5-(4-isopropyl-2-methoxy-phenyl)-l-((R)-2-methoxy-l-methyl-ethyI)-3-methyl- lH-pyrrolo[3,2-b]pyridine;
6-Ethyl-l-((R)-2-fluoro-l-methyl-ethyl)-5-(4-isopropyl-2-methoxy-phenyl)-3-methyl-lH- pyrrolo [3 ,2-bjpyridine; 6-Ethyl-l -((R)-2-fluoro-l -methyl-ethyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3- methyl-lH-pyrrolo[3,2-b]pyridine;
{ 5 -Chloro-3 - [7-chloro-6-ethyl- 1 -((R)-2-methoxy- 1 -methyl-ethyl)-3 -methyl- 1 H- pyrrόlo[3,2-bjpyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine;
{5-Chloro-3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-ylj-6-isopropyl-pyridin-2-yl} -methyl-amine;
{5-Bromo-3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- bjpyridin-5-yl]-6-isopropyl-pyridin-2-yl} -methyl-amine;
{5-Cyclopropyl-3-[6-ethyl-l-((R)-2-methoxy-l-methyl-ethyl)-3-methylriFI-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine; { 5-Ethy 1-3 - [6-ethy 1- 1 -((R)-2-methoxy- 1 -methyl-ethy l)-3 -methy 1- 1 H-pyrrolo [3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine;
(S)-2-[6-Bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3-methyl-pyrrolo[3,2-b]pyridin- l-yl]-butan-l-ol;
6-Bromo-5-(6-isopropyl-2-ιnethoxy-pyridιn-3-yl)-l-((S)-l-methoxymethyl-propyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-l-methoxymethyl-propyl)-3-methyl-lH- pyrrolo[3,2-b]pyridine;
5-Ethyl-6-[l-(l-ethyl-propy0-3,6-dimethyl-lH-pyrrolo[3,2-bjpyridin-5-yl]-3-isopropyl- 3H-imidazo[4,5-b]pyridine; (3S,4R)-3-(2-Fluoro-ethoxy)-4-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester;
(3S,4R)-3-(2-Fluoro-ethoxy)-4-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid methyl ester;
(3S,4R)-3-(2-Fluoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid benzyl ester;
(3S,4R)-3-(2-Flιιoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-yl]-pyrrolidine-l-carboxylic acid methyl ester; l-[(3R,4S)-4-(2-Fluoro-ethoxy)-l-methanesιιlfonyl-pyrrolidin-3-yl]-5-(6-isopropyl-2- methoxy-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine; l-[(3R,4S)-4-(2-Fluoro-ethoxy)-l-methyl-pyrrolidin-3-yl]-5-(6-isopropyl-2-methoxy- pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine; (3S,4R)-3-(2-Fluoro-ethoxy)-4-[5-(6-isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl- pyrrolo[3,2-b]pyridin-l-ylj-pyrrolidine-l-carboxylic acid 2-morpholin-4-yl-ethyl ester;
3-Chloro-l-isopropyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-lH-pyrrolo[3,2- bjpyridine;
3-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6- methyl- lH-pyrrolo[3 ,2-bjpyridine;
3-Chloro-l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6- methy 1- 1 H-pyrrolo[3 ,2-b]pyridine;
3-Bromo-l-((S)-2-methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6- methyl-lH-pyrrolo[3 ,2-bjpyridine; l-((S)-2-Methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl- lH-pyrrolo[3,2-b]pyridine;
3-Fluoro-l-((S)-2-methoxy-l-methyl-ethy0-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6- methyl-lH-pyrrolo[3 ,2-bjpyridine; • 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-me'thyl-ethyl)-6-methyl-lH- pyrrolo[3,2-b]pyridine;
3-Chloro-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6- methyl- 1 H-pyrrolo[3 ,2-bjpyridine;
(R)-2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-pyrrolo[3,2-b]pyridin-l-yl]- butan-1-ol; 3-Bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6- methyl- 1 H-pyrrolo [3 ,2-bjpyridine ;
(R)-2-[3-Chloro-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-pyrrolo[3,2-b]pyridin- l-yl]-butan-l-ol;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((R)-l-methoxymethyl-propyl)-6-methyl-lH- pyrrolo[3,2-b]pyridine;
3-Chloro-5-(6-isopropyl-2-methoxy-pyridin-3-yl)- 1 -((R)- 1 -methoxymethyl-propyl)-6- methyl-lH-pyrrolo[3 ,2-bjpyridine; l-[l-((S)-2-Methoxy-l-methyl-ethyl)-5-(2-methoxy-4-trifiιιoromethoxy-phenyl)-6- methyl-lH-pyrrolo[3,2-b]pyridin-7-yl]-pyrrolidine-2,5-dione; l-[5-(6-Isopropyl-2-methoxy-pyridin-3-y 1)-1 -((R)-l -methoxymethy l-propyl)-6-methyl- lH-pyrrolo[3,2-b]pyridin-7-yl]-pyrrolidine-2,5-dione; {3-[3-Chloro-l-((S)-2-methoxy-l-methyl-ethyl)-6-methyl-lH-pyrrolo[3,2-b]pyridin-5- ylj-6-isopropyl-pyridin-2-yl} -methyl-amine;
{3-[3-Chloro-l-((R)-l-methoxymethyl-propyl)-6-methyl-lH-pyrrolo[3,2-b]pyridin-5-yl]- 6-isopropyl-pyridin-2-yl}-methyl-amine;
3 -Chloro-5-(2-ethyl-6-isopropyl-pyridin-3 -y 1)- 1 -((S)-2-methoxy- 1 -methyl-ethy l)-6- • methyl-lH-pyrrolo[3,2-b]pyridine; ■
3-Chloro-5-(6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6-methyl-lH- pyrrolo[3,2-b]pyridine;
6-Ethy 1-7- [ 1 -((R)- 1 -hydroxymethy 1-propy l)-3 ,6-dimethyl- 1 H-pyrrolo [3 ,2-b]pyridin-5 -y 1 j- 4-isopropyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one; 6-Ethyl-2,4-diisopropyl-7-[l-((R)-l-methoxymethyl-propyl)-3,6-dimethyl-lH- pyrro lo [3 ,2-b] pyridin-5-yl]-4H-pyrido [2,3 -b]pyrazin-3 -one;
2,6-Diethyl-4-isopropyl-7-[l-((R)-l-methoxymethyl-propyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-4H-pyrido[2,3-b]pyrazin-3-one;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6-methyl-lH- pyrrolo[3,2-b]pyridine-3-carbonitrile;
- 5-(6-Isopropyl-2-methylamino-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-6-methyl- lH-pyrrolo[3,2-b]pyridine-3-carbonitrile;
. 6-Ethyl-7-[6-ethyl-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2-bjpyridin- 5-yl]-4-isopropyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one; 5-(2-Ethyl-6-methoxy-pyridin-3-yl)-l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(2-Ethyl-6-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)r3,6-dimethyl-lH- pyrrolo[3 ,2-b] pyridine;
5-(2-Ethyl-6-isopropoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl- 1 H-pyrrolo [3 ,2-b] pyridine; { 6-Ethy 1-5 -[ 1 -((S)-2-methoxy- 1 -methy 1-ethy l)-3 , 6-dimethy 1- 1 H-pyrrolo [3 ,2-b]pyridin-5 - yl]-pyridin-2-yl} -dimethyl-amine;
5-(2,6-Diethyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; 5-(2,6-Diethyl-pyridin-3-yl)-l-isopropyl-3,6-dimethyl-lH-pyr.rolo[3,2-b]pyridine;
5-(2-Ethyl-6-isopropoxy-pyridin-3-yl)-l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine;
[6-Ethyl-5-(l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2-bjpyridin-5-yl)-pyridin-2-yl]- dimethyl-amine;
5-(6-Cyclopropylmethoxy-2-ethyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine;
2-[5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-bjpyridin-l-yl]-2- methy 1-propan- 1 -o 1 ; 5-(6-Cyclopropyl-2-ethyl-pyridin-3-yl)- l-((S)-2 -methoxy- l-methyl-ethyl)-3,6-dimethyl-
1 H-pyrrolo [3 ,2-b] pyridine;
5-(6-Ethoxy-2-ethyl-pyridin-3-yl)- 1 -((S)-2-methoxy- 1 -methyl-ethyl)-3,6-dimethyl- 1 H- ' pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l -(2-methoxy- 1 , 1 -dimethyl-ethyl)-3,6-dimethyl- lH-pyrrolo[3,2-b]pyridine;
(R)-2-[5-(2-Ethyl-6-methoxy-pyridin-3-yl)-3,6-dimethyl-pyrrolo[3,2-b]pyridin-l-ylj- butan-1-ol;
6-Ethyl-2-methoxy-5-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-N-methyl-nicotinamide; 5-(2-Ethyl-6-methoxy-pyridin-3-yl)-l-((R)-l-methoxymethyl-propyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine; l-{6-Ethyl-2-methoxy-5-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo [3 ,2-b]pyridin-5 -y 1 j-pyridin-3 -yl } -ethanone;
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)- 1 -(2-methoxy- 1 , 1 -dim ethyl-ethy l)-3, 6-dimethy 1- 1 H- ' pyrrolo[3,2-b]pyridine;
{6-Isopropyl-3-[l-(2-methoxy-l,l-dimethyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-pyridin-2-yl] -methyl-amine;
5-(6-Ethoxy-2-ethy l-pyridin-3 -yl)-l-((R)-l -methoxymethy 1-propy l)-3 , 6-dimethy 1- 1 H- pyrrolo[3,2-b]pyridine; 5-(6-Cyclopropylmethoxy-2-ethyl-pyridin-3-yl)-l-((R)-l-methoxymethyl-propyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(2-Ethy l-6-isopropoxy-pyridin-3 -y 1)- 1 -((R)- 1 -methoxymethy l-propyl)-3 , 6-dimethyl- lH-pyrrolo[3,2-b]pyridine; 6-Ethyl-5-(2-ethyl-6-methoxy-pyridin-3-yl)-l -((R)-2-fIuoro- 1 -methoxymethyl-ethyl)-3- methy 1- 1 H-pyrrolo[3 ,2-b]pyridine ;
5-[2-Ethyl-6-(2-methoxy-ethoxy)-pyridin-3 -yl]- 1 -((S)-2-methoxy- 1 -methyl-ethyl)-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine; 5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6,7- trimethyl-lH-pyrrolo[3,2-b]pyridine;
{ 6-Isopropyl-3 -[ 1 -((S)-2-methoxy- 1 -methyl-ethyl)-3 ,6,7-trimethy 1- 1 H-pyrrolo [3 ,2- b]pyridin-5-yl]-pyridin-2-yl}-methyl-amine; , •
5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6,7-trimethyl- lH-pyrrolo[3,2-b]pyridine;
{6-Isopropyl-3-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6,7-trimethyl-lH-pyrrolo[3,2- bjpyridin-5-yl]-pyridin-2-yl}-dimethyl-amine;
5-(2-Azetidin-l-yl-6-isopropyl-pyridin-3-yl)τl-((S)-2-methoxy-l-methyl-ethy0-3,6,7- trimethy 1- 1 H-pyrrolo [3 ,2-bjpyridine; ' [3-(3,6-Dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-y[)-6-isopropyl-pyridin-2-yl]-(2- methoxy-ethyl)-amine;
6-Isopropyl-3-(l -isopropyl-3, 6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-pyridin-2-yl]-(2- methoxy-ethy l)-am ine ;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl- ■ lH-pyrrolo[3,2-b]pyridine;
{6-Isopropyl-3-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-ylj-pyridin-2-yl}-dimethyl-amine;
[6-Isopropyl-3-(l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2-bjpyridin-5-yl)-pyridin-2-yl]- dimethyl-amine; [3-(3,6-Dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]- dimethyl-amine;
, 5-(2-Azetidin-l-yl-6-isopropyl-pyridin-3-yl)-3,6-dimethyl-l-propyl-lH-pyrrolo[3,2- bjpyridine;
5-(2-Azetidin-l-yi-6-isopropyl-pyridin-3-yl)-l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine;
5-(2-Azetidin-l-yl-6-isopropyl-p'yridin-3-yl)-l-((S)-2 -methoxy- l-methyl-ethyl)-3, 6- dinlethyl-lH-pyrrolo[3,2-b]pyridine; 5-[2-(3,3-Difluoro-azetidin-l-yl)-6-isopropyl-pyridin-3-yl]-l-((S)-2-methoxy-l-methyl- ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(2-Ethoxy-6-isopropyl-pyridin-3-y0-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl- lH-pyrrolo[3 ,2-bjpyridine; 5-(2-Isopropoxy-6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethy0-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl- lH-pyrrolo[3,2-b]pyridine;
[3-(3,6-Dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridin-5-yl)-6-isopropyl-pyridin-2-yl]- isopropy 1-amine;
Isopropyl-[6-isopropyl-3-(l -isopropyl-3, 6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)- pyridin-2-yl]-amine;
{6-Isopropyl-3-[l-(2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5- yl]-pyridin-2-yl}-(2-methoxy-ethyl)-amine; Isopropyl- { 6-isopropyl-3 -[ 1 -((S)-2 -methoxy- 1 -methyl-ethy l)-3 ,6-dimethyl- 1 H- pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-amine;
Ethyl-{6-isopropyl-3-[l-((S)-2-methoXy-l,-methyl-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-pyridin-2-yl} -amine;- l-Isopropyl-5-[6-isopropyl-2-(4-methyl-piperazin-l-yl)-pyridin-3-yl]-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridine;
[5-Chloro-6-isopropyl-3-(l-isopropyl-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridin-5-yl)- pyridin-2-yl]-ethyl-amine; l-Isbpropyl-5-(6-isopropyi-2-methyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2- bjpyridine; ' 5-(6-Isopropyl-2-methyl-pyridin-3-yl)-3,6-dimethyl-l-propyl-lH-pyrrolo[3,2-b]pyridine; l-Isopropyl-5-(6-isopropyl-pyridin-3-yl)-3,6-dimethyl-lH-pyrrolo[3,2-b]pyridine;
5-(6-Isopropyl-2-methoxy-pyridin-3-yl)-6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine;
Cyclopropyl-{6-isopropyl-3-[l-((S)-2-methoxy-l-methyl-ethyl)-3,6-dimethyl-lH- pyrrolo[3,2-b]pyridin-5-yl]-pyridin-2-yl}-amine;
/ 5-(6-Isopropyl-pyridin-3-yl)-6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-b]pyridine; 5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrrolo[3,2-b jpyridine;
Ethyl-{6-isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrrolo[3,2-bjpyridin-5-yl]-pyridin-2-yl}-amine; {6-Isopropyl-3-[6-methoxy- 1 -((S)-2 -methoxy- 1 -methyl-ethyl)-3-methyl-l H-pyrrolo[3,2- b]pyridin-5-yl]-pyridin-2-yl}-dimethyl-amine;
{6-Isopropyl-3-[6-methoxy-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-pyridin-2-yl} -methyl-amine;
6-Chloro-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl- IH-pyrrolo [3 ,2-b]pyridine;
6-Chloro-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-l-((S)-2-methoxy-l-methyl-ethyl)-3- methyl- IH-pyrrolo [3 ,2-bjpyridine;
6-Chloro-5-(6-isopropyl-pyridin-3 -yl)- 1 -((S)-2 -methoxy- 1 -methyl-ethyl)-3 -methyl- 1 H- pyrrolo[3,2-b]pyridine; {3-[6-Chloro-l-((S)-2-methoxy-.l-methyl-ethyl)-3-methyl-lH-pyrrol9[3,2-b]pyridin-5- yl]-6-isopropyl-pyridin-2-yl}-dimethyl-amine;
{3-[6-Chloro-l-((S)-2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrroio[3,2-b]pyridin-5- yl]-6-isopropyl-pyridin-2-yl} -methyl-amine;
{ 3 -[6-Chloro- 1 -((S)-2-methoxy- 1 -methy 1-ethy l)-3 -methy 1- 1 H-pyrrolo [3 ,2-b] pyrid in-5- yl]-6-isopropyl-pyridin-2-yl}-ethyl-amine;
{3-[6-Chloro-l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3-methyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-methyl-amine;
6-Chloro-5-(2-ethyl-6-isopropyl-pyridin-3-yO-l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3- methyl-lH-pyrrolo[3,2-b]pyridine; 6-Chloro-l-((R)-l-fluoro-methyl-2-methoxy-ethy0-5-(6-isopropyl-2-methyl-pyridin-3- y l)-3 -methyl- 1 H-pyrrolo [3 ,2-bjpyridine;
{5-Chloro-3-[l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-ylj-6-isopropyl-pyridin-2-yl}-methyl-amine; l-(R)-l-Fluoromethyl-2-methoxy-ethyl)-5-(6-isopropyl-2-methyl-pyridin-3-y0-3,6- dimethyl-lH-pyrrolo[3,2-b]pyridine;
Ethyl-{3-[l-((R)-l-fluoromethyl-2-methoxy-ethyl)-3,6-dimethyl-lH-pyrrolo[3,2- b]pyridin-5-yl]-6-isopropyl-pyridin-2-yl}-amine; 2-Bromo-7-(l-ethyl-propyl)-3-(2-ιnethoxy-4-trifluoromethoxy-phenyl)-5-methyl-5H- pyrro lo [2,3 -b] pyrazine ;
7-(l-Ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-5H-pyrrolo[2,3- b] pyrazine; 2-Ethyl-7-(l-ethyl-propyl)-3-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-5H- pyrrolo[2,3-b]pyrazine;
7-(l-Ethyl-propyO-3-(2-methoxy-4-trifluoromethoxy-phenyl)-2,5-dimethyl-5H- pyrrolo[2,3-bjpyrazine;
2-Ethyl-7-( 1 -ethy 1-propy l)-3 -(6-isopropy l-2-methoxy-pyridin-3 -y l)-5 -methyl-5H- py rro lo [2, 3 -b] pyrazine;
2-Ethyl-3-(2-ethyl-6-isopropyl-pyridin-3-yl)-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3- bjpyrazine;
. {3-[2-Ethyl-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-yl]-6-isopropyl- pyridin-2-yl} -methyl-amine; Diethyl-{4-ethyl-5-[2-ethyl-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3-bjpyrazin-3-yl]- pyridin-2-yl}-amine;
2-Ethyl-7-(l-'ethyl-propyl)-3-(3-isopropyl-5-methoxy-2,3-dihydro-furo[3,2-b]pyridin-6- yl)-5-methyl-5H-pyrroio[2,3-b]pyrazine;
2-[3-(2-Methoxy-4rtrifluoromethoxy-phenyl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-7- yl]-propan-l-ol;
7-(2 -Methoxy- l-methylr-ethyl)-3-(2-methoxy-4-triflιιoromethoxy-phenyl)-2,5-dimethyl- 5H-pyrrolo[2,3-b]pyrazine;
2-[3-(2-Methoxy-4-trifluoromethoxy-phenyl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-7- yfj-propionic acid methyl ester; ■ 2-[3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]- propan-1-ol;
Methanesulfonic acid 2-[3-(6-isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H- pyrrolo[2,3-b]pyrazin-7-ylj-propyl ester;
3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-7-(2-methoxy-l -methyl-ethyl)-2,5-dimethyl-5H- pyrrolo[2,3-b]pyrazine;
3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-7-(l-methyl-2-morpholin-4-yl- ethyl)-5H-pyrrolo[2,3-b]pyrazine; 7-sec-Butyl-3-(6-isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H-pyrrolo[2,3- bjpyrazine;
7-Isopropyl-3 -(6-isopropy 1-2 -methoxy-pyridin-3 -y l)-2, 5 -dimethyl-5H-pyrrolo[2, 3 - bjpyrazine; 2-[3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]- butan-1-ol;
, 3-(6-Isopropyl-2-methoxy-pyridin-3-yl)-7-(l-methoxymethyl-propyl)-2,5-dimethyl-5H- pyrrolo [2,3 -b] pyrazine;
Methanesulfonic acid 2-[3-(6-isopropyl-2-methoxy-pyridin-3-yl)-2,5-dimethylr5H- pyrrolo[2,3-b]pyrazin-7-yl]-butyl ester;
2-Ethyl-7-isopropyl-3-(6-isopropyl-2-methoxy-pyridin-3-yl)-5-methyl-5H-pyrrolo[2,3- bjpyrazine;
3-(2-Ethyl-6-isopropyl-pyridin-3-yl)-7-(2-methoxy-l-methyl-ethyl)-2,5-dimethyl-5H- pyrrolo[2,3-b] pyrazine; 2-Ethyl-3-(2-ethyl-6-isopropyl-pyridin-3-yl)-7-isopropyl-5-methyl-5H-pyrrolo[2,3- b]pyrazine;
[3-(2-Ethyl-7-isopropyl-5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-yi)-6-isopropyl-pyridin-2- ylj-methyl-a'mine;
{6-Isopropyl-3-[7-(2-methoxy-l-methyl-ethyl)-2,5-dimethyl-5H-pyrrolo[2,3-b]pyrazin-3- yl]-pyridin-2-yl}-methyl-amine;
{4-Ethyl-5-[2-ethyl-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-yl]-pyridin- 2-yl} -dimethyl-amine;
Ethyl-{4-ethyl-5-[2-ethyl-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3-bjpyrazin-3-yl]- pyridin-2-yl}-methyl-amine; 2,2'-Diethyl-7]7,-bis-(l-ethyl-propyl)-5,5'-dimethyl-5H,5Η-[3,3,]bi[pyrrolo[2,3- bjpyrazinylj;
5-Ethyl-6-[2-ethyl-7-(l-ethyl-propyl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-yl]-3- isopropyl-3H-imidazo[4,5-b]pyridine;
2-Ethyl-7-(2-methoxy-ethyl)-3-(2-methoxy-4-triflιιoromethoxy-phenyl)-5-methyl-5H- pyrrolo[2,3-b]pyrazine;
3-[2-Ethyl-3-(2-methoxy-4-triflιιoromethoxy-phenyl)-5-methyl-5H-pyrrolo[2,3- bjpyrazin-7-yl]-propionitrile; 5 -B romo-3 -( 1 -ethyl-propyl)-6-(2-methoxy-4-trifluoromethoxy-phenyl)- 1 -methyl- 1 H- pyrrolo[2,3-bjpyridine;
3-(l-Ethyl-propyl)-6-(2-methoxy-4-trifluoromethoxy-phenyI)-l,5-dimethyl-lH- pyrrolo[2,3-bjpyridine; 5-Chloro-3-(l-ethyl-propyl)-6-(2-methoxy-4-trifluoromethoxy-phenyl)-l-methyl-lH- pyrrolo[2,3-bjpyridine;
3-(l-Ethyl-propyl)-6-(2-methoxy-4-trifluoromethoxy-phenyl)-l,5-dimethyl-lH- pyrrolo[2,3-b]pyridine;
3-sec-Butyl-6-(6-isopropyl-2-methoxy-pyridin-3-yl)-l,5-dimethyl-lH-pyrrolo[2,3- bjpyridine;
3-sec-Butyl-6-(2-ethyl-6-isopropyl-pyridin-3-yO-l,5-dimethyl-lH-pyrrolo[2,3-bjpyridine; [3-(3-sec-Butyl-l,5-dimethyl-lH-pyrrolo[2,3-b]pyridin-6-yl)-6-isopropyl-pyridin-2-ylj- methyl-amine;
2→[6-(6-Isopropyl-2 -methoxy-pyridin-3 -yl)- 1 , 5 -dimethyl- 1 H-pyrrolo[2,3 -b jpyridin-3 -yl] - butan-1-ol;
6-(6-Isopropyl-2-methoxy-pyridin-3-yl)-3-(l-methoxy.methyl-propyl)-l,5-dimethyl-lH- pyrrolo[2,3-b]pyridine;
5-Bromo-3-isopropyl-6-(6-isopropyl-2-methoxy-pyridin-3-yl)-l-methyl-lH-pyrr.olo[2,3- bjpyridine; 3-Isopropyl-6-(6-isopropyl-2-methoxy-pyridin-3-yl)-l,5-dimethyl-lH-pyrrolo[2,3- b]pyridine;
3-(l-Ethoxymethyl-propyl)-6-(6-isopropyl-2-methoxy-pyridin-3-yl)-l,5-dimethyl-lH- pyrrolo[2,3-b]pyridine; and
5-Ethyl-3-isopropyl-.6-(6-isopropyl-2-methoxy-pyridin-3-y0-l-methyl-lH-pyrrolo[2,3- b]pyridine.
42. A compound or salt according to any of Claims 1-41 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits an IC50 value for CRF receptors of less than or equal to 1 micromolar.
43. A compound or salt according to any of Claims 1-41 wherein^ in a standard in vitro CRF receptor binding assay the compound exhibits an IC50 value for CRF receptors of less than or equal to 100 nanomolar.
44. A compound or salt according to any of Claims 1-41 wherein, in a standard in vitro CRF receptor binding assay, the compound exhibits an IC50 value for CRF receptors of less than or equal to 10 nanomolar.
45. A method for treating an anxiety disorder, a stress-related disorder, or an eating disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to any of Claims 1-41.
46.- A method for treating an depression or bipolar disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to any of Claims 1-41.
47. A method for treating anorexia nervosa, bulimia nervosa, or obesity, comprising administering to a patient in need .of such treatment a therapeutically effective amount of a compound or salt according to any of Claims 1-41.
48. A compound or salt according to any of Claims 1-41, wherein in a standard in vitro Na channel functional assay the compound does not show any statistically significant detectable Na channel modulatory activity at the p < 0.05 level of significance in a standard parametric test of statistical significance.
49. A method for demonstrating the presence of CRF receptors in cell or tissue samples, said method comprising: preparing a plurality of matched cell or tissue samples, preparing at least one control sample by contacting (under conditions that permit binding of CRF to CRF receptors within cell and tissue samples) at least one of the matched cell or tissue samples (that has not previously been contacted with any compound or salt of any of Claims 1-41) with a control solution comprising a detectably-labeled preparation of a selected compound or salt of any of Claims 1-41 at a first measured molar concentration, said control solution further comprising an unlabelled preparation of the selected compound or salt at a second measured molar concentration, which second measured concentration is greater than said first measured concentration, preparing at least one experimental sample by contacting (under conditions that permit binding of CRF to CRF receptors within cell and tissue samples) at least one of the matched cell or tissue samples (that has not previously been contacted with any compound or salt of any of Claims 1-41) with an experimental solution comprising the detectably-labeled preparation of the selected compound or salt at the first measured molar concentration, said experimental solution not further comprising an unlabelled preparation of any compound or salt of any of Claims 1-41 at a concentration greater than or equal to said first measured concentration; washing the at least one control sample to remove unbound selected compound or salt to produce at least one washed control sample; washing the at least one experimental sample to remove unbound selected compound or salt to produce at least one washed experimental sample; measuring the. amount of detectable label of any remaining bound detectably-labeled selected compound or salt in the at least one washed control sample; measuring the amount detectable label of any remaining bound detectably-labeled selected compound or salt in the at least one washed experimental sample; ' comparing the amount of detectable label measured in each of the at least one washed experimental sample to the amount of detectable label measured in each of the at least one washed control sample wherein, a comparison that indicates the detection of a greater amount of detectable label in the at least one washed experimental sample than is detected in any of the at least one - washed control samples demonstrates the presence of CRF receptors in that experimental sample."
50. A method of inhibiting the binding of CRF to a CRFl Receptor, which method comprises: contacting a solution comprising CRF and a compound or salt of any of Claims 1 to 41 with a cell expressing the CRF receptor, wherein the compound or salt is present in the solution at a concentration sufficient to inhibit in vitro CRF binding to IMR32 cells.
51. The method of Claim 50 wherein the cell expressing the CRF receptor is a neuronal cell that is contacted in vivo in an animal, and wherein the solution is a body fluid of said animal.
52. The method of Claim 51 wherein the animal is a human patient.
53. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of any of Claims 1-41.
54. A package comprising a pharmaceutical composition of claim 53 in a container and further comprising indicia comprising at least one of: instructions for using the composition to treat a patient suffering from an anxiety disorder, or instructions for using the composition to treat a patient suffering from a stress-related disorder, or instructions for using the composition to treat a patient suffering from an eating disorder.
55. A package comprising a pharmaceutical composition of claim 53 in a container and further comprising indicia comprising at least one Of: instructions for using the composition to treat a patient suffering from depression or instructions for using the composition to treat a patient suffering from a bipolar disorder.
PCT/US2004/028899 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands WO2005023806A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2006526210A JP2007504271A (en) 2003-09-05 2004-09-03 Heteroaryl-fused pyridines, pyrazines and pyrimidines which are CRF1 receptor ligands
AP2006003559A AP2006003559A0 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
CA002537829A CA2537829A1 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
EP04788585A EP1680424A2 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
AU2004270713A AU2004270713A1 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
EA200600372A EA200600372A1 (en) 2003-09-05 2004-09-03 CONDENSED WITH PYRIDINE HETEROARIL, PIRASINS AND PyRMIDINES AS LIGANDS OF THE CORTICOTROPIN-REALIZING FACTOR RECEPTOR (CRF 1)
BRPI0414087-7A BRPI0414087A (en) 2003-09-05 2004-09-03 compound, methods for treating a disorder, for demonstrating the presence of crf receptors in cell or tissue samples, and for inhibiting the binding of crf to a crf1 receptor, pharmaceutical composition, and packaging.
IL174084A IL174084A0 (en) 2003-09-05 2006-03-02 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
NO20061180A NO20061180L (en) 2003-09-05 2006-03-14 Heteroberl-chain pyridines, pyrazines and pyrimidines as CRF1 receptor ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50041403P 2003-09-05 2003-09-05
US60/500,414 2003-09-05

Publications (2)

Publication Number Publication Date
WO2005023806A2 true WO2005023806A2 (en) 2005-03-17
WO2005023806A3 WO2005023806A3 (en) 2005-06-02

Family

ID=34272952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/028899 WO2005023806A2 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands

Country Status (19)

Country Link
US (2) US20050113379A1 (en)
EP (1) EP1680424A2 (en)
JP (1) JP2007504271A (en)
KR (1) KR20060088534A (en)
CN (1) CN1878773A (en)
AP (1) AP2006003559A0 (en)
AR (1) AR045582A1 (en)
AU (1) AU2004270713A1 (en)
BR (1) BRPI0414087A (en)
CA (1) CA2537829A1 (en)
CR (1) CR8274A (en)
EA (1) EA200600372A1 (en)
EC (1) ECSP066408A (en)
IL (1) IL174084A0 (en)
MA (1) MA28086A1 (en)
NO (1) NO20061180L (en)
TW (1) TW200530232A (en)
WO (1) WO2005023806A2 (en)
ZA (1) ZA200601978B (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007029629A1 (en) * 2005-09-06 2007-03-15 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having pgd2 receptor antagonistic activity
WO2007069671A1 (en) 2005-12-15 2007-06-21 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
EP1933842A2 (en) * 2005-10-11 2008-06-25 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2008083070A1 (en) * 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
US7563800B2 (en) 2006-12-19 2009-07-21 Roche Palo Alto Llc Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
US7601726B2 (en) 2005-08-25 2009-10-13 Roche Palo Alto Llc Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors
WO2010084050A2 (en) 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
US7834037B2 (en) 2005-11-04 2010-11-16 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2305652A2 (en) 2005-12-08 2011-04-06 Novartis AG Trisubstituted quinazolinone derivatives as vanilloid antagonists
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8324225B2 (en) 2006-05-26 2012-12-04 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2012164473A1 (en) 2011-05-27 2012-12-06 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US8415355B2 (en) 2008-08-22 2013-04-09 Novartis Ag Pyrrolopyrimidine compounds and their uses
US8551981B2 (en) 2010-10-08 2013-10-08 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US8957074B2 (en) 2010-02-19 2015-02-17 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of CDK4/6
JP2015044854A (en) * 2007-12-07 2015-03-12 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2940022A1 (en) * 2014-04-30 2015-11-04 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9725440B2 (en) 2007-05-09 2017-08-08 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US9751890B2 (en) 2008-02-28 2017-09-05 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9822130B2 (en) 2014-11-21 2017-11-21 Merck Sharp & Dohme Corp. Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US9840499B2 (en) 2007-12-07 2017-12-12 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2018048953A1 (en) * 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
US10076513B2 (en) 2010-04-07 2018-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070542A1 (en) * 2003-09-03 2005-03-31 Hodgetts Kevin J. 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
CA2611312C (en) 2005-06-06 2013-12-03 Intra-Cellular Therapies, Inc. Organic compounds
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2007133756A2 (en) * 2006-05-15 2007-11-22 Neurogen Corporation Crf1 receptor ligands comprising heteroaryl fused bicycles
JP5837278B2 (en) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． New use
US20080146549A1 (en) * 2006-12-18 2008-06-19 Coleman Peter R Accelerated opiate dependence detoxification process
ES2588238T3 (en) * 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivatives of pyrazolopyrimidin-4,6-dione and its use as a pharmaceutical product
WO2010068311A1 (en) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor
JP5710492B2 (en) 2008-12-06 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Organic compounds
WO2010065148A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
PE20120209A1 (en) 2008-12-06 2012-03-18 Intra Cellular Therapies Inc DERIVATIVES OF IMIDAZO- [1,2-a] -PIRAZOLO [4,3-e] PYRIMIDINE OR PYRIMIDO- [1,2-a] -PIRAZOLO [4,3-e] PYRIMIDINE AS INHIBITORS OF PHOSPHODIESTERASE 1 (PDE1)
AU2009322901A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
KR20110098731A (en) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2822951B1 (en) * 2012-03-06 2017-07-26 Bayer Intellectual Property GmbH Substituted azabicycles and use thereof
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
DK2970279T3 (en) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
EP3193878B1 (en) 2014-09-17 2021-01-06 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
JP7401442B2 (en) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド new use
CN110437846B (en) * 2019-08-30 2022-02-25 陕西师范大学 Fluorine substituted benzoxazole liquid crystal compound containing acetylene bond and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO2002000623A2 (en) * 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US20020065290A1 (en) * 1995-05-12 2002-05-30 Neurogen Corporation Novel deazapurine derivatives: a new class of CRF1 specific ligands
US6436932B1 (en) * 1998-04-02 2002-08-20 Neurogen Corporation Aminoalkyl substituted pyrrolo[3,2-e] pyridine and pyrrolo[2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
WO2004096130A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (en) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same
CZ68199A3 (en) * 1996-08-28 1999-11-17 Pfizer Inc. 6,5-heterobicyclic derivatives, pharmaceutical composition based thereon and method of treating diseases
DE10229777A1 (en) * 2002-07-03 2004-01-29 Bayer Ag Indoline-phenylsulfonamide derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US20020065290A1 (en) * 1995-05-12 2002-05-30 Neurogen Corporation Novel deazapurine derivatives: a new class of CRF1 specific ligands
US6436932B1 (en) * 1998-04-02 2002-08-20 Neurogen Corporation Aminoalkyl substituted pyrrolo[3,2-e] pyridine and pyrrolo[2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
WO2002000623A2 (en) * 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
WO2004096130A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BILODEAU, DENIS ET AL: "Methyl- and phenylmercury complexes of azaindolylazaindole" INORGANICA CHIMICA ACTA , 261(1), 7-13 CODEN: ICHAA3; ISSN: 0020-1693, 1997, XP002319237 *
CAMPOS P J ET AL: "A versatile synthesis of pyrrolo-, furo- and thienopyridines via photocyclization of 3-amino-2-alkene imines in an acid medium" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 55, no. 49, 3 December 1999 (1999-12-03), pages 14079-14088, XP004585075 ISSN: 0040-4020 *
KANAZAWA, K.; ASHIDA, H.; DANNO, G.;: "Comparison in Metabolic Activity of Cytochrome P450 1A1 on Heterocyclic Amines between Human and Rat" J. AGRIC. FOOD CHEM, vol. 47, no. 12, 1999, pages 4956-4961, XP002319238 *
PAETZEL, MICHAEL ET AL: "Cyclization of N-cyanovinyl-lactam imines to condensed 4-aminopyridines or substituted aminopyrazole" JOURNAL OF HETEROCYCLIC CHEMISTRY , 29(5), 1067-8 CODEN: JHTCAD; ISSN: 0022-152X, 1992, XP002319236 *
TAYLOR, EDWARD C. ET AL: "Intramolecular Diels-Alder reactions of 1,2,4-triazines. A general synthesis of furo[2,3-b]pyridines, 2,3-dihydropyrano[2,3-b]pyridines, and pyrrolo[2,3-b]pyridines" TETRAHEDRON , 43(21), 5145-58 CODEN: TETRAB; ISSN: 0040-4020, 1987, XP002319235 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7601726B2 (en) 2005-08-25 2009-10-13 Roche Palo Alto Llc Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors
US8623903B2 (en) 2005-09-06 2014-01-07 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
WO2007029629A1 (en) * 2005-09-06 2007-03-15 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having pgd2 receptor antagonistic activity
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
EP1933842A2 (en) * 2005-10-11 2008-06-25 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
JP2009521399A (en) * 2005-10-11 2009-06-04 アミラ ファーマシューティカルス，インコーポレーテッド 5-lipoxygenase-activated protein (FLAP) inhibitors
EP1933842A4 (en) * 2005-10-11 2009-10-21 Amira Pharmaceuticals Inc 5-lipoxygenase-activating protein (flap) inhibitors
US7834037B2 (en) 2005-11-04 2010-11-16 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US11084804B2 (en) 2005-11-08 2021-08-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2305652A2 (en) 2005-12-08 2011-04-06 Novartis AG Trisubstituted quinazolinone derivatives as vanilloid antagonists
WO2007069671A1 (en) 2005-12-15 2007-06-21 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
US8324225B2 (en) 2006-05-26 2012-12-04 Novartis Ag Pyrrolopyrimidine compounds and their uses
US7563800B2 (en) 2006-12-19 2009-07-21 Roche Palo Alto Llc Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
WO2008083070A1 (en) * 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
US9725440B2 (en) 2007-05-09 2017-08-08 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US9776968B2 (en) 2007-12-07 2017-10-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US10597384B2 (en) 2007-12-07 2020-03-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9840499B2 (en) 2007-12-07 2017-12-12 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US12065432B2 (en) 2007-12-07 2024-08-20 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP2015044854A (en) * 2007-12-07 2015-03-12 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US9751890B2 (en) 2008-02-28 2017-09-05 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
US8415355B2 (en) 2008-08-22 2013-04-09 Novartis Ag Pyrrolopyrimidine compounds and their uses
US8962630B2 (en) 2008-08-22 2015-02-24 Novartis Ag Pyrrolopyrimidine compounds and their uses
US9416136B2 (en) 2008-08-22 2016-08-16 Novartis Ag Pyrrolopyrimidine compounds and their uses
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2010084050A2 (en) 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
WO2010096426A3 (en) * 2009-02-20 2011-01-27 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8957074B2 (en) 2010-02-19 2015-02-17 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of CDK4/6
US9309252B2 (en) 2010-02-19 2016-04-12 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of CDK4/6
US11052075B2 (en) 2010-04-07 2021-07-06 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10076513B2 (en) 2010-04-07 2018-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US8551981B2 (en) 2010-10-08 2013-10-08 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
WO2012164473A1 (en) 2011-05-27 2012-12-06 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US9624217B2 (en) 2014-02-03 2017-04-18 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10047085B2 (en) 2014-02-03 2018-08-14 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10807980B2 (en) 2014-02-03 2020-10-20 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
EP2940022A1 (en) * 2014-04-30 2015-11-04 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10087184B2 (en) 2014-10-14 2018-10-02 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of RORγ
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US9822130B2 (en) 2014-11-21 2017-11-21 Merck Sharp & Dohme Corp. Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10829448B2 (en) 2015-08-05 2020-11-10 Vitae Pharmaceuticals, Llc Substituted benzoimidazoles as modulators of ROR-γ
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11077108B2 (en) 2016-09-07 2021-08-03 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
WO2018048953A1 (en) * 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma

Also Published As

Publication number Publication date
KR20060088534A (en) 2006-08-04
ZA200601978B (en) 2007-05-30
JP2007504271A (en) 2007-03-01
AP2006003559A0 (en) 2006-04-30
NO20061180L (en) 2006-03-31
TW200530232A (en) 2005-09-16
AR045582A1 (en) 2005-11-02
EP1680424A2 (en) 2006-07-19
US20050113379A1 (en) 2005-05-26
US20060199823A1 (en) 2006-09-07
AU2004270713A1 (en) 2005-03-17
CA2537829A1 (en) 2005-03-17
BRPI0414087A (en) 2006-10-31
MA28086A1 (en) 2006-08-01
IL174084A0 (en) 2008-02-09
ECSP066408A (en) 2006-09-18
CN1878773A (en) 2006-12-13
WO2005023806A3 (en) 2005-06-02
CR8274A (en) 2008-06-10
EA200600372A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
EP1680424A2 (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
KR102073797B1 (en) Aminopyridazinone compounds as protein kinase inhibitors
EP1756104B1 (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
US20050070542A1 (en) 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
KR101410453B1 (en) Certain chemical entities, compositions and methods
EP2225227B1 (en) 1&#39;,3&#39;-Dihydrospiro[imidazolidin-4,2&#39;-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3&#39;]-pyrroles as CGRP antagonists
US20080015196A1 (en) Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
EP2205590B1 (en) Cgrp antagonists
US7557103B2 (en) Imidazopyridazine compounds
US20070129364A1 (en) Pyrrolopyridine kinase inhibiting compounds
CN105051029A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors
WO2007133756A2 (en) Crf1 receptor ligands comprising heteroaryl fused bicycles
PT880523E (en) Pyrazolopyrimidines as crf receptor antagonists
KR20220061958A (en) Heterobicyclic amides as inhibitors of CD38
EP3126366B1 (en) Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1h-imidazo[1,2-b]pyrazole derivatives as ros1 inhibitors
US6943173B2 (en) 5-substituted 2-aryl-4-pyrimidinones
JP2024506814A (en) Quinoline and azaquinoline as CD38 inhibitors
AU2004261591A1 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
EP2065382A1 (en) CGRP antagonists
EP2065386A1 (en) CGRP antagonists
MXPA06002556A (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480032703.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 174084

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2537829

Country of ref document: CA

Ref document number: 1020067004564

Country of ref document: KR

Ref document number: 418.06

Country of ref document: BZ

Ref document number: PA/a/2006/002556

Country of ref document: MX

Ref document number: 2004270713

Country of ref document: AU

Ref document number: 2006526210

Country of ref document: JP

Ref document number: 545696

Country of ref document: NZ

Ref document number: 2004788585

Country of ref document: EP

Ref document number: CR2006-008274

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200600372

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2006/01978

Country of ref document: ZA

Ref document number: 200601978

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003559

Country of ref document: AP

ENP Entry into the national phase

Ref document number: 2004270713

Country of ref document: AU

Date of ref document: 20040903

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004270713

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06031674

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1200600506

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 2004788585

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067004564

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0414087

Country of ref document: BR